{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from gensim.models import KeyedVectors\n",
    "import fse # fast sentence embeddings\n",
    "from fse.models import uSIF\n",
    "import nltk\n",
    "import os\n",
    "import requests\n",
    "\n",
    "\n",
    "from spacy import util\n",
    "import spacy\n",
    "\n",
    "from IPython.core.display import display, HTML"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# !~/Work/solr-7.7.2/bin/solr start -p 8157"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "path_w2v = '/home/santosh/Work/models/word2vec/CORD-19/'\n",
    "sif_model = KeyedVectors.load(path_w2v+'CORD-19-p2v_sif_2017.bin')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loading from /home/santosh/Work/models/SpaCy/en-cord19-lg/best/\n"
     ]
    }
   ],
   "source": [
    "spacy_model_path = '/home/santosh/Work/models/SpaCy/en-cord19-lg/best/'\n",
    "\n",
    "print(\"Loading from\", spacy_model_path)\n",
    "nlp2 = util.load_model_from_path(spacy_model_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "col_dict = {}\n",
    "seven_colours = ['#00FFFF', '#B0C4DE', '#ADFF2F', '#FFA07A', '#E6E6FA', '#FFC0CB', '#FFFF00', '#BC8F8F', '#7FFFD4', '#D8BFD8']\n",
    "for label, colour in zip(nlp2.pipe_labels['ner'], seven_colours):\n",
    "    col_dict[label] = colour\n",
    "\n",
    "options = {'ents': nlp2.pipe_labels['ner'], 'colors':col_dict}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_results_from_solr(solr_query_):\n",
    "    try:\n",
    "        r = requests.get(solr_query_)\n",
    "    \n",
    "        if r.status_code == 200:\n",
    "\n",
    "            json_data = r.json()\n",
    "            return json_data\n",
    "\n",
    "        else:\n",
    "            print('result_not_suceeded')\n",
    "            return False\n",
    "    \n",
    "    except(ConnectionError):\n",
    "        return False\n",
    "        \n",
    "\n",
    "def generate_solr_query(query_result):\n",
    "\n",
    "    list_indexs = []\n",
    "    similarity_scores = []\n",
    "    for each_result in query_result:\n",
    "        list_indexs.append(each_result[0])\n",
    "        similarity_scores.append(each_result[1])\n",
    "\n",
    "    solr_query = 'http://localhost:8157/solr/cord19_paragraph_index/select?q=index_key:('\n",
    "    for each_index in list_indexs:\n",
    "        solr_query = solr_query+str(each_index)+' '\n",
    "\n",
    "    solr_query = solr_query+')&rows=300'\n",
    "\n",
    "#     print(solr_query)\n",
    "    \n",
    "    return solr_query, dict(zip(list_indexs,similarity_scores))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_results_dict(top_results, scores):\n",
    "    html_markup_list = [None] * len(scores) # [pre define the list, later use to input results based on scores]\n",
    "    \n",
    "    for er in top_results['response']['docs']:\n",
    "        data_dict = {}\n",
    "        \n",
    "        data_dict['title'] = '<a href = \"https://doi.org/'+er['source'].strip()+'\">'+er['title']+'</a>'\n",
    "        data_dict['authors'] = er['authors']\n",
    "        data_dict['paragraph'] = spacy.displacy.render(nlp2(er['paragraph']), style='ent', jupyter=False, options=options, minify=True)\n",
    "        \n",
    "        key_index = list(scores).index(er['index_key'])\n",
    "        \n",
    "        data_dict['document_score'] = round(scores[er['index_key']],2)\n",
    "        \n",
    "        html_markup_list[key_index] = data_dict\n",
    "        \n",
    "    return list(filter(None, html_markup_list)) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "def convert_html(top_results, scores):\n",
    "    html_markup_list = [None] * len(scores) # [pre define the list, later use to input results based on scores]\n",
    "    \n",
    "    for er in top_results['response']['docs']:\n",
    "        title = '<a href = \"https://doi.org/'+er['source'].strip()+'\"><h2> '+er['title']+'</h2></a>'\n",
    "        authors = '<h6> '+er['authors']+'</h6>'\n",
    "        paragraph = '<p>'+spacy.displacy.render(nlp2(er['paragraph']), style='ent', jupyter=False, options=options, minify=True)+'<p>'\n",
    "        \n",
    "        key_index = list(scores).index(er['index_key'])\n",
    "        \n",
    "        document_score = '<i>'+'relevance: '+ str(round(scores[er['index_key']],2))+'</i>'\n",
    "        \n",
    "        html_markup_list[key_index] = title+ ' ('+ document_score +')' + '\\n'+authors+'\\n'+ paragraph\n",
    "        \n",
    "    return list(filter(None, html_markup_list)) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [],
   "source": [
    "# query = \"What is the incubation days of SARS-CoV-2\" \n",
    "\n",
    "# query = \"incubation days coronavirus 2019-nCoV\"#  COVID-19\n",
    "# query = 'socio economic poverty behaviour'\n",
    "\n",
    "# query = 'what is the influence of pre-existing diseases and comorbidities'\n",
    "# query = 'public health mitigation measures that could be effective for control'\n",
    "# query = 'socio-economic and behavioral factors to understand the economic impact of the SARS-CoV-2 virus and whether there were differences. '\n",
    "# query = 'what are the risk factors for death in COVID-19'\n",
    "# query = 'what is the basic reproductive number of SARS-CoV-2 in days'\n",
    "# query = 'what is the serial interval days SARS-CoV-2'\n",
    "# query = 'what do we know about the environmental factors influencing SARS-CoV-2'\n",
    "query = 'what do we know about drugs using to treat SARS-CoV-2'\n",
    "# query = 'Transmission dynamics of the virus SARS-CoV-2'\n",
    "# query ='risk of fatality among symptomatic hospitalized patients'\n",
    "# query = 'Efforts targeted at a universal coronavirus vaccine'\n",
    "# query = ''\n",
    "\n",
    "query_result = sif_model.sv.similar_by_sentence(nltk.word_tokenize(query), model=sif_model, topn=300)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/santosh/anaconda3/envs/scispacy/lib/python3.6/runpy.py:193: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n",
      "  \"__main__\", mod_spec)\n",
      "/home/santosh/anaconda3/envs/scispacy/lib/python3.6/runpy.py:193: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n",
      "  \"__main__\", mod_spec)\n",
      "/home/santosh/anaconda3/envs/scispacy/lib/python3.6/runpy.py:193: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n",
      "  \"__main__\", mod_spec)\n",
      "/home/santosh/anaconda3/envs/scispacy/lib/python3.6/runpy.py:193: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n",
      "  \"__main__\", mod_spec)\n",
      "/home/santosh/anaconda3/envs/scispacy/lib/python3.6/runpy.py:193: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n",
      "  \"__main__\", mod_spec)\n",
      "/home/santosh/anaconda3/envs/scispacy/lib/python3.6/runpy.py:193: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n",
      "  \"__main__\", mod_spec)\n",
      "/home/santosh/anaconda3/envs/scispacy/lib/python3.6/runpy.py:193: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n",
      "  \"__main__\", mod_spec)\n",
      "/home/santosh/anaconda3/envs/scispacy/lib/python3.6/runpy.py:193: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n",
      "  \"__main__\", mod_spec)\n",
      "/home/santosh/anaconda3/envs/scispacy/lib/python3.6/runpy.py:193: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n",
      "  \"__main__\", mod_spec)\n",
      "/home/santosh/anaconda3/envs/scispacy/lib/python3.6/runpy.py:193: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n",
      "  \"__main__\", mod_spec)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<a href = \"https://doi.org/10.1101/2020.01.29.924100\"><h2> Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines</h2></a> (<i>relevance: 0.72</i>)\n",
       "<h6> Liu, X.; Wang, X.-J.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">To present, these are still no clinically approved <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> or drugs specific for coronaviruses, which makes it more difficult for curing 2019-nCoV caused diseases and controlling the associated pandemic. With the hope to identify candidate drugs for 2019-nCoV, we adopted a computational approach to screen for available commercial medicines which may function as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">M pro of 2019-nCoV.<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark></div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.31.929547\"><h2> Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model</h2></a> (<i>relevance: 0.72</i>)\n",
       "<h6> Beck, B. R.; Shin, B.; Choi, Y.; Park, S.; Kang, K.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> found in Wuhan of China (2019-nCoV) is rapidly spreading, and the incidence rate is increasing worldwide. Due to the lack of effective treatment options for 2019-nCoV, various strategies are being tested in China, including drug repurposing. In this study, we used our pretrained deep <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">learning<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of 2019-nCoV. The result showed that atazanavir, an antiretroviral medication used to treat and prevent the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human immunodeficiency virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), is the best chemical compound, showing a inhibitory potency with Kd of 94.94 nM against the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCoV 3C-like proteinase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, followed by <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">efavirenz<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (199.17 nM), <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">darunavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are all</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.25.965582\"><h2> Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19</h2></a> (<i>relevance: 0.72</i>)\n",
       "<h6> Ko, M.; Chang, S. Y.; Byun, S. Y.; Choi, I.; d'Alexandry d'Orengiani, A. L. P. H.; Shum, D.; Min, J.-Y.; Windisch, M. P.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Together, we identified 12 FDA-approved drugs that could be considered for repositioning to MERS-CoV or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> therapy. Especially the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cardiotonic drugs ouabain<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">digitoxin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">digoxin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with a TI greater than 100 in monotherapy or combined with remdesivir, a drug that is currently in clinical trials for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, or with other therapeutics, might lead to drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">synergism<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.71</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">order<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to further verify the screening results of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug database and utilize the current resource of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> immediately, we constructed a database of 78 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for deep calculation, including compounds already on the market and currently undergoing clinical trials to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.71</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">order<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to further verify the screening results of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug database and utilize the current resource of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> immediately, we constructed a database of 78 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for deep calculation, including compounds already on the market and currently undergoing clinical trials to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.31.929695\"><h2> Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases</h2></a> (<i>relevance: 0.7</i>)\n",
       "<h6> Lin, S.; Shen, R.; He, J.; Li, X.; Guo, X.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The trial fifth edition of diagnosis and treatment guideline of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> issued by National Health Commission of the People's Republic of China (http://www.nhc.gov.cn/) recommends to use Kaletra for treatment. Kaletra, an anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drug which is composed of two <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CAS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>#: 155213-67-5) and lopinavir (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CAS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>#: 192725-17-0), might have therapeutic effect on <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> diseases like <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and MERS [7] [8] [9] [10] . However, whether it can inhibit <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 or treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> lacks clinical evidences and randomized clinical trials, and the safety of its use in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients is unclear. Otherwise, Lanjuan <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Li<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> scientist, academician of Chinese Academy of Engineering, recommended <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">darunavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CAS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>#: 206361-99-1), also an <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV protease inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, as a treatment for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Although the inhibitory effect of darunavir on <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 has been verified in vitro, its therapeutic effect on <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is still unknown. At the same time, the mechanism of how these drugs inhibit <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 is also unknown.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.986836\"><h2> A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19</h2></a> (<i>relevance: 0.7</i>)\n",
       "<h6> Yiyue Ge; Tingzhong Tian; Suling Huang; Fangping Wan; Jingxin Li; Shuya Li; Hui Yang; Lixiang Hong; Nian Wu; Enming Yuan; Lili Cheng; Yipin Lei; Hantao Shu; Xiaolong Feng; Ziyuan Jiang; Ying Chi; Xiling Guo; Lunbiao Cui; Liang Xiao; Zeng Li; Chunhao Yang; Zehong Miao; Haidong Tang; Ligong Chen; Hainian Zeng; Dan Zhao; Fengcai Zhu; Xiaokun Shen; Jianyang Zeng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The outbreak of the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> named <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-CoV-2 (2019-nCoV) has infected over 110,000 people worldwide by 8th March, 2020. Apart from China, other countries or regions including South Korea, Iran, and Europe have reported a rapid increase in the number of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> cases, implying that this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> has posed a global health threat. Under the current circumstance of the absence of the specific vaccines and medicines against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2, it is urgent to discover effective therapies especially drugs to treat the resulting <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> disease and prevent the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> from further spreading. Considering that the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of a new drug generally takes years, probably the best therapeutic shortcut is to apply the drug repositioning strategy (i.e., finding the new uses of old drugs) [1, 2, 3] to identify the potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> effects against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 of existing drugs that have been approved for clinical use or to enter clinical trials. Those existing drugs with potent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> efficacy can be directly applied to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in a short time, as their safety has been verified in principle in clinical trials.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1097/CM9.0000000000000777\"><h2> Science in the fight against the novel coronavirus disease</h2></a> (<i>relevance: 0.69</i>)\n",
       "<h6> Wang, Jian-Wei; Cao, Bin; Wang, Chen</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Effective therapeutics and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are urgently needed to decrease <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> mortality. As specific therapies <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> 2019-nCoV are lacking, it may be useful to repurpose drugs already licensed for marketing or clinical trials to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients in an <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> response; researchers are actively working to identify such drugs. At the time of preparation of this manuscript, the Chinese Academy of Medical Sciences and the China-Japan Friendship Hospital had launched a multi-center, randomized, double-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, placebocontrolled clinical trial in Wuhan to test the effectiveness of remdesivir as an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against 2019-nCoV, [12, 13] and studies have already shown that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine phosphate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is an effective treatment for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. [14] Clinical trials are also underway to validate the effectiveness of various other licensed drugs against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.13.991307\"><h2> Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza</h2></a> (<i>relevance: 0.68</i>)\n",
       "<h6> Timothy R. Abbott; Girija Dhamdhere; Yanxia Liu; Xueqiu Lin; Laine Goudy; Leiping Zeng; Augustine Chemparathy; Stephen Chmura; Nicholas S. Heaton; Robert Debs; Tara Pande; Drew Endy; Marie La Russa; David B. Lewis; Lei S. Qi</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Notably, the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 RdRP gene<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IAV NA gene<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> that we <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> in our study are also the targets of two <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, Remdesivir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Remdesivir, created by Gilead Sciences (<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> code <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">GS-5734<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), is an <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRP inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> that was developed to treat Ebola and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Marburg virus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and has been reported to have <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against MERS and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 36-38 . Remdesivir is already administered for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> through compassionate use requests, and clinical trials for its use against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> have already started in the U.S.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.29.971093\"><h2> The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding.</h2></a> (<i>relevance: 0.68</i>)\n",
       "<h6> Mycroft-West, C. J.; Su, D.; Elli, S.; Guimond, S. E.; Miller, G. J.; Turnbull, J. E.; Yates, E. A.; Guerrini, M.; Fernig, D. G.; Andrade de Lima, M.; Skidmore, M. A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, there are no commercially available medicinal products designed to treat and/or prevent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> associated with the new <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> outbreak. Here, we describe preliminary tests for the ability of the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 S1 RBD to <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind heparin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>, an important prerequisite for the underpinning research related to the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">heparin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-based therapeutic.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3346/jkms.2020.35.e89\"><h2> The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR</h2></a> (<i>relevance: 0.68</i>)\n",
       "<h6> Lim, Jaegyun; Jeon, Seunghyun; Shin, Hyun Young; Kim, Moon Jung; Seong, Yu Min; Lee, Wang Jun; Choe, Kang Won; Kang, Yu Min; Lee, Baeckseung; Park, Sang Joon</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Unfortunately, no drug or vaccine has yet been approved to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus disease 2019<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) . Favipiravir, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, remdesivir and galidesivir could be good candidates as potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for the treatment. 2 And many clinical trials on anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs, LPV/r and experimental <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agent<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, remdesevir are in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> process in China (http://clinicaltrials.gov/show/NCT04261907, http://clinicaltrials.gov/show/NCT04255017). 2 There are reports that remdesevir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimalarial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> agent, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> effectively inhibited <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 in vitro. 3 If these clinical studies are successful, they can provide us with more efficient treatment options and suggest better choices for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> treatment in high-risk groups (elderly patients or patients with underlying diseases). </div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.67</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and could probably be used for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.67</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and could probably be used for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.25.965582\"><h2> Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19</h2></a> (<i>relevance: 0.67</i>)\n",
       "<h6> Ko, M.; Chang, S. Y.; Byun, S. Y.; Choi, I.; d'Alexandry d'Orengiani, A. L. P. H.; Shum, D.; Min, J.-Y.; Windisch, M. P.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In 2015, the Middle East respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (MERS-CoV) reached the Republic of Korea, resulting from nosocomial transmission, and was the largest epidemic outside of the Arabian Peninsula. To date, despite various strategies to identify CoV interventions, there are only limited therapeutic options available. To address these unmet medical needs, we used a South Korean MERS-CoV clinical isolate and screened 5,406 compounds, including US Food and Drug Administration (FDA)-approved drugs and bioactive molecules, confirmed 221 hits by dose-response curve analysis in the primary assay, and selected 54 hits with a therapeutic index (TI) greater than 6. Time-ofaddition studies with 12 FDA-approved drugs demonstrated that eight and four therapeutics act on the early-and late stages of the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral life cycle<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, respectively. Among the early acting drugs, three therapeutics with a TI greater than 100 were <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cardiotonic agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Together, our results identify potential therapeutic options for treatment of MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and could provide a basis for a wider range of coronaviruses, including the currently <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emerging coronavirus disease 2019<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) outbreak.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/jcm9030623\"><h2> Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review</h2></a> (<i>relevance: 0.67</i>)\n",
       "<h6> Pang, Junxiong; Wang, Min Xian; Ang, Ian Yi Han; Tan, Sharon Hui Xuan; Lewis, Ruth Frances; Chen, Jacinta I. Pei; Gutierrez, Ramona A.; Gwee, Sylvia Xiao Wei; Chua, Pearleen Ee Yong; Yang, Qian; Ng, Xian Yi; Yap, Rowena K. S.; Tan, Hao Yi; Teo, Yik Ying; Tan, Chorh Chuan; Cook, Alex R.; Yap, Jason Chin-Huat; Hsu, Li Yang</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Potential &amp; ongoing therapeutics trials of 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.Regeneron <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pharmaceuticals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has developed monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> to treat MERS that are now being tested in early <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> studies. A company spokesperson said that researchers have begun to identify similar <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> that might work against 2019-nCoV. With Ebola, it took Regeneron six months to develop candidate treatments and test them in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v12020244\"><h2> Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV</h2></a> (<i>relevance: 0.66</i>)\n",
       "<h6> Xu, Jiabao; Zhao, Shizhe; Teng, Tieshan; Abdalla, Abualgasim Elgaili; Zhu, Wan; Xie, Longxiang; Wang, Yunlong; Guo, Xiangqian</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Both <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 are CoVs; hence, the treatment strategies of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> could be relevant for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [74] . In 2003, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> was mainly treated by isolation of the patients, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hormones<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and symptomatic treatments, and many drugs such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">glucocorticoid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [29] and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> [75] . Now, isolation, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and symptomatic treatments are still mainly adopted for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> treatment. As effective drugs for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hormones<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and interferons can also be used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [74] . Lopinavir is one kind of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> used to treat <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>, with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> as a booster. Lopinavir and/or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has anti <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> activity in vitro. Hong Kong scholars found that, compared with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> alone, patients treated with lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> had lower risk of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acute respiratory distress syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ARDS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) or <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">death<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> caused by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV [76, 77] . Lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has also been clinically tested in treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and showed wonderfully effective treatment for some patients, but the general clinical effect has not been determined [78] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.idm.2020.02.001\"><h2> An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov)</h2></a> (<i>relevance: 0.65</i>)\n",
       "<h6> Tang, Biao; Bragazzi, Nicola Luigi; Li, Qian; Tang, Sanyi; Xiao, Yanni; Wu, Jianhong</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, there exist no vaccines or anti-viral treatments officially approved for the prevention or management of the disease. Anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">retroviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> drugs belonging to the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, including Lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, usually utilized for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV/AIDS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients, seem to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">exert<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> anti-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral effects<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> against coronaviruses. GS-734 (Remdesivir), a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogue <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-drug, originally developed against the Ebola and the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Marburg viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, has been recently suggested to be effective also against coronaviruses. Other potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceuticals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> include <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogues<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RNA synthesis inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Also, Umifenovir (Abidol), used for treating severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> cases, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-inflammatory drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and EK1 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">peptide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have been proposed as possible drugs against coronaviruses (Lu, 2020) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.idm.2020.02.001\"><h2> An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov)</h2></a> (<i>relevance: 0.65</i>)\n",
       "<h6> Tang, Biao; Bragazzi, Nicola Luigi; Li, Qian; Tang, Sanyi; Xiao, Yanni; Wu, Jianhong</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, there exist no vaccines or anti-viral treatments officially approved for the prevention or management of the disease. Anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">retroviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> drugs belonging to the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, including Lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, usually utilized for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV/AIDS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients, seem to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">exert<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> anti-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral effects<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> against coronaviruses. GS-734 (Remdesivir), a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogue <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-drug, originally developed against the Ebola and the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Marburg viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, has been recently suggested to be effective also against coronaviruses. Other potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceuticals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> include <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogues<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RNA synthesis inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Also, Umifenovir (Abidol), used for treating severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> cases, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-inflammatory drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and EK1 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">peptide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have been proposed as possible drugs against coronaviruses (Lu, 2020) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.idm.2020.02.001\"><h2> An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov)</h2></a> (<i>relevance: 0.65</i>)\n",
       "<h6> Tang, Biao; Bragazzi, Nicola Luigi; Li, Qian; Tang, Sanyi; Xiao, Yanni; Wu, Jianhong</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, there exist no vaccines or anti-viral treatments officially approved for the prevention or management of the disease. Anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">retroviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> drugs belonging to the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, including Lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, usually utilized for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV/AIDS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients, seem to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">exert<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> anti-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral effects<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> against coronaviruses. GS-734 (Remdesivir), a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogue <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-drug, originally developed against the Ebola and the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Marburg viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, has been recently suggested to be effective also against coronaviruses. Other potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceuticals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> include <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogues<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RNA synthesis inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Also, Umifenovir (Abidol), used for treating severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> cases, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-inflammatory drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and EK1 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">peptide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have been proposed as possible drugs against coronaviruses (Lu, 2020) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.29.971093\"><h2> The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding.</h2></a> (<i>relevance: 0.65</i>)\n",
       "<h6> Mycroft-West, C. J.; Su, D.; Elli, S.; Guimond, S. E.; Miller, G. J.; Turnbull, J. E.; Yates, E. A.; Guerrini, M.; Fernig, D. G.; Andrade de Lima, M.; Skidmore, M. A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The rapid spread of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 represents a significant challenge to global health authorities and, as there are no currently approved drugs to treat, prevent and/or mitigate its effects, repurposing existing drugs is both a timely and appealing strategy. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Heparin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, a well tolerated <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anticoagulant drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, has been used successfully for over 80 years with limited and manageable side effects. Furthermore, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">heparin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> belongs to a unique <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceuticals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that has effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antidotes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> available, which makes its use safer.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1128/mSphere.00422-18\"><h2> A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants</h2></a> (<i>relevance: 0.65</i>)\n",
       "<h6> Trombetta, Ryan P.; Dunman, Paul M.; Schwarz, Edward M.; Kates, Stephen L.; Awad, Hani A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In summary, we utilized an AK <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">release cytotoxicity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> assay-based <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HTS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and identified 4 drugs, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">daunorubicin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ketoconazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, rifapentine, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sitafloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, that display bactericidal potency against a stable hemB <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> strain (UAMS-1112). Identification of these drugs demonstrates the usefulness of this approach in identifying bactericidal agents against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and provides a strategy for drug repurposing to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> associated with S. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Among these drugs, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sitafloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> displayed the highest potential in treating such <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> due to its high therapeutic ratio and its significant effectiveness against S. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus biofilm<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in comparison to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gentamicin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which is the clinical standard for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">osteomyelitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Future studies will continue to screen drug and chemical libraries using the AK screen against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> but also investigate the efficacy and safety of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sitafloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in combination with clinically used <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in the treatment of established, implant-associated <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">osteomyelitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in a preclinical <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rodent<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> model (65) . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chemicals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and compound libraries. A library consisting of 853 FDA-approved drugs was purchased from <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Selleck<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> Chemical (Houston, TX). <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Daunorubicin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sitafloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and rifapentine were also obtained from Selleck Chemical. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ketoconazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gentamicin sulfate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were purchased from Alfa-Aesar (Ward Hill, MA). <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Antimicrobial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> stocks were prepared according to recommendations and stored at 20C.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11060485\"><h2> Hepatitis E Virus Drug Development</h2></a> (<i>relevance: 0.64</i>)\n",
       "<h6> Kinast, Volker; Burkard, Thomas L; Todt, Daniel; Steinmann, Eike</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Identification of novel therapy options can encompass several strategies. While some rely on de novo identification of compounds, another approach is to reuse already existing compounds, a process which is termed drug repurposing. Drug repurposing can generally be described as the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">idea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of using drugs or drug candidates for another than their primary indication. The pharmacokinetic and pharmacodynamic profile, including undesirable effects, is often already elucidated in vivo in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The current first choice of anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> treatment, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RBV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, is an example for a repurposed drug that was originally developed for treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory syncytial virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>) in infants [17] . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RBV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has not only been administered for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> but also against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral hemorrhagic fevers<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [18] and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> [19] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1007/s13238-020-00693-y\"><h2> Puzzle of highly pathogenic human coronaviruses (2019-nCoV)</h2></a> (<i>relevance: 0.64</i>)\n",
       "<h6> Li, Jing; Liu, Wenjun</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the early stages of an outbreak, most people do not have a reliable understanding of the susceptibility of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Looking <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">back<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> on the medications used to fight <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV, initially <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was recognized as a widely active <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that was effective against a range of RNA <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> but was of little use to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients. The in vitro activities of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> on the replication of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV are highly variable, depending on the type of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> used for assays. Many <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients were treated with a combination of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">corticosteroids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, given such poor prognosis linked to drug side effects (Cinatl et al., 2003a) . In some countries, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon alpha<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) is used in combination with <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immunoglobulin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> or <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">thymosin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and has a therapeutic effect (Zhao et al., 2003) . In addition, there are reports that <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon beta<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) is significantly better than <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and also that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">polyethylene glycol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-modified <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> prevented <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, reduced <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, and reduced histopathology during treatment (Cinatl et al., 2003b; Haagmans et al., 2004) . To identify potential drugs for 2019-nCoV, the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (Mpro) was modeled by Prof. Zihe Rao's group at Tsinghua University, Beijing, China. They selected a series of potential drugs which exist in the market or the selfbuilt database's high-cost medicinal compounds and medicinal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> sources database compounds. Thirty drug candidates, consisting of biologically active <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drugs, that have the potential to show therapeutic effects against 2019-nCoV, were chosen for testing for the clinical treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in patients infected with 2019-nCoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v12020244\"><h2> Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV</h2></a> (<i>relevance: 0.64</i>)\n",
       "<h6> Xu, Jiabao; Zhao, Shizhe; Teng, Tieshan; Abdalla, Abualgasim Elgaili; Zhu, Wan; Xie, Longxiang; Wang, Yunlong; Guo, Xiangqian</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">molecular markers for the identification of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and also help to develop new drugs against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1097/jcma.0000000000000270\"><h2> The outbreak of COVID-19: An overview</h2></a> (<i>relevance: 0.64</i>)\n",
       "<h6> Wu, Y. C.; Chen, C. S.; Chan, Y. J.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">1. Remdesivir: The experimental drug is a novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogue <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">prodrug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> by Gilead Sciences, Inc. It is an unapproved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> being developed for Ebola and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. In a case report on the first case of 2019-nCoV in the United States administering remdesivir for compassionate use on day 11 after illness resulted in decreasing viral loads in <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nasopharyngeal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oropharyngeal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> samples and the patient's clinical <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">condition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> improved. 9 However, randomized controlled trials are needed to determine the safety and efficacy of this drug for treatment of patients with 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. 2. Convalescent therapies (<mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plasma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> from recovered <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients): This strategy had been used to support passive immunization. Based on the studies from MERS, the therapeutic agents with potential benefits include convalescent <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plasma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon-beta<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> combination therapy, and lopinavir. 19 However, there are no experience on <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and no randomized controlled clinical trials for this management at present. 3. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>: lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> had been tried to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> disease with apparent favorable clinical response. 20 In vitro <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-associated coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> at 48 hours for lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was demonstrated at concentrations of 4 and 50 g/mL, respectively. A recent report found uncanny similarity of unique insertions in the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCoV spike protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> to <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1 gp120<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Gag<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. 21 Will anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs affect the 2019-nCoV treatment outcome? Further randomized controlled trials in patients with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are mandatory. 4. Vaccine: There is currently no vaccine available for preventing 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The spike <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> may serve as a vaccine candidate, but the effect to <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> requires further evaluation.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1097/JCMA.0000000000000270\"><h2> Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP)</h2></a> (<i>relevance: 0.64</i>)\n",
       "<h6> Wu, Yi-Chi; Chen, Ching-Sung; Chan, Yu-Jiun</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">1. Remdesivir: The experimental drug is a novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogue <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">prodrug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> by Gilead Sciences, Inc. It is an unapproved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> being developed for Ebola and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. In a case report on the first case of 2019-nCoV in the United States administering remdesivir for compassionate use on day 11 after illness resulted in decreasing viral loads in <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nasopharyngeal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oropharyngeal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> samples and the patient's clinical <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">condition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> improved. 9 However, randomized controlled trials are needed to determine the safety and efficacy of this drug for treatment of patients with 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. 2. Convalescent therapies (<mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plasma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> from recovered <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients): This strategy had been used to support passive immunization. Based on the studies from MERS, the therapeutic agents with potential benefits include convalescent <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plasma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon-beta<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> combination therapy, and lopinavir. 19 However, there are no experience on <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and no randomized controlled clinical trials for this management at present. 3. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>: lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> had been tried to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> disease with apparent favorable clinical response. 20 In vitro <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-associated coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> at 48 hours for lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was demonstrated at concentrations of 4 and 50 g/mL, respectively. A recent report found uncanny similarity of unique insertions in the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCoV spike protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> to <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1 gp120<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Gag<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. 21 Will anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs affect the 2019-nCoV treatment outcome? Further randomized controlled trials in patients with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are mandatory. 4. Vaccine: There is currently no vaccine available for preventing 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The spike <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> may serve as a vaccine candidate, but the effect to <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> requires further evaluation.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.64</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The first strategy is to test existing broad-spectrum anti-virals 18 . Interferons, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cyclophilin inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> used to treat <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> fall into this category. The advantages of these therapies are that their <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metabolic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> characteristics, dosages used, potential efficacy and side effects are clear as they have been approved for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. But the disadvantage is that these therapies are too &quot;broad-spectrum&quot; and cannot kill coronaviruses in a <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> manner, and their side effects should not be underestimated. The second strategy is to use existing molecular databases to screen for molecules that may have therapeutic effect on <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> 19, 20 . High-throughput screening makes this strategy possible, and new functions of many drug molecules can be found through this strategy, for example, the discovery of anti-<mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> drug lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The third strategy is directly based on the genomic information and pathological characteristics of different coronaviruses to develop new <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> drugs from <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">scratch<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.64</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The first strategy is to test existing broad-spectrum anti-virals 18 . Interferons, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cyclophilin inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> used to treat <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> fall into this category. The advantages of these therapies are that their <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metabolic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> characteristics, dosages used, potential efficacy and side effects are clear as they have been approved for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. But the disadvantage is that these therapies are too &quot;broad-spectrum&quot; and cannot kill coronaviruses in a <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> manner, and their side effects should not be underestimated. The second strategy is to use existing molecular databases to screen for molecules that may have therapeutic effect on <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> 19, 20 . High-throughput screening makes this strategy possible, and new functions of many drug molecules can be found through this strategy, for example, the discovery of anti-<mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> drug lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The third strategy is directly based on the genomic information and pathological characteristics of different coronaviruses to develop new <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> drugs from <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">scratch<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.2147/DDDT.S159767\"><h2> Computer-aided design of amino acid-based therapeutics: a review</h2></a> (<i>relevance: 0.64</i>)\n",
       "<h6> Farhadi, Tayebeh; Hashemian, Seyed MohammadReza</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the current study, all FDA-approved therapeutics (in 2018) were retrieved from DrugBank (https://www.drugbank. ca/biotech_drugs) and an analysis was conducted to compare their percentages. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-based therapies, gene or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-based therapies, vaccines, allergenics and <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell transplant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> therapies made up 8.05%, 0.17%, 2.64%, 16.20% and 0.14% of total approved therapeutics, respectively. Small-molecule drugs made up 72.76% of the approved therapeutics ( Figure 3 ).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.12688/f1000research.22211.2\"><h2> Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Kruse, Robert L.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Repurposing currently available <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> medications Ideal agents to fight 2019-nCoV would be approved small molecule drugs that could inhibit different aspects of the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral life cycle<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, ultimately inhibiting replication. Two classes of potential targets are <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral polymerases 28 and<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> 29 , both of which are components of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human immunodeficiency virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatitis C virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> regimens. Pilot clinical studies are already ensuing by desperate clinicians with various repurposed <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> medicines. This has been done in every viral outbreak previously with limited success, outside of case reports 30 . Indeed, during the Ebola outbreak, none of the repurposed small molecule drugs were definitively shown to improve the clinical course across all patients 31 . The 2019-nCoV could be different, and there are initial positive reports that lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which are <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, have some clinical efficacy against 2019-nCoV, similar to prior studies using them against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 32 . Research should continue to be undertaken to screen other clinically available <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> culture models of 2019-nCoV, in hopes that a drug candidate would emerge useful against the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that could be rapidly implemented in the clinic. One promising example could be remdesivir, which interferes with the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral polymerase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and has shown efficacy against MERS in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mouse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models 33 . For further information, reviews of previous drug repurposing efforts for coronaviruses are provided 34,35 . Though these repurposed medications may hold promise, it is still reasonable to pursue novel, 2019-nCoV specific therapies to complement potential repurposed drug candidates.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.12688/f1000research.22211.2\"><h2> Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Kruse, Robert L.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Repurposing currently available <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> medications Ideal agents to fight 2019-nCoV would be approved small molecule drugs that could inhibit different aspects of the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral life cycle<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, ultimately inhibiting replication. Two classes of potential targets are <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral polymerases 28 and<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> 29 , both of which are components of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human immunodeficiency virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatitis C virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> regimens. Pilot clinical studies are already ensuing by desperate clinicians with various repurposed <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> medicines. This has been done in every viral outbreak previously with limited success, outside of case reports 30 . Indeed, during the Ebola outbreak, none of the repurposed small molecule drugs were definitively shown to improve the clinical course across all patients 31 . The 2019-nCoV could be different, and there are initial positive reports that lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which are <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, have some clinical efficacy against 2019-nCoV, similar to prior studies using them against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 32 . Research should continue to be undertaken to screen other clinically available <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> culture models of 2019-nCoV, in hopes that a drug candidate would emerge useful against the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that could be rapidly implemented in the clinic. One promising example could be remdesivir, which interferes with the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral polymerase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and has shown efficacy against MERS in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mouse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models 33 . For further information, reviews of previous drug repurposing efforts for coronaviruses are provided 34,35 . Though these repurposed medications may hold promise, it is still reasonable to pursue novel, 2019-nCoV specific therapies to complement potential repurposed drug candidates.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Abstract <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 has caused tens of thousands of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and more than one thousand <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">deaths<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. There are currently no registered therapies for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Because of time consuming process of new drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, drug repositioning may be the only solution to the epidemic of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sudden infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. We systematically analyzed all the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> encoded by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 genes, compared them with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ligand<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> screening, a total of 21 targets (including two <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> targets) were screened against compound libraries including <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug database and our own database of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Structure and screening results of important targets such as <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">3-chymotrypsin-like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (3CLpro), Spike, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RNA-dependent RNA polymerase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>), and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">papain like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (PLpro) were discussed in detail. In addition, a database of 78 commonly used <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> including those currently on the market and undergoing clinical trials for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lead compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and targets for further in vitro and in vivo studies of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Abstract <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 has caused tens of thousands of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and more than one thousand <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">deaths<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. There are currently no registered therapies for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Because of time consuming process of new drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, drug repositioning may be the only solution to the epidemic of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sudden infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. We systematically analyzed all the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> encoded by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 genes, compared them with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ligand<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> screening, a total of 21 targets (including two <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> targets) were screened against compound libraries including <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug database and our own database of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Structure and screening results of important targets such as <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">3-chymotrypsin-like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (3CLpro), Spike, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RNA-dependent RNA polymerase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>), and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">papain like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (PLpro) were discussed in detail. In addition, a database of 78 commonly used <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> including those currently on the market and undergoing clinical trials for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lead compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and targets for further in vitro and in vivo studies of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.30.927889\"><h2> Machine intelligence design of 2019-nCoV drugs</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Nguyen, D. D.; Gao, K.; Wang, R.; Wei, G.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Wuhan <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, called 2019-nCoV, is a newly emerged <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that infected more than 9692 people and leads to more than 213 fatalities by January 30, 2020. Currently, there is no effective treatment for this epidemic. However, the viral protease of a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is well-known to be essential for its replication and thus is an effective drug target. Fortunately, the sequence identity of the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCoV protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and that of severe-acute respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV) is as high as 96.1%. We show that the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitor binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> sites of 2019-nCoV and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV are almost identical, which means all potential <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> chemotherapies are also potential 2019-nCoV drugs. Here, we report a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">family<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of potential 2019-nCoV drugs generated by a machine intelligence-based <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">generative network complex<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (GNC). The potential effectiveness of treating 2019-nCoV by using some existing <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs is also analyzed.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ijid.2020.02.018\"><h2> Discovery and development of safe-in-man broad-spectrum antiviral agents</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjrs, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">We have developed a database for safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> BSAAs, which is available at https://drugvirus.info/ (Figure 3) . The drug annotations were obtained from PubChem, DrugBank, DrugCentral, PubMed and clinicaltrials.gov databases ( Thus, safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> BSAAs may represent drug candidates for prophylaxis and treatment of 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ijid.2020.02.018\"><h2> Discovery and development of safe-in-man broad-spectrum antiviral agents</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjrs, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">We have developed a database for safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> BSAAs, which is available at https://drugvirus.info/ (Figure 3) . The drug annotations were obtained from PubChem, DrugBank, DrugCentral, PubMed and clinicaltrials.gov databases ( Thus, safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> BSAAs may represent drug candidates for prophylaxis and treatment of 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.03.20020263\"><h2> Network-based Drug Repurposing for Human Coronavirus</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">We posit that the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> PPIs provide an unbiased, rational roadmap for repurposing drugs for potential treatment of HCoVs in which they were not originally approved.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.25.965582\"><h2> Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Ko, M.; Chang, S. Y.; Byun, S. Y.; Choi, I.; d'Alexandry d'Orengiani, A. L. P. H.; Shum, D.; Min, J.-Y.; Windisch, M. P.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Our approach aimed to identify FDA-approved drugs and bioactives that could be promptly repositioned or developed, respectively, to treat MERS-CoV and potentially COVID-19-infected patients. In previously reported studies, small molecule libraries, including approximately 300 drugs with FDA-approval or in clinical <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, were screened against MERS-CoV (De Wilde et al., 2014; Dyall et al., 2014) . Here, our screening included 1,247 FDA-approved drugs, which covers approximately 60% of all FDA-approved compounds. As a result, we identified drugs that were not found in previous studies, indicating that there are still opportunities for identifying novel FDAapproved drugs and bioactives by screening larger compound libraries. Moreover, we corroborated four previously identified hits, including <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emetine dihydrochloride<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ouabain<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cycloheximide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and nelfinavir <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mesylate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. This strongly suggests that despite the use of different viral isolates, both our <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> assays and previously published screens reproducibly identified drugs that could be repurposed as potential therapeutic options for patients <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">suffering<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (Dyall et al., 2014) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1371/journal.pone.0194868\"><h2> MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Cong, Yu; Hart, Brit J.; Gross, Robin; Zhou, Huanying; Frieman, Matthew; Bollinger, Laura; Wada, Jiro; Hensley, Lisa E.; Jahrling, Peter B.; Dyall, Julie; Holbrook, Michael R.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, no prophylactic or therapeutic options are proven as effective interventions for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with MERS-CoV, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV), or any other coronaviruses. To rapidly identify potential therapeutic options against emerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, investigators have adopted the approach of screening existing licensed drugs for efficacy against novel viral pathogens. Screening licensed drugs could expedite the implementation of new medical countermeasures by providing an avenue for off-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">label<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> use of compounds shown to be useful for the treatment of specific <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11111064\"><h2> Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Wang, Xiaohuan; Xia, Shuai; Zou, Peng; Lu, Lu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In consideration of worldwide attention to recent ZIKV outbreaks, many efforts have been made to explore potential effective therapies. Currently, there is no approved practicable prophylactic vaccine, and eliminating <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Aedes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, the main vector of ZIKV, remains the primary preventive measure. The high throughput screening of already-approved drugs has been carried out to provide anti-ZIKV drug candidates [41] [42] [43] . By using this method, we found a potent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, Ery-Est, against ZIKV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.30.927889\"><h2> Machine intelligence design of 2019-nCoV drugs</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Nguyen, D. D.; Gao, K.; Wang, R.; Wei, G.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The present work makes use of a recently developed <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">generative network complex<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (GNC) 17 to explore potential <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> for curing 2019-nCoV. We generate anticoronaviral therapeutic candidates for 2019-nCoV and evaluate their druggable properties. We also examine the potential of repurposing <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, Aluvia and Norvir, for 2019-nCoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11040385\"><h2> Screening of an FDA-Approved Drug Library with a Two-Tier System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia Syndrome Virus</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Yuan, Shuofeng; Chan, Jasper Fuk-Woo; Ye, Zi-Wei; Wen, Lei; Tsang, Terance Gi-Wai; Cao, Jianli; Huang, Jingjing; Chan, Chris Chun-Yiu; Chik, Kenn Ka-Heng; Choi, Garnet Kwan-Yue; Cai, Jian-Piao; Yin, Feifei; Chu, Hin; Liang, Mifang; Jin, Dong-Yan; Yuen, Kwok-Yung</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">As exemplified by the recent epidemics caused by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and Middle East respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> coronaviruses, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zika virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, the de novo <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatments invariably lags behind the rapid progression of emerging viral outbreaks [28] [29] [30] . Thus, drug repurposing programs have been increasingly conducted to find clinically approved drugs with in vitro and/or in vivo activity against emerging <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> [31] . The candidate drug compounds identified in these drug repurposing programs have the advantages of being clinically available with known <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmacokinetics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, pharmacodynamics, and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">side effect<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> profiles. This information would facilitate more rapid <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of the repurposed drug compounds into clinical use. SFTSV is an emerging <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tick-borne bunyavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that causes severe disease in infected <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> with very limited <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment options. In this study, we established a robust two-tier drug screening platform and then used it to screen a drug library consisting 1528 FDA-approved drug compounds to successfully identify five drugs that were able to inhibit SFTSV replication at low micromolar levels. These included antibacterial and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antifungal disinfectants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (hexachlorophene and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">triclosan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">multi-kinase inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> for the treatment of advanced solid <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">organ tumors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (regorafenib), small molecule <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">agonist<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">c-mpl receptor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immune thrombocytopenic purpura<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aplastic anemia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (eltrombopag), and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiprotozoal agent<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">broxyquinoline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11040385\"><h2> Screening of an FDA-Approved Drug Library with a Two-Tier System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia Syndrome Virus</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Yuan, Shuofeng; Chan, Jasper Fuk-Woo; Ye, Zi-Wei; Wen, Lei; Tsang, Terance Gi-Wai; Cao, Jianli; Huang, Jingjing; Chan, Chris Chun-Yiu; Chik, Kenn Ka-Heng; Choi, Garnet Kwan-Yue; Cai, Jian-Piao; Yin, Feifei; Chu, Hin; Liang, Mifang; Jin, Dong-Yan; Yuen, Kwok-Yung</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">As exemplified by the recent epidemics caused by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and Middle East respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> coronaviruses, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zika virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, the de novo <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatments invariably lags behind the rapid progression of emerging viral outbreaks [28] [29] [30] . Thus, drug repurposing programs have been increasingly conducted to find clinically approved drugs with in vitro and/or in vivo activity against emerging <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> [31] . The candidate drug compounds identified in these drug repurposing programs have the advantages of being clinically available with known <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmacokinetics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, pharmacodynamics, and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">side effect<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> profiles. This information would facilitate more rapid <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of the repurposed drug compounds into clinical use. SFTSV is an emerging <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tick-borne bunyavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that causes severe disease in infected <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> with very limited <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment options. In this study, we established a robust two-tier drug screening platform and then used it to screen a drug library consisting 1528 FDA-approved drug compounds to successfully identify five drugs that were able to inhibit SFTSV replication at low micromolar levels. These included antibacterial and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antifungal disinfectants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (hexachlorophene and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">triclosan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">multi-kinase inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> for the treatment of advanced solid <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">organ tumors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (regorafenib), small molecule <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">agonist<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">c-mpl receptor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immune thrombocytopenic purpura<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aplastic anemia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (eltrombopag), and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiprotozoal agent<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">broxyquinoline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>). </div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2019.01327\"><h2> Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections</h2></a> (<i>relevance: 0.63</i>)\n",
       "<h6> Behzadi, Mohammad Amin; Leyva-Grado, Victor H.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">It also addresses the current therapies employing broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for the treatment of MERS-CoV-infected patients ( Table 1) . Greater advances have been achieved in the field of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Currently, three groups of drugs are approved for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, including the newly approved <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral polymerase inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> baloxavir marboxil and only one approved for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, the polyclonal palivizumab. Although effective, these drugs have limitations such as a reduced window of opportunity, potential to produce drug-resistant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and high cost (Palivizumab). This highlights the need for more and better <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to treat these <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. MERS-CoV recently emerged as a zoonotic <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and, therefore, no effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are approved for treatment.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11010059\"><h2> From SARS to MERS, Thrusting Coronaviruses into the Spotlight</h2></a> (<i>relevance: 0.62</i>)\n",
       "<h6> Song, Zhiqi; Xu, Yanfeng; Bao, Linlin; Zhang, Ling; Yu, Pin; Qu, Yajin; Zhu, Hua; Zhao, Wenjie; Han, Yunlin; Qin, Chuan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Despite the presence of extensive research reporting on <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and MERS-CoV therapies, it was not possible to establish whether treatments benefited patients during their outbreak. In the absence of fundamental, clinically proven, effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy against <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and MERS-CoV, patients mainly receive supportive care supplemented by diverse combinations of drugs. Several approaches are being considered to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV [113] and MERS-CoV (Table 4 , MERS-CoV-related table previously reviewed by de Wit et al. in Nature Reviews Microbiology, 2016 [10] ), including the use of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, IFNs, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of viral and <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> proteases.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.62</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The primary and secondary outcomes and safety indicators will be used to evaluate the efficacy and The clinical medicines used for the treatment and prevention of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are mainly M2 ion 77 channel blockers (for example, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and rimantadine) and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (NA) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 78 (for example, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) 6,7 . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, however, is prone to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">drug resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and 79 is only effective against the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> 8 . In addition, the treatment efficiency of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is lower than that of the NA <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Therefore, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is not recommended routinely for the antibacterial, anti-inflammatory and clearing heat-toxicity effects. The <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">root<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, or the whole <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, has 110 been widely been used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">colds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sore throat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bronchitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">malaria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> and other diseases 18 . system. To develop <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> into a <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> drug with less side effects that can be widely used in the 130 prevention and treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, an in-depth study needs to be conducted.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11040385\"><h2> Screening of an FDA-Approved Drug Library with a Two-Tier System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia Syndrome Virus</h2></a> (<i>relevance: 0.62</i>)\n",
       "<h6> Yuan, Shuofeng; Chan, Jasper Fuk-Woo; Ye, Zi-Wei; Wen, Lei; Tsang, Terance Gi-Wai; Cao, Jianli; Huang, Jingjing; Chan, Chris Chun-Yiu; Chik, Kenn Ka-Heng; Choi, Garnet Kwan-Yue; Cai, Jian-Piao; Yin, Feifei; Chu, Hin; Liang, Mifang; Jin, Dong-Yan; Yuen, Kwok-Yung</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Despite the clinical and public health importance of SFTSV, treatment options remain very limited. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> exhibits some inhibitory effects on SFTSV replication in vitro and in a <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">type I interferon receptor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>-deficient <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mouse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> model, but it was not found to be effective in a retrospective cohort of patients [2, 7] . Comparatively, favipiravir (T-705), an <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RNA-dependent RNA polymerase inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> with broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities, demonstrated higher in vitro and in vivo <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> effects against SFTSV. However, favipiravir is not clinically approved or readily available in many countries affected by SFTSV, including China. To identify drug compounds that can be used to treat patients or reduce the transmission of SFTSV, especially in the hospital setting, we conducted a drug repurposing program by screening a Food and Drug Administration (FDA)-approved drug library consisting of 1528 drug compounds. We first established a robust two-tier (ELISA followed by viral load reduction assay) screening platform for SFTSV. Using this drug screening platform, we identified five drug compounds with anti-SFTSV activity in vitro, and characterized the anti-SFTSV mechanism of the most potent drug, hexachlorophene, as an entry <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of SFTSV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v12020244\"><h2> Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV</h2></a> (<i>relevance: 0.62</i>)\n",
       "<h6> Xu, Jiabao; Zhao, Shizhe; Teng, Tieshan; Abdalla, Abualgasim Elgaili; Zhu, Wan; Xie, Longxiang; Wang, Yunlong; Guo, Xiangqian</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">More effective treatments are still under continuing exploration: On Jan. 25th, 2020, a <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">joint<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> research team from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Shanghai Tech University screened and identified 30 potential drugs that are reported to be effective against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 [79] . A high-resolution <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">crystal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> structure of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 coronavirus 3CL hydrolase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (Mpro) was announced after the outbreak of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in the world [80] , and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> coronaviruses (HCoVs) have been treated as severe pathogens in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory tract infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Nelfinavir was predicted to be a potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 main protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> [81] . The first patient in the US had been trial-treated with intravenous remdesivir (a novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogue <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">prodrug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>) due to a severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [82, 83] . No adverse reactions were observed during the administration, and the patient's <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">condition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> was effectively improved [84] . Clinical trials of remdesivir for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> just started on Feb. 5th and 12th, 2020 in Wuhan and Beijing, respectively, and the experimental results remain unclear [85, 86] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.62</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Two principles guided our screening work. The first is that the anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) components contained in the source <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> should be absorbable via <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> prescription. This principle requires that the herbs selected should contain biologically proven anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) ingredients, and that these <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> should pass the drug-likeness and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> bioavailability evaluations. Therefore, we conducted a three-step screening process. First, we extracted natural compounds verified in PubMed as being effective in treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or MERS <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and then cross-checked these compounds in the Chinese herbal databases. There were 115 overlapping compounds. This method was an expeditious way to identify natural components both preexisting in Chinese herbal treatment and having a high possibility of anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) activity. This is important, as the anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> effects of the selected compounds have been biologically confirmed, and the genetic similarities between <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or MERS <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are high [24, 25] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.62</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Two principles guided our screening work. The first is that the anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) components contained in the source <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> should be absorbable via <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> prescription. This principle requires that the herbs selected should contain biologically proven anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) ingredients, and that these <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> should pass the drug-likeness and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> bioavailability evaluations. Therefore, we conducted a three-step screening process. First, we extracted natural compounds verified in PubMed as being effective in treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or MERS <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and then cross-checked these compounds in the Chinese herbal databases. There were 115 overlapping compounds. This method was an expeditious way to identify natural components both preexisting in Chinese herbal treatment and having a high possibility of anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) activity. This is important, as the anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> effects of the selected compounds have been biologically confirmed, and the genetic similarities between <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or MERS <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are high [24, 25] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/molecules23071724\"><h2> Asymmetric Primaquine and Halogenaniline Fumardiamides as Novel Biologically Active Michael Acceptors</h2></a> (<i>relevance: 0.62</i>)\n",
       "<h6> Raji, Zrinka; Beus, Maja; Michnov, Hana; Vlaini, Josipa; Persoons, Leentje; Kosalec, Ivan; Jamplek, Josef; Schols, Dominique; Keser, Toma; Zorc, Branka</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Michael acceptors are present in other classes of drugs. Examples of such drugs are <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">entacapone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (antiparkinsonic) [7] , <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dimethyl fumarate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (antipsoriatic; since 2013 used in treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">multiple sclerosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) [5] , rupintivir (experimental <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human rhinoviruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>) [8] , <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">exemestane<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cytostatic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) [9] , and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ethacrynic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diuretic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) [10] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1007/s00335-018-9760-9\"><h2> Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice</h2></a> (<i>relevance: 0.61</i>)\n",
       "<h6> Cockrell, Adam S.; Leist, Sarah R.; Douglas, Madeline G.; Baric, Ralph S.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The ultimate goal for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mouse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> model <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> is capturing disease etiologies that closely reflect what is observed during <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, so the efficacy of various therapeutic countermeasures can be evaluated for effective resolution of pathogenic outcomes. A number of hCoV-directed drug, <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, and vaccine therapeutics were evaluated for efficacy against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV until 2012 when the focus of therapeutic <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> shifted to MERS-CoV [reviewed in (Dyall et al. 2017; Zumla et al. 2016) ]. Currently, there are no FDA-approved therapeutics for the specific treatment of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> or MERS-CoV. Various combinations/types of broad spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (e.g., <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) combined with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> therapies (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> or ), and/ or immune modulators (e.g., <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">corticosteroids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) were ineffective for <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and MERS-CoV, and in some cases appeared to worsen disease [reviewed in (Dyall et al. 2017; Zumla et al. 2016)] . A recent clinical trial seeks to interfere with MERS-CoV replication using a combination therapy that includes FDA-approved <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (Lopinavir/ <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) (https ://clini caltr ials.gov/ct2/show/study /NCT02 84584 3). Repurposing FDA-approved drugs has been the interest of numerous therapeutic studies, but little is known regarding the efficacy of drug therapeutics against <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> or MERS-CoV outside of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-based in vitro studies [reviewed in (Dyall et al. 2017) ]. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Mouse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models confer distinct advantages for therapeutic examination including cost savings through small scale production for testing, and experimental reproducibility.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/molecules23123346\"><h2> Drug Repurposing for Japanese Encephalitis Virus Infection by Systems Biology Methods</h2></a> (<i>relevance: 0.61</i>)\n",
       "<h6> Lv, Bo-Min; Tong, Xin-Yu; Quan, Yuan; Liu, Meng-Yuan; Zhang, Qing-Ye; Song, Yun-Feng; Zhang, Hong-Yu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Drug repurposing has recently become a very popular method for drug discovery; drug repurposing provides old drugs (including approved drugs, under research drugs, and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">withdrawn<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs) with new indications by exploring new molecular <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and targets [6, 7] . With this strategy, finding an alternative agent to treatment JEV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> will be <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fast<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> and safe. During the past decades, the traditional method for drug repurposing depends on high-throughput screening of small-molecule libraries consisting of approved and developing drugs [8]. However, the success rate of high-throughput screening for effective repurposed drugs has dropped dramatically [9] . With the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of computational methods, the high-throughput omics data, virtual screening, and text mining have been used for drug repurposing [9,10]. One of the computational methods for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> repurposing is to target pathogen to block its lifecycle. Using the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">crystal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> structure of the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">E protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and the strategy of structural-based virtual screening (SBVS), Leal et al. identified a compound exhibiting marked <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against DENV with its EC50 being 3.1 M [11] . The other methods for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> repurposing are <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> genes to inhibit pathogen <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Identifying the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> participating in the pathogen <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> process is the basis of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> drug repurposing approaches [9] . Quan et al. identified 170 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Mycobacterium tuberculosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Mtb<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-associated genes by theoretical genetic analysis, and obtained high potential anti-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Mtb<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drugs by <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> these genes [12] . Therefore, it is possible to rapidly identify effective therapeutics for JEV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> using the method of drug repurposing through <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> JEV-susceptible genes.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.25.965582\"><h2> Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19</h2></a> (<i>relevance: 0.61</i>)\n",
       "<h6> Ko, M.; Chang, S. Y.; Byun, S. Y.; Choi, I.; d'Alexandry d'Orengiani, A. L. P. H.; Shum, D.; Min, J.-Y.; Windisch, M. P.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Unfortunately, CoV-specific FDA-approved drugs are still not available in the clinics.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2017-021032\"><h2> Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC(4) E): the ALIC(4) E protocol</h2></a> (<i>relevance: 0.61</i>)\n",
       "<h6> Bongard, Emily; van der Velden, Alike W; Cook, Johanna; Saville, Ben; Beutels, Philippe; Munck Aabenhus, Rune; Brugman, Curt; Chlabicz, Slawomir; Coenen, Samuel; Colliers, Annelies; Davies, Melanie; De Paor, Muireann; De Sutter, An; Francis, Nick A; Glinz, Dominik; Godycki-wirko, Maciek; Goossens, Herman; Holmes, Jane; Ieven, Margareta; de Jong, Menno; Lindbaek, Morten; Little, Paul; Martinn-Torres, Frederico; Moragas, Ana; Pauer, Jzsef; Pfeiferov, Markta; Radzeviciene-Jurgute, Ruta; Sundvall, Pr-Daniel; Torres, Antoni; Touboul, Pia; Varthalis, Dionyssios; Verheij, Theo; Butler, Christopher C</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, the most suitable <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agent<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> available for pragmatic evaluation in ALIC 4 E is <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Tamiflu<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (NI). The US Food and Drug Administration (FDA) approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in 1999. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was classified by the WHO as an essential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> until 2017 7 8 , and many countries have stockpiles of the drug to ensure it is readily available to treat seasonal and pandemic <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 3 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.61</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Objective: In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and also contain compounds that might directly inhibit <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV), an ongoing <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that causes <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Methods: There were two main steps in the screening process. In the first step we conducted a literature search for natural compounds that had been biologically confirmed as against sever acute respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or Middle East respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Resulting compounds were cross-checked for listing in the Traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> Systems Pharmacology Database. Compounds meeting both requirements were subjected to absorption, distribution, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metabolism<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">excretion<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (ADME) evaluation to verify that <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> administration would be effective. Next, a <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> analysis was used to test whether the compound had the potential for direct 2019-nCoV <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> interaction. In the second step we searched Chinese herbal databases to identify <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> containing the selected compounds. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> containing 2 or more of the compounds identified in our screen were then checked against the catalogue for classic herbal usage. Finally, network pharmacology analysis was used to predict the general in vivo effects of each selected herb. Results: Of the natural compounds screened, 13 that exist in traditional Chinese medicines were also found to have potential anti-2019-nCoV activity. Further, 125 Chinese herbs were found to contain 2 or more of these 13 compounds. Of these 125 herbs, 26 are classically catalogued as treating viral <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Network pharmacology analysis predicted that the general in vivo roles of these 26 herbal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> were related to regulating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, immune/<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inflammation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> reactions and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hypoxia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> response. Conclusion: Chinese herbal treatments classically used for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral respiratory infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> might contain direct anti-2019-nCoV compounds.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.61</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Objective: In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and also contain compounds that might directly inhibit <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV), an ongoing <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that causes <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Methods: There were two main steps in the screening process. In the first step we conducted a literature search for natural compounds that had been biologically confirmed as against sever acute respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or Middle East respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Resulting compounds were cross-checked for listing in the Traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> Systems Pharmacology Database. Compounds meeting both requirements were subjected to absorption, distribution, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metabolism<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">excretion<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (ADME) evaluation to verify that <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> administration would be effective. Next, a <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> analysis was used to test whether the compound had the potential for direct 2019-nCoV <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> interaction. In the second step we searched Chinese herbal databases to identify <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> containing the selected compounds. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> containing 2 or more of the compounds identified in our screen were then checked against the catalogue for classic herbal usage. Finally, network pharmacology analysis was used to predict the general in vivo effects of each selected herb. Results: Of the natural compounds screened, 13 that exist in traditional Chinese medicines were also found to have potential anti-2019-nCoV activity. Further, 125 Chinese herbs were found to contain 2 or more of these 13 compounds. Of these 125 herbs, 26 are classically catalogued as treating viral <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Network pharmacology analysis predicted that the general in vivo roles of these 26 herbal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> were related to regulating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, immune/<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inflammation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> reactions and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hypoxia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> response. Conclusion: Chinese herbal treatments classically used for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral respiratory infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> might contain direct anti-2019-nCoV compounds.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1128/mSphere.00422-18\"><h2> A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants</h2></a> (<i>relevance: 0.61</i>)\n",
       "<h6> Trombetta, Ryan P.; Dunman, Paul M.; Schwarz, Edward M.; Kates, Stephen L.; Awad, Hani A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">easily be adapted for other drug/chemical libraries to identify compounds bactericidal against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. KEYWORDS <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Staphylococcus aureus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, small-colony variants, high-throughput screen, drug repurposing, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> D rug discovery is a crucial process to identify candidate compounds, molecules, and biologics that can potentially be developed into clinically effective therapeutics. However, this discovery process is costly and fraught with risk of frustrating failures. The associated costs of a successful drug launch can <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reach<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> $800 million in research and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> expenses, and the drug can take up to 15 years to develop (1, 2) . Despite these huge expenditures, nearly 86.2% of drug candidates that make it to phase 1 trials fail to achieve drug approval (3) . The time, costs, and high failure rate of drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> have prompted <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> companies to pursue alternative avenues for effective therapeutics. One promising avenue is drug repositioning or repurposing, which is the process of discovering new uses for existing drugs. Drugs that are Food and Drug Administration (FDA) approved and repurposed have the ability to go directly to preclinical and clinical trials, reducing the lengthy amount of time for preclinical drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and, thus, reducing costly risks of failure (4) . There are numerous examples of success using this repurposing approach, including screens that have identified candidate therapies for the ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Alzheimer's disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>, and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatitis C virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (5) (6) (7) (8) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1093/infdis/jiy285\"><h2> Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates</h2></a> (<i>relevance: 0.61</i>)\n",
       "<h6> Pascal, Kristen E; Dudgeon, Drew; Trefry, John C; Anantpadma, Manu; Sakurai, Yasuteru; Murin, Charles D; Turner, Hannah L; Fairhurst, Jeanette; Torres, Marcela; Rafique, Ashique; Yan, Ying; Badithe, Ashok; Yu, Kevin; Potocky, Terra; Bixler, Sandra L; Chance, Taylor B; Pratt, William D; Rossi, Franco D; Shamblin, Joshua D; Wollen, Suzanne E; Zelko, Justine M; Carrion, Ricardo; Worwa, Gabriella; Staples, Hilary M; Burakov, Darya; Babb, Robert; Chen, Gang; Martin, Joel; Huang, Tammy T; Erlandson, Karl; Willis, Melissa S; Armstrong, Kimberly; Dreier, Thomas M; Ward, Andrew B; Davey, Robert A; Pitt, Margaret L M; Lipsich, Leah; Mason, Peter; Olson, William; Stahl, Neil; Kyratsous, Christos A</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Background. For most classes of drugs, rapid <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of therapeutics to treat emerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is challenged by the timelines needed to identify compounds with the desired efficacy, safety, and pharmacokinetic profiles. Fully <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> (mAbs) provide an attractive method to overcome many of these hurdles to rapidly produce therapeutics for emerging diseases.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10090453\"><h2> Host-Directed Antivirals: A Realistic Alternative to Fight Zika Virus</h2></a> (<i>relevance: 0.61</i>)\n",
       "<h6> Saiz, Juan-Carlos; de Oya, Nereida Jimnez; Blzquez, Ana-Beln; Escribano-Romero, Estela; Martn-Acebes, Miguel A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A great <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">effort<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> is being lately made to find compounds to fight ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> by applying different approaches, from repurposing of drugs with known <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity to the screening of bioactive molecules from different libraries, as well as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. However, most of the already tested drugs have been found to inhibit <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> in vitro, and only a few have been tested in vivo. Hence, since, in many instances, the results will be difficult to extrapolate to <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, it would be hard for most of the tested <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to complete the entire drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> pipeline. In addition, it should be remarked that many drugs could have untoward effects and, thus, careful evaluation should be conducted before using them in clinical practice, as the main target populations for anti-ZIKV therapy will be pregnant women and patients with other medical complications.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.03.972133\"><h2> AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Tang, B.; He, F.; Liu, D.; Fang, M.; Wu, Z.; Xu, D.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The focused drug repurposing of known approved drugs (such as lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) has been reported failed for curing <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 infected patients. It is urgent to generate new chemical entities against this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. As a key enzyme in the life-cycle of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">3C-like main protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (3CL pro or M pro ) is the most attractive for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> design. Based on a recently solved structure (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PDB ID<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>: 6LU7), we developed a novel advanced deep Q-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">learning<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> network with the fragment-based drug design (ADQN-FBDD) for generating potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lead compounds targeting SARS-CoV-2 3CL pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> . We obtained a series of derivatives from those <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lead compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> by our structure-based optimization policy (SBOP). All the 47 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lead compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> directly from our AI-model and related derivatives based on SBOP are accessible in our molecular library at https://github.com/tbwxmu/2019-nCov. These compounds can be used as potential candidates for researchers in their <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of drugs against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.12688/f1000research.22211.2\"><h2> Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Kruse, Robert L.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In this article, I will outline different potential treatment options that could be pursued as a therapy for 2019-nCoV <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, keeping the focus on agents that could be rapidly tested in patients today and broadly effective in spite of limited knowledge of the biology of 2019-nCoV. Simply stated, there is limited time for basic studies of 2019-nCoV in research labs, while patients need effective therapies today. I finally propose the best potential treatment option in my opinion, along with instructions on how to manufacture the therapy for testing in patients today.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.12688/f1000research.22211.2\"><h2> Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Kruse, Robert L.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In this article, I will outline different potential treatment options that could be pursued as a therapy for 2019-nCoV <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, keeping the focus on agents that could be rapidly tested in patients today and broadly effective in spite of limited knowledge of the biology of 2019-nCoV. Simply stated, there is limited time for basic studies of 2019-nCoV in research labs, while patients need effective therapies today. I finally propose the best potential treatment option in my opinion, along with instructions on how to manufacture the therapy for testing in patients today.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/jcm9030623\"><h2> Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Pang, Junxiong; Wang, Min Xian; Ang, Ian Yi Han; Tan, Sharon Hui Xuan; Lewis, Ruth Frances; Chen, Jacinta I. Pei; Gutierrez, Ramona A.; Gwee, Sylvia Xiao Wei; Chua, Pearleen Ee Yong; Yang, Qian; Ng, Xian Yi; Yap, Rowena K. S.; Tan, Hao Yi; Teo, Yik Ying; Tan, Chorh Chuan; Cook, Alex R.; Yap, Jason Chin-Huat; Hsu, Li Yang</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">However, in the years following two major <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> outbreaks <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV in 2003 and MERS-CoV in 2012, there remains no consensus on the optimal therapy for either disease [116, 117] . Well-designed clinical trials that provide the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gold<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> standard for assessing the therapeutic measures are scarce. No <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> have successfully completed a preclinical <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> program despite large efforts exploring <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The bulk of potential therapeutic strategies remain in the experimental phase, with only a handful crossing the in vitro hurdle. Stronger efforts are required in the research for treatment options for major coronaviruses given their pandemic potential. Effective treatment options are essential to maximize the restoration of affected populations to good health following <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Clinical trials have commenced in China to identify effective treatments for 2019-nCoV based on the treatment evidence from <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and MERS. There is currently no effective specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with high-level evidence; any specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy should be provided in the context of a clinical study/trial. Few treatments have shown real curative action against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and MERS and the literature generally describes isolated cases or small case series.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.07.981928\"><h2> Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti-COVID-19 drug design</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Rut, W.; Groborz, K.; Zhang, L.; Sun, X.; Zmudzinski, M.; Hilgenfeld, R.; Drag, M.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In December 2019, the first cases of a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> infection were diagnosed in Wuhan, China. Due to international travel and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-to-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> transmission, the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> spread rapidly inside and outside of China. Currently, there is no effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, therefore research efforts are focused on the rapid <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of vaccines and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 M pro protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> constitutes one of the most attractive <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> targets. To address this emerging problem, we have synthesized a combinatorial library of fluorogenic substrates with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">glutamine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in the P1 position. We used it to determine the substrate preferences of the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 proteases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, using natural and a large panel of unnatural <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amino acids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The results of our work provide a structural framework for the design of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or diagnostic tests.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s12906-018-2163-3\"><h2> Taraxacum officinale and Urtica dioica extracts inhibit dengue virus serotype 2 replication in vitro</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Flores-Ocelotl, Mara R.; Rosas-Murrieta, Nora H.; Moreno, Diego A.; Vallejo-Ruiz, Vernica; Reyes-Leyva, Julio; Domnguez, Fabiola; Santos-Lpez, Gerardo</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Multiple studies have reported the discovery or obtaining of compounds with anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dengue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> properties [8, 16-18, 29, 42-47] , however, up to now there are no commercially available drugs for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dengue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41467-019-13659-4\"><h2> SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Gassen, Nils C.; Niemeyer, Daniela; Muth, Doreen; Corman, Victor M.; Martinelli, Silvia; Gassen, Alwine; Hafner, Kathrin; Papies, Jan; Msbauer, Kirstin; Zellner, Andreas; Zannas, Anthony S.; Herrmann, Alexander; Holsboer, Florian; Brack-Werner, Ruth; Boshart, Michael; Mller-Myhsok, Bertram; Drosten, Christian; Mller, Marcel A.; Rein, Theo</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">These results encouraged us to test other potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SKP2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Autophagy<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>-inducing, FDA-approved drugs and drugs from clinical trials were of particular interest as these could become more readily available for treatment in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Of note, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">valinomycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (VAL), which has been shown to target <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV in vitro 45, 56 , is also known to act as an <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SKP2 inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> 44 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/molecules23123346\"><h2> Drug Repurposing for Japanese Encephalitis Virus Infection by Systems Biology Methods</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Lv, Bo-Min; Tong, Xin-Yu; Quan, Yuan; Liu, Meng-Yuan; Zhang, Qing-Ye; Song, Yun-Feng; Zhang, Hong-Yu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">At present, the treatment of JEV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> mainly depends on symptomatic therapy and supportive therapy. Unfortunately, the effect of the existing treatment is far from perfect. Approximately 30-50% of survivors were reported to experience serious sequelae [2] . Although many drugs have been found to have anti-JEV activity, the evaluation of these drugs mainly focused on <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models and <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cellular<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> levels with few clinical trials reported. Therefore, it is it is necessary to rapidly identify effective therapeutics for JEV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> using the drug repurposing method. Furthermore, since JEV belongs to the same <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">genus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> as DENV and ZIKV, identifying the agents may provide treatment strategies for those <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> as well.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Whether the screened <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> really work on these targets needs further verification. We also do not recommend the application of new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to compounds for which no target has been predicted.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Whether the screened <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> really work on these targets needs further verification. We also do not recommend the application of new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to compounds for which no target has been predicted.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11100964\"><h2> Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Andersen, Petter I.; Krpina, Klara; Ianevski, Aleksandr; Shtaida, Nastassia; Jo, Eunji; Yang, Jaewon; Koit, Sandra; Tenson, Tanel; Hukkanen, Veijo; Anthonsen, Marit W.; Bjoras, Magnar; Evander, Magnus; Windisch, Marc P.; Zusinaite, Eva; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">To identify potential BSAAs, we have reviewed approved and investigational safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> using drug bank and clinical trials websites, respectively. In addition, we reviewed investigational and approved safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> antibacterial, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antifungal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiprotozoal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, antiemetic, etc. agents, for which <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities have been reported in PubMed. By excluding vaccines and interferons, we identified 108 molecules that inhibit the replication of several <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [16] . Most recently, novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities have been reported for some of these agents [17] . Forty-three compounds were used in this study, and their suppliers and catalogue numbers are summarized in Table S1 . To obtain 10 mM stock solutions compounds were dissolved in <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dimethyl sulfoxide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">DMSO<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, Sigma-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Aldrich<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Steinheim<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, Germany) or milli-Q <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">water<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The solutions were stored at 80  C until use.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11030274\"><h2> Ebola Virus Entry: From Molecular Characterization to Drug Discovery</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Salata, Cristiano; Calistri, Arianna; Alvisi, Gualtiero; Celestino, Michele; Parolin, Cristina; Pal, Giorgio</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Finally, by using a <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">VLP<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-based approach, the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anthelmintic drugs albendazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mebendazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have been reported to inhibit EBOV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [82] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the fight against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, scientists have come up with three strategies for developing new drugs 17 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the fight against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, scientists have come up with three strategies for developing new drugs 17 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11030274\"><h2> Ebola Virus Entry: From Molecular Characterization to Drug Discovery</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Salata, Cristiano; Calistri, Arianna; Alvisi, Gualtiero; Celestino, Michele; Parolin, Cristina; Pal, Giorgio</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Among CADs that have been proved to inhibit EBOV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in screening experiments, there are also the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antifungal drugs terconazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and triparanol, formerly used as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cholesterol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-lowering drugs, now <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">withdrawn<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> due to their numerous toxic side effects [85] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.03.20020263\"><h2> Network-based Drug Repurposing for Human Coronavirus</h2></a> (<i>relevance: 0.6</i>)\n",
       "<h6> Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Drug combinations, offering increased therapeutic efficacy and reduced toxicity, play an important role in treating various <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [61] . However, our ability to identify and validate effective combinations is limited by a combinatorial explosion, driven by both the large number of drug pairs and dosage combinations. In our recent study, we proposed a novel network-based methodology to identify clinically efficacious drug combinations [25] . Relying on approved drug combinations for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hypertension<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, we found that a drug combination was therapeutically effective only if it was captured by the 'Complementary Exposure' pattern: the targets of the drugs both hit the disease module, but target separate neighborhoods ( Figure 6A ). Here we sought to identify drug combinations that may provide a synergistic effect in treating HCoVs with welldefined mechanism-of-action by network analysis. For the 16 potential repurposable drugs ( Figure 5A) , we showcased three network-predicted candidate drug combinations in the potential treatment of HCoVs.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.986836\"><h2> A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Yiyue Ge; Tingzhong Tian; Suling Huang; Fangping Wan; Jingxin Li; Shuya Li; Hui Yang; Lixiang Hong; Nian Wu; Enming Yuan; Lili Cheng; Yipin Lei; Hantao Shu; Xiaolong Feng; Ziyuan Jiang; Ying Chi; Xiling Guo; Lunbiao Cui; Liang Xiao; Zeng Li; Chunhao Yang; Zehong Miao; Haidong Tang; Ligong Chen; Hainian Zeng; Dan Zhao; Fengcai Zhu; Xiaokun Shen; Jianyang Zeng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Notably, the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> efficacy of CVL218 even surpassed arbidol, which is one of the standard treatments for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in the Diagnosis and Treatment Protocol for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Novel Coronavirus Pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (Trial Version 6) promulgated by the Chinese government (http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df 351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf). In particular, arbidol inhibited <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 replication by 21.73% at 3 M, much lower than that of CVL218 at the same concentration ( Figure 2A ). In contrast, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (drugs used for preventing <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>) and baricitinib (JAK1/2 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which was recommended in [18] to treat showed no inhibitory activities against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 at the concentration of 3 M or 3.2 M.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1128/mSphere.00422-18\"><h2> A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Trombetta, Ryan P.; Dunman, Paul M.; Schwarz, Edward M.; Kates, Stephen L.; Awad, Hani A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">FDA-Approved Drugs Bactericidal against S. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and is not effective in preventing reoccurrence of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in cases of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">osteomyelitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (15) . Due to their reduced susceptibility to conventional <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, novel drug discovery and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> are essential for efficacious treatments against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-related <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. However, drug discovery is a notoriously slow, expensive, and high-risk process. Poor profitability and uncertain regulatory requirements for market approval have slowed discovery initiatives from large <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> companies, which led to a critical need to find new approaches for new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (45) (46) (47) . One such approach is drug repurposing, which enables an expedited and efficient strategy for identifying new applications for approved drugs to treat disease (48) . Incidentally, 30% of newly FDA-approved drugs are <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">repurposed agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (49) . Conventional high-throughput screens typically use whole-<mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, bacterial <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> assays, which makes screening very challenging due to the slow and abnormal <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> characteristics of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Hence, this study uses an AK <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">release<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>-based <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell death<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> reporter assay (35) for an <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HTS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of an FDA-approved Selleck drug library for <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bactericidal activity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> against S. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. We demonstrate the ability of this screening approach to identify 4 FDA-approved drugs, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">daunorubicin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ketoconazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, rifapentine, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sitafloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, as bactericidal drugs against S. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/ijms19103266\"><h2> Traditional Chinese Medicine as a Potential Source for HSV-1 Therapy by Acting on Virus or the Susceptibility of Host</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Li, Wen; Wang, Xiao-Hua; Luo, Zhuo; Liu, Li-Fang; Yan, Chang; Yan, Chang-Yu; Chen, Guo-Dong; Gao, Hao; Duan, Wen-Jun; Kurihara, Hiroshi; Li, Yi-Fang; He, Rong-Rong</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The emergence of drug resistant viral strains encourages the search for novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, including new chemical drugs, TCM, marine drug, etc. Drug sources and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">drug resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> have always been the restraining factors in the research and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-HSV-1 drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Several compounds have been already identified to inhibit <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in vitro and/or in vivo, thus efficient <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">synthesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> should be developed to produce enough bioactive agents to meet the needs of clinical researches. Opening new areas of resources, and exploring new methods and techniques are effective ways in solving the problem of drug source.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11020166\"><h2> Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> He, Lei; Tai, Wanbo; Li, Jiangfan; Chen, Yuehong; Gao, Yaning; Li, Junfeng; Sun, Shihui; Zhou, Yusen; Du, Lanying; Zhao, Guangyu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">(&gt;35%) (http://www.who.int/emergencies/mers-cov/en/). This situation calls for a consistent <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">effort<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> to develop effective countermeasures, including therapeutic <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> and vaccines, to prevent and treat MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.983056\"><h2> Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Rui Xiong; Leike Zhang; Shiliang Li; Yuan Sun; Minyi Ding; Yong Wang; Yongliang Zhao; Yan Wu; Weijuan Shang; Xiaming Jiang; Jiwei Shan; Zihao Shen; Yi Tong; Liuxin Xu; Chen Yu; Yingle Liu; Gang Zou; Dimitri Lavillete; Zhenjiang Zhao; Rui Wang; Lili Zhu; Gengfu Xiao; Ke Lan; Honglin Li; Ke Xu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Our data once again proved that DHODHi could further reduce <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cytokine storm<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> than <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">DAA drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> when using <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-A-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> infected <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> as a model. We believe that a similar immune-regulating role of DHODHi will exist in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients. Thus, by <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> DHODH, the single key enzyme in <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral genome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> replication and immuneregulation, a dual-action of DHODH can be realized in fighting against a broad spectrum of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and the corresponding pathogenic-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inflammation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. We hope our study may quickly and finally benefit the patients now <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">suffering<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> from severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">other infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by emerging and reemerging <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The copyright holder for this preprint (which was not peer-reviewed) is the . was kindly provided by Bo Zhang from Wuhan Virology Institute of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CAS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 52 . DHODH <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> S312 and S416 were synthesized using our previously reported synthetic routes 27, 53 . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Leflunomide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Teriflunomide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Brequinar<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Adenosine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Uridine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Cytidine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Guanosine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Orotic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, Dihydroorotate were purchased from Sigma-Aldrich. The copyright holder for this preprint (which was not peer-reviewed) is the . DHODH in the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> was 20 M, and the concentration of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in the syringe was 150 M for S312 or 100 M for S416. All titration experiments were performed by adding the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in steps of 2 L. The data were analyzed using Microcal origin software by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fitting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> to a one-site <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> model.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11111064\"><h2> Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Wang, Xiaohuan; Xia, Shuai; Zou, Peng; Lu, Lu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">To determine the ready-to-use <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, we screened a drug library consisting of FDA-approved medical drugs with good safety, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">erythromycin estolate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (Ery-Est), which could be safely used by pregnant women, was found to inhibit ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> efficiently. Ery-Est, one of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">macrolide antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, is the lauryl <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sulfate ester<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">propionyl erythromycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (Ery) ( Figure 1A) , and it has commonly been used for clinical <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacterial infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Besides, some <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">macrolide antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have been studied to treat a wide spectrum of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. For example, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">clarithromycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">macrolide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy have been utilized to treat <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory syncytial virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and Middle East respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (MERS-CoV) <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> respectively, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ivermectin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">azithromycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Azi<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) were identified to effectively inhibit ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [17] [18] [19] [20] [21] [22] [23] . To the best of our knowledge, this is the first time the anti-ZIKV activity of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ery-Est<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> has been reported. Its <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> effects in vitro and in vivo were also investigated in the present study. Furthermore, we explored the inhibitory mechanism of Ery-Est against ZIKV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.15171/ijoem.2020.1921\"><h2> The Novel Coronavirus: A Bird's Eye View</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Habibzadeh, Parham; Stoneman, Emily K.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">There are no vaccines or specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for 2019-nCoV. 39 Nonetheless, there are ongoing efforts for vaccine <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. 40 Remdesivir, an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> developed for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, was used for the treatment of the first US case of 2019-nCoV. 41 An ongoing randomized controlled trial evaluating the efficacy and safety of lopinavir-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon- 2b<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> in patients infected The <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Novel Coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> with the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> was launched on January 10, 2020. 42 However, isolation and supportive care including <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oxygen<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy, fluid management, and administration of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobials<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for treatment of secondary <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacterial infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> to alleviate the symptoms and prevent end-<mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">organ<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> dysfunction is currently recommended by WHO for suspected and confirmed cases requiring hospital admission. 43</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.04.934232\"><h2> Design of multi epitope-based peptide vaccine against E protein of human COVID-19: An immunoinformatics approach</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Abdelmageed, M. I.; Abdelmoneim, A. H.; Mustafa, M. I.; Elfadol, N. M.; Murshed, N. S.; Shantier, S. W.; Makhawi, A. M.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">At present, there is no vaccine or approved treatment for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, but Chinese traditional <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, such ShuFengJieDu Capsules and Lianhuaqingwen <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Capsule<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, could be possible treatments for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. However, there are no clinical trials approving the safety and efficacy for these drugs [22] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11080742\"><h2> Inhibitory Effects of Antiviral Drug Candidates on Canine Parvovirus in F81 cells</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Zhou, Hongzhuan; Su, Xia; Lin, Lulu; Zhang, Jin; Qi, Qi; Guo, Fangfang; Xu, Fuzhou; Yang, Bing</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In this study, which is aimed at identifying anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> drugs for potential therapeutic use, a CPE-based assay was developed for screening <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> from an FDA-approved drug library. After screening, the top three drugs, Nitazoxanide, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Closantel Sodium<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Closantel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, with higher percentage CPE <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, were selected and further confirmed by qPCR and IFA. In addition, the identified drugs can inhibit different subspecies of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> variants and displayed broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Hence, these drugs may provide potential options for the treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.05.936013\"><h2> Potentially highly potent drugs for 2019-nCoV</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Nguyen, D.; Gao, K.; Chen, J.; Wang, R.; Wei, G.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The World Health Organization (WHO) has declared the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> outbreak a global health <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Currently, there is no effective anti-2019-nCoV medication. The sequence identity of the 3CL proteases of 2019-nCoV and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is 96%, which provides a sound foundation for structural-based drug repositioning (SBDR). Based on a <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS 3CL protease X<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ray crystal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> structure, we construct a 3D homology structure of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCoV 3CL protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. Based on this structure and existing experimental datasets for <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS 3CL protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, we develop an SBDR model based on machine <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">learning<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and mathematics to screen 1465 drugs in the DrugBank that have been approved by the U.S. Food and Drug Administration (FDA). We found that many FDA approved drugs are potentially highly potent to 2019-nCoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10120678\"><h2> Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Cui, Qinghua; Cheng, Han; Xiong, Rui; Zhang, Gang; Du, Ruikun; Anantpadma, Manu; Davey, Robert A.; Rong, Lijun</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Although there is still no FDA approved therapy for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> use, several classes of anti-EBOV drugs are in preclinical or clinical <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> including but not limited to: <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antihistamines<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimuscarinics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">estrogen receptor antagonists<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">calcium<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-channel blockers, topical <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anesthetics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and selective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">serotonin reuptake inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [11, 30, 31] . In this study, we screened a small library of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bedaquiline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (an FDA approved second line anti-<mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tuberculosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> drug) derivatives for identification of </div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.983056\"><h2> Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Rui Xiong; Leike Zhang; Shiliang Li; Yuan Sun; Minyi Ding; Yong Wang; Yongliang Zhao; Yan Wu; Weijuan Shang; Xiaming Jiang; Jiwei Shan; Zihao Shen; Yi Tong; Liuxin Xu; Chen Yu; Yingle Liu; Gang Zou; Dimitri Lavillete; Zhenjiang Zhao; Rui Wang; Lili Zhu; Gengfu Xiao; Ke Lan; Honglin Li; Ke Xu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">When we prepared the manuscript, a severe outbreak of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 occurred in Wuhan in December 2019, we responded quickly to examine the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity of DHODHi against this new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The data in <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Fig. 2C<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> showed that all the DHODHi tested is low toxic to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 susceptible Vero E6 <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>. Teriflunomide had a solid <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> efficacy of EC50=26.06uM (at MOI=0.05, ~2.4-fold stronger than Favipiravir [EC50=61.88M] 29 ) (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Fig. 2C upper right<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) , whereas its <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-drug <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Leflunomide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> showed less <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of EC50=63.56uM (data not shown). We therefore further did immuno-florescent assay to visualize the drug efficacy. To determine more carefully the efficacy of Teriflunomide, which can be transferred to clinical treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 immediately as an approved drug, a bit low MOI of 0.03 (Fig. 2C upper left) were applied. In this <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">condition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, the EC50 of Teriflunomide could <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reach<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> 6M with SI&gt;33, indicating that Teriflunomide with effective EC50 and SI values have all the potentials to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2-induced <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> disease as an 'old drug in new use' option.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41598-018-37290-3\"><h2> Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Marrugal-Lorenzo, Jos A.; Serna-Gallego, Ana; Berastegui-Cabrera, Judith; Pachn, Jernimo; Snchez-Cspedes, Javier</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The repositioning of drugs already approved by regulatory agencies for other indications is an emerging alternative for the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapies. The repositioning process involves lower risks and costs than the de novo <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drugs. Currently, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adenovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> show a steady increment with a high clinical impact in immunosuppressed and immunocompetent patients. The lack of a safe and efficacious drug to treat these <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> supports the search for new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Here we evaluated the anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adenovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> activity of niclosanide, oxyclozanide, and rafoxanide, three salicylanilide anthelmintic drugs. Also, we carried out the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cytotoxicity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> evaluation and partial characterization of the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mechanism of action<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of these drugs. The salicylanilide anthelmintic drugs showed significant anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adenovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> activity at low micromolar concentrations with little <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cytotoxicity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Moreover, our mechanistic assays suggest differences in the way the drugs <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">exert<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adenovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> activity. Niclosamide and rafoxanide target <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">transport<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of the HAdV particle from the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">endosome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> to the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nuclear envelope<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, whilst oxyclozanide specifically targets <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adenovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> immediately early gene E1A transcription. Data suggests that the studied salicylanilide anthelmintic drugs could be suitable for further clinical evaluation for the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adenovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in immunosuppressed patients and in immunocompetent individuals with community-acquired <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/ijms20061463\"><h2> A Systematic Review of Phytochemistry, Pharmacology and Pharmacokinetics on Astragali Radix: Implications for Astragali Radix as a Personalized Medicine</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Guo, Zhenzhen; Lou, Yanmei; Kong, Muyan; Luo, Qing; Liu, Zhongqiu; Wu, Jinjun</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">As an effective and safe herbal drug widely used to treat various diseases, AR has played an indispensable role in healthcare in China and other countries. It is worth mentioning that AR is a popular herb frequently coadministered with many other herbal or chemical drugs for efficacy improvement in clinics. According to the historical literature and modern clinical reports, AR has been used as an essential ingredient in over 200 Chinese herb prescriptions for treating various complicated diseases. However, the potential risks of herb-herb or herb-drug interactions intensively exist during the combination therapy in clinics, which could easily cause an undesirable variation in the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plasma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> concentrations of coadministered drugs, thereby resulting in treatment failure or toxicologically unsafe consequences [254] [255] [256] . Therefore, the potential herb-herb or herb-drug interactions arising from the coadministration of AR and other herbal or chemical drugs must be evaluated. Further studies need to be conducted to confirm the safe combination therapy of AR.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.21.914929\"><h2> Novel ionophores active against La Crosse virus identified through rapid antiviral screening</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Sandler, Z. J.; Vu, M. N.; Menachery, V. D.; Mounce, B. C.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">compounds and identify novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is one means to accelerate drug discovery for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> 47 with no approved treatments. We used this approach to screen hundreds of compounds against 48 La <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Crosse virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, an emerging <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bunyavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that causes significant disease, including <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">encephalitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. 49</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">options for treating life-threatening zoonotic <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are very limited. Although the outbreaks of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in 2003 and MERS-CoV in 2012 triggered extensive research efforts, there are currently no drugs that can treat any zoonotic <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The transient nature of this epidemic is one of the major reasons why no prototypecoronavirus <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has progressed to the (early) preclinical stage to date. As with the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 17 years ago and the current <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2, emerging coronaviruses in the future may continue to pose a threat to global public health. Therefore, finding broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that may reduce the effects of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> infection remains a challenging research focus. Given the time-consuming nature of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drug development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and registration, existing treatments for other diseases may be the only fastest treatment option for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emerging infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. For most of these drugs that have been prepared, the medication has sufficient experience and dosage, and their safety and ADME situation are well known.In this study, based on the results of bioinformatics analysis, 20 homology structures of 18 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and 1 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> were built, plus <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> structure, totally 21 targets were setup for high throughput virtual <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ligand<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> screening. The special double scoring system <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ICM<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> soft allowed us to evaluate the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results more accurately. The score of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ICM<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> software is calculated by the overall empirical function of predicted physical interaction, whiles the mfScore (mean force Score) is computed by the knowledge-based potential functions derived from statistics of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ligand<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>-receptor complex in <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PDB50,51 .From<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> results, we can deduce that <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 Spike protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> have strong <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> affinity to <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, although weaker than that of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV Spike protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. Unexpectedly, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Bat-CoV RaTG13 Spike protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> only has slightly weaker <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> affinity with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> compared to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2. It is speculated that the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> may be capable of infecting <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> directly, or it is close. If <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 evolved from <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Bat-CoV RaTG13<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, there may be no more than one or two <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> evolutionsinvolved. But there are no published articles that directly related to intermediate <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hosts<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> yet. According to the most recent research paper on the clinical characteristics of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 52 , <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 can spread rapidly by <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-to-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> transmission, this was consistent with observed <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> results of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 Spike RBD and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, for both of ours and previous prediction 25 . However, the <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fast<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> growing incidents of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and related <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">deaths<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> implied the weaker <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 Spike with <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> ACE2 compared to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> Spike may not fully explained the current situation of this epidemic. There must have some other receptors of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> facilitating mechanisms in the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 Spike-RBD may take other lower <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">energy binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> conformation different from current <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV Spike-RBD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> conformation found in the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">crystal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> structure, probably by induce <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fitting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. These need to be further investigated.To search potential <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> therapeutic drugs as soon as possible, we first screened potential compounds from a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug database (2924 compounds) and a small in-house database of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (about 1066 compounds). A series of clinical drugs and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with anti-viral, anti-bacterial and anti-inflammatory effects exhibited high <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> affinity to different target <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, indicating their potential utility for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2.We have identified a number of compounds that might have anti-viral activity from the approved drugs library, such as anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> drugs (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, valganciclovir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">thymidine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-bacterial drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cefpiramide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sulfasalazine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, phenethicillin, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lymecycline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">demeclocycline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">doxycycline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, oxytetracycline and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tigecycline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">asthmatic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs (montelukast, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fenoterol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reproterol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), and hepatoprotective drug <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">silybin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The original pharmacological actions of these drugs could be helpful for the therapy of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infection pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, such as flavanoids like <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neohesperidin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hesperidin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">baicalin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">kaempferol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 3deoxy-11,12-didehydroandrographolide from <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Andrographis paniculata<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and a series of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">xanthones<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> from the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Swertia genus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, with anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inflammation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> activity could effectively interact with these targets of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2. Therefore, the herbal medicines containing these compounds as major components might be meaningful for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.For <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> target, although several compounds could <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> through virtual screening in our studies, no compound was found to <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> with the contact surface of ACE2-Spike complex, suggesting that these compounds are only the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2 enzyme<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> activities, rather than <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> driven <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Just like what described in recently published research 53 , most of selected compounds are also unable to <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> with the contact surface of ACE2-Spike complex. Actually, these potential <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2 inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> may not be suitable to use as drugs for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> because the poor prognosis would be induced by the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2 enzyme<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> activities, for <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> was considered as a protective factor of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lung<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> injury54 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">options for treating life-threatening zoonotic <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are very limited. Although the outbreaks of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in 2003 and MERS-CoV in 2012 triggered extensive research efforts, there are currently no drugs that can treat any zoonotic <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The transient nature of this epidemic is one of the major reasons why no prototypecoronavirus <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has progressed to the (early) preclinical stage to date. As with the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 17 years ago and the current <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2, emerging coronaviruses in the future may continue to pose a threat to global public health. Therefore, finding broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that may reduce the effects of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> infection remains a challenging research focus. Given the time-consuming nature of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drug development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and registration, existing treatments for other diseases may be the only fastest treatment option for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emerging infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. For most of these drugs that have been prepared, the medication has sufficient experience and dosage, and their safety and ADME situation are well known.In this study, based on the results of bioinformatics analysis, 20 homology structures of 18 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and 1 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> were built, plus <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> structure, totally 21 targets were setup for high throughput virtual <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ligand<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> screening. The special double scoring system <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ICM<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> soft allowed us to evaluate the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results more accurately. The score of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ICM<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> software is calculated by the overall empirical function of predicted physical interaction, whiles the mfScore (mean force Score) is computed by the knowledge-based potential functions derived from statistics of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ligand<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>-receptor complex in <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PDB50,51 .From<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> results, we can deduce that <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 Spike protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> have strong <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> affinity to <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, although weaker than that of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV Spike protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. Unexpectedly, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Bat-CoV RaTG13 Spike protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> only has slightly weaker <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> affinity with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> compared to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2. It is speculated that the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> may be capable of infecting <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> directly, or it is close. If <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 evolved from <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Bat-CoV RaTG13<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, there may be no more than one or two <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> evolutionsinvolved. But there are no published articles that directly related to intermediate <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hosts<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> yet. According to the most recent research paper on the clinical characteristics of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 52 , <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 can spread rapidly by <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-to-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> transmission, this was consistent with observed <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> results of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 Spike RBD and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, for both of ours and previous prediction 25 . However, the <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fast<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> growing incidents of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and related <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">deaths<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> implied the weaker <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 Spike with <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> ACE2 compared to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> Spike may not fully explained the current situation of this epidemic. There must have some other receptors of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> facilitating mechanisms in the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 Spike-RBD may take other lower <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">energy binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> conformation different from current <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV Spike-RBD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> conformation found in the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">crystal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> structure, probably by induce <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fitting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. These need to be further investigated.To search potential <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> therapeutic drugs as soon as possible, we first screened potential compounds from a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug database (2924 compounds) and a small in-house database of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (about 1066 compounds). A series of clinical drugs and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with anti-viral, anti-bacterial and anti-inflammatory effects exhibited high <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> affinity to different target <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, indicating their potential utility for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2.We have identified a number of compounds that might have anti-viral activity from the approved drugs library, such as anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> drugs (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, valganciclovir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">thymidine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-bacterial drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cefpiramide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sulfasalazine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, phenethicillin, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lymecycline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">demeclocycline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">doxycycline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, oxytetracycline and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tigecycline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">asthmatic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs (montelukast, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fenoterol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reproterol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), and hepatoprotective drug <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">silybin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The original pharmacological actions of these drugs could be helpful for the therapy of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infection pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, such as flavanoids like <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neohesperidin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hesperidin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">baicalin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">kaempferol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 3deoxy-11,12-didehydroandrographolide from <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Andrographis paniculata<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and a series of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">xanthones<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> from the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Swertia genus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, with anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inflammation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> activity could effectively interact with these targets of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2. Therefore, the herbal medicines containing these compounds as major components might be meaningful for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.For <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> target, although several compounds could <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> through virtual screening in our studies, no compound was found to <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> with the contact surface of ACE2-Spike complex, suggesting that these compounds are only the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2 enzyme<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> activities, rather than <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> driven <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Just like what described in recently published research 53 , most of selected compounds are also unable to <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> with the contact surface of ACE2-Spike complex. Actually, these potential <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2 inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> may not be suitable to use as drugs for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> because the poor prognosis would be induced by the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2 enzyme<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> activities, for <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> was considered as a protective factor of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lung<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> injury54 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.986836\"><h2> A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Yiyue Ge; Tingzhong Tian; Suling Huang; Fangping Wan; Jingxin Li; Shuya Li; Hui Yang; Lixiang Hong; Nian Wu; Enming Yuan; Lili Cheng; Yipin Lei; Hantao Shu; Xiaolong Feng; Ziyuan Jiang; Ying Chi; Xiling Guo; Lunbiao Cui; Liang Xiao; Zeng Li; Chunhao Yang; Zehong Miao; Haidong Tang; Ligong Chen; Hainian Zeng; Dan Zhao; Fengcai Zhu; Xiaokun Shen; Jianyang Zeng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">To demonstrate that our computational pipeline for drug repositioning can yield reasonably accurate prediction results, we also validated our network-based knowledge mining algorithm ( Figure 1B) using the retrospective data of the two coronaviruses that are closely related to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 and had been relatively well studied in the literature, i.e., <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and MERS-CoV. With the aid of our developed text mining tool BERE, we found that many of the drugs that had been reported previously in the literature to have <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities against the corresponding <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, were also among the top list of our predicted results ( Table 2) . For example, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, an FDA-approved drug for treating <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">malaria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> [7] , which was previously reported to exhibit micromolar <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> activity in vitro [8] , was also repurposed for <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> the same <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> by our prediction framework. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Gemcitabine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which was originally approved for treating certain types of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancers<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [9] , was also predicted for <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>-CoV with validation by previous in vitro studies [10] . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Cyclosporine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, a <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">calcineurin inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> approved as an immunomodulatory drug [11] , was observed to block the replication of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV [12] , and also successfully predicted by our approach. Among the predicted top list for MERS-CoV, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">miltefosine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which was approved for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">leishmaniasis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [13] , was previously identified to have anti-MERS-CoV activity [14] . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chlorpromazine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">imatinib<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which were used for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">schizophrenia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [15] and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">leukemia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [16] , respectively, were also selected by our computational pipeline as anti-MERS-CoV drugs and can be validated by previous in vitro experiments [10] . Thus, the above retrospective study illustrated that our computational framework is able to predict effective drug candidates against a specific <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s13567-019-0625-3\"><h2> Antiviral activity of itraconazole against type I feline coronavirus infection</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Takano, Tomomi; Akiyama, Misuzu; Doki, Tomoyoshi; Hohdatsu, Tsutomu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">However, none of drugs scientifically demonstrated to exhibit a therapeutic effect on <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">FIP<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are practically used. To solve these problems, it is desirable to identify a potent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agent<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for FCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> among drugs generally used for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cats<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1002/prp2.532\"><h2> Pharmacological plasticityHow do you hit a moving target?</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Parnham, Michael J.; Geisslinger, Gerd</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Apart from highly specific drugs such as monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, it may be worth reconsidering the rational approach to drug therapy, namely of using a single specific drug to hit a single target, like</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The clinical medicines used for the treatment and prevention of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are mainly M2 <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ion channel blockers<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> (eg, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and rimantadine) and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (NA) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (eg, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>). 6 7 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, however, is prone to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">drug resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and is only effective against the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. 8 In addition, the treatment efficiency of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is lower than that of the NA <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Therefore, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is not recommended routinely for the prevention and treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. NA <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, the main choice for the clinical treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, can specifically suppress both <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> A and B, but because of intensive use, viral strains resistant towards NA <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have also been found (including the pandemic H1N1 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>). NA <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> also have potential side effects on the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nervous system<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>. 9 Compared with Western <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, Chinese herbal medicines, widely used in Chinese clinics, can regulate multiple targets for treatment and can improve the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immune function<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, which is an advantage in relieving <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">upper respiratory tract<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> symptoms. 10 Considering the pandemic H1N1 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and other <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that may occur in the future, investigating the potential use of Chinese herbal medicines for the prevention and treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is of great research value.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.28.922922\"><h2> Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Li, Y.; Zhang, J.; Wang, N.; Li, H.; Shi, Y.; Guo, G.; Liu, K.; Zeng, H.; Zou, Q.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 Novel Coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) is a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> identified as the cause of the outbreak of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> first detected in Wuhan, China. Investigations on the transmissibility, severity, and other features associated with this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are ongoing. Currently, there is no vaccine or therapeutic <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> to prevent the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and more time is required to develop an effective immune strategy against the pathogen. In contrast, specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> the key protease involved in replication and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proliferation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are the most effective means to alleviate the epidemic. The main protease of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> is essential for the life cycle of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, which showed 96.1% of similarity with the main proteaseof 2019-nCoV, is considered to be an attractive target for drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. In this study, we have identified 4 small molecular drugs with high <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> capacity with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV main protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> by high-throughput screening based on the 8,000 clinical drug libraries, all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of 2019-nCoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v12020244\"><h2> Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV</h2></a> (<i>relevance: 0.59</i>)\n",
       "<h6> Xu, Jiabao; Zhao, Shizhe; Teng, Tieshan; Abdalla, Abualgasim Elgaili; Zhu, Wan; Xie, Longxiang; Wang, Yunlong; Guo, Xiangqian</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Does traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have any effect on the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2?</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10090453\"><h2> Host-Directed Antivirals: A Realistic Alternative to Fight Zika Virus</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Saiz, Juan-Carlos; de Oya, Nereida Jimnez; Blzquez, Ana-Beln; Escribano-Romero, Estela; Martn-Acebes, Miguel A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Current search for ZIKV <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is being conducted with different approaches: by screening of compounds libraries; by the repurposing of drugs of known active efficacy against other diseases now in use in clinical practice, many of which display broad-spectrum activity; and by testing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Two different strategies can be applied when pursuing for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, those searching for compounds directed to viral targets (direct-acting <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) and those aimed to target <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cellular<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> components needed for the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral life cycle<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (<mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-directed <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/jcm9030623\"><h2> Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Pang, Junxiong; Wang, Min Xian; Ang, Ian Yi Han; Tan, Sharon Hui Xuan; Lewis, Ruth Frances; Chen, Jacinta I. Pei; Gutierrez, Ramona A.; Gwee, Sylvia Xiao Wei; Chua, Pearleen Ee Yong; Yang, Qian; Ng, Xian Yi; Yap, Rowena K. S.; Tan, Hao Yi; Teo, Yik Ying; Tan, Chorh Chuan; Cook, Alex R.; Yap, Jason Chin-Huat; Hsu, Li Yang</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">There were two independent reviewers each focusing on <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, MERS, and 2019-nCoV, respectively. A third independent reviewer was engaged to resolve any conflicting article of interest. We used the key words &quot;<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>&quot;, &quot;<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>&quot;, &quot;MERS&quot;, &quot;<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 Novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>&quot;, &quot;Wuhan <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>&quot; to identify the diseases in the search strategy. The systematic searches for diagnosis, therapeutic drugs and vaccines were carried out independently and the key words &quot;drug&quot;, &quot;therapy&quot;, &quot;vaccine&quot;, &quot;diagnosis&quot;, &quot;point of care testing&quot; and &quot;rapid diagnostic test&quot; were used in conjunction with the disease key words for the respective searches.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41598-019-46666-y\"><h2> Selective and competitive inhibition of kynurenine aminotransferase 2 by glycyrrhizic acid and its analogues</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Yoshida, Yukihiro; Fujigaki, Hidetsugu; Kato, Koichi; Yamazaki, Kyoka; Fujigaki, Suwako; Kunisawa, Kazuo; Yamamoto, Yasuko; Mouri, Akihiro; Oda, Akifumi; Nabeshima, Toshitaka; Saito, Kuniaki</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">As a pharmacological agent, GL has anti-inflammatory 51,52 and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities 53 and inhibits <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatic fibrosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 54 and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tumour growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 55 . Following improvements in solubility, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Glycyrrhizin salts<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, such as diammonium glycyrrhizinate and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dipotassium glycyrrhizinate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, have anti-inflammatory effects that are similar to those of GL 56, 57 . Furthermore, drugs containing GL, such as stronger neo-minophagen C and glycyron tablets (Minophagen <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, Tokyo, Japan), are commercially available and have been used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic liver disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 58, 59 . Thus, the use of GL as a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">KAT2 inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">schizophrenia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> represents a drug repositioning process through which new therapeutic uses for existing drugs are discovered.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.00531\"><h2> Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Pizzorno, Andrs; Padey, Blandine; Terrier, Olivier; Rosa-Calatrava, Manuel</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently approved drugs for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.31.929547\"><h2> Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Beck, B. R.; Shin, B.; Choi, Y.; Park, S.; Kang, K.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In this study, we applied our pre-trained MT-DTI model to identify commercially available <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that could potentially disrupt 2019-nCoV's <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral components<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, such as <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteinase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RNA-dependent RNA polymerase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">and/or helicase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. Since the model utilizes simplified molecular-input line-entry system (SMILES) strings and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amino acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (AA) sequences, which are 1D string inputs, it is possible to quickly apply target <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that do not have experimentally confirmed 3D <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">crystal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> structures, such as viral <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of 2019-nCoV. We share a list of top commercially available <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that could potentially hinder the multiplication cycle of 2019-nCoV with the hope that effective drugs can be developed based on these AI-proposed drug candidates and act against 2019-nCoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10040152\"><h2> Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Cui, Qinghua; Du, Ruikun; Anantpadma, Manu; Schafer, Adam; Hou, Lin; Tian, Jingzhen; Davey, Robert A.; Cheng, Han; Rong, Lijun</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are considered to be a natural combinatorial chemical source because they contain structurally diversified bioactive chemicals, thus making them a valuable reservoir for new drug discovery. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or their direct derivatives account for 34% of new medicines approved by the US Food and Drug Administration (FDA) between 1981 and 2010 [3] . Traditional Chinese medicines (TCMs), which are mostly derived from <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, have been used in China and other countries/regions to treat various diseases for more than 2000 years, and are now gaining popularity in Europe and North America as complementary alternative treatments. A growing number of TCMs have been proven to have <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities with low toxicity and a few herbs have been approved by the China Food and Drug Administration to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> by <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, including <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">herpes simplex virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatitis B virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">enterovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory syncytial virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> [4] . Thus, TCMs represent an alternative source to identify novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapeutics.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2019.01327\"><h2> Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Behzadi, Mohammad Amin; Leyva-Grado, Victor H.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">To date, there are no licensed vaccines or therapeutics for prevention or treatment of MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and therapy is focused on supportive care to relive symptoms and in more severe cases to also support function of vital <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">organs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> (Modjarrad, 2016; Mustafa et al., 2018) . Since no specific treatment is available, supportive therapy and the use of broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are currently the options for treatment . A broad range of therapeutics have been used in the clinic to treat MERS-CoV-infected patients, and their use is based on knowledge obtained during the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) outbreak in 2003 and the recent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> pandemic in 2009 (Mo and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Fisher<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, 2016) . Furthermore, comprehensive clinical studies are lacking and only field data are available (Dyall et al., 2017) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ijid.2020.02.018\"><h2> Discovery and development of safe-in-man broad-spectrum antiviral agents</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjrs, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Clinical trials are the most critical and time-consuming step of a drug candidates' journey to being approved ( Figure 2C ). However, safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> BSAAs make this journey relatively short, because they have been already at phase 0, I and, sometime, at IIa of clinical trials as antibacterial, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiprotozoal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, anticancer, etc. agent; i.e. they have been administered at sub-therapeutic doses to healthy volunteers to ensure the drugs are not harmful to the participants. Thus, safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> BSAAs enter phase II and III, which assess the efficacy, effectiveness, safety and side effects of the drugs in clinic. It is important, however, to differentiate acute and chronic <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> when repurposing BSAAs, given that drug concentrations and duration of the treatment could be different, and therefore, drug safety issues should be considered. </div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/molecules23071599\"><h2> Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Yu, Fei; Li, Wen; Wang, Lili; Dai, Yu; Lu, Xin; Wang, Qian; Xie, Lan; Jiang, Shibo</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In summary, our results suggest that these newly identified NNRTIs can be used in combination with NRTIs, such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">AZT<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, as salvage therapy for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV/AIDS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients who have failed to respond to currently available antiretroviral drugs, or as anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV microbicides<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> for prevention of sexual <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> transmission.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s12906-018-2163-3\"><h2> Taraxacum officinale and Urtica dioica extracts inhibit dengue virus serotype 2 replication in vitro</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Flores-Ocelotl, Mara R.; Rosas-Murrieta, Nora H.; Moreno, Diego A.; Vallejo-Ruiz, Vernica; Reyes-Leyva, Julio; Domnguez, Fabiola; Santos-Lpez, Gerardo</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently there are no specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> compounds for the treatment, however, several research groups have sought <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> compounds by molecular <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> [5, 6] or using medicinal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to inhibit a viral target [7, 8] . Current treatment to severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dengue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is supportive fluid therapy under medical supervision [9] . Having no specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy or an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agent<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dengue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> treatment, different methods for prevention have been established by controlling the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mosquito reproduction<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> or spread [10, 11] . Due to the lack of new molecules, some clinical researches have proposed the repurposing of well-known drugs such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">prednisolone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, balapiravir, celgosivir, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lovastatin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, however, although those drugs are safe, they have not been successful at decreasing viral load, antigenemia, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> or inducing a beneficial effect to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dengue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients [12] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.sjbs.2016.09.020\"><h2> Middle East respiratory syndrome coronavirus (MERS-CoV): Impact on Saudi Arabia, 2015</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Faridi, Uzma</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">There is no specific treatment for the MERS-CoV till date, It was thought that the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> which target main protease and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">papain-like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> can be effective for MERS also (because both the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are from same beta-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">corona virus family<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) but those drugs are not 100% effective on MERS (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Lei<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> et al., 2014) . Although MERS-CoV can be inhibited by <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">type I interferons<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> in vitro but patients will not be cured completely. Some drugs like <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (plus IFNa2b) (Omrani et al., 2014) , <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cyclosporin A<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mycophenolic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chlorpromazine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">loperamide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and lopinavir inhibit MERS-CoV <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> in vitro but their activity on the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is yet to be established. However, they can be the future drugs for MERS-CoV. ''Prevention is better than Cure&quot; is the best proverb for MERS until we have the specific treatment for MERS. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Camel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> owners, health workers, and pilgrims are easiest targets for MERS-CoV so they should take extra precautions, like health workers should wear protective <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gears<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> like gloves and masks while treating the patients, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Camel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> owners should avoid direct contact with <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">camel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>'s <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">eye<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nasal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> fluid, and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">faeces<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>. Good <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> surveillance and control measures can prevent the major outbreak of MERS during mass gathering activities like Haj or Umrah. The Ministry of Health, Saudi Arabia has done a commendable job to overcome this serious issue by spreading awareness, proper diagnosis and treatment which clearly shows the significant fall in a number of cases reported.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.sjbs.2016.09.020\"><h2> Middle East respiratory syndrome coronavirus (MERS-CoV): Impact on Saudi Arabia, 2015</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Faridi, Uzma</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">There is no specific treatment for the MERS-CoV till date, It was thought that the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> which target main protease and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">papain-like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> can be effective for MERS also (because both the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are from same beta-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">corona virus family<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) but those drugs are not 100% effective on MERS (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Lei<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> et al., 2014) . Although MERS-CoV can be inhibited by <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">type I interferons<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> in vitro but patients will not be cured completely. Some drugs like <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (plus IFNa2b) (Omrani et al., 2014) , <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cyclosporin A<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mycophenolic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chlorpromazine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">loperamide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and lopinavir inhibit MERS-CoV <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> in vitro but their activity on the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is yet to be established. However, they can be the future drugs for MERS-CoV. ''Prevention is better than Cure&quot; is the best proverb for MERS until we have the specific treatment for MERS. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Camel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> owners, health workers, and pilgrims are easiest targets for MERS-CoV so they should take extra precautions, like health workers should wear protective <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gears<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> like gloves and masks while treating the patients, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Camel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> owners should avoid direct contact with <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">camel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>'s <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">eye<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nasal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> fluid, and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">faeces<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>. Good <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> surveillance and control measures can prevent the major outbreak of MERS during mass gathering activities like Haj or Umrah. The Ministry of Health, Saudi Arabia has done a commendable job to overcome this serious issue by spreading awareness, proper diagnosis and treatment which clearly shows the significant fall in a number of cases reported.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">For the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of medicines treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2, the fastest way is to find potential molecules from the marketed drugs. Once the efficacy is determined, it can be approved by the Green Channel or approved by the hospital ethics committee for rapid clinical treatment of patients. Herein, bioinformatics analysis on the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> encoded by the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> genes was systematically conducted, and the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 were compared with other coronaviruses, such as <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and MERS-CoV. We conducted homology modeling to build all possible <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> structures, including <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral papain like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (PLpro), main protease (3CLpro, also named <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">3-chymotrypsin-like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>), <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RNA-dependent RNA polymerase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>), <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">helicase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, Spike, etc. Further, we used these <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> relative <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> ACE2 and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">type-II transmembrane serine protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">TMPRSS2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) enzymes] as targets to screen <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> U. S Food and Drug Administration (FDA)-approved drug database (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug database, ZDD), our own database of traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (including reported common <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral components<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> from traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), and the database of commonly used <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (78 compounds) by virtual <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ligand<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> screening method. This study predicts a variety of compounds that may inhibit novel coronaviruses and provides scientists with information on compounds that may be effective. Subsequent validation of anti-viral effects in vitro and in vivo will provide useful information for clinical treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">For the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of medicines treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2, the fastest way is to find potential molecules from the marketed drugs. Once the efficacy is determined, it can be approved by the Green Channel or approved by the hospital ethics committee for rapid clinical treatment of patients. Herein, bioinformatics analysis on the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> encoded by the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> genes was systematically conducted, and the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 were compared with other coronaviruses, such as <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and MERS-CoV. We conducted homology modeling to build all possible <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> structures, including <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral papain like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (PLpro), main protease (3CLpro, also named <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">3-chymotrypsin-like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>), <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RNA-dependent RNA polymerase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>), <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">helicase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, Spike, etc. Further, we used these <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> relative <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> ACE2 and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">type-II transmembrane serine protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">TMPRSS2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) enzymes] as targets to screen <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> U. S Food and Drug Administration (FDA)-approved drug database (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug database, ZDD), our own database of traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (including reported common <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral components<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> from traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), and the database of commonly used <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (78 compounds) by virtual <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ligand<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> screening method. This study predicts a variety of compounds that may inhibit novel coronaviruses and provides scientists with information on compounds that may be effective. Subsequent validation of anti-viral effects in vitro and in vivo will provide useful information for clinical treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">While specific vaccines and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are the most effective methods to prevent and treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, there are not yet effective treatments that target the 2019-nCoV. <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of these treatments may require months or years, meaning that a more immediate treatment or control mechanism should be found if possible. Herbs used in traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> present a potentially valuable resource to this end. The effectiveness of herbal treatment to control <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">contagious disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> was demonstrated during the 2003 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) outbreak [3] . As such, the Chinese government is encouraging the use of herbal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in fighting this new <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. However, the application of herbal treatment is mainly guided by the type of herb (based on the catalogue of classic literature on herbs) and the patient's symptoms or signs. There is often not enough information to predetermine whether the herbs in question can directly target the viral cause, in other words, herbal usage is generally not guided by viral <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathology<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. We think more detailed knowledge about the direct <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> effects of different <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> would be greatly helpful to the doctors selecting them.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">While specific vaccines and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are the most effective methods to prevent and treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, there are not yet effective treatments that target the 2019-nCoV. <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of these treatments may require months or years, meaning that a more immediate treatment or control mechanism should be found if possible. Herbs used in traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> present a potentially valuable resource to this end. The effectiveness of herbal treatment to control <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">contagious disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> was demonstrated during the 2003 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) outbreak [3] . As such, the Chinese government is encouraging the use of herbal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in fighting this new <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. However, the application of herbal treatment is mainly guided by the type of herb (based on the catalogue of classic literature on herbs) and the patient's symptoms or signs. There is often not enough information to predetermine whether the herbs in question can directly target the viral cause, in other words, herbal usage is generally not guided by viral <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathology<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. We think more detailed knowledge about the direct <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> effects of different <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> would be greatly helpful to the doctors selecting them.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.12688/f1000research.22211.2\"><h2> Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Kruse, Robert L.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, despite an urgent need to find options to help these patients and preclude potential <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">death<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> therapy, and an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oligonucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> strategy <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">angiotensin-converting enzyme 2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>), fused to an <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immunoglobulin Fc domain<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (ACE2-Fc), providing a neutralizing <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> with maximal <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">breath<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> to avoid any viral escape, while also helping to recruit the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immune system<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> to build lasting <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immunity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. The ACE2-Fc therapy would also supplement decreased <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> levels in the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lungs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> during <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, thereby directly treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acute respiratory distress<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> pathophysiology as a third <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mechanism of action<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. The sequence of the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2-Fc protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> is provided to investigators, allowing its possible use in recombinant <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein expression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> systems to start producing drug today to treat patients under compassionate use, while <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">formal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.12688/f1000research.22211.2\"><h2> Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Kruse, Robert L.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, despite an urgent need to find options to help these patients and preclude potential <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">death<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> therapy, and an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oligonucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> strategy <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">angiotensin-converting enzyme 2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>), fused to an <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immunoglobulin Fc domain<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (ACE2-Fc), providing a neutralizing <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> with maximal <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">breath<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> to avoid any viral escape, while also helping to recruit the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immune system<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> to build lasting <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immunity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. The ACE2-Fc therapy would also supplement decreased <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> levels in the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lungs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> during <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, thereby directly treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acute respiratory distress<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> pathophysiology as a third <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mechanism of action<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. The sequence of the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2-Fc protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> is provided to investigators, allowing its possible use in recombinant <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein expression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> systems to start producing drug today to treat patients under compassionate use, while <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">formal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1177/2040206618764483\"><h2> Nucleosides for the treatment of respiratory RNA virus infections</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Jordan, Paul C; Stevens, Sarah K; Deval, Jerome</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In this review, we summarized the exciting advances in discovery and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogs as potential new treatments for respiratory RNA <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The medical need is high because very few drugs have been approved for the treatment of respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> despite worldwide health impacts attributed to them. The approved drugs include <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, peramivir, and favipiravir (Japan only) for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and palivizumab for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, all of which have limitations that prevent their widespread use in a therapeutic setting. Drug candidates intended for use against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rhinovirus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, such as the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">capsid inhibitor pleconaril<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> rupintrivir, have been tested in the clinic without success.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/cancers11010027\"><h2> Endolysosomal Ca(2+) Signalling and Cancer Hallmarks: Two-Pore Channels on the Move, TRPML1 Lags Behind!</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Faris, Pawan; Shekha, Mudhir; Montagna, Daniela; Guerra, Germano; Moccia, Francesco</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Only NED-19, tetrandrin and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">naringenin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were hitherto probed to halt <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tumor growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">vascularization<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>. Unfortunately, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tetrandrine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">naringenin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> may target multiple <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">signalling pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and are not approved for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> use worldwide [228] . However, the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">effort<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> to identify novel drugs to effectively treat a number of diseases associated to EL Ca 2+ -permeable channels, such as TPCs, is now coming of age and is predicted to rapidly enlarge our arsenal of selective TPC <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which could be also testable for anticancer treatments.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11080742\"><h2> Inhibitory Effects of Antiviral Drug Candidates on Canine Parvovirus in F81 cells</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Zhou, Hongzhuan; Su, Xia; Lin, Lulu; Zhang, Jin; Qi, Qi; Guo, Fangfang; Xu, Fuzhou; Yang, Bing</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is a widely distributed <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and contains at least three main subspecies: CPV-2a, CPV-2b, and CPV-2c [4, 6, 8] . Currently, commercial vaccines cannot provide complete protection against all <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> variants. Moreover, no effective drug is available to control <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> except for supportive and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">symptom<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-based care. Hence, it is important to develop an alternative treatment against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. In this study, we developed a CPE-based assay to screen <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> from a FDA-approved drug library, and successfully identified three FDA-approved <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. These drugs might provide potential treatment options for anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.14.988345\"><h2> SARS-CoV-2 invades host cells via a novel route: CD147-spike protein</h2></a> (<i>relevance: 0.58</i>)\n",
       "<h6> Ke Wang; Wei Chen; Yu-Sen Zhou; Jian-Qi Lian; Zheng Zhang; Peng Du; Li Gong; Yang Zhang; Hong-Yong Cui; Jie-Jie Geng; Bin Wang; Xiu-Xuan Sun; Chun-Fu Wang; Xu Yang; Peng Lin; Yong-Qiang Deng; Ding Wei; Xiang-Min Yang; Yu-Meng Zhu; Kui Zhang; Zhao-Hui Zheng; Jin-Lin Miao; Ting Guo; Ying Shi; Jun Zhang; Ling Fu; Qing-Yi Wang; Huijie Bian; Ping Zhu; Zhi-Nan Chen</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Therefore, intensive researches are urgently needed to elucidate the invasive mechanisms of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2, thereby providing a potential target for developing specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11060485\"><h2> Hepatitis E Virus Drug Development</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Kinast, Volker; Burkard, Thomas L; Todt, Daniel; Steinmann, Eike</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Figure 3. Overview of molecules/extracts with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The depicted molecules/extracts are classified according to the strategy that was used to identify them. So far, the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of only four drugs (Sofosbuvir, pegIFN-, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">silvestrol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) was approved in experimental settings beyond in vitro <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> culture systems. Both drugs in the clinics are used off-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">label<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and therefore have not been tested in clinical trials against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10110597\"><h2> Reverse Genetic Approaches for the Generation of Recombinant Zika Virus</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> vila-Prez, Gins; Nogales, Aitor; Martn, Vernica; Almazn, Fernando; Martnez-Sobrido, Luis</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Because the very recent emergence of ZIKV, there are not currently approved vaccines or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> available to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> by this important <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> pathogen. Therefore, the generation of prophylactic (vaccines) and therapeutic (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) options for the treatment of ZIKV are urgently required. The <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of ZIKV reverse genetic systems provide investigators with a powerful tool for the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of vaccines and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to counteract disease caused by this important <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> pathogen.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.983056\"><h2> Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Rui Xiong; Leike Zhang; Shiliang Li; Yuan Sun; Minyi Ding; Yong Wang; Yongliang Zhao; Yan Wu; Weijuan Shang; Xiaming Jiang; Jiwei Shan; Zihao Shen; Yi Tong; Liuxin Xu; Chen Yu; Yingle Liu; Gang Zou; Dimitri Lavillete; Zhenjiang Zhao; Rui Wang; Lili Zhu; Gengfu Xiao; Ke Lan; Honglin Li; Ke Xu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Acute <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, such as <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV, MERS-CoV, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zika virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and the very recent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 are an increasing and probably lasting global threat 1 . Broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (BSA) are clinically needed for the effective control of emerging and re-emerging viral <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. However, although great efforts have been made by the research community to discover therapeutic <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for coping with such <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergencies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, specific and effective drugs or vaccines with low toxicity have been rarely reported 2 . Thus, unfortunately, there is still no effective drugs for the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-CoV-2 at present, which outbreak in December 2019 firstly identified by several Chinese groups [3] [4] [5] , and now has quickly spread throughout China and to more than 90 other countries, infecting 101,923 patients and killing 3486 ones by March 7, 2020 6 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.23.20026963\"><h2> Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Weiliang Cao</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> was an batacoronavirus which was <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">transmitted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> by droplets and direct contact with a patient's <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">body fluids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, other ways of it transmission was unclear 8, 9 . Until 16 February 2020, the number of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients was more than 70 000, yet the number of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> was still rising 5 . However, there are still no effective treatment for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, the main treatment is symptomatic and supportive therapy to alleviate symptoms and maintain <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">organ<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> function in severe diseases 10 . Although some studies have reported that some drugs can be used against the 2019-nCov, these drugs still in the research stage 11 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fcimb.2019.00193\"><h2> Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Peyclit, Lucie; Baron, Sophie Alexandra; Rolain, Jean-Marc</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The emergence of new <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> mechanisms, the failure of classical <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in clinic, the decrease in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in the industry are all challenges that lead us to consider new strategies for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Indeed, in recent years controversy has intensified over strains resistant to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">carbapenem<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and/or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">colistin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Various therapeutic solutions are used to overcome administration of last line <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. In this context, drug repurposing, which consists of using a non-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> compound to treat multi-drug resistant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MDR<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>), is encouraged. In this review, we first report what may have led to drug repurposing. Main definitions, advantages and drawbacks are summarized. Three major methods are described: phenotypic, computational and serendipity. In a second time we will focus on the current knowledge in drug repurposing for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">carbapenem<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">colistin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-resistant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> with different studies describing repurposed compounds tested on Gram-negative <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Furthermore, we show that drug combination therapies can increase successful by drug repurposing strategy. In conclusion, we discuss the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> industries that have little interest in reprofiling drugs due to lack of profits. We also consider what a clinician might think of the indications of these uncommon biologists to treat <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MDR<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacterial infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and avoid therapeutic impasses.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2020.00298\"><h2> Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Du, Ning Wang; Jian, Shang; Shibo, Jiang; Lanying</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Although a variety of vaccines have been developed against <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and MERS-CoV, most of them are in the preclinical studies, and only several have been tested in clinical trials 4,5 (Du et al., 2016b; <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Cho<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> et al., 2018) . Nevertheless, no vaccines have been approved for the prevention of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and MERS in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, demonstrating the need to develop effective and safe vaccines to control current MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, or to be stockpiled for potential use against re-emerged <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV or SARSr-CoV. Particularly, effective and safe vaccines are urgently needed to prevent and control the current outbreak of 2019-nCoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Analysis of therapeutic targets for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B, https://doi.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Analysis of therapeutic targets for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B, https://doi.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/pathogens8040192\"><h2> Analysis of Resistance of Ebola Virus Glycoprotein-Driven Entry Against MDL28170, An Inhibitor of Cysteine Cathepsins</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Hoffmann, Markus; Kaufmann, Svenja Victoria; Fischer, Carina; Maurer, Wiebke; Moldenhauer, Anna-Sophie; Phlmann, Stefan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Multiple compounds have been shown to interfere with different steps of the EBOV lifecycle [34] , including <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cellular cysteine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> proteases [32, [35] [36] [37] [38] [39] . However, none of these compounds has been approved by regulatory agencies for treatment of EVD. The reasons for the lack of approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> include (i) unknown <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> efficacy in vivo (most data <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">stem<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> from in vitro experimentation), (ii) potential unwanted side-effects in patients, and (iii) potential <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> by the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> during treatment. Therefore, promising compounds and new targets for intervention should be characterized regarding the aforementioned points in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">order<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to identify new options for treatment of EVD.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s12931-018-0784-1\"><h2> The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Lambkin-Williams, Rob; Noulin, Nicolas; Mann, Alex; Catchpole, Andrew; Gilbert, Anthony S.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The two main classes of currently effective antiinfluenza drugs are the NA <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Relenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Tamiflu<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), peramivir (Rapivab) [153] and M2 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, although <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">drug resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> makes this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> unusable [154] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41598-019-56481-0\"><h2> In Vivo Activity of Amodiaquine against Ebola Virus Infection</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> DeWald, Lisa Evans; Johnson, Joshua C.; Gerhardt, Dawn M.; Torzewski, Lisa M.; Postnikova, Elena; Honko, Anna N.; Janosko, Krisztina; Huzella, Louis; Dowling, William E.; Eakin, Ann E.; Osborn, Blaire L.; Gahagen, Janet; Tang, Liang; Green, Carol E.; Mirsalis, Jon C.; Holbrook, Michael R.; Jahrling, Peter B.; Dyall, Julie; Hensley, Lisa E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Repurposing drugs continues to be of interest to the healthcare professional community for the treatment of emerging and re-emerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hemorrhagic fever viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> such as Ebola, Marburg, and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Lassa viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Extensive efforts to screen approved and established drugs for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity led to a panel of drugs with broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity profiles that are available, affordable, have well-characterized PK/safety profiles and could be used under the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> Use Authorization (EUA) mechanism 5, 6, 13, 14 . While a number of FDA-approved compounds have proven to be efficacious against EBOV in vitro or in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">murine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models of disease, clinical evaluation or evaluation in more relevant disease models, such as NHPs, has been limited.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.26.964882\"><h2> Structure of Mpro from COVID-19 virus and discovery of its inhibitors</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Peng, C.; Duan, Y.; Yu, J.; Wang, L.; Yang, K.; Liu, F.; Jiang, R.; Yang, X.; You, T.; Liu, X.; Yang, X.; Bai, F.; Liu, H.; Liu, X.; Guddat, L. W.; Xu, W.; Xiao, G.; Qin, C.; Shi, Z.; Jiang, H.; Rao, Z.; Yang, H.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">192 multi-drug targets in preventing <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. In further studies, selection and 193 characterization of drug-resistant mutants will help clarify the mode of cinanserin's action. 194 Discussion 195 Our <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">crystal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> structural and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> data have shown that the drug leads identified can <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> 196 to the substrate-<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> pocket of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19 virus M pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> , which is highly conserved among 197 all <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CoV M pro s.<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> This strongly supports our hypothesis that <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of a single <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 198 agent <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting M pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> or in combination with other potential therapies could provide an 199 effective first line of defense against all CoV-associated diseases. 200 In the last twenty years, new <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> agents have emerged to cause epidemics, such 201 as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and MERS 7 . The timely <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for clinical use 202 is extremely challenging because conventional drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> approaches normally 203 take years of investigations and cost billions of dollars. The repurposing of approved 204 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drugs and drug candidates provides an alternative approach to rapidly 205 identify potential drug leads to manage rapidly emerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-based 206</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2018.00750\"><h2> Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Nan, Yuchen; Zhang, Yan-Jin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The first antisense ON tested in clinical trials beginning in 1993 was designed to target <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">p53<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acute myelogenous leukemia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (Bayever et al., 1993) . As a medical milestone for the application of antisense technology, the first antisense drug (Fomivirsen) was approved by the FDA in 1998 for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cytomegalovirus retinitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immunodeficient<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients (Marwick, 1998; Wikipedia, 2017) . Since then, numerous antisense drugs have been tested in clinical trials for a variety of other <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> diseases. To date, five antisense compounds have received marketing authorization from the FDA, including Eteplirsen. Currently, more than 100 ongoing clinical trials of antisense compounds are listed on the website ClinicalTrials.gov (Godfrey et al., 2017) . However, compared with traditional drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, industrial <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of therapeutic siRNA, DNA-based ON, or ON analogs for control of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gene expression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> have been less successful, as exemplified by the removal of the first commercially available antisense drug, Fomivirsen, from the market.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fcimb.2019.00193\"><h2> Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Peyclit, Lucie; Baron, Sophie Alexandra; Rolain, Jean-Marc</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A drug <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is assigned to a molecule to describe and group similary together drugs because of their therapeutic use, their biochemical mechanism, by their way of action or their chemical structure. As defined by Waksman in 1947, &quot;an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is a chemical substance, produced by micro-organisms, which has the capacity to inhibit the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of and even to destroy <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and other micro-organisms&quot; (Mohr, 2016) . The current trend therefore seems to be <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">moving<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> away from this definition. Indeed, in recent years, drug repositioning seems to have been &quot;a promising field in drug discovery that identifies new therapeutic opportunities for existing drugs&quot; (Doan et al., 2011) . The common <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">idea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is that to accelerate discovery of new treatment, using old drugs that could potentially treat disease for which the treatments used no longer work or when we no longer have therapeutic solutions must be used (Langedijk et al., 2015) . Sir James Black, pharmacologist and Nobel laureate said in 1888: &quot;The most fruitful basis for the discovery of a new drug is to start with an old drug&quot; (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chen<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> et al., 2016) . It could help to overcome an initial bottleneck in drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> process. It may therefore be a better compromise between risk and reward than other approaches to drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (Ashburn and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Thor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, 2004) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In conclusion, this work has identified several Chinese medicinal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> classified as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-effective that might directly inhibit the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, 2019-nCoV. Additionally, we propose screening principles and methods which may provide guidance in screening <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> from other natural drug databases.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In conclusion, this work has identified several Chinese medicinal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> classified as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-effective that might directly inhibit the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, 2019-nCoV. Additionally, we propose screening principles and methods which may provide guidance in screening <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> from other natural drug databases.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.05.936013\"><h2> Potentially highly potent drugs for 2019-nCoV</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Nguyen, D.; Gao, K.; Chen, J.; Wang, R.; Wei, G.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Drug repositioning (also known as drug repurposing), which concerns the investigation of existing drugs for new therapeutic target indications, has emerged as a successful strategy for drug discovery due to the reduced costs and expedited approval procedures [3] [4] [5] . Several successful examples unveil its great values in practice: Nelfinavir, initially developed to treat the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human immunodeficiency virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), is now being used for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> treatments. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was firstly designed to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by type A <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza viral infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and is being used for Parkinson's disease later on [6] . In recent years, the rapid <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of drug-related datasets, as well as open data initiatives, has led to new developments for computational drug repositioning, particularly, structural-based drug repositioning (SBDR). Machine <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">learning<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, network analysis, and text mining and semantic inference are three major computational approaches commonly applied in drug repositioning [7] . The rapid accumulation of genetic and structural databases [8] , the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of low-dimensional mathematical representations of complex biomolecular structures [9, 10] , and the availability of advanced deep <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">learning<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> algorithms have made machine <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">learning<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>-based drug reposition a promising approach [7] . Considering the urgent need for anti-2019-nCoV drugs, a computational drug repositioning is one of the most feasible strategies for discovering 2019-nCoV drugs.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.02186\"><h2> Common Nodes of VirusHost Interaction Revealed Through an Integrated Network Analysis</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Bsl, Korbinian; Ianevski, Aleksandr; Than, Thoa T.; Andersen, Petter I.; Kuivanen, Suvi; Teppor, Mona; Zusinaite, Eva; Dumpis, Uga; Vitkauskiene, Astra; Cox, Rebecca J.; Kallio-Kokko, Hannimari; Bergqvist, Anders; Tenson, Tanel; Merits, Andres; Oksenych, Valentyn; Bjrs, Magnar; Anthonsen, Marit W.; Shum, David; Kaarb, Mari; Vapalahti, Olli; Windisch, Marc P.; Superti-Furga, Giulio; Snijder, Berend; Kainov, Denis; Kandasamy, Richard K.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Azithromycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, is an FDA-approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">macrolide family<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. It is also an investigational agent against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and experimental agent against EBOV, HRV-A, ZIKV, and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Cidofovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is an FDA-approved anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CMV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> drug. It is also investigational agent against AdV, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">BKV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, HPV, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, HSV-2, and experimental drug against B19V. Dibucaine is an FDAapproved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> local anesthetic. In addition, it is experimental anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-A, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-B, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-D, and EBOV agent. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Gefitinib<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is an FDA approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anticancer drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. It has also <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">BKV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CMV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and VACV. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Minocycline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is a broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and experimental anti-DENV, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">WNV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> agent. Oritavancin is a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">semisynthetic glycopeptide antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> used for the treatment of Gram-positive bacterial <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">skin infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. It also inhibits EBOV, MERS-CoV, and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pirlindole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antidepressant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which is also experimental anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-A, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-B, and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-D agent. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Azacitidine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is a chemical analog of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cytidine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which is used in the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">myelodysplastic syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. It is also an experimental anti-AdV, The measurements were repeated three times (p &lt; 0.05).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1128/mSphere.00422-18\"><h2> A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Trombetta, Ryan P.; Dunman, Paul M.; Schwarz, Edward M.; Kates, Stephen L.; Awad, Hani A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Drug repurposing offers an expedited and economical route to develop new clinical therapeutics in comparison to traditional drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Growthbased high-throughput screening is concomitant with drug repurposing and enables rapid identification of new therapeutic uses for investigated drugs; however, this traditional method is not compatible with microorganisms with abnormal <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> patterns such as <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Staphylococcus aureus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> small-colony variants (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>). <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> subpopulations are auxotrophic for key compounds in <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">biosynthetic pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, which result in low <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> rate. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV formation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is also associated with reduced <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> susceptibility, and the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>'s ability to revert to the normal <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> state is thought to contribute to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">recurrence<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of S. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Thus, there is a critical need to identify <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> agents that are potent against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">order<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to effectively treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Accordingly, here we describe adapting an <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adenylate kinase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (AK)-based <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell death<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> reporter assay to identify members of a Food and Drug Administration (FDA)approved drug library that display <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bactericidal activity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> against S. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Four library members, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">daunorubicin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ketoconazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, rifapentine, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sitafloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, exhibited potent <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV bactericidal activity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> against a stable S. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Further investigation showed that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sitafloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was potent against <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">methicillin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-susceptible and -resistant S. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, as well as S. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> within an established <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">biofilm<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Taken together, these results demonstrate the ability to use the AK assay to screen small-molecule libraries for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> bactericidal agents and highlight the therapeutic potential of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sitafloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to be repurposed to treat chronic S. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> associated with <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and/or <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">biofilm growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> states. IMPORTANCE Conventional <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> fail to successfully treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic osteomyelitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">endocarditis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and device-related and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">airway infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>. These recurring <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are associated with the emergence of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, which are recalcitrant to conventional <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Studies have investigated <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapies to treat <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-related <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> but have had little success, emphasizing the need to identify novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drugs. However, drug discovery is a costly and time-consuming process. An alternative strategy is drug repurposing, which could identify FDA-approved and wellcharacterized drugs that could have off-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">label<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> utility in treating <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. In this study, we adapted a high-throughput AK-based assay to identify 4 FDA-approved drugs, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">daunorubicin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ketoconazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, rifapentine, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sitafloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which display <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against S. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, suggesting an avenue for drug repurposing in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">order<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to effectively treat <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-related <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Additionally, this screening paradigm can Citation Trombetta RP, Dunman PM, Schwarz EM, Kates SL, Awad HA. 2018. A highthroughput screening approach to repurpose FDA-approved drugs for bactericidal applications against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Staphylococcus aureus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> small-colony variants. mSphere 3:e00422-18.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ijid.2020.02.018\"><h2> Discovery and development of safe-in-man broad-spectrum antiviral agents</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjrs, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the use of the drug in public, to surveil for rare effects (U.S Food and Drug Administration, 2018; Umscheid et al., 2011). Forty-eight safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> BSAAs undergo clinical studies as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. There are currently 21 compounds in phase I, 34 agents in phase II and 11 compounds in phase III clinical trials. For example, nitazoxanide, remdesivir and brincidofovir are under clinical investigations against different <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (one BSAAs were approved by FDA, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">EMA<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or other agencies. These BSAAs altogether target 15 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. For example, favipiravir, also known as T-705, was approved against FLUAV in Japan; <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cidofovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is an injectable <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> medication used as a treatment for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CMV retinitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in people with AIDS; <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, also known as tribavirin, is used for treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>; <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pleconaril<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is used against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">picornaviridae family<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, including <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">enterovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rhinovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>; and valacyclovir is used against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CMV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, EBV, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HBV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, HSV-2 and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">VZV infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.Twenty BSAAs are undergoing surveillance studies (phase IV). <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Azithromycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cyclosporine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ezetimibe<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mycophenolic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, nitazoxanide and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rapamycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> progressed to phase IV studies without approvals from</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ijid.2020.02.018\"><h2> Discovery and development of safe-in-man broad-spectrum antiviral agents</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjrs, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"># Contributed equally J o u r n a l P r e -p r o o f Highlights  We reviewed discovery and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> process of broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>.  We summarized the information on 119 safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> agents in freely accessible database.  Further studies will increase the number of broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, expand spectrum of their indications, and identify drug combinations for treatment of emerging and re-emerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ijid.2020.02.018\"><h2> Discovery and development of safe-in-man broad-spectrum antiviral agents</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjrs, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"># Contributed equally J o u r n a l P r e -p r o o f Highlights  We reviewed discovery and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> process of broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>.  We summarized the information on 119 safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> agents in freely accessible database.  Further studies will increase the number of broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, expand spectrum of their indications, and identify drug combinations for treatment of emerging and re-emerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fcimb.2019.00193\"><h2> Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Peyclit, Lucie; Baron, Sophie Alexandra; Rolain, Jean-Marc</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Question of drug repurposing remains rather wide. Although this seems to be a better solution, drug combinations can also lead to adverse interactions. First, toxic side effects can be increased. Then, concerning compound galenic, physicochemical interactions and differences in stability, solubility and conservation can result from the combination of two molecules making it incompatible. Formulation then becomes more complicated (Sun et al., 2016a) . On the other hand, we must change this <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">vision<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> where each drug belongs to only one box. Clinicians may have difficulty understanding why a biologist recommends the use of an anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-inflammatory drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to treat their <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cystic fibrosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patient's <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteremia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> rather than a last resort <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> they have always used. Communication in this <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sense<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> remains essential between health professionals and clinical studies to prove these activities are critical. However, with current knowledge on drug repurposing as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibacterial agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and the problematic to find an alternative therapeutic in some situations, screening of non-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in a &quot; la carte&quot; way can be an issue (Figure 4) . In the area of personalized <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, we could imagine a personalized <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> susceptibility testing in case of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by a highly resistant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacterium<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. If all last-line <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have been tested and appear insufficient to successfully treat the patient, testing non-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that are potentially active on the pathogen, alone or in combination with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, could help clinicians use these drugs. As previously reported by Kadri et al., these difficultto-threat <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> refer to <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that are resistant to all first-line <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. It represents less than 1% of isolates and those that are resistant to second-line <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are even rare (Kadri et al., 2018) . This solution, combined with monitoring of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">serum<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> levels and adverse events such as <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dialysis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of a nephrotoxic drug (Rolain and Baquero, 2016) , could offer great potential for treating a patient with this <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MDR bacterium<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>. The problem remains to be able to routinely test a large panel of molecules, in an automated, reproducible, and not too expensive way.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.4142/jvs.2018.19.6.788\"><h2> Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Choi, Joo-Hyung; Jeong, Kwiwan; Kim, Su-Mi; Ko, Mi-Kyeong; You, Su-Hwa; Lyoo, Young S.; Kim, Byounghan; Ku, Jin-Mo; Park, Jong-Hyeon</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Thus far, vaccination is the preferred method for prevention of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">FMDV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. However, the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immune response<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> takes 7 to 30 days [10] . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> using chemical compounds are easily synthesized and scaled up in bulk, and they can be stored for a long period because chemical compounds are more stable than biologics. In addition, it was reported that such agents act directly on <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> as <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RNA inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and are not specific to certain serotypes; thus, they may be administered to <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> use when <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">FMD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> occurs. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">FMD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> has never been eradicated and occurs in many countries in the world; regardless, research on <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to prevent and treat FMDVs is still limited.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3855/jidc.12425\"><h2> 2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Ralph, R.; Lew, J.; Zeng, T.; Francis, M.; Xue, B.; Roux, M.; Ostadgavahi, A. T.; Rubino, S.; Dawe, N. J.; Al-Ahdal, M. N.; Kelvin, D. J.; Richardson, C. D.; Kindrachuk, J.; Falzarano, D.; Kelvin, A. A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, supportive care is the only treatment option for patients with severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or MERS illness and there are no licensed therapeutics or vaccines. There are, however, several vaccine candidates as well as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> candidates for prophylactic and therapeutic treatment of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Mechanical ventilation and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pulmonary<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> rescue therapy were utilized for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> but have had limited benefit for MERS patients [32] . Extracorporeal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">membrane oxygenation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> has been employed for MERS though its use is limited due to numerous factors [26] . <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Renal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> replacement therapy has been used extensively in MERS treatment [25, 33, 34] . The efficacy of a variety of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapeutics has been investigated for MERS with limited success. Moderate improvements in clinical outcomes were noted in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">common marmosets<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> treated with a combination of lopinavir (LPV) and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (RTV) [35] . Additional investigations of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity in vitro have demonstrated that <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN beta<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFNb<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) had superior activity as compared to other <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> types [36, 37] . A randomized control trial investigating the efficacy of LPV/<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RTV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>-<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFNb<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> in MERS patients is currently ongoing [38] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fcimb.2019.00196\"><h2> Multiplex Platforms for the Identification of Respiratory Pathogens: Are They Useful in Pediatric Clinical Practice?</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Esposito, Susanna; Mencacci, Antonella; Cenci, Elio; Camilloni, Barbara; Silvestri, Ettore; Principi, Nicola</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">When multiplex assays are used, the benefits of determining which <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> agent(s) is (are) potentially responsible for an <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RTI<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are strongly limited by the low number of drugs that are active against the respiratory targets that are currently available on these diagnostic platforms. Presently, only drugs against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and atypical <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are licensed. Furthermore, it is debated that these drugs should be used in all the subjects <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">suffering<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> from <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> due to sensitive agents. The systematic use of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (European Center for Disease Prevention and Control, 2018) and baloxavir marboxil (Hayden et al., 2018) is not recommended for all the cases of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> because <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is frequently a mild disease, and the advantage of drug administration is limited to a marginal reduction in the disease duration. Consequently, the use of these drugs is reserved only for extremely severe cases, although their true efficacy in these cases has not been definitively demonstrated (Lessler et al., 2009; European Center for Disease Prevention and Control, 2018) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s12985-018-1023-6\"><h2> Inhibition of enterovirus 71 replication and viral 3C protease by quercetin</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Yao, Chenguang; Xi, Caili; Hu, Kanghong; Gao, Wa; Cai, Xiaofeng; Qin, Jinlan; Lv, Shiyun; Du, Canghao; Wei, Yanhong</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">No approved direct-acting <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is available for EV71 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> to date [15] . Thus, the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of effective anti-EV71 agent is quite urgent and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">possesses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> important significance. At present, the prevention of EV71 epidemics mainly depends upon public surveillance. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">type I interferon<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pleconaril<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are the common agents used to treat EV71 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [16, 17] . In addition, some compounds, such as rupintrivir [18, 19] , showed activity against EV71 in both <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell lines<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models; however, clinical applications are not yet available, therefore more efforts are needed to develop drugs to conquer EV71 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities of the 115 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were reportedly confirmed with enzyme-based (<mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-free) or <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-based experimental systems. To be utilized as a Chinese herbal <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, they must be absorbable via <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> prescription. Therefore, we performed ADME screening for the 115 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, reducing the number of candidates to 13.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities of the 115 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were reportedly confirmed with enzyme-based (<mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-free) or <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-based experimental systems. To be utilized as a Chinese herbal <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, they must be absorbable via <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> prescription. Therefore, we performed ADME screening for the 115 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, reducing the number of candidates to 13.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Intermediate and Widespread Treatment IND Applications to the FDA, 2010 to 2016 Also see Supplemental Figure 1. IND  investigational new drug. Adapted with permission from U.S. Food and Drug Administration (FDA) (43).CONCLUSIONS For patients with terminal or severe and debilitating illnesses who have few treatment options, the wait for approval of investigational therapeutics may be too long, and effective treatment may come too late to prevent severe debilitation or <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">death<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. The FDA has long had mechanisms to approve &quot;compassionate use&quot; for individual patients, but more recently has developed expanded access <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> for groups and entire classes of patients to access investigational treatments or, if enrolled in a latephase clinical trial, to continue treatment with an investigational drug or biologic after clinical trials are concluded and the treatment awaits final FDA approval. In addition, FDA mechanisms allow <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency release<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of investigational drugs and biologics in a declared public health <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">release<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> of unapproved drugs for patient populations carries special risks: larger patient populations may be exposed to drugs of unproven value, with unknown risks. In cases where <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> trials would be</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Intermediate and Widespread Treatment IND Applications to the FDA, 2010 to 2016 Also see Supplemental Figure 1. IND  investigational new drug. Adapted with permission from U.S. Food and Drug Administration (FDA) (43).CONCLUSIONS For patients with terminal or severe and debilitating illnesses who have few treatment options, the wait for approval of investigational therapeutics may be too long, and effective treatment may come too late to prevent severe debilitation or <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">death<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. The FDA has long had mechanisms to approve &quot;compassionate use&quot; for individual patients, but more recently has developed expanded access <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> for groups and entire classes of patients to access investigational treatments or, if enrolled in a latephase clinical trial, to continue treatment with an investigational drug or biologic after clinical trials are concluded and the treatment awaits final FDA approval. In addition, FDA mechanisms allow <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency release<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of investigational drugs and biologics in a declared public health <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">release<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> of unapproved drugs for patient populations carries special risks: larger patient populations may be exposed to drugs of unproven value, with unknown risks. In cases where <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> trials would be</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jmii.2020.02.001\"><h2> Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Lee, Ping-Ing; Hsueh, Po-Ren</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The next important factor to consider for the 2019-nCoV outbreak is our ability to contain the spread of this new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. There was a lag of three months between the commencement of the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> epidemic and the initiation of investigation by healthcare officials in 2003 in China. 10 Consequently, the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> spread to approximately 8100 people in 29 countries and resulted in 774 <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">deaths<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. 10 Since mild illness is uncommon in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and infected individuals are easily identifiable, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> could be contained effectively and eradicated without vaccination or effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy. 10 Currently, there are a limited number of studies from China that investigate the efficacy and potential of lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (Kaletra), a combination of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> used to treat and prevent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV/AIDS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, in the treatment of 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. 11 Other agents, including <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogues<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, remdesivir, umifenovir (arbidol), <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tenofovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> disoproxil (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">TDF<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lamivudine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (3TC), along with several Chinese traditional medicines, are reported as viable options for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> pathogenic <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. 11 Clinical efficacy of remdesivir for the treatment of the first US case of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by 2019-nCoV was recently reported. 12 However, these data are derived from preliminary stages of studies and are insufficient to support the implementation for clinical use in treatment of 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. 11, 12 The severe lack of information during the initial stage of the 2019-nCoV outbreak posed challenges to and complicated the containment of the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in specific limited areas. A higher proportion of mild 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> facilitates rapid spreading of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Present efforts for containment may not be completely effective. However, we can hope that these efforts may delay the spread of 2019-nCoV, and provide us with sufficient time to develop effective vaccines and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jmii.2020.02.001\"><h2> Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Lee, Ping-Ing; Hsueh, Po-Ren</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The next important factor to consider for the 2019-nCoV outbreak is our ability to contain the spread of this new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. There was a lag of three months between the commencement of the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> epidemic and the initiation of investigation by healthcare officials in 2003 in China. 10 Consequently, the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> spread to approximately 8100 people in 29 countries and resulted in 774 <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">deaths<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. 10 Since mild illness is uncommon in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and infected individuals are easily identifiable, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> could be contained effectively and eradicated without vaccination or effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy. 10 Currently, there are a limited number of studies from China that investigate the efficacy and potential of lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (Kaletra), a combination of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> used to treat and prevent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV/AIDS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, in the treatment of 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. 11 Other agents, including <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogues<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, remdesivir, umifenovir (arbidol), <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tenofovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> disoproxil (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">TDF<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lamivudine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (3TC), along with several Chinese traditional medicines, are reported as viable options for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> pathogenic <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. 11 Clinical efficacy of remdesivir for the treatment of the first US case of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by 2019-nCoV was recently reported. 12 However, these data are derived from preliminary stages of studies and are insufficient to support the implementation for clinical use in treatment of 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. 11, 12 The severe lack of information during the initial stage of the 2019-nCoV outbreak posed challenges to and complicated the containment of the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in specific limited areas. A higher proportion of mild 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> facilitates rapid spreading of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Present efforts for containment may not be completely effective. However, we can hope that these efforts may delay the spread of 2019-nCoV, and provide us with sufficient time to develop effective vaccines and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.29.971093\"><h2> The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding.</h2></a> (<i>relevance: 0.57</i>)\n",
       "<h6> Mycroft-West, C. J.; Su, D.; Elli, S.; Guimond, S. E.; Miller, G. J.; Turnbull, J. E.; Yates, E. A.; Guerrini, M.; Fernig, D. G.; Andrade de Lima, M.; Skidmore, M. A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The subfractionation of existing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">heparin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> preparations against <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anticoagulant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities (with proven low-toxicity profiles, good bioavailability and industrial-scale manufacturing) for off-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">label<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> pathologies, provides an attractive strategy for quickly and effectively responding to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and for the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of next generation <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">heparin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-based therapeutics.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2019.01327\"><h2> Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Behzadi, Mohammad Amin; Leyva-Grado, Victor H.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Given the inherit limitations of these currently approved compounds and the potential risk for the arising of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, there is still an urgent need for developing new anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs. These novel drugs should have some (ideally all) of the following characteristics: effective when delivered late in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, low propensity for developing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, broad activity (<mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> and B), improved effectiveness compared to the standard of care, and can be easily administered in uncomplicated as well as complicated cases of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (Koszalka et al., 2017; Shaw, 2017) . Next, we will summarize the most advanced (phase 2 and 3 clinical trials), promising drug candidates.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1002/prp2.532\"><h2> Pharmacological plasticityHow do you hit a moving target?</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Parnham, Michael J.; Geisslinger, Gerd</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">cines or drugs. With global concern awakened by recent epidemics of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Severe Acute Respiratory Syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, Ebola and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zika viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, the need for effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has become more urgent. The most promising way forward with the most capricious of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, such as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human immunodeficiency virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), appears to be to hit the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> at different sites with multivalent vaccines.17 This multi-barreled approach has also proved effective in the drug therapy of <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>. With a combination of drugs, including non-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide reverse transcriptase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, and viral entry <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, the introduction of Highly Active Anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Retroviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Therapy, composed of at least three different drugs, has effectively reduced the mutation rate and enabled many <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronically HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-infected patients to live relatively normal lives.18 Such combination therapy directed at a specific viral target is also under extensive investigation for the therapy of other viral infec-If the target is not specific and the use of the therapeutic armament is too indiscriminate, like a shotgun, the long-term therapeutic outcome can be potentially worse than the disease originally <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. This was the case in the 1960s, when the indiscriminate</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.986836\"><h2> A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Yiyue Ge; Tingzhong Tian; Suling Huang; Fangping Wan; Jingxin Li; Shuya Li; Hui Yang; Lixiang Hong; Nian Wu; Enming Yuan; Lili Cheng; Yipin Lei; Hantao Shu; Xiaolong Feng; Ziyuan Jiang; Ying Chi; Xiling Guo; Lunbiao Cui; Liang Xiao; Zeng Li; Chunhao Yang; Zehong Miao; Haidong Tang; Ligong Chen; Hainian Zeng; Dan Zhao; Fengcai Zhu; Xiaokun Shen; Jianyang Zeng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In this study, we applied a data-driven framework that combines both machine <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">learning<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and statistical analysis methods to systematically integrate large-scale available <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-related data and identify the drug candidates against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 from a set of over 6000 drug candidates (mainly including approved, investigational and experimental drugs). Our in silico screening process followed by experimental validation revealed that a poly-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ADP<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-ribose polymerase 1 (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PARP1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, CVL218, currently in Phase I clinical trial, may serve as a potential drug candidate to treat Our in vitro assays demonstrated that CVL218 can exhibit effective inhibitory activity against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 replication in a dose-dependent manner and with no obvious <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cytopathic effect<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. In addition, we found that in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human peripheral blood mononuclear cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (PBMCs), CVL218 is able to suppress the CpG-induced production of IL-6, which has been reported previously to be of high relevance to the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral pathogenesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, especially for those intensive care unit (ICU) patients infected by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2. Further in vivo pharmacokinetic and toxicokinetic studies in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rats<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">monkeys<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> showed that CVL218 was highly distributed in the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lung tissue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and no apparent sign of toxicity was observed, which makes it an appealing potential drug candidate for the treatment of the novel <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Moreover, our molecular <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> study suggested that CVL218 may <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> to the N-terminal domain of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleocapsid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> (N) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, providing a possible mode of its <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> action against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2. Based on the data present in this study and previous</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.04.934232\"><h2> Design of multi epitope-based peptide vaccine against E protein of human COVID-19: An immunoinformatics approach</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Abdelmageed, M. I.; Abdelmoneim, A. H.; Mustafa, M. I.; Elfadol, N. M.; Murshed, N. S.; Shantier, S. W.; Makhawi, A. M.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Although both <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">flu<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs are used currently in China for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine phosphate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, an old drug for treatment of <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">malaria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>, has recently found to have apparent efficacy and acceptable safety against 79] ; nevertheless more studies are required to standardize these therapies. In addition, there has been some success in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mouse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models of MERS-CoV and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and candidate vaccines where the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">envelope (E) protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> is mutated or deleted have been described [80] [81] [82] [83] [84] [85] [86] . To best of our knowledge, this is the first study to identify certain <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">peptides<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">envelope (E) protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> as candidates for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Accordingly, these epitopes were strongly recommended as promising epitopes vaccine candidate against <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">T cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10060294\"><h2> The Interplay of Viral and Host Factors in Chikungunya Virus Infection: Targets for Antiviral Strategies</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Wong, Kai Zhi; Chu, Justin Jang Hann</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Despite the significant healthcare threat posed by the CHIKV, there are still no available vaccines or therapeutics for CHIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [1, 35] . Patients are usually given analgesics and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-inflammatory drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to relieve symptoms. Even though there are a number of anti-CHIKV compounds being reported, precise mechanistic data of these compounds, as well as efficacy studies in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mouse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models, are lacking. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are the only two drugs that have been tested in clinical trials [40] . Despite having promising in vitro data, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was found to be ineffective in clinical trials [41, 42] . On the other hand, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was found to be effective in alleviating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic symptoms<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. However, the clinical trial cohort (20 patients) was too small to provide conclusive evidence [43] . Therefore, there is a pressing need to identify and develop novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> CHIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/jcm9030623\"><h2> Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Pang, Junxiong; Wang, Min Xian; Ang, Ian Yi Han; Tan, Sharon Hui Xuan; Lewis, Ruth Frances; Chen, Jacinta I. Pei; Gutierrez, Ramona A.; Gwee, Sylvia Xiao Wei; Chua, Pearleen Ee Yong; Yang, Qian; Ng, Xian Yi; Yap, Rowena K. S.; Tan, Hao Yi; Teo, Yik Ying; Tan, Chorh Chuan; Cook, Alex R.; Yap, Jason Chin-Huat; Hsu, Li Yang</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (MERS-CoV) and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Meta<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reverse transcription<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">kit<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or drug combinations supported by high-level evidence.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1177/2040206618758524\"><h2> Addressing the selectivity and toxicity of antiviral nucleosides</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Feng, Joy Y</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogs have played significant roles in <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapies and are valued for their impressive potency and high barrier to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. They have been approved for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">herpes simplex<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> virus-1, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HBV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and new drugs are being developed for the treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, Ebola, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> MERS, and other emerging <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. However, this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of compounds has also experienced a high <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">attrition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> rate in clinical trials due to toxicity. In this review, we discuss the utility of different biochemical and <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-based assays and provide recommendations for assessing toxicity liability before entering <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> toxicity studies.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2020.00150\"><h2> Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Takayama-Ito, Mutsuyo; Saijo, Masayuki</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">SFTSV infects a variety of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cultured cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, including L929, Vero E6, Vero, and DH82 <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> (Yu et al., 2011) . Several studies have been conducted to identify effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against SFTSV by screening compound libraries or testing agents that are effective against other <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (Table 1) . Because it has been suggested that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> may potentially be effective in treatment of multiple <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, testing approved drugs is considered as a reasonable strategy (De Clercq and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Li<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, 2016) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.05.935072\"><h2> The Essential Facts of Wuhan Novel Coronavirus Outbreak in China and Epitope-based Vaccine Designing against COVID-19</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Sarkar, B.; Ullah, M. A.; Johora, F. T.; Taniya, M. A.; Araf, Y.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The current experiment was conducted to develop potential vaccines against the Wuhan <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (strain <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2) (Wuhan seafood market <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) exploiting the strategies of reverse vaccinology (Figure 01 ).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.03.20020263\"><h2> Network-based Drug Repurposing for Human Coronavirus</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Coronaviruses (HCoVs), including <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV), Middle east respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (MERS-CoV), and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> 2019-nCoV. Drug repurposing, represented as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> repurposing methodology implementing a systems pharmacology-based network <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> platform, quantifying the interplay between the HCoV-<mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> interactome and drug targets in the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human protein-protein interaction network<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV has the highest <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> sequence identity with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV (79.7%) among the six other known pathogenic HCoVs. Specifically, the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">envelope<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> and <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleocapsid proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> of 2019-nCoV are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/jcm9030623\"><h2> Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Pang, Junxiong; Wang, Min Xian; Ang, Ian Yi Han; Tan, Sharon Hui Xuan; Lewis, Ruth Frances; Chen, Jacinta I. Pei; Gutierrez, Ramona A.; Gwee, Sylvia Xiao Wei; Chua, Pearleen Ee Yong; Yang, Qian; Ng, Xian Yi; Yap, Rowena K. S.; Tan, Hao Yi; Teo, Yik Ying; Tan, Chorh Chuan; Cook, Alex R.; Yap, Jason Chin-Huat; Hsu, Li Yang</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">[47] Molecules developed by the university scientists inhibit two <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> enzymes and prevent its replication. The discovered drug targets are said to be more than 95% similar to enzyme targets found on the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Researchers note that identified drugs may not be available to address the ongoing outbreak but they hope to make it accessible for future outbreaks.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.30.927574\"><h2> Nucleotide Analogues as Inhibitors of Viral Polymerases</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Ju, J.; Kumar, S.; Li, X.; Jockusch, S.; Russo, J. J.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Coronaviruses such as the newly discovered <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> from Wuhan, China, 2019-nCoV, and the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that cause <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and MERS, have resulted in regional and global public health <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergencies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Based on our molecular insight that the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatitis C virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> use a similar <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral genome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatitis C<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ProTide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> Prodrug approach used in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of Sofosbuvir with the use of 3'-blocking groups that we have previously built into <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogues that function as polymerase terminators.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/jcm9020575\"><h2> Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Deng, Sheng-Qun; Peng, Hong-Juan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A. Treatment principle: based on symptomatic treatment, actively prevent and treat complications, treat basic diseases, prevent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">secondary infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and timely apply <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">organ<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> function support. B.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/molecules23071599\"><h2> Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Yu, Fei; Li, Wen; Wang, Lili; Dai, Yu; Lu, Xin; Wang, Qian; Xie, Lan; Jiang, Shibo</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Results suggest that these new NNRTIs may be used to treat patients against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> mutants resistant to the currently available RTIs. </div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.986836\"><h2> A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Yiyue Ge; Tingzhong Tian; Suling Huang; Fangping Wan; Jingxin Li; Shuya Li; Hui Yang; Lixiang Hong; Nian Wu; Enming Yuan; Lili Cheng; Yipin Lei; Hantao Shu; Xiaolong Feng; Ziyuan Jiang; Ying Chi; Xiling Guo; Lunbiao Cui; Liang Xiao; Zeng Li; Chunhao Yang; Zehong Miao; Haidong Tang; Ligong Chen; Hainian Zeng; Dan Zhao; Fengcai Zhu; Xiaokun Shen; Jianyang Zeng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Thus, CVL218 may have great potential to be repurposed as an effective therapeutic agent to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-CoV-2 and prevent future epidemic outbreak.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.23.20026856\"><h2> Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Guo-Qing Qian; Nai-Bin Yang; Feng Ding; Ada Hoi Yan Ma; Zong-Yi Wang; Yue-Fei Shen; Chun-Wei Shi; Xiang Lian; Jin-Guo Chu; Lei Chen; Zhi-Yu Wang; Da-Wei Ren; Guo-Xiang Li; Xue-Qin Chen; Hua-Jiang Shen; Xiao-Min Chen</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, no <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have been proven to be effective treatment for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. It is reported that combination of Lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> had been applied to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 patients with substantial clinical benefit. 22 As an emerging <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, all the patients received <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in Ningbo cohort, including Kaletra (Lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) and Umifenovir, 9 cases received <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">methylprednisolone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to treat high <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, SpO2 93% and hypoxiemia. The dose of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">methylprednisolone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> depends on disease severity between 1mg/kg to 2mg/kg. However, the outcome is still unclear.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/pathogens8030144\"><h2> Antiviral Effect of Lithium Chloride and Diammonium Glycyrrhizinate on Porcine Deltacoronavirus In Vitro</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Zhai, Xiaofeng; Wang, Shilei; Zhu, Mengyan; He, Wei; Pan, Zhongzhou; Su, Shuo</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">PDCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> can cause <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">vomiting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">watery diarrhea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in piglets and seriously damage the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pig<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> industry. Until now, there are no records of clinically effective agents for the treatment of PDCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and no compound has shown <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity [35] . Therefore, there is an urgent need to develop a good approach for preventing PDCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Because neither specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> nor vaccines are available for newly emerging <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and it is not possible to develop small-molecule drugs and vaccines that act on PDCoV in a short period of time, the novel use of traditional drugs has long been considered to be an important means of finding new therapies <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> new <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [36] . It has been reported that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">LiCl<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and DG, which are often deemed broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral reagents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, have <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> properties against coronaviruses such as <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IBV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PEDV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. However, it remains unknown whether <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">LiCl<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or DG has an inhibitory effect on PDCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2018.02551\"><h2> Prediction of Antimicrobial Potential of a Chemically Modified Peptide From Its Tertiary Structure</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Agrawal, Piyush; Raghava, Gajendra P. S.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The emergence of drug-resistant pathogenic strains is one of the major threats for the survival of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and livestock; <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> designed to eliminate these pathogens are losing their sensitivity (Price et al., 2012; Veltri et al., 2018) . The rapid emergence of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has endangered the efficacy of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and one of the potential causes of this is the misuse and overuse of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (Gould and <mark class=\"entity\" style=\"background: #E6E6FA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Bal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ENZY</span></mark>, 2013; Sengupta et al., 2013; Wright, 2014) . Hence, there is a need to develop more potent and effective drugs to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> deadly diseases occurring worldwide. In the past few decades, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">peptide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-based therapeutics has been preferred for the drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> over the small molecule-based drugs. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Peptide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-based drugs are highly selective, efficacious, safer and well tolerated compared to conventional small molecule-based drugs (Otvos and Wade, 2014) . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">peptide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-based drugs cover around 10% of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> market as per the current report and will continue to grow in future (Bruno et al., 2013; Craik et al., 2013) . Currently, more than 239 therapeutic <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">peptides<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have been already approved by US-FDA (Fosgerau and Hoffmann, 2015; Usmani et al., 2017) and therefore researchers nowadays are focusing more on <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">peptide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-based drugs.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s13020-018-0165-1\"><h2> SWOT analysis and revelation in traditional Chinese medicine internationalization</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Tang, Haitao; Huang, Wenlong; Ma, Jimei; Liu, Li</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Compared with the research and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (R&amp;D) of TCM, there are some problems in R&amp;D of chemical <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. First, the process of chemical drug discovery is long and arduous that it begins from the search of a potential candidate to the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of a marketable drug. The course could be as long as more than a decade [18] . Second, the R&amp;D cost for a new drug can be, in average, more than 800 million USD in the United States (US) [19] . Third, the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of new chemical drugs remains very a low rate of success. Among thousands chemical compounds only a few candidates could <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reach<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> their first markets as new drugs in recent years. Finally, synthetic chemical drugs are often associated with undesirable side effects in patients. It is now clear that the need of therapeutic intervention in many clinical conditions cannot be satisfactorily <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">met<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> by synthetic chemical drugs. Since the research and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of new chemical drugs remain time-consuming, capital-intensive, safety issues, and undesired side effects, much <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">effort<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> has been put in the search for alternative routes for drug discovery in China [20] . TCM has a long history of use, with extensive literature and clinical applications covering thousands of years. Such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">berberine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, an active ingredient from <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Coptis chinensis Franch<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, is widely used for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in China [21] . As TCM has the advantages of treatment of special diseases safety, and so on, there are many countries and regions begin to study it. At present, more than 150 countries and regions [22] have established natural botanical institutions, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> companies are increasingly focusing on research and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">botanicals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, paying attention to the construction of traditional botanical studies and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> teams, and focusing on the search for effective natural medicines to replace chemical treatments. Furthermore, there are over 1300 medicinal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> used in Europe [23] . As safe and healthy treatments are associated with a return to nature, TCM can make up for the shortcomings of Western <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in many areas. We can find the solutions to different kinds of diseases that are hard to cure by using the innovations and developments of TCM. TCM displays a distinctive curative effect for different diseases that are hard to cure and for technological difficulties that are recognized worldwide, such as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tumours<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [24] , <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic liver disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [25] and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic kidney disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [26] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">and toxic materials are recommended to be used, such as Ban-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Lan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-Gen, Jin-Yin-<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Hua<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and103Yu-Xing-Cao 14 . One herbal <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for clearing away heat and toxic materials, Chou-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ling<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Dan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 104 (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>; Laggera pterodonta) of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">family<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Laggera Sch-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Bip<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> ex Hochst, widely cultivated in Yunnan 105 province in China, has been approved and listed in &quot;Yunnan Chinese herbal <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 15 &quot;, &quot;Kunming 106 common folk herbal <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 16 &quot; and &quot;Yunnan Material Medical 17 &quot; for antibacterial, anti-inflammatory107and clearing heat-toxicity effects. The <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">root<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, or the whole <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, has been widely been used to treat 108 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">colds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sore throat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bronchitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">malaria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> and other diseases18 . According to a previous study by our109 research group, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> was effective against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in vivo and in vitro. Many active fractions have 110 been isolated from Laggera pterodonta, including Fr 14, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pterodontic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which had a wide spectrum 111 of anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> activity. The <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sesquiterpenoids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of Laggera pterodonta also prevented an increase 112 in cytokine and chemokine <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">expression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> 19,20,21 . Laggera pterodonta may be used to develop an 113 innovative <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and further studies should be performed to investigate the mechanism of 114 action in detail. 115 Currently, there are a variety of commercially available <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> preparations, and a Chinese patent 116 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> containing <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> as the main ingredient, in China. A observational clinical study, conducted 117 by the Second Affiliated Hospital of Kunming Medical University during the outbreak of H1N1 118 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in 2009, found that comparing with the clinical curative effect of Yinqiao Jiedu tablets, 119 a Chinese patent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> containing <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> had a better anti-viral effect, effectively reduced the 120 number of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in respiratory <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">secretions<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and accelerated the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> clearance. Additionally, good 121 efficacy and safety and the quick relief of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sore throat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and other symptoms, without adverse 122 reactions, has been shown in the treatment of children with <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> (H1N1) 22 . However, it is 123 lacking the evidence-based <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">EBM<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) clinical study to evaluate the efficacy and safety of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 124 Granules in the treatment of seasonal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. In additional, previous clinical studies have focused on 125</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1371/journal.pone.0190306\"><h2> Use of influenza antivirals in patients hospitalized in Hong Kong, 2000-2015</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Cowling, Benjamin J.; Chui, Celine S. L.; Lim, Wey Wen; Wu, Peng; Hui, Christopher K. M.; Peiris, J. S. Malik; Chan, Esther W.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Introduction <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Influenza virus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> cause considerable morbidity and mortality each year. A number of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can be used to treat <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> [1] . The M2 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and rimantadine that have been used since the 1960s and 1990s respectively, although neither are currently recommended for use against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> because of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> in the currently circulating strains [1, 2] . The <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase inhibitors oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were approved by the US Food and Drug Administration in 1999, and a third <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> peramivir was approved in 2014 although it had been available during the 2009 pandemic with an <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> use authorization. Peramivir and rimantadine are not registered in Hong Kong. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, the most widely used anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drug globally, has proven efficacy in reducing the duration of uncomplicated <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> illness in randomized controlled trials [3] , and observational studies have indicated a benefit in severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [3] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.17.952895\"><h2> Functional pangenome analysis suggests inhibition of the protein E as a readily available therapy for COVID-2019.</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Alam, I.; Kamau, A. K.; Kulmanov, M.; Arold, S. T.; Pain, A. T.; Gojobori, T.; Duarte, C. M.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Our pangenomic analysis suggests that the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> E of all <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> preserves its critical motifs used for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathogenesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Hence, we predict that the readily available and approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Hexamethylene amiloride<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and SB203580), that proved efficient for alleviating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ARDS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-1-infected <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models should also be effective against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2. While not preventing future spreading of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, these <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> might reduce the mortality rate while effective vaccines are being developed.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v12020244\"><h2> Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Xu, Jiabao; Zhao, Shizhe; Teng, Tieshan; Abdalla, Abualgasim Elgaili; Zhu, Wan; Xie, Longxiang; Wang, Yunlong; Guo, Xiangqian</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">As a large number of people have left Wuhan, the control of the epidemic situation is extremely urgent, and the treatments of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are imminent. On Feb. 14th, 2020, there were more than 54,000 confirmed patients in Hubei province, China [55] . Due to the lack of effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, the prognosis of patients solely depends on their age and physical <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">condition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [74] . Although it was reported that the clinically recovered patients exceed the number of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dead<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, the majority of the patients are still not cured in hospital. In addition, the potential adaptive mutation of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 makes it difficult for vaccine <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Therefore, it is urgent for us to develop more sensitive inspection methods and effective drugs.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.03.20020263\"><h2> Network-based Drug Repurposing for Human Coronavirus</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Finally, we aimed to systematically identify repurposable drugs by specifically <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> nCoV <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> only. Thus, our current network models cannot predict repurposable drugs from the existing anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> drugs that target <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> only. Thus, combination of the existing anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> drugs (such as remdesivir [76] ) with the networkpredicted repurposable drugs (Figure 5 ) or drug combinations (Figure 6 ) may improve coverage of current network-based methodologies by utilizing multi-<mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">layer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> network framework.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ijid.2020.02.018\"><h2> Discovery and development of safe-in-man broad-spectrum antiviral agents</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjrs, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">For phase II, patients with the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in question are invited to join the study, where they are administered the BSAAs at the ideal therapeutic doses. Phase III is the longest of the phases, and include multiple levels of securities to the studies, such as the use of placebos and double-blinded studies, to ensure the data is asunbiased as possible. Upon completing phase III, depending on its performance and efficacy, BSAAs may end either being approved or dropped. The U.S Food and Drug Administration (FDA) estimates that only 25-30% BSAA candidates which enters phase III are approved for use in the public (U.S Food and Drug Administration, 2018). After approval and marketing of the drug, phase IV may be initiated to follow J o u r n a l P r e -p r o o f up on the use of the drug in public, to surveil for rare effects (U.S Food and Drug Administration, 2018; Umscheid et al., 2011). Forty-eight safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> BSAAs undergo clinical studies as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. There are currently 21 compounds in phase I, 34 agents in phase II and 11 compounds in phase III clinical trials. For example, nitazoxanide, remdesivir and brincidofovir are under clinical investigations against different <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (one BSAAs were approved by FDA, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">EMA<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or other agencies. These BSAAs altogether target 15 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. For example, favipiravir, also known as T-705, was approved against FLUAV in Japan; <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cidofovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is an injectable <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> medication used as a treatment for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CMV retinitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in people with AIDS; <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, also known as tribavirin, is used for treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>; <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pleconaril<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is used against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">picornaviridae family<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, including <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">enterovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rhinovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>; and valacyclovir is used against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CMV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, EBV, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HBV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, HSV-2 and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">VZV infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Twenty BSAAs are undergoing surveillance studies (phase IV). <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Azithromycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cyclosporine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ezetimibe<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mycophenolic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, nitazoxanide and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rapamycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> progressed to phase IV studies without approvals from national or international authorities (NCT01779570, NCT02058173, NCT02564471, NCT00821587, NCT03360682, NCT02328963, NCT02768545, NCT01624948,</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1177/2040206618783924\"><h2> Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Vere Hodge, R Anthony</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Mike Sofia described his past work on sofosbuvir and his current work with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HBV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. His <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">talk<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> on sofosbuvir followed on from that of Phillip (Phil) Furman, the Elion Awardee at the 2015 ICAR. Both Phil and Mike worked at Pharmasset Inc. until it was bought by Gilead Inc. Then Mike continued at Gilead to assist in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of sofosbuvir. The clinical introduction of sofosbuvir transformed the therapy of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, becoming the '<mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">backbone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>' of various combination therapies. When so many firms were searching for anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> drugs, what special factors enabled Pharmasset to discover such a uniquely active drug? My comments are based on both Phil's and Mike's lectures.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.31.929547\"><h2> Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Beck, B. R.; Shin, B.; Choi, Y.; Park, S.; Kang, K.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Another <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-HIV drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Prezcobix<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of Johnson &amp; Johnson, which consists of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">darunavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and cobicistat, was to be sent to China (16) , and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">darunavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is also predicted to have a Kd of 90.38 nM against <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCoV's helicase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (Table 3) . However, there was no current supporting literature found for darunavir to be used as a CoV therapeutic.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fcimb.2019.00196\"><h2> Multiplex Platforms for the Identification of Respiratory Pathogens: Are They Useful in Pediatric Clinical Practice?</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Esposito, Susanna; Mencacci, Antonella; Cenci, Elio; Camilloni, Barbara; Silvestri, Ettore; Principi, Nicola</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> can be treated with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which is the only licensed drug for the treatment of this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. However, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is difficult to use, costly, and teratogenic, and there is weak evidence for its efficacy. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is typically used in severe cases that occur in immunocompromised subjects (Brendish and Clark, 2017) . Although several new drugs against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are in <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, and it is likely that in next few years some of them will be licensed for universal use, the present treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> remains based on supporting measures, such as hydration and O 2 administration (Xing and Proesmans, 2019) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Of course, it should be pointed out that Chinese herbs that have not been identified through this screening process may still have beneficial effects. Further, considering that the biologically validated <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> reported in the literature cannot cover all <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> natural compounds, and the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> included in the Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> database are not complete, the process that we have followed may have excluded herbs that would be well suited to this treatment. Nevertheless, the purpose of this screening was to provide a rational approach for selecting Chinese herbal medicines with a high potential efficacy in treating 2019-nCoV and related <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The specific dosage and usage of each herb should be determined based on patients' manifestations. Finally, the key step in this screening was molecular <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. The 3D structures of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> used here are based on reported gene sequences. If the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> mutates during transmission, a new screening is recommended.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Of course, it should be pointed out that Chinese herbs that have not been identified through this screening process may still have beneficial effects. Further, considering that the biologically validated <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> reported in the literature cannot cover all <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> natural compounds, and the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> included in the Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> database are not complete, the process that we have followed may have excluded herbs that would be well suited to this treatment. Nevertheless, the purpose of this screening was to provide a rational approach for selecting Chinese herbal medicines with a high potential efficacy in treating 2019-nCoV and related <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The specific dosage and usage of each herb should be determined based on patients' manifestations. Finally, the key step in this screening was molecular <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. The 3D structures of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> used here are based on reported gene sequences. If the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> mutates during transmission, a new screening is recommended.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">It is a challenge to screen out the herbs containing anticoronavirus (2019-nCoV) compounds from the large number of those possibly being used for patients infected with this pathogen, especially in very short time. Here, we propose two principles to guide such work: <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> effectiveness and traditional usage compatibility. The first principle refers to the fact that most Chinese herbal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">orally<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> ingested after boiling with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">water<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, meaning that the anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) ingredients in selected <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> should be absorbable via <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> preparation. The second principle recognizes that candidate <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> should be consistent with the type classifications for traditional herbal usage, since type-guided applications are integral to herbal use, as mentioned above. Following these two principles, we used a 6-step selection process (3 for each principle), including drug-likeness, evaluation of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> bioavailability, molecular <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, network pharmacology analysis and other methods to identify herbs that have both a high possibil-ity of containing effective anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) compounds and are classified as treating <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-caused <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">It is a challenge to screen out the herbs containing anticoronavirus (2019-nCoV) compounds from the large number of those possibly being used for patients infected with this pathogen, especially in very short time. Here, we propose two principles to guide such work: <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> effectiveness and traditional usage compatibility. The first principle refers to the fact that most Chinese herbal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">orally<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> ingested after boiling with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">water<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, meaning that the anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) ingredients in selected <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> should be absorbable via <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> preparation. The second principle recognizes that candidate <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> should be consistent with the type classifications for traditional herbal usage, since type-guided applications are integral to herbal use, as mentioned above. Following these two principles, we used a 6-step selection process (3 for each principle), including drug-likeness, evaluation of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> bioavailability, molecular <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, network pharmacology analysis and other methods to identify herbs that have both a high possibil-ity of containing effective anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) compounds and are classified as treating <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-caused <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/jcm9030623\"><h2> Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Pang, Junxiong; Wang, Min Xian; Ang, Ian Yi Han; Tan, Sharon Hui Xuan; Lewis, Ruth Frances; Chen, Jacinta I. Pei; Gutierrez, Ramona A.; Gwee, Sylvia Xiao Wei; Chua, Pearleen Ee Yong; Yang, Qian; Ng, Xian Yi; Yap, Rowena K. S.; Tan, Hao Yi; Teo, Yik Ying; Tan, Chorh Chuan; Cook, Alex R.; Yap, Jason Chin-Huat; Hsu, Li Yang</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">With the possible expansion of 2019-nCoV globally [8] and the declaration of the 2019-nCoV outbreak as a Public Health <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of International Concern by the World Health Organization, there is an urgent need for rapid diagnostics, vaccines and therapeutics to detect, prevent and contain 2019-nCoV promptly. There is however currently a lack of understanding of what is available in the early phase of 2019-nCoV outbreak. The systematic review describes and assesses the potential rapid diagnostics, vaccines and therapeutics for 2019-nCoV, based in part on the developments for MERS-CoV and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.2147/DDDT.S159767\"><h2> Computer-aided design of amino acid-based therapeutics: a review</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Farhadi, Tayebeh; Hashemian, Seyed MohammadReza</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A summary of the FDA-approved small-and large-molecule therapeutics. Notes: Number and percentage of FDA-approved therapeutics (in 2018) is shown inside the pie diagram. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-based therapies: 8.05% (n=277), gene and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> acidbased therapies: 0.17% (n=6), vaccines: 2.64% (n=91), allergenics: 16.20% (n=557), <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell transplant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> therapies: 0.14% (n=5), small-molecule drugs: 72.76% (n=2,501). Abbreviation: FDA, US Food and Drug Administration. Drug Design, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and Therapy 2018:12 submit your manuscript <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">| www.dovepress.com<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> Dovepress Dovepress</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/jcm9030623\"><h2> Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Pang, Junxiong; Wang, Min Xian; Ang, Ian Yi Han; Tan, Sharon Hui Xuan; Lewis, Ruth Frances; Chen, Jacinta I. Pei; Gutierrez, Ramona A.; Gwee, Sylvia Xiao Wei; Chua, Pearleen Ee Yong; Yang, Qian; Ng, Xian Yi; Yap, Rowena K. S.; Tan, Hao Yi; Teo, Yik Ying; Tan, Chorh Chuan; Cook, Alex R.; Yap, Jason Chin-Huat; Hsu, Li Yang</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A PRISMA flow diagram of the search strategy for diagnostics, vaccine and therapeutics of 2019-nCoV, MERS-CoV and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Herbal therapies are common treatments used by patients with seasonal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in China and are deserving of rigorous examination. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is one of the common anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs used in many areas of China. Herbal remedies have been found to be of benefit in treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and many pharmacological studies of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are underway. However, currently there is not enough clinical evidence to evaluate whether the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> product is suitable and to tally safe for treating and preventing seasonal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. This protocol is designed to investigate the objective treatment effectiveness of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Our previous study showed that some components of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> had <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, especially in the early stage of the illness 19 . Accordingly, we will recruit patients within 72 h of illness onset.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2018.01547\"><h2> Advancements in Host-Based Interventions for Influenza Treatment</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Yip, Tsz-Fung; Selim, Aisha Sami Mohammed; Lian, Ida; Lee, Suki Man-Yan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">(69), while corilagin is isolated from medicinal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and herbs. The identification of effective compounds and the systemic investigation of the use of traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (TCM) in the treatment of IAV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> open new frontiers in research and therapeutics.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.2147/DDDT.S151282\"><h2> Bispecific antibodies: design, therapy, perspectives</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> Sedykh, Sergey E; Prinz, Victor V; Buneva, Valentina N; Nevinsky, Georgy A</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Blinatumomab and catumaxomab, approved for use as medicines, are designed to treat oncological diseases. In perspective, one can expect the construction of new platforms that will allow <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of full processes from BsAb <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">expression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> to preclinical tests. To develop new antitumor drugs, it is necessary to search for new combinations of BsAb targets to increase the therapeutic effect and reduce side effects; specific features of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tumors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> also should be taken into account. BsAbs can be used in combination with other medications, eg, drugs controlling the <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell cycle<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">indoleamine dioxygenase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and vaccines. There is no doubt that continuous <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of new approaches to BsAb production is required to control oncological diseases.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.56</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">therapies are common treatments used by patients with seasonal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in China and 549 are deserving of rigorous examination. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is one of the common anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs used in 550 many areas of China. Herbal remedies have been found to be of benefit in treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and 551 many pharmacological studies of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are underway. However, currently there is not enough 552 clinical evidence to evaluate whether the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> product is suitable and to tally safe for treating and 553 preventing seasonal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. This protocol is designed to investigate the objective treatment 554 effectiveness of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Our previous study showed that some components of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> had <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 555 activity against the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, especially in the early stage of the illness 22 . Accordingly, we 556 will recruit patients within 72 h of illness onset.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Herbal therapies are common treatments used by patients with seasonal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in China and are deserving of rigorous examination. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is one of the common anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs used in many areas of China. Herbal remedies have been found to be of benefit in treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and many pharmacological studies of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are underway. However, currently there is not enough clinical evidence to evaluate whether the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> product is suitable and to tally safe for treating and preventing seasonal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. This protocol is designed to investigate the objective treatment effectiveness of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Our previous study showed that some components of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> had <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, especially in the early stage of the illness. 22 Accordingly, we will recruit patients within 72 hours of illness onset.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10080433\"><h2> Potential Therapeutic Agents for Feline Calicivirus Infection</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Fumian, Tulio M.; Tuipulotu, Daniel Enosi; Netzler, Natalie E.; Lun, Jennifer H.; Russo, Alice G.; Yan, Grace J. H.; White, Peter A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Valopicitabine, the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">prodrug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> form of 2CMC, was used in pre-clinical studies to treat <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, however, after dose-related gastrointestinal adverse events, the drug has been placed on clinical hold by the US Food and Drug Administration (FDA). Although promising results were obtained here and in other studies [58, 60] , concerns over adverse side-effects may limit its future clinical use to treat calicivirus <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The drugs used in this clinical trial (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> granules and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) have been approved for clinical use, so there are no potential safety hazards. To ensure that study patients receive effective treatment during rehabilitation, the placebo control group will be provided with basic drugs.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.23.20026690\"><h2> The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Minfeng Liao; Yang Liu; Jin Yuan; Yanling Wen; Gang Xu; Juanjuan Zhao; Lin Chen; Jinxiu Li; Xin Wang; Fuxiang Wang; Lei Liu; Shuye Zhang; Zheng Zhang</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Since December, 2019, a disease outbreak caused by a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (now given the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">name SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-CoV-2) started in Wuhan, and has quickly spread in China and subsequently inmany other countries [1] . The WHO has declared the new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (CoV) <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> as a global public health <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and named the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> infected disease-19 . The genome analysis showed that the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> is a <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV like <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>-lineage <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> [2] and likely originates from <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bats<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> [3] . <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 uses <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human ACE2 protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> as their receptors [4] , which explains its similarly high transmissibility. The clinical data indicated that the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> varied from asymptomatic to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acute respiratory distress syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ARDS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), similar as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [5] [6] [7] . Although researchers are racing against time to develop vaccines and test <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in clinical trials [8] , there is no effective prophylactic and clinical treatment for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> yet.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.03.20020263\"><h2> Network-based Drug Repurposing for Human Coronavirus</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Although investment in biomedical and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> research and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> has increased significantly over the past two decades, the annual number of new treatments approved by the U.S. Food and Drug Administration (FDA) has remained relatively constant and limited [6] . A recent study estimated that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> companies spent $2.6 billion in 2015, up from $802 million in 2003, in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of an FDA-approved new chemical entity drug [7] . Drug repurposing, represented as an effective drug discovery strategy from existing drugs, could significantly shorten the time and reduce the cost compared to de novo drug discovery and randomized clinical trials [8] [9] [10] . However, experimental approaches for drug repurposing is costly and timeconsuming. [11] Computational approaches offer novel testable hypotheses for systematic drug repositioning [8-10, 12, 13] . However, traditional structure-based methods are limited when three-dimensional (3D) structures of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are unavailable, which, unfortunately, is the case for the majority of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and viral targets. In addition, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> single <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> often have high risk of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">drug resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> by the rapid <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">evolution<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> genomes [1] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/medethics-2016-103474\"><h2> The Ebola clinical trials: a precedent for research ethics in disasters</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Calain, Philippe</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In parallel to the controversy about the design of Ebola therapeutic trials, the moral justifications for 'compassionate' use have been vividly debated. 27 29 Compassionate use is technically regulated by the US administration under the provisions of the &quot;Expanded access to investigational drugs for treatment use&quot; 45 and it has typically been applied to new drugs for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tuberculosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> patients. 46 Similarly, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">'emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>', 'special' or 'restricted' access programmes exist in several countries to regulate the off trial use of unregistered interventions. These programmes are generally, but not always, bound to the legal obligation to collect data on adverse events and-less frequently -efficacy. 47 The WHO panel did not take any position to encourage or discourage the compassionate use of experimental products during the course of the Ebola epidemic. It simply declared a moral obligation to share 'transparently and rapidly' all scientific data generated by any <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sort<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of use of investigational products. This uncontroversial recommendation did not seem to have been taken seriously by all researchers in possession of clinical EVD data. It took until April 2015 for WHO to be able to publicise summaries on 14 EVD patients treated under 'compassionate use' protocols outside of Africa. 48 Regrettably, none of the patients treated in the USA appear in this series. Twelve of the 14 patients received experimental treatments, including 6 who were given combinations of two or more investigational drugs. This makes inferences about the efficacy of those drugs the more difficult. It also shows that the presumptions of collective equipoise are far from universal.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/molecules23071599\"><h2> Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Yu, Fei; Li, Wen; Wang, Lili; Dai, Yu; Lu, Xin; Wang, Qian; Xie, Lan; Jiang, Shibo</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In summary, the new NNRTIs under <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, DAPA-2e, DAAN-14h, and DAAN-15h, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">possess<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> improved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> strains, particularly those resistant to RTIs. Here we found that combining these new NNRTIs with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">AZT<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> resulted in <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">synergism<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, or strong <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">synergism<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, against divergent laboratory-adapted and primary <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> strains, as well as those resistant to NRTIs and NNRTIs. Therefore, these new NNRTIs can be further developed as new additions to the anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drug arsenal, and they can be effectively used as salvage therapy for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV/AIDS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients who have failed to respond to currently available antiretroviral drugs or as anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV microbicides<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> for prevention of sexual <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> transmission. Nevertheless, pre-clinical studies on the in vivo efficacy and safety, including the long term toxicity, of these NNRTI/NRTI combinations and on the selection of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> drug mutants are warranted in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">order<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to establish the therapeutic potential of these drug combinations in clinic application. In addition, the combinations of these investigational NNRTIs with the modern, preferred NRTIs such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tenofovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">TDF<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/TAF) and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">FTC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> should also be tested in the future.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1002/cti2.1067\"><h2> Harnessing hostvirus evolution in antiviral therapy and immunotherapy</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Heaton, Steven M</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Types and targets of current Food and Drug Administrationapproved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark></div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fcimb.2019.00193\"><h2> Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Peyclit, Lucie; Baron, Sophie Alexandra; Rolain, Jean-Marc</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The fight to treat multi-drug resistant (<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MDR<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>) <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> must also include a change in mentality. Rolain and Baquero denounced the fact that society does not accept the use of toxic but effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in treatment of life-threatening <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, but on the other hand society can tolerate potential toxicities of other drugs, such as anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. With the progress of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in the management of adverse reactions and the improved monitoring of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> concentrations, old drugs or dosages rejected due to their <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adverse effects<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> have to be reconsidered (Rolain and Baquero, 2016) . In this way, one other promising alternative on which this review focuses is drug repurposing, also called repositioning (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Mercorelli<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> et al., 2018) . This therapeutic shift is the subject of several studies in different pathologies including <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (Sleire et al., 2017) , <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">heart diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> , <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Alzheimer's disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> (Kim, 2015) or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">depression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (Ebada, 2017) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.sjbs.2016.09.020\"><h2> Middle East respiratory syndrome coronavirus (MERS-CoV): Impact on Saudi Arabia, 2015</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Faridi, Uzma</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The incidences are getting reduced because of the awareness of the disease but still we don't have a particular drug or vaccine against MERS-CoV. There is a great need for a new drug for the treatment of this deadly <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and vaccine to prevent the disease. Many research laboratories are working to understand the disease completely and to discover the drug or vaccine for MERS-CoV. So we can hope that in future MERS will be treatable as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">common Cold<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.sjbs.2016.09.020\"><h2> Middle East respiratory syndrome coronavirus (MERS-CoV): Impact on Saudi Arabia, 2015</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Faridi, Uzma</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The incidences are getting reduced because of the awareness of the disease but still we don't have a particular drug or vaccine against MERS-CoV. There is a great need for a new drug for the treatment of this deadly <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and vaccine to prevent the disease. Many research laboratories are working to understand the disease completely and to discover the drug or vaccine for MERS-CoV. So we can hope that in future MERS will be treatable as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">common Cold<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.00531\"><h2> Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Pizzorno, Andrs; Padey, Blandine; Terrier, Olivier; Rosa-Calatrava, Manuel</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In this context, drug repurposing stands as a worthwhile attractive alternative to fill part of this so-called innovation gap. Drug repurposing, also termed drug repositioning, defines the process of identifying and validating a new therapeutic indication for an existing or developmental drug (38, 42, 43) . The basis of drug repurposing relies on bypassing long, risky and expensive preclinical and early clinical evaluation stages by focusing on available extensive <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> clinical, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmacokinetics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and safety data as the starting point for further <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (Figure 1 ). An extended definition could also include not only already marketed drugs but also &quot;<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sleeping<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>&quot; candidates that have seen their <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> abandoned in advanced phases of clinical evaluation (e.g., Phase II/III trials) due to non-satisfactory efficacy for their first intended medical use, which might find a second life in a novel therapeutic indication Noteworthy, repurposing arguably accounts for 30% of the new drug products approved by the FDA (44) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">helicase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, E-channel, Spike and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, more <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were predicted to <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> with them, especially E-channel, <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>, 3CLpro and PLpro, indicating that these targets are more likely to be useful for the discovery of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 therapeutic drugs from known anti-virals, and should be the focus of our subsequent research.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">helicase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, E-channel, Spike and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, more <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were predicted to <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> with them, especially E-channel, <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>, 3CLpro and PLpro, indicating that these targets are more likely to be useful for the discovery of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 therapeutic drugs from known anti-virals, and should be the focus of our subsequent research.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> granules have been approved as Over-thecounter (OTC) drugs for many years and the drug meet the Chinese Pharmacopoeia (2015). 37 So the dosage determination in this study is according to the instruction manual. However, in this clinical trial, we will evaluate the efficacy and safety, and the dosage of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.31.929547\"><h2> Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Beck, B. R.; Shin, B.; Choi, Y.; Park, S.; Kang, K.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">designed to target viral proteinases. However, in our prediction, they may also <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> to the replication complex components of 2019-nCoV with an inhibitory potency with Kd &lt; 1000 nM. In addition, we also found that several <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, such as Kaletra, could be used for the treatment of 2019-nCoV, although there is no real-world evidence supporting the prediction. Overall, we suggest that the list of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> identified by the MT-DTI model should be considered, when establishing effective treatment strategies for 2019-nCoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.03.20020263\"><h2> Network-based Drug Repurposing for Human Coronavirus</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Owing to lack of the complete drug target information (such as the molecular 'promiscuity' of drugs), the dose-response and dose-toxicity effects for both repurposable drugs and drug combinations cannot be identified in current network models. For example, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Mesalazine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, an approved drug for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inflammatory bowel disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, is . CC-BY-NC 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.08.20032821\"><h2> Clinical Characteristics of Two Human to Human Transmitted Coronaviruses: Corona Virus Disease 2019 versus Middle East Respiratory Syndrome Coronavirus.</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Ping Xu; Guo-Dong Sun; Zhi-Zhong Li</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Up to now, no effective strategy has been found for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [50] . Currently, the measure to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is to control the source of the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>; taking personal protective works to reduce the risk of transmission; and early diagnosing, isolating and supportive treating for confirmed patients. In the present study, our systematic results of cure rate of drug for MERS-COV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> indicated that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and intravenous <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immunoglobulin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> all had been effective for MERS-COV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, with the cure rate of those drugs was 74.2%, 69.2%, 67.1% and 62.5% respectively. Thus, we . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fphar.2018.01448\"><h2> Systems Pharmacology Dissection of Multi-Scale Mechanisms of Action of Huo-Xiang-Zheng-Qi Formula for the Treatment of Gastrointestinal Diseases</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Zhao, Miaoqing; Chen, Yangyang; Wang, Chao; Xiao, Wei; Chen, Shusheng; Zhang, Shuwei; Yang, Ling; Li, Yan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">(1) 132 chemicals out of 1,192 components in 11 herbs, and 48 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/enzymes are identified as candidate compounds and FD-related targets of HXZQ prescription, respectively. And the systematic use of these active ingredients may supply useful clues on the combination therapies for FD treatment.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.31.929547\"><h2> Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Beck, B. R.; Shin, B.; Choi, Y.; Park, S.; Kang, K.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">unexpected and rapidly spreading <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> such <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV, MERS-CoV, and 2019-nCoV at the frontline of the disease control until better therapeutic measures are developed. Nevertheless, we hope our prediction results may support and helpful to experimental therapy options for China and other countries identified 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.986836\"><h2> A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Yiyue Ge; Tingzhong Tian; Suling Huang; Fangping Wan; Jingxin Li; Shuya Li; Hui Yang; Lixiang Hong; Nian Wu; Enming Yuan; Lili Cheng; Yipin Lei; Hantao Shu; Xiaolong Feng; Ziyuan Jiang; Ying Chi; Xiling Guo; Lunbiao Cui; Liang Xiao; Zeng Li; Chunhao Yang; Zehong Miao; Haidong Tang; Ligong Chen; Hainian Zeng; Dan Zhao; Fengcai Zhu; Xiaokun Shen; Jianyang Zeng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In this study we reported a top down data <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">integration<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> approach by combining both machine <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">learning<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and statistical analysis techniques, followed by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">web<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-lab experimental validation, to identify potential drug candidates for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. We showed that the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PARP1 inhibitor CVL218<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> discovered by our in silico drug repurposing framework may have the therapeutic potential for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Although we mainly conducted in vitro assays to experimentally validate the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-SARS-CoV-2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> effects of olaparib and CVL218 due to limited time, it is natural to speculate that other <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PARP1 inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> may also have <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, based on our computational prediction and experimental validation results.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s12929-019-0592-z\"><h2> Development of therapeutic antibodies for the treatment of diseases</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Lu, Ruei-Min; Hwang, Yu-Chyi; Liu, I-Ju; Lee, Chi-Chiu; Tsai, Han-Zen; Li, Hsin-Jung; Wu, Han-Chung</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Many mAbs are under <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, currently only four have been approved by the US FDA: raxibacumab and obiltoxaximab for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhalational anthrax<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [63] , palivizumab for prevention of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory syncytial virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in high-risk infants [64] , and ibalizumab for treatment of <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> patients [65] . Ibalizumab (Trogarzo) is a humanized <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IgG4<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> mAb that is used as a <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CD4 domain 2-directed<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> post-attachment <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1 inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The US FDA approved ibalizumab for adult patients infected with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> who were previously treated and are resistant to currently available therapies.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/healthcare8010051\"><h2> Outbreak of Novel Coronavirus (SARS-Cov-2): First Evidences From International Scientific Literature and Pending Questions</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Amodio, Emanuele; Vitale, Francesco; Cimino, Livia; Casuccio, Alessandra; Tramuto, Fabio</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Unfortunately, to date, there are no vaccines against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2, and there is the awareness that several months may be required to undergo extensive testing, and determine vaccine safety and efficacy before a potential wide use. Similarly, there is no single specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy; <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and the main treatments are supportive care (e.g., supportive therapy and monitoring-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oxygen<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy and fluid management). In the last days, recombinant <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and infusions of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blood plasma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> from people who have recovered from the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are under evaluation, to treat infected subjects with encouraging results [14] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s13020-018-0165-1\"><h2> SWOT analysis and revelation in traditional Chinese medicine internationalization</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Tang, Haitao; Huang, Wenlong; Ma, Jimei; Liu, Li</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Third, some new TCM drugs are being successfully developed based on many years of clinical practice; these drugs can generally have precise effects and have only less adverse side effects [14] . Only minimal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adverse effects<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> were reported for Chinese medicines used in treating type 2 DM indicating certain advantages in the prevention of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diabetes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and delay of its complications [15] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.28.922922\"><h2> Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Li, Y.; Zhang, J.; Wang, N.; Li, H.; Shi, Y.; Guo, G.; Liu, K.; Zeng, H.; Zou, Q.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The discovery and clinical application of specific drugs against 2019-nCoV is an effective means to alleviate the current epidemic. However, there are no clinically effective drugs for this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> for the moment. Although 2019-nCoV is significantly different from <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, which breakout in Beijing 17 years before [3] , the sequence identity between themis as high as 79.5%. Further sequence alignment revealed that the similarity of the sequence of the main protease between 2019-nCoV and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV is up to 96.1%. Previous study demonstrated that the main protease of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> is essential for the life cycle of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and is considered to be an attractive target for drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> [4] . Thus, this <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> could be used as a homologous target to screening drugs that inhibiting the replication and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proliferation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of 2019-nCoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1093/pcmedi/pbaa002\"><h2> A precision medicine approach to managing Wuhan Coronavirus pneumonia</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Minjin Wang, Yanbing Zhou, Zhiyong Zong, Zongan Liang, Yu Cao, Hong Tang, Bin Song, Zixing Huang, Yan Kang, Ping Feng, Binwu Ying, Weimin Li</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Ideally, infected patients should be treated with a customized treatment <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. However, currently, no specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapies are available for 2019-nCoV. The National Health Commission recommends the following treatment for infected individuals. 8 (i) General treatment recommendations:</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s12916-020-01533-w\"><h2> Q&A: The novel coronavirus outbreak causing COVID-19</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Fisher, Dale; Heymann, David</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In terms of therapeutics there is no known effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> agent. There are over 200 registered clinical trials registered in China alone. Putative agents include <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>; Griffithsin, a spike <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogues<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> eg. remdesivir, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> such as lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Immunomodulatory and other <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> agents include <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and immunoglobulins. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Corticosteroids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> will potentially have benefit for immune mediated <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lung<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> damage late in the course of disease [6] . Much of the theory <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">stems<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> from what we have learnt from limited trials in other <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">corona viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [7] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3399/bjgpopen18X101493\"><h2> Hajj: what it means for general practice</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Mughal, Faraz; Chew-Graham, Carolyn A; Saad, Ahmad</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Medication and list of drugs 10</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.03.972133\"><h2> AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Tang, B.; He, F.; Liu, D.; Fang, M.; Wu, Z.; Xu, D.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">TCIs have the chemical reaction step with the target, where usually k3 &gt;&gt; k4; and 3) for <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">TCIs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, the <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> process is controlled by k1 k3/(k2 k4), which is bigger than k1/k2 in non-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">covalent inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. In some extreme cases k4 = 0, and hence, these irreversible <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> covalently <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> the target until the target disappears. 7, 8 Considering the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS 3CL pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> may be also bio-active to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2, we have created a molecular library including all the reported SARS-3CL <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (284 molecules) 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and we will also <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">add<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> new validated molecular structures into this library with our research progresses. To date, there are no clinically approved vaccines or drugs specifically <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>-CoV-2.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">PubMed literature concerning natural compounds against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or MERS <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> activity was selected using the query ''<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> AND <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> AND (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> OR MERS OR <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV OR MERS-CoV).&quot; After careful reading of the studies returned by this search, the natural compounds that had biologically confirmed <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities were compared with the Traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> Systems Pharmacology database (TCMSP, http://www.tcmspw.com/browse.php?qc=herbs), the Encyclopedia of Traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (ETCM, http://www.nrc.ac.cn:9090/ETCM/) and SymMap (https://www.symmap.org/). Natural compounds both associated with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity and contained in herbs were examined in the next step of our study.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">PubMed literature concerning natural compounds against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or MERS <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> activity was selected using the query ''<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> AND <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> AND (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> OR MERS OR <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV OR MERS-CoV).&quot; After careful reading of the studies returned by this search, the natural compounds that had biologically confirmed <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities were compared with the Traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> Systems Pharmacology database (TCMSP, http://www.tcmspw.com/browse.php?qc=herbs), the Encyclopedia of Traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (ETCM, http://www.nrc.ac.cn:9090/ETCM/) and SymMap (https://www.symmap.org/). Natural compounds both associated with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity and contained in herbs were examined in the next step of our study.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1007/s10534-019-00197-1\"><h2> Biguanide is a modifiable pharmacophore for recruitment of endogenous Zn(2+) to inhibit cysteinyl cathepsins: review and implications</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Lockwood, Thomas D.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Biguanide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was recognized as an anti-hyperglycemic agent in the 1920s (Slotta and Tschesche 1929) , and then ignored after <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">insulin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> was discovered. In the 1940s hundreds of thousands of chemicals were blindly screened for anti-malarial action. From this multitude of chemicals, various derivatives of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">biguanide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were found to have anti-malarial action. A large number of different <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">biguanide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> derivatives were synthesized and tested as described in old papers and patent applications (e.g. Curd et al. 1945; Curd and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Rose<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> 1946) . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Proguanil<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was discovered in this work (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Fig. 7<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Proguanil<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is now widely used to prevent or treat <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">malaria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> in combination with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">atovaquone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (Malarone).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.01.20029074\"><h2> Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Li Tan; Qi Wang; Duanyang Zhang; Jinya Ding; Qianchuan Huang; Yi-Quan Tang; Qiongshu Wang; Hongming Miao</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Therefore, we suggested that LYM% should be used as an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">indicator<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for evaluating the effectiveness of clinical drugs or therapies. We suggest more medical staff apply and improve our proposed TLM to give patients more timely and appropriate treatments.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1177/2040206618783924\"><h2> Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Vere Hodge, R Anthony</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In sofosbuvir Phase III studies, four separate trials recruited patients with different genotypes, 1 and 4, 2, 3 and 5 and 6, respectively. By this time, the SVR for 12 weeks (SVR 12 ) had become the accepted measure for an <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> cure. The <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SVR 12<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> were 90, 97, 93 and 100%, respectively. To further optimise the cure rates, Gilead combined sofosbuvir with an NS5A <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, ledipasvir, which became Harvoni V R . However, ledipasvir has now been largely replaced by velpatasvir, another NS5A <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> but with an improved genetic barrier to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. This combination is Epclusa V R which gives &gt;96% cure rate for all genotypes 1-6. Sofosbuvirbased cure regimens have been shown to be effective in patients co-infected with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, in previously difficult- ) received approval from the USA Food and Drug Administration (FDA) in December 2013. Since then, more than a million patients have been cured on sofosbuvir-based regimens. Although at least 15 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/tide drugs have entered clinical <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, sofosbuvir remains the only approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/tide drug for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> therapy. It is the drug of choice to act as the '<mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">backbone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>' of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> combination therapies -only sofosbuvir has a sufficiently high genetic barrier to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> combined with an excellent safety profile. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> could become a <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rare disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> if the issues regarding patient access can be resolved.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1155/2019/8303648\"><h2> Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Criscuolo, E.; Caputo, V.; Diotti, R. A.; Sautto, G. A.; Kirchenbaum, G. A.; Clementi, N.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> represent a global concern, and the most effective strategy to reduce them is vaccination. Unfortunately, not every disease can currently be prevented through vaccines. However, many strategies have been developed against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> agents, such as the generation of neutralizing <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [124] [125] [126] [127] [128] [129] [130] , and innovative approaches are currently under <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> [131] [132] [133] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.03.20020263\"><h2> Network-based Drug Repurposing for Human Coronavirus</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In this study, we presented a network-based methodology for systematic identification of putative repurposable drugs and drug combinations for potential treatment of HCoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.986836\"><h2> A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Yiyue Ge; Tingzhong Tian; Suling Huang; Fangping Wan; Jingxin Li; Shuya Li; Hui Yang; Lixiang Hong; Nian Wu; Enming Yuan; Lili Cheng; Yipin Lei; Hantao Shu; Xiaolong Feng; Ziyuan Jiang; Ying Chi; Xiling Guo; Lunbiao Cui; Liang Xiao; Zeng Li; Chunhao Yang; Zehong Miao; Haidong Tang; Ligong Chen; Hainian Zeng; Dan Zhao; Fengcai Zhu; Xiaokun Shen; Jianyang Zeng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PARP1 inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> are originally used for <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> homologous <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">recombination repair<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> defects in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancers<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and mainly categorized as oncology drugs. Thus, it would generally need more safety data to justify any repurposing of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PARP1 inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> for non-oncology indications. Fortunately, there are numerous existing pre-clinical and clinical studies on repurposing <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PARP1 inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> into non-oncological diseases, including the aforementioned <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acute diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (e.g., <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acute respiratory distress syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ARDS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">stroke<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) [52] and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (e.g., <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rheumatoid arthritis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">vascular diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) [52, 53] . All these evidences indicate the possibility of repurposing <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PARP1 inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> as a safe therapeutic agent to treat the current acute <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lung disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. In addition, our pharmacokinetic and toxicokinetic data in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rats<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">monkeys<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> shown in our study indicate that CVL218 may have a relatively acceptable safety profile to be repositioned for the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> purpose. Moreover, CVL218 has been approved to enter Phase I clinical trial in 2017 by National Medical Products Administration (NMPA) in China for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> treatment. The preliminary data from the Phase I clinical trial have shown that CVL218 is well tolerated in ascending dose studies at doses as high as 1000 mg QD and 500 mg BID, and no Grade II and above adverse events have been observed, which indicates that CVL218 is also quite safe and well tolerated in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41467-018-02828-6\"><h2> Bismuth antimicrobial drugs serve as broad-spectrum metallo--lactamase inhibitors</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Wang, Runming; Lai, Tsz-Pui; Gao, Peng; Zhang, Hongmin; Ho, Pak-Leung; Woo, Patrick Chiu-Yat; Ma, Guixing; Kao, Richard Yi-Tsun; Li, Hongyan; Sun, Hongzhe</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Combination therapy comprising an available <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and a nonantibiotic that is usually an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">-lactamase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> has been considered as a more economical and effective alternative than <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of monotherapy with new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 2,13-17 . Such combination therapies are currently used clinically to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> from <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">serine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>--lactamases (SBLs)-positive <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> e.g., Augmentin  (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amoxicillin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">clavulanate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), Zosyn  (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">piperacillin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/tazobactam), and recent Avycaz  (ceftazidime/ avibactam). However, up till now, no equivalent therapy is available for MBLs-positive <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacterial infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, as no <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MBL inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> has been clinically approved and all clinically used SBL <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are not effective toward MBLs 18 . It remains a significant challenge to design MBL <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, particularly broad-spectrum MBL <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, given the structural diversity and mechanistic complexities of MBLs 14 . Though <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chelation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> agents such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ethylenediamine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-N,N,N,N-tetraacetate (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">EDTA<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) and aspergillomarasmine A 19 significantly inhibit MBLs, such indiscriminate <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chelating<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zn(II<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) might result in untoward effects on natural or endogenous <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metalloproteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that are critical for many biological functions 18 . Currently, most organic molecule-based <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MBL inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, including <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pyridine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> dicarboxylates, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">thiol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-derivatives, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and even <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">carbapenem<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogs, are designed by mimicking the substrates of specific types of MBLs, and have been shown to reduce <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MBL<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> activity of specific types both in vitro and in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models 14, [19] [20] [21] [22] [23] [24] . However, it still remains questionable whether or when these <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can be approved for clinical usage. Moreover, these <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> may readily encounter microbial <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> owing to rapid <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">evolution<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of MBLs 21, 25 . Therefore, more effective therapeutic strategies are urgently needed.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1177/2040206618783924\"><h2> Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA</h2></a> (<i>relevance: 0.55</i>)\n",
       "<h6> Vere Hodge, R Anthony</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Mark Pallansch described the need for an effective anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">poliovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> compounds and to the ongoing work investigating <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pocapavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (V-073, <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">capsid inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, preventing viral RNA <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">release<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>) and V-7404 (3C PI). The greatest medical need is to treat those <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCID<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients in whom <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">poliovirus infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> has continued for many years. Experience with other longlasting <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> indicates that drug therapy requires a combination of drugs, which includes at least one <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/tide <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with a high genetic barrier to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Therefore, it may be timely to prepare a <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">'plan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> B', approaching companies with a good panel of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/tide compounds.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.00531\"><h2> Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Pizzorno, Andrs; Padey, Blandine; Terrier, Olivier; Rosa-Calatrava, Manuel</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">&quot;We do not need to find new drugs; rather we need to find the patients who can benefit from existing drugs&quot; the saying <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">goes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Although somehow exaggerated, this statement summarizes pretty clearly the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">essence<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> behind the drug repurposing initiative. Finding new indications for already-existing drugs has many benefits, mainly by improving cost-effectiveness, reducing risks, and shortening time to market (37, 41) . The purpose of this review was to foster discussion on drug repurposing as an option to complete and implement our current anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> therapeutic arsenal. We are facing an important need for the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> strategies that improve treatment effectiveness-especially in the case of severe diseasesand that are less prone to selection for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. In that regard, the identification and validation by different and complementary means of repurposed drugs is incontestably of great interest, notably in combination with current classic virustargeted <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. In addition, the deposition of data, including negative results, into public database should be encouraged, as it would facilitate efforts to repurpose licensed or orphaned drugs, and consecutively increase our chances to find new efficient <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. With a growing number of academic groups and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> companies working on this emerging field, we should most certainly see interesting progress and efficient novel anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> therapies <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reaching<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> regulatory market approval in a near future.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.05.936013\"><h2> Potentially highly potent drugs for 2019-nCoV</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Nguyen, D.; Gao, K.; Chen, J.; Wang, R.; Wei, G.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) caused the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> outbreak in Wuhan, China, in late December 2019 and has rapidly spread around the world. By Feb 5, 2020, more than 24000 individuals were infected and more than 490 fatalities had been reported. The World Health Organization (WHO) has declared this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> outbreak a global health <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Currently, there is no specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for this epidemic. Considering the severity of this widespread dissemination and health threats, panic patients misled by <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">media<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> flocked to the pharmacies for Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> herbs which were reported to &quot;inhibit&quot; the 2019-nCoV, despite no clinical evidence supporting the claim. Many researchers are engaged in developing anti-2019-nCoV drug s [1, 2] . However, new drug discovery and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> is a long, costly and rigorous scientific process. A more effective approach is to search for anti-2019-nCoV therapies from the existing FDA-approved drug database.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1042/BSR20181729\"><h2> Efficacy of traditional Chinese medication Tangminling pill in Chinese patients with type 2 diabetes</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Cheng, Jing; Zheng, Jia; Liu, Yanping; Hao, Panpan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Tangminling pill is effective and safe for glycemic control and -<mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> function in T2DM patients, and it could be used to treat T2DM as a promising complementary approach. However, more rigorously designed trials are warranted to investigate the impacts of Tangminling pill on <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diabetes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and diabetic complications.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.29.971093\"><h2> The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding.</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Mycroft-West, C. J.; Su, D.; Elli, S.; Guimond, S. E.; Miller, G. J.; Turnbull, J. E.; Yates, E. A.; Guerrini, M.; Fernig, D. G.; Andrade de Lima, M.; Skidmore, M. A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Traditional drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> processes are slow and ineffective against emerging public health threats such as the current <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> outbreak which makes the repurposing of existing drugs a timely and attractive alternative. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Heparin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, a well-tolerated <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anticoagulant pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, has been used safely in <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for over 80 years and alongside its <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anticoagulant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities, its ability to prevent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, including <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronaviridae<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, has been described 1 . Furthermore, the closely related <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">glycosaminoglycan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">GAG<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>) member, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">heparan sulfate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (HS), is known to <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> CoV surface <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and to be used by <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> for its attachment to <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">target cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> 9 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10040211\"><h2> Gemcitabine and Nucleos(t)ide Synthesis Inhibitors Are Broad-Spectrum Antiviral Drugs that Activate Innate Immunity</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Shin, Hye Jin; Kim, Chonsaeng; Cho, Sungchan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogs have been historically used for anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> chemotherapy because they inhibit <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cellular<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> DNA/RNA polymerases [1] . More recently, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogs have expanded their therapeutic applications and are being used to develop <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against a wide range of serious and life-threatening <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Some <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analog drugs <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> specific viral polymerases (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acyclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">herpesviruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zidovudine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human immunodeficiency virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), and sofosbuvir for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatitis C virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>)) have been successful in clinical trials [2] [3] [4] [5] and are currently in use for the treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-infected patients. Another <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analog drugs such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, more broadly-acting on various <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, has been used in conjunction with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> [6] . Importantly, extensive studies on the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> action of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have established the underlying molecular framework of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">response to the recently reported <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-AIDS drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> tablets, which have a poor effect on the treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and have toxic side effects, we analyzed it in conjunction with the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results. The molecular <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results show that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>'s possible target is Nsp3c or E-channel. Lopinavir's possible target is Nsp3b, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp3c<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">helicase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, NRBD or E-channel. Some of these targets (such as Nsp3b, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp3c<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, E-channel) may be false positives due to the model inaccuracy for small flexible <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or partial model. For both lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, we did not observe possible <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> to major targets like 3CLpro, PLpro, <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>, and so on. This <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> result implies lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> tablets may not be suitable for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The results of the entire article are based on computer virtual screening. We have not <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">conduct<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> further in vivo and in vitro anti-viral experiments yet, because we want to share our results with scientists in anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 research as soon as possible. Our subsequent research will try to solve the three-dimensional structures of all 24 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 and their drug complexes, providing more target information for drug intervention and long-term drug design, perform in vivo and in vitro evaluations for candidate drugs obtained in this study, and prepare for clinical trial applications.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">response to the recently reported <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-AIDS drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> tablets, which have a poor effect on the treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and have toxic side effects, we analyzed it in conjunction with the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results. The molecular <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results show that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>'s possible target is Nsp3c or E-channel. Lopinavir's possible target is Nsp3b, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp3c<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">helicase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, NRBD or E-channel. Some of these targets (such as Nsp3b, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp3c<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, E-channel) may be false positives due to the model inaccuracy for small flexible <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or partial model. For both lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, we did not observe possible <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> to major targets like 3CLpro, PLpro, <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>, and so on. This <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> result implies lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> tablets may not be suitable for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The results of the entire article are based on computer virtual screening. We have not <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">conduct<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> further in vivo and in vitro anti-viral experiments yet, because we want to share our results with scientists in anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 research as soon as possible. Our subsequent research will try to solve the three-dimensional structures of all 24 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 and their drug complexes, providing more target information for drug intervention and long-term drug design, perform in vivo and in vitro evaluations for candidate drugs obtained in this study, and prepare for clinical trial applications.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/medethics-2016-103474\"><h2> The Ebola clinical trials: a precedent for research ethics in disasters</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Calain, Philippe</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, it is thus open to interpretation if in vitro evidence of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> alone could be considered as a sufficient criterion, in the absence of additional <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> evidence of efficacy and safety. The matter is even more complex, considering that some candidate interventions to treat EVD rely on plausible disease modifying mechanisms, instead of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity. Regardless of their proposed mechanisms, some among the candidate drugs have already been tested in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and approved for more common indications. Testing them in EVD trials would thus qualify as a case of drug repurposing-that is, the use of an approved drug or a drug under <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> for a different indication than that for which it was originally developed. 21 In fact, some of the trials that took place in West Africa 3 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">met<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> the definition of drug repurposing for EVD. Regrettably, the latest WHO guidance 5 22 does not refer explicitly to the case of repurposing, or to any eligibility scheme for the selection of unproven interventions. Figure 1 illustrates what such a scheme could look like, mapping the acceptable trade off between presumed efficacy and toxicity.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">If the drug is not being developed for commercial use, and the sponsor seeking EA intends to treat more than 1 patient, then the FDA requires an intermediate-size EA IND or protocol. If, on the other hand, the drug is being developed for marketing for EA use, then a treatment IND or protocol, not intermediate-size IND or protocol, will be necessary.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">If the drug is not being developed for commercial use, and the sponsor seeking EA intends to treat more than 1 patient, then the FDA requires an intermediate-size EA IND or protocol. If, on the other hand, the drug is being developed for marketing for EA use, then a treatment IND or protocol, not intermediate-size IND or protocol, will be necessary.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1177/2040206618758524\"><h2> Addressing the selectivity and toxicity of antiviral nucleosides</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Feng, Joy Y</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">As <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> vary greatly in duration and severity, the safety threshold of an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/tide needs to be considered in the context of its efficacy and treatment duration. For example, compounds to treat acute and deadly <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> such as Ebola would likely have different safety criteria than drugs used to control <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> such as <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HBV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Existing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tides<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are routinely screened against emerging <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and it is possible that a compound that failed to achieve an adequate therapeutic window against one <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> may be suitable for treating other <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2018.01547\"><h2> Advancements in Host-Based Interventions for Influenza Treatment</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Yip, Tsz-Fung; Selim, Aisha Sami Mohammed; Lian, Ida; Lee, Suki Man-Yan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Clypearin and corilagin were both found to be potent anti-IAV compounds, with a higher therapeutic index than TG003 in vitro (69) . Clypearin is isolated from herbs used by Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> practitioners for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory tract diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> </div><p><hr>\n",
       "<a href = \"https://doi.org/10.1097/jcma.0000000000000270\"><h2> The outbreak of COVID-19: An overview</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Wu, Y. C.; Chen, C. S.; Chan, Y. J.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Because of the potential mortality of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, many investigational treatments are underway:</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1097/JCMA.0000000000000270\"><h2> Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP)</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Wu, Yi-Chi; Chen, Ching-Sung; Chan, Yu-Jiun</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Because of the potential mortality of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, many investigational treatments are underway:</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2020.00150\"><h2> Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Takayama-Ito, Mutsuyo; Saijo, Masayuki</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Because all these mentioned drugs have inhibitory effect on SFTSV replication, combination therapies with some drugs, which have different mechanisms of action should be considered. Although, it should be considered that an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against SFTS would be administrated to a pre-symptomatic exposed individual, the main targets of these drugs are certainly patients with suggestive symptoms of SFTS. SFTSV circulates between <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mammals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ticks<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in Southeast Asia, indicating that we cannot escape the risk of being infected with SFTSV. SFTS is classified in a disease category of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral hemorrhagic fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with high case fatality rate. Recently, cases of SFTS have been reported, wherein the patients were infected with SFTSV from <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cats<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, which might be infected with SFTSV from <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tick<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (Kida et al., 2019) . Therefore, we are hopeful that specific treatments with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> will be developed and approved for patients with SFTS as early as possible.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1128/mSphere.00422-18\"><h2> A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Trombetta, Ryan P.; Dunman, Paul M.; Schwarz, Edward M.; Kates, Stephen L.; Awad, Hani A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Further drug characterization was performed to assess the efficacy of each of these four drugs against various S. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> strains and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">biofilm<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cytotoxicity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The results of this characterization demonstrated <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sitafloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was the best-performing drug due to its low <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MIC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and various S. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aureus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> strains, its potency against established <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">biofilm<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and its low <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cytotoxicity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. However, the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> had a comparable spontaneous <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> frequency to that of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rifampin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which is known to produce resistant mutants in clinic when treated as a monotherapy, suggesting the need to be used in combination therapy to mitigate this issue (61, 62) . Sitafloxacin was developed in Japan and approved in 2008 for treating respiratory and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">urinary tract infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (63) . Here, we showed <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sitafloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>'s efficacy against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and biofilm, which has not been reported (59) . This is significant since implant-associated <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">osteomyelitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is a <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> associated with both <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">biofilm<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Thus, we propose that a repurposing approach using the AK <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">release<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> assay as the basis of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HTS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> can be an effective approach to identify new uses of approved drugs for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, including <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. For example, the repurposing of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sitafloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for this <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">orthopedic infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> could prove valuable for its potential efficacy in the treatment of implant-associated <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">osteomyelitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. This approach has decided advantages in saving money and time as opposed to novel drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (60) . The full potential of this assay as an <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HTS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> tool is that it can be scalable to large drug or novel chemical libraries, which should be screened not only against lab strains but also against various clinical isolates of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> strains associated with many <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.29.924100\"><h2> Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Liu, X.; Wang, X.-J.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In summary, basing on the structural information of clinical effective medicines for 2019-nCoV, we have predicted a list of commercial medicines which may function as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for 2019-nCoV by <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> its main protease M <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> . Compared to lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, most of these predicted drugs could form more <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hydrogen<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> bounds with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCoV M pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> , thus may have higher mutation <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tolerance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> than lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.16.994236\"><h2> The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Erik Procko</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The rapid and escalating spread of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS coronavirus 2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2) 6 poses an immediate public health <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and no approved therapeutics or 7</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.26.964882\"><h2> Structure of Mpro from COVID-19 virus and discovery of its inhibitors</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Peng, C.; Duan, Y.; Yu, J.; Wang, L.; Yang, K.; Liu, F.; Jiang, R.; Yang, X.; You, T.; Liu, X.; Yang, X.; Bai, F.; Liu, H.; Liu, X.; Guddat, L. W.; Xu, W.; Xiao, G.; Qin, C.; Shi, Z.; Jiang, H.; Rao, Z.; Yang, H.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">we used our FRET assay, to screen a library of ~10,000 compounds consisting of 156 approved drugs, clinical trial drug candidates and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Primary hits included 157 seven compounds that are either FDA-approved drugs or clinical trial/preclinical drug 158 candidates. We then determined their IC50 values, which are in the range from 0.67 to 21.4 159 M (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Fig. 3<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>). Amongst them, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">disulfiram<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and carmofur are FDA-approved drugs, whilst 160 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ebselen<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, shikonin, tideglusib, PX-12 and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">TDZD-8<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> are currently in clinical trials or 161 preclinical studies. Ebselen has the strongest <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">M pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> activity with an IC50 of 0.67 162</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10040152\"><h2> Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Cui, Qinghua; Du, Ruikun; Anantpadma, Manu; Schafer, Adam; Hou, Lin; Tian, Jingzhen; Davey, Robert A.; Cheng, Han; Rong, Lijun</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In contrast to synthetic small molecules, TCMs (and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) have better coverage of biologically relevant chemical space and are more likely to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reach<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">intracellular<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> site of action [3, 37] . In fact, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, including TCMs, are one of the most important sources for discovery and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of new drugs. Many <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-derived compounds were reported with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> effects, and some of them have been investigated for their <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> efficacy in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> studies and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> clinical trials. Between 1981 and 2014, approximately 70% of approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> small molecule drugs were originally derived from botanic <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or their derivatives [38] . The current study focused on evaluating TCMs to identify potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-Ebola agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, using a <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-based screening high-throughput protocol developed by us [5, 39] , and we showed that <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">R. rosea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> extract is an effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-filoviral agent<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, particularly against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">R. rosea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> extract had an IC 50 value of 0.25 g/mL in the pseudovirus <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> assay and an IC 50 value of 3.9 g/mL in an <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> EBOV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> assay, respectively, while it inhibited <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Marburg virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> with an IC 50 value of 4.0 g/mL in pseudovirus assay and an IC 50 value of~25 g/mL in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> assay, respectively (Figures 2 and 4) . The anti-EBOV activity of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">R. rosea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is better than that (IC 50~6 .25 g/mL) of the best reported TCM <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Prunella vulgaris<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> extract so far [40] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Twenty structures including 19 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 targets and 1 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> target were built by homology modeling. Library of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug database, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, 78 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were screened against these targets plus <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. This study provides drug repositioning candidates and targets for further in vitro and in vivo studies of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2. (Mengzhu Zheng), xingzhouli@aliyun.com (Xingzhou <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Li<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>).  These authors made equal contributions to this work.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Twenty structures including 19 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 targets and 1 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> target were built by homology modeling. Library of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug database, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, 78 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were screened against these targets plus <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. This study provides drug repositioning candidates and targets for further in vitro and in vivo studies of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2. (Mengzhu Zheng), xingzhouli@aliyun.com (Xingzhou <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Li<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>).  These authors made equal contributions to this work.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.20.20025874\"><h2> Rapid colorimetric detection of COVID-19 coronavirus using a reverse tran-scriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic plat-form: iLACO</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Lin Yu; Shanshan Wu; Xiaowen Hao; Xuelong Li; Xiyang Liu; Shenglong Ye; Heng Han; Xue Dong; Xin Li; Jiyao Li; Jianmin Liu; Na Liu; Wanzhong Zhang; Vicent Pelechano; Wei-Hua Chen; Xiushan Yin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The recent outbreak of a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-CoV-2 (also known as 2019-nCoV) threatens global health, given serious cause for concern. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 is a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-to-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> pathogen that caused <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (known as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>). By press time, more than 70,000 infected people had been confirmed worldwide. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 is very similar to the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> broke out 17 years ago. However, it has increased transmissibility as compared with the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, e.g. very often infected individuals without any symptoms could still transfer the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to others. It is thus urgent to develop a rapid, accurate and onsite diagnosis methods in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">order<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to effectively identify these early infects, treat them on time and control the disease spreading. Here we developed an isothermal LAMP based method-iLACO (isothermal LAMP based method for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) to amplify a fragment of the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ORF1ab gene<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> using 6 primers. We assured the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">species<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-specificity of iLACO by comparing the sequences of 11 related <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> by <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">BLAST<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> (including 7 similar coronaviruses, 2 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and 2 normal coronaviruses). The sensitivity is comparable to Taqman based qPCR detection method, detecting synthesized RNA equivalent to 10 copies of 2019-nCoV <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Reaction time varied from 15-40 minutes, depending on the loading of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in the collected samples. The accuracy, simplicity and versatility of the new developed method suggests that iLACO assays can be conveniently applied with for 2019-nCoV threat control, even in those cases where specialized molecular biology equipment is not available.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1128/AAC.02373-19\"><h2> Screening of Natural Extracts for Inhibitors against Japanese Encephalitis Virus Infection</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Guo, Jiao; Jia, Xiaoying; Liu, Yang; Wang, Shaobo; Cao, Junyuan; Zhang, Bo; Xiao, Gengfu; Wang, Wei</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">JEV continues to spread in Asia and other parts of the world, causing severe clinical manifestations such as permanent neurological or psychiatric sequelae. Currently, there is no safe and effective treatment for JEV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Recently, Wang et al. performed a library screen of 1,018 FDA-approved compounds and reported that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">manidipine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">calcium<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> blocker using in the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hypertension<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, inhibited JEV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in vitro and in vivo (11). Similarly, <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Fang<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> et al. tested <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">1,280<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> FDA-approved drugs and found that</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1097/CM9.0000000000000757\"><h2> Personal knowledge on novel coronavirus pneumonia</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Kang, Han-Yujie; Wang, Yi-Shan; Tong, Zhao-Hui</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Supportive treatment remains the mainstay for <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NCP<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>. Respiratory support ensures that the patient is not <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hypoxic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and also protects other <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">organs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>. There are currently no effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drugs should be administered strictly and rationally. Shuanghuanglian and similar drugs have demonstrated inhibitory effects against the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in in vitro experiments. However, their clinical effects are unknown, and clinical experiments are required to demonstrate their efficacy.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/healthcare8010051\"><h2> Outbreak of Novel Coronavirus (SARS-Cov-2): First Evidences From International Scientific Literature and Pending Questions</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Amodio, Emanuele; Vitale, Francesco; Cimino, Livia; Casuccio, Alessandra; Tramuto, Fabio</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">There are currently no vaccines against coronaviruses, including <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">compounds were docked with 19 constructed targets of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 and 2 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> targets to predict their possible targets, and also to search possible <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> partners of certain important targets. Special attentions were paid to the drugs currently in clinical trials. All results of calculated <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> scores were listed in the Supporting excel file (anti-virals_vs_targets_scores), significant scores (score&lt;-32, mfScore&lt;-110) were highlighted in brighten yellow. Remdesivir (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">GS-5734<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, is an <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>. It can inhibit <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> by inhibiting <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">synthesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of viral <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and has not yet been approved for marketing in any country. On January 31 of this year, the New England Journal of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> reported the diagnosis and treatment of the first <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 patient in the United States 47 . Remdesivir showed some potential in the treatment of the first patient with <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> infection. On Vero E6 <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, the EC 50 of remdesivir for <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> is 0.77 mol/L, and the selection index SI is greater than 129 48 . Remdesivir is currently undergoing a randomized, double-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, controlled phase III clinical study in China. Our molecular <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results show that the potential targets of remdesivir is Nsp3b (score=-36.5), <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> (mfScores=-112.8), E-channel (mfScore=-125.1), and TMPRSS2 (score=-36.23, mfScores=-109.4).For <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>, from generated <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> model, remdesivir could <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> to the RNA-<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> channel of the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and the <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> mode and site were highly similar to that of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coxsackievirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> B3 (CVB3)</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">compounds were docked with 19 constructed targets of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 and 2 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> targets to predict their possible targets, and also to search possible <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> partners of certain important targets. Special attentions were paid to the drugs currently in clinical trials. All results of calculated <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> scores were listed in the Supporting excel file (anti-virals_vs_targets_scores), significant scores (score&lt;-32, mfScore&lt;-110) were highlighted in brighten yellow. Remdesivir (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">GS-5734<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, is an <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>. It can inhibit <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> by inhibiting <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">synthesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of viral <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and has not yet been approved for marketing in any country. On January 31 of this year, the New England Journal of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> reported the diagnosis and treatment of the first <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 patient in the United States 47 . Remdesivir showed some potential in the treatment of the first patient with <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> infection. On Vero E6 <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, the EC 50 of remdesivir for <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> is 0.77 mol/L, and the selection index SI is greater than 129 48 . Remdesivir is currently undergoing a randomized, double-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, controlled phase III clinical study in China. Our molecular <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results show that the potential targets of remdesivir is Nsp3b (score=-36.5), <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> (mfScores=-112.8), E-channel (mfScore=-125.1), and TMPRSS2 (score=-36.23, mfScores=-109.4).For <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>, from generated <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> model, remdesivir could <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> to the RNA-<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> channel of the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and the <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> mode and site were highly similar to that of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coxsackievirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> B3 (CVB3)</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41422-020-0282-0\"><h2> Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Wang, Manli; Cao, Ruiyuan; Zhang, Leike; Yang, Xinglou; Liu, Jia; Xu, Mingyue; Shi, Zhengli; Hu, Zhihong; Zhong, Wu; Xiao, Gengfu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Our findings reveal that remdesivir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are highly effective in the control of 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in vitro. Since these compounds have been used in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> patients <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">suffering<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> from the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> disease.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.31.929547\"><h2> Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Beck, B. R.; Shin, B.; Choi, Y.; Park, S.; Kang, K.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCoV 3C-like proteinase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> was predicted to <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> with atazanavir (Kd 94.94 nM), followed by <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">efavirenz<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and other <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that have a predicted affinity of Kd &gt; 100 nM potency (Table   1 ). No other <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitor antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was found in the Kd &lt; 1,000 nM range. Although there is . CC-BY-NC-ND 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org /10.1101 /10. /2020 no real-world evidence about whether these drugs will act as predicted against 2019-nCoV yet, some case studies have been identified. For example, a <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> study of lopinavir along with other <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV proteinase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> of the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CoV proteinase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (PDBID 1UK3) suggests atazanavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which are listed in the present prediction results, may inhibit the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CoV proteinase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> in line with the inhibitory potency of lopinavir (14) . According to the prediction, viral <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteinase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> drugs were predicted to act more favorably on the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> process than viral <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteinase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> through the DTI model (Table 2 -6) . The results include <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> other than <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteinase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">guanosine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogues (e.g., <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acyclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ganciclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">penciclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reverse transcriptase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">integrase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">It should be noted that although the terms &quot;compassionate use&quot; or &quot;preapproval access&quot; are often used informally to refer to the use of an investigational drug to treat a patient outside of a clinical trial, these terms are not defined or described in FDA regulations, which simply refer to expanded access to investigational drugs.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">It should be noted that although the terms &quot;compassionate use&quot; or &quot;preapproval access&quot; are often used informally to refer to the use of an investigational drug to treat a patient outside of a clinical trial, these terms are not defined or described in FDA regulations, which simply refer to expanded access to investigational drugs.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/pathogens8040192\"><h2> Analysis of Resistance of Ebola Virus Glycoprotein-Driven Entry Against MDL28170, An Inhibitor of Cysteine Cathepsins</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Hoffmann, Markus; Kaufmann, Svenja Victoria; Fischer, Carina; Maurer, Wiebke; Moldenhauer, Anna-Sophie; Phlmann, Stefan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Multiple compounds have been shown to interfere with different steps of the EBOV lifecycle [34] , including <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cellular cysteine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> proteases [32, [35] [36] [37] [38] [39] . However, none of these compounds has been approved by regulatory agencies for treatment of EVD. The reasons for the lack of approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> include (i) unknown <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> efficacy in vivo (most data <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">stem<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> from in vitro experimentation), (ii) potential unwanted side-effects in patients, and (iii) potential <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> by the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> during treatment. Therefore, promising compounds and new </div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2019.02752\"><h2> Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MuLBSTA Score</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Guo, Lingxi; Wei, Dong; Zhang, Xinxin; Wu, Yurong; Li, Qingyun; Zhou, Min; Qu, Jieming</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Despite intense efforts, the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy to prevent or treat respiratory <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is under limitation. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Influenza antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were commonly used on the basis of international recommendations (Jefferson et al., 2014) . However, <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> has a relatively strict time window and several secondary effects like <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nausea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">renal syndromes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, and it's hard to use for unconscious patients (Lee et al., 2017) . There is no effective listed <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or vaccine approved for the prevention or treatment of non-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (Heylen et al., 2017) . In our study, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was commonly used as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy; while <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acyclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ganciclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">foscarnet<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were used for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cytomegalovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> or <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">herpes simplex virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Nevertheless, early <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment did not prevent progression to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> consistent with earlier studies (Elizaga et al., 2001; Chemaly et al., 2012) . The <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">confused<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> choice of respiratory <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> therapy makes it urgent to predict mortality more accurately.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2020.00150\"><h2> Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Takayama-Ito, Mutsuyo; Saijo, Masayuki</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Favipiravir exhibited higher effectiveness than <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in in vitro and in vivo studies (Tani et al., 2016 (Tani et al., , 2018 . Meanwhile, favipiravir remained effective when it was used following SFTSV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models (Tani et al., 2016 (Tani et al., , 2018 indicating its potential as an effective drug for treating SFTS patient. Currently, clinical trials are underway to evaluate the efficacy of favipiravir for treating patients with SFTS in Japan (Cyranoski, 2018; Spengler et al., 2018) . Besides, it would be desirable to use intravenous administration because SFTS patients with severe symptoms could have difficulty in taking drugs <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">orally<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41598-019-56481-0\"><h2> In Vivo Activity of Amodiaquine against Ebola Virus Infection</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> DeWald, Lisa Evans; Johnson, Joshua C.; Gerhardt, Dawn M.; Torzewski, Lisa M.; Postnikova, Elena; Honko, Anna N.; Janosko, Krisztina; Huzella, Louis; Dowling, William E.; Eakin, Ann E.; Osborn, Blaire L.; Gahagen, Janet; Tang, Liang; Green, Carol E.; Mirsalis, Jon C.; Holbrook, Michael R.; Jahrling, Peter B.; Dyall, Julie; Hensley, Lisa E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">World Health Organization guidelines. In an Ebola treatment center in Liberia, EVD patients receiving the combination <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimalarial artesunate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amodiaquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> had a lower risk of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">death<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> compared to those treated with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">artemether<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lumefantrine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. As <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">artemether<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">artesunate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are derivatives of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">artemisinin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, the beneficial <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (EBOV) effect observed could possibly be attributed to the change from <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lumefantrine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amodiaquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Amodiaquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is a widely used <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimalarial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in the countries that experience outbreaks of EVD and, therefore, holds promise as an approved drug that could be repurposed for treating EBOV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. We investigated the potential anti-EBOV effect of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amodiaquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in a well-characterized nonhuman <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">primate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> model of EVD. Using a similar 3-day <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimalarial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> dosing strategy as for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> patients, <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plasma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> concentrations of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amodiaquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in healthy <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> were similar to those found in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. However, the treatment regimen did not result in a survival benefit or decrease of disease signs in EBOV-infected <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. While <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amodiaquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> on its own failed to demonstrate efficacy, we cannot exclude potential therapeutic value of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amodiaquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> when used in combination with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">artesunate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or another <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2020.00150\"><h2> Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Takayama-Ito, Mutsuyo; Saijo, Masayuki</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Severe <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> with thrombocytopenia <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (SFTS) is an emerging <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tick<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-borne <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by SFTS <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (SFTSV), which is a novel <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bunyavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. SFTSV was first isolated from patients who presented with <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, thrombocytopenia, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">leukocytopenia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and multiorgan dysfunction in China. Subsequently, it was found to be widely distributed in Southeast Asia (Korea, Japan, and Vietnam). SFTSV can be <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">transmitted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> not only from <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ticks<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> but also from domestic <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, companion <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Because the case fatality rate of SFTS is high (6-30%), <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of specific and effective treatment for SFTS is required. Studies of potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for SFTS-specific therapy have been conducted on existing or newly discovered agents in vitro and in vivo, with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and favipiravir being the most promising candidates. While <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> experiments and retrospective studies have demonstrated the limited efficacy of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, it was also speculated that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> would be effective in patients with a viral load &lt;1  10 6 copies/mL. Favipiravir showed higher efficacy than <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against SFTSV in in vitro assays and greater efficacy in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models, even administrated 3 days after the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> inoculation. Although clinical trials evaluating the efficacy of favipiravir in SFTS patients in Japan are underway, this has yet to be confirmed. Other drugs, including hexachlorophene, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">calcium channel blockers<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, 2  -fluoro-2  -deoxycytidine, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">caffeic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amodiaquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and interferons, have also been evaluated for their inhibitory efficacy against SFTSV. Among them, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">calcium channel blockers<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> are promising because in addition to their efficacy in vitro and in vivo, retrospective clinical data have indicated that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nifedipine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, one of the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">calcium channel blockers<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, reduced the case fatality rate by &gt;5-fold. Although further research is necessary to develop SFTS-specific therapy, considerable progress has been achieved in this area. Here we summarize and discuss recent advances in <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against SFTSV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1177/2040206618764483\"><h2> Nucleosides for the treatment of respiratory RNA virus infections</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Jordan, Paul C; Stevens, Sarah K; Deval, Jerome</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In this section, we aim to answer the following questions that are important to medicinal chemists, biologists, and drug developers working in the field of Virology. Are there clinically relevant <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogs that are potent against one or multiple respiratory <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>? How were these molecules first identified, and which ones have been approved for commercial use? Why aren't molecules like <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and its analogs more widely used to treat respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>? What are the current approaches to develop new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogs against respiratory RNA <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>?</div><p><hr>\n",
       "<a href = \"https://doi.org/10.14218/JCTH.2018.00005\"><h2> Recent Advances Towards the Development of a Potent Antiviral Against the Hepatitis E Virus</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Anang, Saumya; Kaushik, Nidhi; Surjit, Milan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Several laboratories have been focusing on identifying suitable drug targets and developing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. 50 Summarized below is the outcome of recent efforts to identify potent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.12688/f1000research.22211.2\"><h2> Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Kruse, Robert L.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The dire situations facing patients in outbreak scenarios demand quick responses by the healthcare community and the biotech industry. Unfortunately, many of the traditional options that guide drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> are inadequate for outbreaks; a process that takes years can't help patients who are <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dying<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> today, and economies that are being halted. In these situations, studies have often been conducted on compassionate use, and clinical trial approvals expedited. This was most recently seen in the 2014-2015 Ebola outbreak, where a variety of clinical trial candidates were studied. Many of these therapies failed, but ultimately a vaccine did emerge that was fully protective against the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> 12 . It is important to note that, unlike the current situation with 2019-nCoV, Ebola had already been studied for years and this particular neutralizing vaccine made and tested in preclinical <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models years prior to the outbreak 13 . For 2019-nCoV, beyond knowing the sequence of spike (S) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (GenBank: MN908947.3), there are no studies on how immunogenic this particular <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> will be beyond surrogate comparisons to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and MERS, which limits the potential ability to quickly produce a vaccine. Moreover, while a vaccine would be greatly effective in helping to stop the spread of 2019-nCoV, an effective therapy is also needed for the patients infected with 2019-nCoV today, similar to the situation of Ebola patients needing effective therapies while vaccines were being developed.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.12688/f1000research.22211.2\"><h2> Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Kruse, Robert L.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The dire situations facing patients in outbreak scenarios demand quick responses by the healthcare community and the biotech industry. Unfortunately, many of the traditional options that guide drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> are inadequate for outbreaks; a process that takes years can't help patients who are <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dying<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> today, and economies that are being halted. In these situations, studies have often been conducted on compassionate use, and clinical trial approvals expedited. This was most recently seen in the 2014-2015 Ebola outbreak, where a variety of clinical trial candidates were studied. Many of these therapies failed, but ultimately a vaccine did emerge that was fully protective against the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> 12 . It is important to note that, unlike the current situation with 2019-nCoV, Ebola had already been studied for years and this particular neutralizing vaccine made and tested in preclinical <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models years prior to the outbreak 13 . For 2019-nCoV, beyond knowing the sequence of spike (S) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (GenBank: MN908947.3), there are no studies on how immunogenic this particular <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> will be beyond surrogate comparisons to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and MERS, which limits the potential ability to quickly produce a vaccine. Moreover, while a vaccine would be greatly effective in helping to stop the spread of 2019-nCoV, an effective therapy is also needed for the patients infected with 2019-nCoV today, similar to the situation of Ebola patients needing effective therapies while vaccines were being developed.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.00531\"><h2> Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Pizzorno, Andrs; Padey, Blandine; Terrier, Olivier; Rosa-Calatrava, Manuel</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">As mentioned above, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are key players in pandemic preparedness programs, being the first choice for the treatment of infected patients as well as for preventive post-exposure prophylaxis of those potentially exposed to the new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, especially during the initial pandemic period in which no vaccine is available. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are as well important in the normal seasonal setting. Although their use is mostly focused on the treatment of severely <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ill<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients and the immunocompromised, some countries, including the USA and Japan, regularly resort to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for the management of uncomplicated <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in otherwise healthy patients (11, 12) . To date, only two classes of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are globally approved and available for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>: M2 ion-channel blockers and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (NA) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The first <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> includes <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adamantane<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> derivatives, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and rimantadine, which inhibit <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proton<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> conductivity of the M2 <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ion channel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> of <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> hence preventing the viral uncoating step of the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral replication cycle<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Nevertheless, although quite efficient in their early days, widespread dissemination of the S31N (and to a much lesser extent V27A) M2 <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> mutation in post-2006 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">H3N2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">post-2009<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> H1N1 circulating strains prompted the WHO to remove both <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and rimantadine from the list of recommended anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> agents for clinical use, in 2009 (6) . As a result, NA <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> stand as the only <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> currently recommended by the WHO (13) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11070604\"><h2> Anti-Respiratory Syncytial Virus Activity of Plantago asiatica and Clerodendrum trichotomum Extracts In Vitro and In Vivo</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Chathuranga, Kiramage; Kim, Myun Soo; Lee, Hyun-Cheol; Kim, Tae-Hwan; Kim, Jae-Hoon; Gayan Chathuranga, W. A.; Ekanayaka, Pathum; Wijerathne, H. M. S. M.; Cho, Won-Kyung; Kim, Hong Ik; Ma, Jin Yeul; Lee, Jong-Soo</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Traditional medicines have been used as remedies against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> for thousands of years, due to their significant anti-inflammatory, anti-microbial activity and low rate of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adverse effects<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [29, 30] . These medicines have been gaining in popularity, due to concerns related to the side effects, high cost, and lack of efficacy of conventional Western medicines [31] . In the years 2001 and 2002, approximately one-quarter of the bestselling drugs worldwide were <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or were derived from <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [32] . Recent publications show that traditional Chinese medicinal herbs account for 10% of the prescription drugs in China. They are perceived as harmless and natural and are widely used in many parts of the world, individually or in combination [33] . In particular, medicinal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> have shown potential therapeutic effects against a wide range of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory tract<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>-related <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, including <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Severe Acute Respiratory Syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) [34] [35] [36] , <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [37, 38] , and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> [26, 27, 39] . Among the thousands of promising medicinal herbs, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Plantago asiatica<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Clerodendrum trichotomum<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are well-known and commonly used in traditional <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in China, Japan, and South Korea [9, 14, 15] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2018.02147\"><h2> Epidemiology and Immune Pathogenesis of Viral Sepsis</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Lin, Gu-Lung; McGinley, Joseph P.; Drysdale, Simon B.; Pollard, Andrew J.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Prospective treatments for specific <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> implicated in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sepsis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are being developed. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pleconaril<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">enteroviral infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> which inhibits viral attachment to the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hosts cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> receptors and prevents uncoating of the viral <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleic acids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. There are data suggesting that the drug would be effective and safe in neonatal virally induced <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sepsis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (248) . The drug recently completed a small phase 2 clinical trial (248) ; however, it is no longer under <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and is not available, even for compassionate use. The benefits of more effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> medicines are clear. They could help both in cases of severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sepsis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> while also providing treatment for more benign <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. It could prove useful to use such drugs alongside <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sepsis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> cases, to allow for the possibility of a viral cause, although this would also open the possibility of the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. There are many specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that have been developed and gone through trials; however, none have yet been tested specifically for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sepsis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Examples that may be beneficial in presentations of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sepsis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in certain situations include <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acyclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which has been proven effective in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (249) , <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, rimantadine, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (250, 251) , and more broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> like <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and favipiravir (250) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Syntex then sought approval to study <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ganciclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CMV colitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, knowing that once marketing approval of the drug was obtained, FDA rules would allow &quot;off-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">label<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>&quot; use for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">retinitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (14) . At this time, EA of nonapproved drugs for treatment of more than 1 patient at a time is achievable only through the FDA, in contrast with access for individual patients, which technically can be legally obtained without the FDA by applying to the manufacturer directly (6) . As with individual EA INDs, specific conditions for group patient access apply: 1) the patients must have a serious or immediately life-threatening disease or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">condition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with no comparable therapy or satisfactory alternative therapy;</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Syntex then sought approval to study <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ganciclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CMV colitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, knowing that once marketing approval of the drug was obtained, FDA rules would allow &quot;off-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">label<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>&quot; use for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">retinitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (14) . At this time, EA of nonapproved drugs for treatment of more than 1 patient at a time is achievable only through the FDA, in contrast with access for individual patients, which technically can be legally obtained without the FDA by applying to the manufacturer directly (6) . As with individual EA INDs, specific conditions for group patient access apply: 1) the patients must have a serious or immediately life-threatening disease or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">condition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with no comparable therapy or satisfactory alternative therapy;</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1371/journal.pntd.0007964\"><h2> Fungal diseases as neglected pathogens: A wake-up call to public health officials</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Rodrigues, Marcio L.; Nosanchuk, Joshua D.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The fact that there are no licensed <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antifungal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> vaccines underscores another clear failure in science. Similarly, reliable diagnostic methods are available for a very limited number of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mycoses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [23] , and therapeutic options are restricted to a few classes of drugs that too frequently are associated to both intrinsic and acquired <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> [24] , toxic, and expensive [25] . In fact, innovative tools to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> invasive <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mycoses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are rare and of slow <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. For illustration, the most recently developed <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antifungals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (echinocandins) were approved for clinical use in 2002 [26] , reinforcing a major science failure in the area. It is noteworthy that this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of drugs is ineffective against various high-mortality <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mycoses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [25] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fphar.2018.01270\"><h2> Elucidating the Interaction of CF Airway Epithelial Cells and Rhinovirus: Using the Host-Pathogen Relationship to Identify Future Therapeutic Strategies</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Ling, Kak-Ming; Garratt, Luke W.; Lassmann, Timo; Stick, Stephen M.; Kicic, Anthony</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">An alternative strategy is to explore drug repurposing. Integrated analysis of disease-gene profiles, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathway<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> analysis, and mining of FDA approved drug databases can be carried out to identify correlations of common <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> with certain compounds or molecules at the network level. Successful examples of drug repurposing based on transcriptomic analyses include the identification of topiramate for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inflammatory bowel disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IBD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cimetidine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lung adenocarcinoma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> Sirota et al., 2011) . Using a large-scale <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">expression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> signature, Lee et al. (2016) have also identified that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ivermectin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">trifluridine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">astemizole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amlodipine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">maprotiline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">apomorphine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mometasone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nortriptyline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> show significant anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proliferative<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> activity against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">glioblastoma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. With the recent establishment of ImmPort, a data repository that promotes research dataset repurposing (Bhattacharya et al., 2018) , the identification of novel targets and repurposed drugs that target these has been accelerated further. Currently, there is paucity of data in CF-related RVtherapy given its impact on CF <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lung disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and thus new interventions are urgently required. The strategy to repurpose already approved drugs could advance <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapies by reducing cost and improving and quality of life for affected individuals.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.27.921627\"><h2> Nelfinavir was predicted to be a potential inhibitor of 2019 nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Xu, Z.; Peng, C.; Shi, Y.; Zhu, Z.; Mu, K.; Wang, X.; Zhu, W.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Based on its function, the main protease (M <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> ) or <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chymotrypsin-like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (3CL <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> ) 4 is suggested to be a potential drug target to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 2019-nCov, which is highly conservable among coronaviruses. Sequence alignment revealed that the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">M pro of 2019-nCov<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> shares 96% similarity with that of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) (Figure 1 ). Studies for identifying the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCov M pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> were quickly performed for discovering and developing drugs against the disease. For example, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Hualiang Jiang<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and collaborators identified 30 drugs and compounds as the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">M pro inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> via <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> modelling and virtual screening, which is a rapid progress in the way to cope with the crisis. In addition, one of the 30 drugs/compounds, remdesivir, was also suggested to be potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against 2019-nCov by Liu et al, 5 For finding more potential drugs as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, we modelled the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCov M pro structures using SARS M pro (PDB ID: 2GTB<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) as template and docked 1903 approved drugs against the model in this study. Fifteen drugs were selected based on the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> score and three dimensional (3D) similarity to available M <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against other <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. For validation, we modelled 10 additional new models of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCov M pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and docked the 15 drugs against the new models, which revealed that 6 drugs (nelfinavir, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">praziquantel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pitavastatin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">perampanel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, eszopiclone, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zopiclone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) have good <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> modes with the new models. <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> free energy calculation were then performed for 4 of the 6 drugs using MM/GBSA and SIE methods. Nelfinavir was identified as the best one with predicted <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> free energies of -24.690.52 kcal/mol by MM/GBSA and -9.420.04 kcal/mol by SIE, respectively. Taking into account its high 3D similarity of <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> mode to the known M <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, we proposed that nelfinavir should be a potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCov M pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/vaccines7020053\"><h2> Current and Novel Approaches in Influenza Management</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Kotey, Erasmus; Lukosaityte, Deimante; Quaye, Osbourne; Ampofo, William; Awandare, Gordon; Iqbal, Munir</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Influenza antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> approved or in clinical trials.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10090448\"><h2> A Human DPP4-Knockin Mouses Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Fan, Changfa; Wu, Xi; Liu, Qiang; Li, Qianqian; Liu, Susu; Lu, Jianjun; Yang, Yanwei; Cao, Yuan; Huang, Weijin; Liang, Chunnan; Ying, Tianlei; Jiang, Shibo; Wang, Youchun</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> 2018, 10, 448 2 of 20 be a long and tough battle [2] . Unfortunately, no clinically-approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> (mAbs), small molecule drugs or vaccines against MERS-CoV are available.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10060283\"><h2> Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Shin, Jin Soo; Jung, Eunhye; Kim, Meehyein; Baric, Ralph S.; Go, Yun Young</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Repurposing clinically validated products is a valuable approach for drug discovery, which has the potential to greatly reduce the time and costs associated with the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and licensure of de novo therapeutics [12] . Prompt response and availability of a therapeutic option are especially critical for controlling the spread of highly <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> pathogens such as MERS-CoV. Along these lines, several Food and Drug Administration (FDA)-approved compounds have been reported to inhibit MERS-CoV replication in <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> culture since its emergence [13] [14] [15] [16] [17] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1080/22221751.2020.1723441\"><h2> An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Jiang, Shibo; Du, Lanying; Shi, Zhengli</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">We have recently designed and engineered a <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pan-CoV fusion inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, EK1 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">peptide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which could inhibit <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of five <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> coronaviruses, including <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and MERS-CoV, and three <mark class=\"entity\" style=\"background: #E6E6FA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ENZY</span></mark>-SL-CoVs [7] . Intranasal application of EK1 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">peptide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> before or after viral challenge, EK1 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">peptide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can protect <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> DPP4-transgenic <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mice<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> from MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, suggesting its potential prophylactic and therapeutic effect against 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Once confirmed, we will develop EK1 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">peptide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> as a t prophylactic or therapeutic for intranasal application to prevent or treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> by 2019-nCoV and other emerging coronaviruses in the future.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s13063-017-2427-0\"><h2> Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-1b (MIRACLE trial): study protocol for a randomized controlled trial</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Arabi, Yaseen M.; Alothman, Adel; Balkhy, Hanan H.; Al-Dawood, Abdulaziz; AlJohani, Sameera; Al Harbi, Shmeylan; Kojan, Suleiman; Al Jeraisy, Majed; Deeb, Ahmad M.; Assiri, Abdullah M.; Al-Hameed, Fahad; AlSaedi, Asim; Mandourah, Yasser; Almekhlafi, Ghaleb A.; Sherbeeni, Nisreen Murad; Elzein, Fatehi Elnour; Memon, Javed; Taha, Yusri; Almotairi, Abdullah; Maghrabi, Khalid A.; Qushmaq, Ismael; Al Bshabshe, Ali; Kharaba, Ayman; Shalhoub, Sarah; Jose, Jesna; Fowler, Robert A.; Hayden, Frederick G.; Hussein, Mohamed A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A clinical pharmacist and the treating physician will evaluate each patient at the time of enrollment and daily throughout the study period until day 14 to identify any interactions between the investigated treatments and other drugs, and they will take action accordingly. Table 1 summarizes common medications that may interact with lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and a suggested action <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2019.00718\"><h2> Potent Inhibition of Zika Virus Replication by Aurintricarboxylic Acid</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Park, Jun-Gyu; vila-Prez, Gins; Madere, Ferralita; Hilimire, Thomas A.; Nogales, Aitor; Almazn, Fernando; Martnez-Sobrido, Luis</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The recent outbreak of ZIKV accompanied with severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathology<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, including <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">microcephaly<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in newborns, prompted many researchers to develop prophylactic vaccines and to identify therapeutic drugs against ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> Larocca et al., 2016; Lessler et al., 2016; Shan et al., 2017; Fink et al., 2018) . Currently, there are no commercially available vaccines and/or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapies for the treatment of ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Therefore, there is an urgent medical need for the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">counter<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> measurements to control ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10040191\"><h2> Combination Kinase Inhibitor Treatment Suppresses Rift Valley Fever Virus Replication</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Bell, Todd M.; Espina, Virginia; Lundberg, Lindsay; Pinkham, Chelsea; Brahms, Ashwini; Carey, Brian D.; Lin, Shih-Chao; Dahal, Bibha; Woodson, Caitlin; de la Fuente, Cynthia; Liotta, Lance A.; Bailey, Charles L.; Kehn-Hall, Kylene</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">One of our overarching goals is to find safe, effective, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and, to this end, we are currently focused on <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-based therapeutics. Worldwide, effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapies to date have been few, so we looked at this problem anew in the hope of finding novel ways to fight deadly <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Our current strategy is to inhibit machinery needed for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to propagate, and, in this case, that deprivation is in the form of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">translational<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> shutoff through <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">kinase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. This study establishes that combination therapy can not only be effective at slowing <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, but that it can be done with lower drug concentrations than what is necessary for individual drug therapy.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1080/01652176.2019.1580827\"><h2> Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies  a comprehensive review</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Singh, Raj Kumar; Dhama, Kuldeep; Chakraborty, Sandip; Tiwari, Ruchi; Natesan, Senthilkumar; Khandia, Rekha; Munjal, Ashok; Vora, Kranti Suresh; Latheef, Shyma K.; Karthik, Kumaragurubaran; Singh Malik, Yashpal; Singh, Rajendra; Chaicumpa, Wanpen; Mourya, Devendra T.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">essence<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of treatment modalities along with effective therapeutics is understood, once there is an outbreak of an <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. There is a need for administering therapeutics to manage the patients during NiV outbreaks and to prevent the mortality. No specific drug has been yet approved for the treatment of this important disease. Limited work has been done to develop therapeutics against NiV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. In preclinical studies, monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> have been used for treatment purposes. Due to the expensive nature of the drugs based on <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, identification of broad spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is essential along with focusing on small interfering RNAs (siRNAs) (Satterfield 2017) . In <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models, the NiV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathogenesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> has been understood by shedding light on the crucial nature of phospho-matrix as well as accessory <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. For the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of novel anti-NiV drugs, such viral <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, fusion <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">glycoprotein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virion<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> surface are attractive targets (<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Mathieu<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> et al. 2012; Satterfield et al. 2015 Satterfield et al. , 2016b Watkinson and Lee 2016; Satterfield 2017) . A monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral G glycoprotein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> has been shown beneficial in a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ferret<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> model of the NiV disease (Bossart et al. 2009 ). A successful outcome of an in vivo study using an investigational therapeutic, i.e. fully humanized monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> m102.4 against NiV, in a nonhuman <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">primate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> model highlights the availability of potential drug for NiV treatment in future (Geisbert et al. 2014 ). All the 12 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">African green monkeys<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that received m102.4 survived the NiV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, whereas the untreated control subjects succumbed to disease between days 8 and 10 after <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. It has been noticed in the recent outbreak in Kerala in South India that the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> ribavirincould be explored as anti-NiV agent (https://indianexpress.com/ article/india/nipah-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-outbreak-in-kerala-everythingyou-need-to-know-5194341/). Supportive therapies such as hydration and ventilator support constitute important aspects of clinical management of NiV cases.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.00531\"><h2> Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Pizzorno, Andrs; Padey, Blandine; Terrier, Olivier; Rosa-Calatrava, Manuel</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">These last 10 years, there has been a remarkable growing interest for drug repurposing in the field of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> discovery, fueled by the incontestable reality of many known <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> still lacking specific treatment. This interest is inversely correlated with the very low number of classic <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> molecules that have been market-approved these last 5 years, mostly for the treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatitis C virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-related pathologies (72) . The best example of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> repurposing approaches are emerging <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> such as Ebola, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zika virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> or MERS-CoV, for which there is an urgent and cost-effective need for therapeutics solutions. Indeed, to rapidly propose a solution in the context of a viral outbreak, one interesting approach consists to look at the available pharmacopeia used to treat pathogens. For example, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, a major <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimalarial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug, has been proposed for the treatment of filoviral <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and more largely for the treatment of other emerging pathogens, as it targets endosomal <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acidification<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, a pivotal step in the replication cycle of a large number of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (73, 74) . Another interesting illustration is the previously cited example of favipiravir, which proved its repurposing potential for the treatment of Zika or Ebola <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (25, 43, 75) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s12929-019-0592-z\"><h2> Development of therapeutic antibodies for the treatment of diseases</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Lu, Ruei-Min; Hwang, Yu-Chyi; Liu, I-Ju; Lee, Chi-Chiu; Tsai, Han-Zen; Li, Hsin-Jung; Wu, Han-Chung</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">It has been more than three decades since the first monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> engineering has dramatically evolved. Current <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> have increasingly fewer <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adverse effects<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> due to their high specificity. As a result, therapeutic <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> have become the predominant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of new drugs developed in recent years. Over the past five years, <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> have become the best-selling drugs in the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> market, and in 2018, eight of the top ten bestselling drugs worldwide were biologics. The global therapeutic monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> market was valued at approximately US$115.2 billion in 2018 and is expected to generate revenue of $150 billion by the end of 2019 and $300 billion by 2025. Thus, the market for therapeutic <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> drugs has experienced <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">explosive growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> as new drugs have been approved for treating various <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> diseases, including many <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancers<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">autoimmune<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metabolic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. As of December 2019, 79 therapeutic mAbs have been approved by the US FDA, but there is still significant <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> potential. This review summarizes the latest market trends and outlines the preeminent <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> engineering technologies used in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of therapeutic <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> drugs, such as humanization of monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, phage display, the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human antibody mouse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, single <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">B cell antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> technology, and affinity <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">maturation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Finally, future applications and perspectives are also discussed.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/333021\"><h2> Rapid Therapeutic Recommendations in the Context of a Global Public Health Crisis using Translational Bioinformatics Approaches: A proof-of-concept study using Nipah Virus Infection</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Shameer, K.; Johnson, K. W.; Readhead, B.; Glicksberg, B.; McCallum, C.; R, A.; Hirsch, J.; Bock, K.; Chelico, J.; Hajizadeh, N.; Oppenheim, M.; Dudley, J.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">that costs billions of dollars and may take more than a decade to deliver a drug to the market. Multiple reports on computational, pre-clinical, off-validation, and other mode-ofsuccess for drug repositioning are available in biomedical literature. But there was no comprehensive, integrative analysis of reported repositioned drugs, their indications, repositioned drug targets, or chemical properties of repositioned drugs. Recently, we compiled drug repositioning investigations from literature and other public data repositories and developed, the first comprehensive resource of drug repurposing (See RepurposeDB: A reference database of drug repositioning investigations -http, //repurposedb.dudleylab.org/). By integrating large-scale data on drugs, indication, side effects, and mechanism of actions, the computational drug repositioning process can be automated. Predictive data can be used for prioritizing candidate drugs for downstream studies including biochemical validation and clinical trials. Thus, computational drug repositioning offers a predictive framework for accelerated therapeutic recommendation in scenarios that requires immediate therapeutic stratification [106-114].</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s13063-017-2427-0\"><h2> Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-1b (MIRACLE trial): study protocol for a randomized controlled trial</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Arabi, Yaseen M.; Alothman, Adel; Balkhy, Hanan H.; Al-Dawood, Abdulaziz; AlJohani, Sameera; Al Harbi, Shmeylan; Kojan, Suleiman; Al Jeraisy, Majed; Deeb, Ahmad M.; Assiri, Abdullah M.; Al-Hameed, Fahad; AlSaedi, Asim; Mandourah, Yasser; Almekhlafi, Ghaleb A.; Sherbeeni, Nisreen Murad; Elzein, Fatehi Elnour; Memon, Javed; Taha, Yusri; Almotairi, Abdullah; Maghrabi, Khalid A.; Qushmaq, Ismael; Al Bshabshe, Ali; Kharaba, Ayman; Shalhoub, Sarah; Jose, Jesna; Fowler, Robert A.; Hayden, Frederick G.; Hussein, Mohamed A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Since the first report of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with the Middle East Respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Syndrome coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (MERS-CoV) was published in 2012, the World Health Organization has been notified of 2123 laboratory-confirmed <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with MERS-CoV from 27 countries and at least 740 reported <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">deaths<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (case fatality 35%) [1] . There is no specific therapy of proven efficacy available and no potential treatment has been tested in a randomized clinical trial (RCT) for evaluation [2] [3] [4] . Based on results from in vitro and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> studies of MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">guanosine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analog <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, in combination with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon alpha<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>), has been used to treat patients with MERS [5] [6] [7] [8] . However, the concentration of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> required to inhibit MERS-CoV in vitro exceeds peak levels in the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blood<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> after therapeutic doses in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> [9] [10] [11] . Furthermore, retrospective studies with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-2a<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-2b<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> or <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-1a<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> in combination with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have not shown a clear benefit in patients with MERS [6] [7] [8] 12] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1371/journal.pone.0194880\"><h2> Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Postnikova, Elena; Cong, Yu; DeWald, Lisa Evans; Dyall, Julie; Yu, Shuiqing; Hart, Brit J.; Zhou, Huanying; Gross, Robin; Logue, James; Cai, Yingyun; Deiuliis, Nicole; Michelotti, Julia; Honko, Anna N.; Bennett, Richard S.; Holbrook, Michael R.; Olinger, Gene G.; Hensley, Lisa E.; Jahrling, Peter B.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (EBOV) <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and nonhuman <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">primates<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is often associated with high morbidity and mortality rates, as well as severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hemorrhagic fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [1] [2] [3] [4] . EBOV is a biosafety level-4 pathogen <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">transmitted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> by contact with bodily <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fluids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, fomites, or droplets from PLOS infected patients. EBOV is considered a significant threat to public health and global security due to its potential to be used as a bioweapon [5] [6] [7] [8] . Currently, no FDA-approved vaccine or therapeutic agents are available, and supportive care remains the standard for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (EVD) treatment. Therefore, accelerated efforts in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of therapeutics is a key objective in the EBOV research community, especially since the 2013-2016 EVD epidemic in Western Africa. Drug discovery and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> requires considerable time and resources to identify an effective drug that will progress to clinical trials [9, 10] . As a result, research investigating the repurposing of drugs for additional indications have become increasingly more prevalent to accelerate the identification of therapeutic drugs for EVD. The off-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">label<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> use of FDA-approved drugs is particularly advantageous as safety concerns and ethical problems have already been addressed [11] [12] [13] [14] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/vaccines7020053\"><h2> Current and Novel Approaches in Influenza Management</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Kotey, Erasmus; Lukosaityte, Deimante; Quaye, Osbourne; Ampofo, William; Awandare, Gordon; Iqbal, Munir</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Ingavirin, a drug developed in Russia, adds on the current list of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-limiting <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> due to its direct interference with the transportation of newly synthesized viral NP [122] [123] [124] . As of 2017, Ingavirin has been approved for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and other viral causes of acute respiratory illness, in Russia, following the completion of phase IV trial.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.03.20020263\"><h2> Network-based Drug Repurposing for Human Coronavirus</h2></a> (<i>relevance: 0.54</i>)\n",
       "<h6> Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Integration<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of drug-target networks, HCoV-<mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> interactions, HCoV-induced transcriptome in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human cell lines<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human protein-protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> interactome network are essential for such identification. Based on comprehensive evaluation, we prioritized 16 putative repurposable drugs ( Figure 5 ) and 3 putative drug combinations (Figure 6 ) for the potential treatment of HCoVs, including 2019-nCoV. However, all network-predicted repurposable drugs and drug combinations must be validated in preclinical models and randomized clinical trials before being used in patients.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11080704\"><h2> Human Antimicrobial Peptides as Therapeutics for Viral Infections</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Ahmed, Aslaa; Siman-Tov, Gavriella; Hall, Grant; Bhalla, Nishank; Narayanan, Aarthi</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">AMPs can also be applied as ointments, gels, or creams. For instance, a gel for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">vaginal candidiasis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> currently in clinical trials is derived from <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> -<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MSH<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [147] . As -<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MSH<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has previously demonstrated <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [146] , this form of treatment could be developed into a cheap and effective strategy to reduce <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> transmission. The treatment can be expanded to other <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sexually transmitted diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, such as <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and include many of the other classes of AMPs demonstrating <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against those particular <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Equally, <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> formulations or intravenous injections are more feasible for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> affecting internal <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">organs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Lactoferrin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has been used as an <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> supplement to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and greatly enhances the effectiveness of treatment [98] . While most studies utilizing <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> LF against other pathogens alone have not provided promising results, different AMPs may prove more effective against different pathogens. An intravenous treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> LF is currently in clinical trials for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteremia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fungal infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [147] . Interestingly, the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> Telaprevir, which is marketed for use against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> suggests that <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">eosinophil peptides<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> that have dual functionality as <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and AMPs may <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">possess<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> properties. In addition, AMPs that directly target <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> can serve as alternatives to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for which <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> has become an issue as it is a challenge for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to change their <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">envelope lipid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> compositions. Nonetheless, more research and investigation are required to assess the full potential of AMPs as novel therapeutics.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/antib8040053\"><h2> Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Wang, Lili; Xu, Jiyan; Kong, Yu; Liang, Ruiying; Li, Wei; Li, Jinyao; Lu, Jun; Dimitrov, Dimiter S.; Yu, Fei; Wu, Yanling; Ying, Tianlei</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In conclusion, our study indicated that the bispecific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have increased the efficacy against MERS-CoV, compared to the neutralizing <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">polypeptide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> alone. Such <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with the advantage of multiple biologics have the potential to be further developed as effective prophylactic and therapeutic agents, and may find wide application in treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ijid.2020.02.018\"><h2> Discovery and development of safe-in-man broad-spectrum antiviral agents</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjrs, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Here, we detail the steps of BSAA repurposing, from discovery of novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities in <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> culture to post-market studies. Moreover, we summarized currently available information on BSAAs in freely available database, focusing on those <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which have been already tested in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibacterials<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, antiprotozoals, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anthelmintics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, etc. Finally, we discuss future perspectives of using safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> BSAAs for treatment of emerging and re-emerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> as well as viral and bacterial <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">co-infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ijid.2020.02.018\"><h2> Discovery and development of safe-in-man broad-spectrum antiviral agents</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjrs, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Here, we detail the steps of BSAA repurposing, from discovery of novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities in <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> culture to post-market studies. Moreover, we summarized currently available information on BSAAs in freely available database, focusing on those <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which have been already tested in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibacterials<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, antiprotozoals, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anthelmintics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, etc. Finally, we discuss future perspectives of using safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> BSAAs for treatment of emerging and re-emerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> as well as viral and bacterial <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">co-infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10020093\"><h2> MERS-CoV: Understanding the Latest Human Coronavirus Threat</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Chafekar, Aasiyah; Fielding, Burtram C.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Interestingly, combination treatment with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and interferons inhibits MERS-CoV replication in vitro, and it was also shown to improve clinical outcomes in MERS-CoV-infected non-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human primates<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. However, this treatment in the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rhesus macaques<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> was initiated very soon after viral challenge (~8 h), resulting in reduced disease severity in the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rhesus macaque<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> model. This appears to simulate mild-to-moderate <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> MERS-CoV cases, making it difficult to extrapolate the outcome of this early intervention in severe <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> cases. Even though the authors recommended that combined <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-2b<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy should be considered as an early intervention therapy for MERS-CoV [115] , we also need to keep in mind that, due to the limited effective therapeutic window of opportunity, broad spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> might not be sufficient to treat severe MERS-CoV patients [122] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.05.20031476\"><h2> Appealing for Efficient, Well Organized Clinical Trials on COVID-19</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Yang Zhao; Yongyue Wei; Sipeng Shen; Mingzhi Zhang; Feng Chen</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">ahead of print. DOI: 10.3760/cma.j.issn.0254-6450.2020.03.004. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Table 1. Characteristics of the 171 Interventional Clinical Trials [n(%)]Notes: *<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chemical drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> include remdesivir, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, triavevirin, leflumite, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">glucocorticoid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, hydroxychloroquine, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">darunavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cobicistat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, etc. Biological therapies include PD1, bevacizumab, <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural killer cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> therapy and convalescent <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plasma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> therapy. TCM treatments include TCM and physical treatment (Qigong and Taiji).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.06.20032144\"><h2> CORONAVIRUS IN PREGNANCY AND DELIVERY: RAPID REVIEW AND EXPERT CONSENSUS</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Edward Mullins; David Evans; Russell Viner; Patrick O'Brien; Eddie Morris</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Therapeutics announced as being under consideration and trial in the outbreak include Kaletra (Lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), Remdesivir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Kaletra (24) is used in the UK during pregnancy for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> where the benefits of treatment outweigh the risks of toxicity seen in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> studies. The use of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> outweighs the risks in the prevention and treatment of <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">malaria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> during pregnancy (25). Remdesivir has been used for the treatment of Ebola in pregnant women(26), however it should be acknowledged that Ebola is a <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">condition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with a CFR of 50% for which there would be higher <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tolerance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adverse effects<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of a potentially beneficial treatment than would be the case for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> where the CFR is around 1%. It would seem reasonable not to exclude seriously <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ill<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> pregnant women from trials of these therapies for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ijid.2020.02.018\"><h2> Discovery and development of safe-in-man broad-spectrum antiviral agents</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjrs, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">: <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Viral diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are one of the leading causes of morbidity and mortality in the world. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-specific vaccines and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are the most powerful tools to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat viral diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. However, broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (BSAAs, i.e. compounds <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> belonging to two or more viral families) could provide additional protection of general population from emerging and reemerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> reinforcing the arsenal of available <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> options. Here, we reviewed discovery and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of BSAAs and summarized the information on 119 safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> agents in freely accessible database (https://drugvirus.info/). Future and ongoing pre-clinical and clinical studies will increase the number of BSAAs, expand spectrum of their indications, and identify drug combinations for treatment of emerging and re-emerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> as well as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">co-infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.12.20034231\"><h2> Heat inactivation of serum interferes with the immunoanalysis of antibodies to SARS-CoV-2</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Xiumei Hu; Taixue An; Bo Situ; Yuhai Hu; Zihao Ou; Qiang Li; Xiaojing He; Ye Zhang; Peifu Tian; Dehua Sun; Yongyu Rui; Qian Wang; Dan Ding; Lei Zheng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The current outbreak of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> disease-2019 (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) caused by a novel <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome coronavirus 2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2) is posing a serious threat to public health. [1] [2] [3] Early diagnosis of suspect cases is critical to reduce and interrupt the transmission of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> from person-to-person. 4 Currently, laboratory testing of viral <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> by real-time <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reverse transcriptase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>-polymerase chain reaction (RT-PCR) assay is the &quot;<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gold<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> standard&quot; for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> diagnosing. 5 However, the requirement of sophisticated instruments and laboratory conditions, tedious experimental procedures, and longer detection time significantly hamper its widespread applicability. 4 <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> produced in the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blood<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> after <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are emerging as a promising <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of biomarkers. 6 The <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 are specific, sensitive, and more importantly, their detection can be much faster and simpler than RT-PCR, which allows rapid screening of suspect cases to be possible. 7 All the biological specimens for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> testing should be considered to be potentially <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Therefore, test must be performed by medical professionals with protective equipment in a qualified laboratory. To further reduce the risk of exposure to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> agents, viral <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inactivation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> before sample handling are usually be recommended. 8, 9 While the sensitivity of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 to the conditions of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inactivation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is unknown, it is reported that many <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> such as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are heat-sensitive and can be killed at 56  for 30 minutes. [10] [11] [12] [13] [14] It is thus inferred that heating at 56  could be an effective approach for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inactivation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. 15 However, the effect of heating at 56  on COVID-19 <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> detection is unclear. The objective of this study was to compare the levels of . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2019.01813\"><h2> The Curious Case of the Nidovirus Exoribonuclease: Its Role in RNA Synthesis and Replication Fidelity</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Ogando, Natacha S.; Ferron, Francois; Decroly, Etienne; Canard, Bruno; Posthuma, Clara C.; Snijder, Eric J.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, there are no FDA-approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for the treatment of CoVs, which is mainly due to limited interest from the side of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> industry, despite the loss of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> lives during the short-lived <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> outbreak and the continuing MERS epidemic. Moreover, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> hits identified so far often <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">suffered<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> from poor selectivity indexes. Drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> efforts were further restricted by the limitations of available <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models and potency failure in clinical trials (Zumla et al., 2016) . Taking into account the combination of ExoN and N7-MTase activities in a single <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and its importance in <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, CoV nsp14 is an attractive target for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Thus far, only two classes of compounds that (in)directly interfere with its activities have been analyzed in more detail: <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogs and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">methyltransferase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s13063-017-2427-0\"><h2> Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-1b (MIRACLE trial): study protocol for a randomized controlled trial</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Arabi, Yaseen M.; Alothman, Adel; Balkhy, Hanan H.; Al-Dawood, Abdulaziz; AlJohani, Sameera; Al Harbi, Shmeylan; Kojan, Suleiman; Al Jeraisy, Majed; Deeb, Ahmad M.; Assiri, Abdullah M.; Al-Hameed, Fahad; AlSaedi, Asim; Mandourah, Yasser; Almekhlafi, Ghaleb A.; Sherbeeni, Nisreen Murad; Elzein, Fatehi Elnour; Memon, Javed; Taha, Yusri; Almotairi, Abdullah; Maghrabi, Khalid A.; Qushmaq, Ismael; Al Bshabshe, Ali; Kharaba, Ayman; Shalhoub, Sarah; Jose, Jesna; Fowler, Robert A.; Hayden, Frederick G.; Hussein, Mohamed A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">For many <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emerging infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, including MERS, patients are often treated with therapeutics on the basis of minimal evidence. For example, patients with MERS have been treated with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> despite the lack of clinical trials exploring the effectiveness of this treatment combination. If these patients had been included in a properly designed study, conclusive evidence might have been generated. Performing such a trial meets a critical need.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Based on the virtual screening results of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2 protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diabetes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drug <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">troglitazone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, anti-hypertensive drug <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">losartan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">analgesia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drug <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ergotamine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-bacterial drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> cefmenoxime, and hepatoprotective drug <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">silybin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, etc., were predicted to <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> with low energy. The <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, such as phyllaemblicin G7</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Based on the virtual screening results of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2 protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diabetes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drug <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">troglitazone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, anti-hypertensive drug <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">losartan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">analgesia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drug <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ergotamine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-bacterial drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> cefmenoxime, and hepatoprotective drug <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">silybin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, etc., were predicted to <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> with low energy. The <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, such as phyllaemblicin G7</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.17.952879\"><h2> X-ray Structure of Main Protease of the Novel Coronavirus SARS-CoV-2 Enables Design of -Ketoamide Inhibitors</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Zhang, L.; Lin, D.; Sun, X.; Rox, K.; Hilgenfeld, R.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">This suggests that P3 moieties more bulky than <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pyridone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> may be accepted here. As the next steps in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of compound 13b towards a potential drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> 2019-nCoV or other coronaviruses, we will undertake tests in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-infected <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> cultures and in a small-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> model (once it will become available for 2019-nCoV). Meanwhile, our <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">crystal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> structures may be used by others for virtual screening and de-novo design of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjgh-2018-001105\"><h2> An updated roadmap for MERS-CoV research and product development: focus on diagnostics</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Kelly-Cirino, Cassandra; Mazzola, Laura T; Chua, Arlene; Oxenford, Christopher J; Van Kerkhove, Maria D</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">There are currently no prophylactic or therapeutic interventions of proven efficacy for any <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Without a specific therapy for MERS, treatment is supportive. 5 54 55 Effective MERS therapeutics are still in the early stages of research and evaluation. Several broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> including nitazoxanide, 56 viral methyltransferase inhibition 57 and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> prodrugs 58 have shown in vitro activity against MERS-CoV. Early results for novel MERS-specific therapeutics that inhibit <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> or have specific neutralising activity are promising. 47 59 60 The WHO R&amp;D Blueprint for MERS has called for three types of vaccines: (1) <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dromedary camel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> vaccine to prevent zoonotic transmission, (2) <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> vaccine for long-term protection of persons at high exposure risk and (3) <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> vaccine for reactive use in outbreak settings. 55 61 MERS-CoV vaccines are in the early stages of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, 55 62 63 with one candidate vaccine in phase I clinical trials (NCT02670187). 64 Neutralising monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> have been designed to target the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MERS-CoV spike protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, 53 65 with ChAdOx1 and modified <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">vaccinia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> Ankara vectors also strong vaccine candidates, 60 66 but none have yet advanced to clinical trials. To accelerate the process, the Coalition for Epidemic Preparedness Innovation has recently launched a call for proposals for the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> MERS-CoV vaccine in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">order<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to engage with developers interested in supporting these efforts. 67</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.983056\"><h2> Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Rui Xiong; Leike Zhang; Shiliang Li; Yuan Sun; Minyi Ding; Yong Wang; Yongliang Zhao; Yan Wu; Weijuan Shang; Xiaming Jiang; Jiwei Shan; Zihao Shen; Yi Tong; Liuxin Xu; Chen Yu; Yingle Liu; Gang Zou; Dimitri Lavillete; Zhenjiang Zhao; Rui Wang; Lili Zhu; Gengfu Xiao; Ke Lan; Honglin Li; Ke Xu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">To identify potent and low-toxicity DHODH <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (DHODHi), we previously conducted a hierarchal structure-based virtual screening (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Fig. 1A<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) against ~280,000 compounds library towards the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ubiquinone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> site of DHODH 26 . We finally obtained two highly potent DHODHi S312 and S416 with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IC50s<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> of 29.2 nM and 7.5 nM through structural optimization 27, 28 , which are &gt; 10-folds potent than the FDA approved DHODHi Teriflunomide (IC50 of 307.1 nM). By using these two potent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, we could fully evaluate DHODH as a valuable <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> target both in infected <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> and in vivo in infected <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. We identified that <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> DHODH offers broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> efficacies against various RNA <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, including the DAA-resistant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and the newly emerged <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-CoV-2. Especially, our potent DHODHi can protect 100% <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mice<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> from lethal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> challenge, which is as good as the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">DAA drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and is even effective in the late phase of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> when <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">DAA<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug is no longer responding.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">study by our research group, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> was effective against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in vivo 112 and in vitro. Many active fractions have been isolated from Laggera pterodonta, including Fr 14, 113 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pterodontic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which had a wide spectrum of anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> activity. The <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sesquiterpenoids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 114 of Laggera pterodonta also prevented an increase in cytokine and chemokine <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">expression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> 19,20,21 . 115 Laggera pterodonta may be used to develop an innovative <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and further studies should 116 be performed to investigate the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mechanism of action<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> in detail. 117 Currently, there are a variety of commercially available <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> preparations, and a Chinese 118 patent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> containing <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> as the main ingredient, in China. A observational clinical study, 119 conducted by the Second Affiliated Hospital of Kunming Medical University during the outbreak of 120 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">H1N1 influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> virus in 2009, found that comparing with the clinical curative effect of Yinqiao 121 Jiedu tablets, a Chinese patent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> containing <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> had a better anti-viral effect, effectively 122 reduced the number of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in respiratory <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">secretions<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and accelerated the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> clearance. 123 Additionally, good efficacy and safety and the quick relief of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sore throat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and other symptoms, 124 without adverse reactions, has been shown in the treatment of children with <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> (H1N1) 22 . 125 However, it is lacking the evidence-based <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">EBM<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) clinical study to evaluate the efficacy 126 and safety of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> Granules in the treatment of seasonal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. In additional, previous clinical 127 studies have focused on Western medical methods to evaluate the efficacy of Chinese herbal 128 medicines, which is not suit, because of a lack of a mature-traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> evaluation 129</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.02186\"><h2> Common Nodes of VirusHost Interaction Revealed Through an Integrated Network Analysis</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Bsl, Korbinian; Ianevski, Aleksandr; Than, Thoa T.; Andersen, Petter I.; Kuivanen, Suvi; Teppor, Mona; Zusinaite, Eva; Dumpis, Uga; Vitkauskiene, Astra; Cox, Rebecca J.; Kallio-Kokko, Hannimari; Bergqvist, Anders; Tenson, Tanel; Merits, Andres; Oksenych, Valentyn; Bjrs, Magnar; Anthonsen, Marit W.; Shum, David; Kaarb, Mari; Vapalahti, Olli; Windisch, Marc P.; Superti-Furga, Giulio; Snijder, Berend; Kainov, Denis; Kandasamy, Richard K.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">FLUAV, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RVFV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and HIV-2 agent. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Itraconazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antifungal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> medication. It is also used as experimental anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HEV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-B, HRV-B, HRV-A, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Par-A3<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and SAFV agent. Nitazoxanide is a broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiparasitic drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which is also investigational agent against FLUAV and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and experimental anti-CHIKV, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HBV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, VACV, RV, JEV, MERS-CoV, NoV, RuV, and ZIKV agent. Lopinavir is an FDA-approved antiretroviral of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitor class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. It is also investigational anti-MERS-CoV and experimental anti-ZIKV agent (Table S2 ). In addition to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of viral proteases (Table S2) , Lopinavir was reported to induce <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host RNaseL production<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> in infected and non-infected <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> (80) . <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RNaseL<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> is endoribonuclease that is a part of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral response<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, which is the most critical <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">node<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-<mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> interactions. Although, the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> mechanisms of action of other compounds are still unknown, these agents could inhibit steps of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, which precede reporter <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein expression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> from viral RNA. In summary, our results indicate that existing BSAs could be re-purposed to other <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. To further expand a spectrum of their activities, these BSAs could be tested against other <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Re-purposing these and other safe-inman <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapeutics could save resources and time needed for <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of novel drugs to quickly address unmet medical needs, because safety profiles of these agents in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are available. Effective treatment with broad-spectrum-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> may shortly become available, pending the results of further pre-clinical studies and clinical trials. This, in turn, means that some broad-spectrum-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> could be used for rapid management of new or emerging drug-resistant strains, as well as for first-line treatment or for prophylaxis of acute <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> or for viral <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">co-infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The most effective and tolerable compounds could expand the available therapeutics for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, improving preparedness and the protection of the general population from viral epidemics and pandemics.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fcimb.2019.00193\"><h2> Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Peyclit, Lucie; Baron, Sophie Alexandra; Rolain, Jean-Marc</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">As a result, alternatives to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to treat resistant germs should be a priority (Bassetti et al., 2017) . The use of old drugs can be a solution like &quot;forgotten&quot; <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> polymyxins, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fosfomycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">minocycline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or mecillinam, which are still used in clinical settings (Cassir et al., 2014) . There is also a renewed interest in <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> combinations to circumvent <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (Lenhard et al., 2016) . For example, the synergistic activity of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sulfonamide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-associated <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">colistin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was evaluated against <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">colistin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-resistant clinical <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (Okdah et al., 2018) . But &quot;non <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>&quot; solutions can also been considered as alternatives for the therapeutic management of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (Aslam et al., 2018) . Various studies showed that <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Clostridium difficile<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> can be inhibited using <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteriophages<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> or several ongoing trials use <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobial peptides<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> as alternatives or preventive treatments in the future (Aslam et al., 2018) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Through in silico and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">biological processing<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, a series of small molecules, including those from <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, have been screened and confirmed to directly inhibit these important <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or Middle East respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (MERS) <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> [17] [18] [19] [20] [21] [22] [23] . The gene sequence of 2019-nCoV has been released, which suggests high similarities between the main <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and those previously identified in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-Cov or MERS-Cov [24, 25] . In this <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sense<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, previously reported <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-SARS-Cov<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> or anti-MERS-Cov <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> may become a valuable guide to finding anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) herbal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> among the traditional Chinese herbs used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Through in silico and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">biological processing<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, a series of small molecules, including those from <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, have been screened and confirmed to directly inhibit these important <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or Middle East respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (MERS) <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> [17] [18] [19] [20] [21] [22] [23] . The gene sequence of 2019-nCoV has been released, which suggests high similarities between the main <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and those previously identified in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-Cov or MERS-Cov [24, 25] . In this <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sense<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, previously reported <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-SARS-Cov<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> or anti-MERS-Cov <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> may become a valuable guide to finding anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV) herbal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> among the traditional Chinese herbs used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.07.981928\"><h2> Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti-COVID-19 drug design</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Rut, W.; Groborz, K.; Zhang, L.; Sun, X.; Zmudzinski, M.; Hilgenfeld, R.; Drag, M.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Hubei province, China. [1] Symptoms of the first patients were <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">flu<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-like and included <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cough<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">myalgia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, but with a tendency to develop a potentially fatal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dyspnea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acute respiratory distress syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. [1b] Genetic analysis confirmed a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">betacoronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> as the causing agent. The <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> was initially named <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV), [1] [2] but shortly thereafter, it was renamed to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2. [3] By March 07, 2020, the WHO had registered &gt;100,000 cumulative cases, in 65 countries, of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus disease 2019<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), with &gt;3400 <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">deaths<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. [4] Currently, there is no approved vaccine or treatment for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Efforts are being made to characterize molecular targets, pivotal for the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of anti-coronaviral therapies. [5] The main protease (M <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> , also known as 3CL <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> ), is one of coronaviral nonstructural <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp5<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) designated as a potential target for drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. [6] M <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> cleaves the viral polyproteins, generating twelve non-structural <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (Nsp4-Nsp16),</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s13020-018-0165-1\"><h2> SWOT analysis and revelation in traditional Chinese medicine internationalization</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Tang, Haitao; Huang, Wenlong; Ma, Jimei; Liu, Li</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Second, TCM can be used to treat various diseases and especially has advantages for treating incurable diseases and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [1, 2] . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Berberine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> exhibits beneficial anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inflammation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> effects for the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inflammatory bowel diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, it also differentially modulates the activities of <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ERK<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>, <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">p38<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> MARK, and <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">JNK<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> to suppress Th17 and Th1 <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">T cell differentiation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> indicating that it could be a potential therapeutic drug to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">type 1 diabetes mellitus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">DM<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) [3] . Even for a disease without an obvious clinical manifestation according to Western <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> principle, TCM treatment can use its theoretical advantages of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome differentiation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and effective timing to relieve the disease and make up for the deficiencies of modern Western <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [4, 5] . For example, in management of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metabolic syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, TCM is an excellent representative in alternative and complementary medicines with a complete theory system and substantial herb remedies. Ginseng, rhizoma coptidis (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">berberine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, the major active compound) and bitter melon were discussed for their potential activities in the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metabolic syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [6] [7] [8] [9] [10] [11] . Recently, a search of active ingredient(s) from some commonly used TCM has revealed a wide variety of compounds that are biologically active with therapeutic potentials. About 62% of the 240 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">species<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> were found to contain chemical compounds with pharmacological procies were found for the treatment of at least one disease and 53% of them for two or more diseases [12] . Virtual mapping between databases of Chinese herbal ingredients and molecular targets of diseases is likely to offer a new avenue for drug discovery [13] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v12030254\"><h2> Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Ahmed, F. Syed; Quadeer, A. Ahmed; McKay, R. Matthew</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Overall, as the identified set of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV epitopes map<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> identically to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2, they present potentially useful candidates for guiding experimental efforts towards developing vaccines against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2. More generally, our study further highlights the potential importance of previous experimental and clinical studies of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV, and its use in concert with emerging data for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2, in searching for effective vaccines to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> epidemic.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fvets.2018.00166\"><h2> Zoonotic Diseases and Phytochemical Medicines for Microbial Infections in Veterinary Science: Current State and Future Perspective</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Shin, Bora; Park, Woojun</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Having used <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for decades, mankind has made tremendous advances in <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, including veterinary <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. However, the increase in <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">drug resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> in pathogens due to overuse and misuse of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has increased both treatment costs and failures. The WHO, the World <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Health Organization, and the Food and Agriculture Organization of the United Nations are attempting to address the worldwide One Health problem (1) . Research should continue to identify new natural substances that exhibit <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and anti-inflammatory activity against multidrug resistant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> without <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adverse effects<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> on <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. A new mechanistic discovery of the action of phytochemicals will allow a better understanding of their pharmacological effects, insights into their medicinal potential, and strategies to discover drugs from <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> sources. Thus, these refined or extracted phytochemical compounds could be potential candidates for improving the treatment of zoonotic diseases in both <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Further research including clinical trials should be performed to obtain more comprehensive knowledge of the use of phytochemicals as drugs in veterinary <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3346/jkms.2020.35.e89\"><h2> The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Lim, Jaegyun; Jeon, Seunghyun; Shin, Hyun Young; Kim, Moon Jung; Seong, Yu Min; Lee, Wang Jun; Choe, Kang Won; Kang, Yu Min; Lee, Baeckseung; Park, Sang Joon</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">We are hoping that the outbreak may subside in a couple of months, with the consistent efforts to prevent the spread of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> worldwide, as in the cases of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and MERS. In the meantime we need to make great efforts to develop <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> as well.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s12929-019-0592-z\"><h2> Development of therapeutic antibodies for the treatment of diseases</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Lu, Ruei-Min; Hwang, Yu-Chyi; Liu, I-Ju; Lee, Chi-Chiu; Tsai, Han-Zen; Li, Hsin-Jung; Wu, Han-Chung</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The newly emergent Middle East respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (MERS-CoV) induces a <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-like disease with an approximately 43% mortality rate [134] . To date, no vaccines or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> medications are available for the prevention or clinical treatment of MERS. A large phage-displayed <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> naive scFv library (Mehta I/II) with 2.7  10 10 clones from the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Dana<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Farber Cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> Institute was used as a resource for the isolation of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> against MERS-CoV [135] . In another project, a research group in Malaysia improved panning strategies with a nave <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> scFv library (library size of 10 9 ) to successfully identify mAbs specific to the MERS-CoV nucleoprotein [136] . Studies such as those described offer insights into the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human antibody response<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to viral pathogen <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and provide examples of how the outbreak scene may be utilized to develop <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-based immunotherapies for the prevention and early treatment of viral pathogens [137] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1002/ame2.12088\"><h2> The characteristics of hDPP4 transgenic mice subjected to aerosol MERS coronavirus infection via an animal noseonly exposure device</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Hao, Xinyan; Lv, Qi; Li, Fengdi; Xu, Yanfeng; Gao, Hong</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Hence, effective small <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models are needed to investigate <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral pathogenesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and evaluate MERS-CoV therapeutics and vaccines.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2020.00298\"><h2> Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Du, Ning Wang; Jian, Shang; Shibo, Jiang; Lanying</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, the newly identified 2019-nCoV is spreading to infect people, resulting in significant global concerns. It is critical to rapidly design and develop effective vaccines to prevent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of this new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Since <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">S protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and its fragments, such as RBD, of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and MERS-CoV are prime targets for developing subunit vaccines against these two highly pathogenic <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> CoVs, it is expected that similar regions of 2019-nCoV can also be used as key targets for developing vaccines against this new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (Jiang et al., 2020) . Similarly, other regions of 2019-nCoV, including S1 and S2 subunits of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">S protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">N protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, can be applied as alternative targets for vaccine <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Taken together, the approaches and strategies in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of subunit vaccines against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and MERS described in this review will provide important information for the rapid design and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of safe and effective subunit vaccines against 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11020092\"><h2> Human Polyclonal Antibodies Produced from Transchromosomal Bovine Provides Prophylactic and Therapeutic Protections Against Zika Virus Infection in STAT2 KO Syrian Hamsters</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Siddharthan, Venkatraman; Miao, Jinxin; Van Wettere, Arnaud J; Li, Rong; Wu, Hua; Sullivan, Eddie; Jiao, Jinan; Hooper, Jay W.; Safronetz, David; Morrey, John D.; Julander, Justin G.; Wang, Zhongde</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, there are no countermeasures available for the prevention or treatment of ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, except for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">symptom<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> relief management. Vaccine <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> is still at its early stages and it is unknown when an approved ZIKV vaccine will be available.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fpubh.2019.00305\"><h2> Infectious Disease Risk Across the Growing Human-Non Human Primate Interface: A Review of the Evidence</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Devaux, Christian A.; Mediannikov, Oleg; Medkour, Hacene; Raoult, Didier</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The Plasmodia that infect great <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">apes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are usually of a different group than those found in OWM, and they are related to parasites inducing <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">malaria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Indeed, characterization of The medication mentioned in the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">right column<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> is indicative but must obviously be adapted according to the characteristics of the pathogen and the patient's symptoms. For more detail see <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MSD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> Manual. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Bacterial diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of non-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human primates<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>: https://www.msdvetmanual.com/exotic-and-laboratory-animals/nonhuman-primates/bacterial-diseases-of-nonhumanprimates. About the parasites that can be passed from NHP to <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (not shown), the majority of them are <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">transmitted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> by the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fecal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>-<mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> route and cause <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gastrointestinal symptoms<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The treatment will depend on the nature of the parasite and the symptoms. Usually, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mebendazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">albendazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ivermectin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are used for antihelmenthic medications, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">praziquantel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is used for treatment of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cestodes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and trematodes, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metronidazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">benzimidazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, artemisin, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mefloquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are used in the treatment of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">intestinal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> protozoa. It is worth noting that <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">malaria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> can be <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">transmitted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> to <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> by infected NHP in areas where the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mosquito<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> vectors are present. Artemisin-based combination therapies are usually the first line treatment for <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">malaria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>. However, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is the preferred treatment when the parasite is sensitive to the drug. For more detail see WHO, International travel and health -chapter 7-Malaria: https://www.who.int/ith/2017-ith-chapter7.pdf; <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MSD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> Manual. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Parasitic diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of non-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human primates<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>: https://www.msdvetmanual.com/exotic-and-laboratory-animals/nonhumanprimates/parasitic-diseases-of-nonhuman-primates.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41392-020-0127-9\"><h2> Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Gao, Wei Zhou; Yisi, Liu; Dongdong, Tian; Cheng, Wang; Sa, Wang; Jing, Cheng; Ming, Hu; Minghao, Fang; Yue</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Unfortunately, there are still no specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> medicines or vaccines recommended for 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. For patients with severe clinical manifestations, an effective clinical treatment scheme is of great importance. On February 7, 2020, the China's National Health Commission released the fifth trial version of Diagnosis and Treatment Scheme for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pneumonitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and provided a systematic treatment strategy for severe cases. Remarkably, systematic <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">corticosteroids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">methylprednisolone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, &lt;1-2 mg per kg <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">body<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> weight, for 3-5 days) was recommended to be an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adjuvant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy 3 , which immediately raised concerns about whether patients infected with this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> could benefit from <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">corticosteroids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy 4 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3346/jkms.2020.35.e89\"><h2> The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Lim, Jaegyun; Jeon, Seunghyun; Shin, Hyun Young; Kim, Moon Jung; Seong, Yu Min; Lee, Wang Jun; Choe, Kang Won; Kang, Yu Min; Lee, Baeckseung; Park, Sang Joon</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Regardless of the case report, I still believe that LPV/r is a promising <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agent<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. However, it is clear that well-designed studies have to be carried out to build more evidence so that they can be recommended as therapeutic agents.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Symptomatic treatment measures are as follows: (a) <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>: <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acetaminophen<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>; (b) severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cough<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with white <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">phlegm<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>: bisolvon; (c) mild <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">asthmatic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> symptoms: longacting <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">theophylline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. No other drugs may be used. Detailed information on drug use will be registered in the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CRF<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. All of the rescue <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> will be provided by <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pan-long-yun-hai Pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and the doctor issues the drug according to the patient's needs. In the event of symptoms that the patients cannot tolerate, such as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe headache<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">myalgia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, the attending doctor will treat the patient according to the actual situation and decide whether to terminate the experiment. The cost will be provided by the research team.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10060283\"><h2> Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Shin, Jin Soo; Jung, Eunhye; Kim, Meehyein; Baric, Ralph S.; Go, Yun Young</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The Middle East respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (MERS-CoV), first identified in Saudi Arabia, is an emerging zoonotic pathogen that causes severe acute respiratory illness in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> with a high fatality rate. Since its emergence, MERS-CoV continues to spread to countries outside of the Arabian Peninsula and gives rise to sporadic <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> following the entry of infected individuals to other countries, which can precipitate outbreaks similar to the one that occurred in South Korea in 2015. Current therapeutics against MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> have primarily been adapted from previous drugs used for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. In search of new potential drug candidates, we screened a library composed of 2334 clinically approved drugs and pharmacologically active compounds. The drug saracatinib, a potent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Src-family of<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tyrosine kinases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (SFK), was identified as an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of MERS-CoV replication in vitro. Our results suggest that saracatinib potently inhibits MERS-CoV at the early stages of the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral life cycle<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> in Huh-7 <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, possibly through the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">suppression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of SFK <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">signaling pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Furthermore, saracatinib exhibited a synergistic effect with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gemcitabine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anticancer drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against several RNA <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. These data indicate that saracatinib alone or in combination with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gemcitabine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can provide a new therapeutic option for the treatment of MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fcimb.2019.00193\"><h2> Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Peyclit, Lucie; Baron, Sophie Alexandra; Rolain, Jean-Marc</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In this review, we will define drug repurposing and its characteristics. We will then make an inventory of what has already been published as a drug for reuse in general and in particular to address the problem of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">carbapenem<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and colistinresistant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Finally, we will see what prospects exist for this therapeutic strategy.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fcimb.2019.00193\"><h2> Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Peyclit, Lucie; Baron, Sophie Alexandra; Rolain, Jean-Marc</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Studies generally screen <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MDR bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> to ensure a broader spectrum of action (Hijazi et al., 2018) and sometimes <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (Table 1) . Seven non-antibacterial compounds inhibited the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of an <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Acinetobacter baumannii<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> strain resistant to most <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> including <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">carbapenems<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>: 3 antineoplastics (5fluorouracil, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">6-thioguanine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and pifithrin-), 1 anti-rheumatic (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">auranofin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), 1 antipsychotic (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fluspirilene<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), 1 anti-inflammatory (Bay 11-7082), and 1 alcohol deterrent (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">disulfiram<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>). <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Fivefluorouracil<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">6-thioguanine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> seemed to be the best candidates for repurposing to treat <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MDR<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> clinical A. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">baumannii<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Their IC90 values or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MIC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were lower than standard <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plasma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> drug concentration levels in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, suggesting a possible use without major adverse events (Cheng et al., 2019) . All mechanisms of action and targets are considered because the objective is to escape therapeutic drug classes. Each repurposed molecule can be used to study a new <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathway<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (Figure 2 ). An <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antifungal agent<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> developed nearly forty years ago, ciclopirox, also has good repurposing criteria, as shown by an American study conducted in 2013 (Carlson-Banning et al., 2013) . Due to its excellent safety profile, it has already been repurposed in various pathologies such as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">myeloma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, or as an anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human immunodeficiency virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drug. It prevents enzyme actions, essential for <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cellular metabolism<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> or functions, by inhibiting the availability of co-factors. Its activity was proved against <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MDR<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> E. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coli<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, K. pneumoniae, and A. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">baumannii<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> strains.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.28.20028068\"><h2> Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Penghui Yang; Yibo Ding; Zhe Xu; Rui Pu; Ping Li; Jin Yan; Jiluo Liu; Fanping Meng; Lei Huang; Lei Shi; Tianjun Jiang; Enqiang Qin; Min Zhao; Dawei Zhang; Peng Zhao; Lingxiang Yu; Zhaohai Wang; Zhixian Hong; Zhaohui Xiao; Qing Xi; Dexi Zhao; Peng Yu; Caizhong Zhu; Zhu Chen; Shaogeng Zhang; Junsheng Ji; Guangwen Cao; Fusheng Wang</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A just finished clinical study in Shanghai did not show any therapeutic effects of lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and abidol on accelerating the clearance <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2. 23 Thus, the current <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> regimen could not alter the course of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.25.965434\"><h2> Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Li, L.; Sun, T.; He, Y.; Li, W.; Fan, Y.; Zhang, J.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Great efforts are being made for the discovery of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, but there are no licensed therapeutic or vaccine for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> available in the market. Developing an effective treatment for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 is therefore a research priority. It is time-consuming and expensive to design novel vaccines against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> by the use of kits and related <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> [12] . Thus, we chose the method of immune-informatics, which is more efficient and more applicable for deep analysis of viral <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antigens<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, B-and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">T-cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> linear <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">epitope<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> prediction, and evaluation of immunogenicity and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virulence<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of pathogens.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s13104-018-3417-3\"><h2> Screening of melatonin, -tocopherol, folic acid, acetyl-l-carnitine and resveratrol for anti-dengue 2 virus activity</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Paemanee, Atchara; Hitakarun, Atitaya; Roytrakul, Sittiruk; Smith, Duncan R.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">De novo drug discovery is both prohibitively expensive [8] and time consuming, and so studies in a wide range of fields have started to explore <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> as a way of cutting short the drug <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> process and additionally developing therapies that are more affordable. This study investigated the anti-DENV effects of 5 commonly used natural compounds that have been shown to have activity against other <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, or to have the potential to have anti-viral activity, namely </div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.05.936013\"><h2> Potentially highly potent drugs for 2019-nCoV</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Nguyen, D.; Gao, K.; Chen, J.; Wang, R.; Wei, G.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In responding to the pressing need for anti-2019-nCoV medications, we develop mathematics-based deep <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">learning<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> models to systematically eventuate FDA approved drugs in the DrugBank for <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCoV 3CL protease inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. With the consensus of two deep <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">learning<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> models based on convolutional neural networks and multitask deep <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">learning<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, we report the top 15 potentially highly potent anti-2019-nCoV 3CL <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which provide timely guidance for the further <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of anti-2019nCoV drugs.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1007/s13238-017-0457-8\"><h2> Current progress in innovative engineered antibodies</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Strohl, William R.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Classes of drugs currently being employed in <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> drug conjugate candidates*</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s12985-018-1026-3\"><h2> Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Zhang, Xuefeng; Wang, Jing; Lu, Jing; Li, Rongrong; Zhao, Shuli</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Hepatitis B virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HBV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> continues to be a serious clinical challenge, which induces the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver cirrhosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatocellular carcinoma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, even leading to mortality, in many areas of the world [1, 2] . Currently, the utility of first-line <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immune system<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> modulators recommended by the World Health Organization can only help to reduce and control the viral load and minimize <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver damage<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, but cannot effectively clear the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and seldom achieve a cure [3, 4] . Thus, these current therapies remain far from satisfactory. In particular, the wide spread of multidrug-resistant <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HBV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> strains is increasingly threatening the efficacy of currently available <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [5, 6] . Therefore, there is an urgent need to actively develop and test promising novel therapies to target <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HBV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10090453\"><h2> Host-Directed Antivirals: A Realistic Alternative to Fight Zika Virus</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Saiz, Juan-Carlos; de Oya, Nereida Jimnez; Blzquez, Ana-Beln; Escribano-Romero, Estela; Martn-Acebes, Miguel A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Since the recent outbreak in 2015 in the Americas, a quite high number of possible <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> candidates are being tested in vitro and in vivo. However, until now, no specific therapy has been approved against any <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">flavivirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> [17] , including ZIKV [18] , and, thus, current treatments are mainly directed toward the relief of symptoms, such as <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rash<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, by administering antipyretics, anti-histamines, and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fluids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dehydration<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [15] . Nevertheless, it should be noted that some commonly used drugs, such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acetylsalicylic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, are contraindicated in ZIKV-infected patients, since they increase the risk of internal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bleeding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and other arboviruses (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dengue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chikungunya viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>) that can co-infect the patients may produce <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hemorrhages<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [3] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Part 2 Traditional usage-compatible herbal selection qi-reinforcing drugs, antitussive antiasthmatics, pungent cool diaphoretics and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">phlegm<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>-resolving medicines may all be used throughout the course of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, whereas drugs belonging to the interior warming group may be best utilized in prevention.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Part 2 Traditional usage-compatible herbal selection qi-reinforcing drugs, antitussive antiasthmatics, pungent cool diaphoretics and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">phlegm<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>-resolving medicines may all be used throughout the course of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, whereas drugs belonging to the interior warming group may be best utilized in prevention.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/ph12040147\"><h2> Alternative Experimental Models for Studying Influenza Proteins, HostVirus Interactions and Anti-Influenza Drugs</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Chua, Sonja C. J. H.; Tan, Hui Qing; Engelberg, David; Lim, Lina H. K.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">To date, only two <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> classes, with some usefulness, are available and very few are under <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> or in trials [8] . The drugs available in the clinic are Matrix 2 (M2) <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ion channel inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>, (e.g., <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and rimantadine) and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (NA) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (e.g., <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) [6] . The emergence of resistant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> strains have rendered M2 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> useless and there is also growing <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> against NA <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> such as the H274Y mutation found in the 2009 H1N1 strain that made the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-resistant [3, 22] . However, there is an obvious fitness cost to <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> holding NA <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> which results in low frequency of such mutations over the years. Newer drugs, such as favipiravir, a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analog that targets the viral polymerase approved in Japan, and baloxavir marboxil, which is a <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cap-dependent endonuclease inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, have been approved in Japan and the US [23] , with pimodivir, a PB2 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, having pre-approval access by the FDA (NCT03834376). Some new drugs are being tested (C10)(C11) in clinical trials, including DAS181 (removes <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sialic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> receptors from <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">glycan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> structures), Nitazoxamide (interferes with HA assembly) and HA monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, such as VIS410 and MHAA4549A [24] . There are potential drugs, such as a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of compounds called <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">naphthalimides<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which antagonize <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NS1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. This <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of compounds has yet to undergo future <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reach<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> clinical trials [25] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In Germany, where the drug was first developed, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">thalidomide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was held to be so safe that no prescription was required for its use, it was advertised for use in pregnant women (19) , and the drug company distributed free samples to its factory employees (18, 19) . given the most severe rating for drugs that contribute to <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fetal deformities<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, and for drugs whose risks prioritizing those who should receive treatment, such as women and children (36) . The fact that the treatment was made available to 2 U.S. citizens and not to Africans, who comprised most of its victims, engendered anger over the social justice of such decisions, providing, as Enserink (35) points out, a tragic validation to the satirical yet somewhat prophetic paper that had appeared in The Onion only weeks before titled &quot;Experts: Ebola vaccine at least 50 white people away&quot; (37) . As of now, 12 products have been approved under the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Rule, 7 of which were issued quickly after the guidance was published ( Table 3 There is a reasonably well-understood pathophysiological mechanism of the toxicity of the toxic substance and its prevention or substantial reduction by the product.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In Germany, where the drug was first developed, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">thalidomide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was held to be so safe that no prescription was required for its use, it was advertised for use in pregnant women (19) , and the drug company distributed free samples to its factory employees (18, 19) . given the most severe rating for drugs that contribute to <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fetal deformities<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, and for drugs whose risks prioritizing those who should receive treatment, such as women and children (36) . The fact that the treatment was made available to 2 U.S. citizens and not to Africans, who comprised most of its victims, engendered anger over the social justice of such decisions, providing, as Enserink (35) points out, a tragic validation to the satirical yet somewhat prophetic paper that had appeared in The Onion only weeks before titled &quot;Experts: Ebola vaccine at least 50 white people away&quot; (37) . As of now, 12 products have been approved under the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Rule, 7 of which were issued quickly after the guidance was published ( Table 3 There is a reasonably well-understood pathophysiological mechanism of the toxicity of the toxic substance and its prevention or substantial reduction by the product.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3892/mmr.2019.10201\"><h2> Potential use of Pichia pastoris strain SMD1168H expressing DNA topoisomerase I in the screening of potential anti-breast cancer agents</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Xin, Jian; Mahtar, Wan Nor Azlin Wan; Siah, Poh Chiew; Miswan, Noorizan; Khoo, Boon Yin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">General chemotherapeutic drugs that are used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">breast cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> include the following: <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anthracyclines<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">doxorubicin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adriamycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">epirubicin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (ellence); taxanes, such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">paclitaxel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Taxol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docetaxel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (Taxotere); <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cyclophosphamide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (cytoxan), <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">capecitabine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (Xeloda) and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">5-fluorouracil<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>; <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">vinorelbine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">navelbine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gemcitabine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Gemzar<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), trastuzumab (Herceptin) and other anti-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hormone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drugs, as well as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">breast cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs that target <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human epidermal growth factor receptor-2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2) . <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Breast cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> chemotherapy is commonly administered <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">orally<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> or by intravenous injection daily (3) . in <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adjuvant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and neo-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adjuvant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> settings, chemotherapeutic drugs are usually given as a combination of two or more drugs, since single-drug chemotherapy is less effective (3) ; however, the toxicity of combined chemotherapy is also greater if the treatment programme is not planned appropriately. an inappropriate combination of chemotherapy may not be able to treat or reduce the spread of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">breast cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and may continuously destroy other dividing <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> and affect surrounding healthy <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tissue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>. indeed, the majority of the current chemotherapies cause pain and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adverse effects<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in patients, including <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nausea and vomiting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">loss of appetite<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fatigue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mouth soreness<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hair<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> loss, weight gain, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">premature menopause<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, reduced <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and increased <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bleeding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (4) (5) (6) . Therefore, it is important to seek effective treatment strategies or combination therapies for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">breast cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> using novel compounds/substances from <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which frequently have reduced toxicity in comparison with traditional chemotherapies. naturally-occurring anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> products may reduce pain, while preventing the spread of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> to other parts of the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">body<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ijid.2020.02.018\"><h2> Discovery and development of safe-in-man broad-spectrum antiviral agents</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjrs, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">revealed that the most abundant are <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogues<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> which inhibit viral RNA and DNA polymerases. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Imatinib<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">erlotinib<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gefitinib<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dasatinib<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, that inhibit <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tyrosine kinases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, are the most abundant hostdirected BSAAs. Most of the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> targets (except <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Bcl-xL protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) are essential for <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> but redundant for the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, which is critical for reducing putative toxicities associated with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blocking cellular pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The limited diversity of the targets and scaffolds could slow down the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of BSAA concept.Emerging BSAAs, such as 5,6-dimethoxyindan-1-one, saliphenylhalamide, andGS-5734 (Denisova et al., 2012;Kuivanen et al., 2017;Muller et al., 2011;Muller et al., 2014;Patil et al., 2017;Sheahan et al., 2017), whose safety profiles in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are not yet available, are not included in the database. However, they could serve asvaluable <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in the future, pending the results of further pre-clinical and clinical investigations. infected with 2019-nCoV, MERS-CoV or <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> developed severe respiratory illness, and many of the infected have <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">died<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. No vaccines and drugs are available for prevention and treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (Eurosurveillance Editorial, 2020). However, safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> BSAAs could be effective against 2019-nCoV and other coronaviruses (Figure 5). For example, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and remdesivir effectively inhibited 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in vitro (Wang et al., 2020). Moreover, teicoplanin, oritavancin, dalbavancin, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">monensin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emetine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> could be repurposed for treatment of 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Oritavancin, dalbavancin and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">monensin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, whereas <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emetine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is an anti-protozoal drug. These drugs have been shown to inhibit several <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">corona<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-as well as some other <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (drugvirus.info) (Shen et al., 2019; Zhou et al., 2016). Importantly, clinical investigations into the effectiveness of lopinavir, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and remdesivir have started recently against 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (https://en.wikipedia.org/wiki/2019-nCoV_acute_respiratory_disease).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ijid.2020.02.018\"><h2> Discovery and development of safe-in-man broad-spectrum antiviral agents</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjrs, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">revealed that the most abundant are <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogues<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> which inhibit viral RNA and DNA polymerases. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Imatinib<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">erlotinib<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gefitinib<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dasatinib<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, that inhibit <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tyrosine kinases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, are the most abundant hostdirected BSAAs. Most of the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> targets (except <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Bcl-xL protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) are essential for <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> but redundant for the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, which is critical for reducing putative toxicities associated with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blocking cellular pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The limited diversity of the targets and scaffolds could slow down the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of BSAA concept.Emerging BSAAs, such as 5,6-dimethoxyindan-1-one, saliphenylhalamide, andGS-5734 (Denisova et al., 2012;Kuivanen et al., 2017;Muller et al., 2011;Muller et al., 2014;Patil et al., 2017;Sheahan et al., 2017), whose safety profiles in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are not yet available, are not included in the database. However, they could serve asvaluable <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in the future, pending the results of further pre-clinical and clinical investigations. infected with 2019-nCoV, MERS-CoV or <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> developed severe respiratory illness, and many of the infected have <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">died<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. No vaccines and drugs are available for prevention and treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (Eurosurveillance Editorial, 2020). However, safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> BSAAs could be effective against 2019-nCoV and other coronaviruses (Figure 5). For example, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and remdesivir effectively inhibited 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in vitro (Wang et al., 2020). Moreover, teicoplanin, oritavancin, dalbavancin, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">monensin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emetine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> could be repurposed for treatment of 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Oritavancin, dalbavancin and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">monensin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, whereas <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emetine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is an anti-protozoal drug. These drugs have been shown to inhibit several <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">corona<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-as well as some other <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (drugvirus.info) (Shen et al., 2019; Zhou et al., 2016). Importantly, clinical investigations into the effectiveness of lopinavir, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and remdesivir have started recently against 2019-nCoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (https://en.wikipedia.org/wiki/2019-nCoV_acute_respiratory_disease).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1126/sciadv.aax5576\"><h2> PRSS contributes to cetuximab resistance in colorectal cancer</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Tan, Zhaoli; Gao, Lihua; Wang, Yan; Yin, Huihui; Xi, Yongyi; Wu, Xiaojie; Shao, Yong; Qiu, Weiyi; Du, Peng; Shen, Wenlong; Fu, Ling; Jia, Ru; Zhao, Chuanhua; Zhang, Yun; Zhao, Zhihu; Sun, Zhiwei; Chen, Hongxing; Hu, Xianwen; Xu, Jianming; Wang, Youliang</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Anti-EGFR<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> therapies based on <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blocking ligand binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> (mAbs) are widely used in clinical practice for <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">EGFR<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>-expressing <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancers<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (3, 6) , and the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-EGFR mAbs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> was a milestone in mCRC treatment. The U.S. Food and Drug Administration approved <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cetuximab<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, a chimeric mAb, for the treatment of patients with irinotecan-refractory and/or oxaliplatinrefractory mCRC (7) (8) (9) (10) . However, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cetuximab<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> therapy has had only a modest impact on mCRC, achieving only approximately 10% objective response rates when used as a monotherapy for chemorefractory mCRC. The key reasons for the limited success of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cetuximab<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in mCRC include severe primary (de novo) and secondary (acquired) <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> to <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">EGFR<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> therapies (11) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.17.952895\"><h2> Functional pangenome analysis suggests inhibition of the protein E as a readily available therapy for COVID-2019.</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Alam, I.; Kamau, A. K.; Kulmanov, M.; Arold, S. T.; Pain, A. T.; Gojobori, T.; Duarte, C. M.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Therapies to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> the spread of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 and the lethality caused by the resulting COVID-2019 are currently focusing primarily on S, the viral spike <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 3,25,26 . However, despite high similarities between <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> S between <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-1 and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, existing neutralizing <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> are ineffective against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 3 . Hence, new <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> that <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> specifically to the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 spike protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> need to be developed, tested and approved for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> use, which would be a time-consuming process.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s40779-020-0233-6\"><h2> A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Jin, Ying-Hui; Cai, Lin; Cheng, Zhen-Shun; Cheng, Hong; Deng, Tong; Fan, Yi-Pin; Fang, Cheng; Huang, Di; Huang, Lu-Qi; Huang, Qiao; Han, Yong; Hu, Bo; Hu, Fen; Li, Bing-Hui; Li, Yi-Rong; Liang, Ke; Lin, Li-Kai; Luo, Li-Sha; Ma, Jing; Ma, Lin-Lu; Peng, Zhi-Yong; Pan, Yun-Bao; Pan, Zhen-Yu; Ren, Xue-Qun; Sun, Hui-Min; Wang, Ying; Wang, Yun-Yun; Weng, Hong; Wei, Chao-Jie; Wu, Dong-Fang; Xia, Jian; Xiong, Yong; Xu, Hai-Bo; Yao, Xiao-Mei; Yuan, Yu-Feng; Ye, Tai-Sheng; Zhang, Xiao-Chun; Zhang, Ying-Wen; Zhang, Yin-Gao; Zhang, Hua-Min; Zhao, Yan; Zhao, Ming-Juan; Zi, Hao; Zeng, Xian-Tao; Wang, Yong-Yan; Wang, Xing-Huan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">(1) Principles. Avoid <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or inappropriate use of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibacterial drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, especially the combination of broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibacterial drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Enhancement of bacteriological surveillance should be performed and promptly given appropriate <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibacterial drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> when it occurs secondary <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacterial infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. (2) According to the clinical manifestations of patients, if the accompanying <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacterial infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> cannot be ruled out, mild patients can take <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibacterial drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against community-acquired <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amoxicillin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">azithromycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, or fluoroquinolones; empirical antibacterial treatment in severe patients should cover all possible pathogens, deescalating therapy until the pathogenic <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are clarified.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.12.977918\"><h2> A Combined Evidence Approach to Prioritize Nipah Virus Inhibitors</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Nishi Kumari; Ayush Upadhyay; Kishan Kalia; Rakesh Kumar; Kanika Tuteja; Priyanka Rani Paul; Eugenia Covernton; Tina Sharma; Vinod Scaria; Anshu Bhardwaj</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In total, there are 34 NVIs similar to 76 FDA approved drugsf. For e.g, 5'-deoxy-5'-methylthioadenosine (NVIC0097) has shown structural similarity against four FDA molecules, namely, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Adenosine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neurotransmitter<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Vidarabine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (active <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">herpes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">vaccinia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> &amp; <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">varicella zoster virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>), Fludarabine (a chemotherapy drug) and Ademetionine (used in the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic liver diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>). In addition, side effects and predicted <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> toxicity as reported in DrugBank is also listed for FDA approved compounds similar to NVIs (http://bioinfo.imtech.res.in/anshu/nipah/fda_app.php). This can aid in prioritization of NVIs with a potential safe profile as opposed to the ones which have reported side effects.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1007/s13238-017-0457-8\"><h2> Current progress in innovative engineered antibodies</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Strohl, William R.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">This year, 2017, marks the 20th anniversary of the approval by the United States Food and Drug Administration (US FDA) of Rituxan (rituximab) and Zenapax (daclizumab), for treatment of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">B cell malignancies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and for use to suppress <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">organ<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> rejection in <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">renal transplants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, respectively (Table 1) . While two <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> had previously been approved by the FDA (Table 1) , the approval of Rituxan and Zenapax in 1997 was a watershed moment in the history of monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> (mAb) therapeutics. The reasons are very different for each molecule. Rituxan has become both a huge medical and commercial success, with indications in <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">B cell malignancies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> as well as in the treatment of <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rheumatoid arthritis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> (RA) (Storz, 2014) . Rituxan is currently the fourth best-selling innovative drug of any kind with 2016 worldwide sales of $8,354 MM (Table 2) , about 85% of those sales coming in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> indications and the other 15% from sales for treatment of RA (La Merie Publishing, 2017) . Including Rituxan, seven of the top ten selling innovative drugs in the world in 2016 were <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, six of which were antibodyrelated molecules (Table 2) . Zenapax, on the other hand, was the first humanized <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> to be FDA approved but it never achieved significant commercial success and was eventually <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">withdrawn<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> from the market in 2009. Daclizumab, however, has been approved recently under the tradename Zinbryta for treatment of relapsing forms of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">multiple sclerosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (MS).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmj.m606\"><h2> Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Xu, Xiao-Wei; Wu, Xiao-Xin; Jiang, Xian-Gao; Xu, Kai-Jin; Ying, Ling-Jun; Ma, Chun-Lian; Li, Shi-Bo; Wang, Hua-Ying; Zhang, Sheng; Gao, Hai-Nv; Sheng, Ji-Fang; Cai, Hong-Liu; Qiu, Yun-Qing; Li, Lan-Juan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Compared with the symptoms of the initial patients with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-Cov-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in Wuhan, those of patients from Zhejiang province in our study were relatively mild. Currently, no effective drug treatment or vaccine exists. It is necessary for monitoring of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to be strengthened and drugs and vaccines to be developed against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-Cov-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> as soon as possible. 1 We thank Song-Jia Tang for assisting with English <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">translation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11111064\"><h2> Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Wang, Xiaohuan; Xia, Shuai; Zou, Peng; Lu, Lu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Recently, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zika virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (ZIKV) has attracted much attention in consideration of its association with severe neurological complications including <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fetal microcephaly<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. However, there are currently no prophylactic vaccines or therapeutic drugs approved for clinical treatments of ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">(MERS-CoV) broke out in the Arabian Peninsula in 2012 with a fatality rate of 35% 3, 4 . Both <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and MERS-CoV are zoonotic <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and their <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hosts<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> are <mark class=\"entity\" style=\"background: #E6E6FA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ENZY</span></mark>/<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">civet<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dromedary<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, respectively 5, 6 . To date, no specific therapeutic drug or vaccine has been approved for the treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Therefore, CoVs are considered to be a kind of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, of which the outbreak poses a huge threat to <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Because Wuhan <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Viral Pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> cases were discovered at the end of 2019, the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> was named as <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> or &quot;2019-nCoV&quot; by the World Health Organization (WHO) on January 12, 2020 7, 8 . Since 2019-nCoV is highly homologous with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, it is considered a close relative of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV. The</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">(MERS-CoV) broke out in the Arabian Peninsula in 2012 with a fatality rate of 35% 3, 4 . Both <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and MERS-CoV are zoonotic <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and their <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hosts<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> are <mark class=\"entity\" style=\"background: #E6E6FA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ENZY</span></mark>/<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">civet<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dromedary<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, respectively 5, 6 . To date, no specific therapeutic drug or vaccine has been approved for the treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Therefore, CoVs are considered to be a kind of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, of which the outbreak poses a huge threat to <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Because Wuhan <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Viral Pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> cases were discovered at the end of 2019, the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> was named as <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> or &quot;2019-nCoV&quot; by the World Health Organization (WHO) on January 12, 2020 7, 8 . Since 2019-nCoV is highly homologous with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, it is considered a close relative of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV. The</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10060283\"><h2> Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Shin, Jin Soo; Jung, Eunhye; Kim, Meehyein; Baric, Ralph S.; Go, Yun Young</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In search of additional MERS-CoV <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, we conducted a screening of 2334 approved drugs and biologically active molecules using a cytopathic-effect (CPE)-based, high-throughput screening (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HTS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) assay. From the results, we identified saracatinib, a potent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Src-family of<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tyrosine kinases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (SFKs), as an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of MERS-CoV as well as other members of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Coronaviridae family<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. We evaluated the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity of saracatinib and found that it suppressed the early stages of the MERS-CoV life cycle in Huh-7 <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> through a possible <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">suppression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of the SFK <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">signaling pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Furthermore, we assessed the combined effect of saracatinib with another chemotherapeutic agent, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gemcitabine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, in Huh-7 <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>. Enhanced effects with lower toxicity were observed in a combination of these two drugs. Data presented in this study suggest that saracatinib alone or in combination with other agents can provide a new therapeutic option for the treatment of MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2018.01546\"><h2> Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Zitzmann, Carolin; Kaderali, Lars</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> infects <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> of the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immune system<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and causes AIDS within 2-15 years post <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. In 2016, the World Health Organization (WHO) estimated that globally 36.7 million people were living with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with 1.8 million new <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in 2016. More than 19.5 million of these were treated with a lifelong antiretroviral therapy (ART), the current standard of care. Nowadays, the replication of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> can be controlled and suppressed by the combination of at least three antiretroviral drugs, e.g., by <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reverse transcriptase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (World Health Organization, 2017b). These drugs have to be taken live-long and treatment regimens need to be adapted regularly to keep the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> under control. To date, no curative drugs and no vaccine against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are available.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1002/prp2.532\"><h2> Pharmacological plasticityHow do you hit a moving target?</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Parnham, Michael J.; Geisslinger, Gerd</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In fact, it has to be admitted that even when a new drug is marketed we know relatively little about its efficacy in a large population and subsequently, many drugs are prescribed too often for unsuitable conditions and patients are too willing to take <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for conditions which may not require such treatment. Aside from this, nonadherence is also a big problem.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11090811\"><h2> Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action</h2></a> (<i>relevance: 0.53</i>)\n",
       "<h6> Wang, Chen; Cheng, Shuihong; Zhang, Yuanyuan; Ding, Yibo; Chong, Huihui; Xing, Hui; Jiang, Shibo; Li, Xuebing; Ma, Liying</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs play an important role in preventing and treating AIDS [27] , a series of ARTs, including <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside reverse transcriptase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (NRTIs), <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">non-nucleoside reverse transcriptase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (NNRTIs), <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">integrase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (IIs), <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PIs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), fusion/entry <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">EIs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), and pharmacokinetic enhancers, have been developed [28] . ART has successfully transformed <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> into a chronic and manageable disease [29] . However, prevalence of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">drug resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and treatment is only effective before <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> develops <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> against the administered drugs [30] . <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> fusion <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have received widespread attention as they act extracellularly, prior to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">invasion<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of </div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s13063-017-2427-0\"><h2> Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-1b (MIRACLE trial): study protocol for a randomized controlled trial</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Arabi, Yaseen M.; Alothman, Adel; Balkhy, Hanan H.; Al-Dawood, Abdulaziz; AlJohani, Sameera; Al Harbi, Shmeylan; Kojan, Suleiman; Al Jeraisy, Majed; Deeb, Ahmad M.; Assiri, Abdullah M.; Al-Hameed, Fahad; AlSaedi, Asim; Mandourah, Yasser; Almekhlafi, Ghaleb A.; Sherbeeni, Nisreen Murad; Elzein, Fatehi Elnour; Memon, Javed; Taha, Yusri; Almotairi, Abdullah; Maghrabi, Khalid A.; Qushmaq, Ismael; Al Bshabshe, Ali; Kharaba, Ayman; Shalhoub, Sarah; Jose, Jesna; Fowler, Robert A.; Hayden, Frederick G.; Hussein, Mohamed A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Background: It had been more than 5 years since the first case of Middle East Respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Syndrome coronavirus infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (MERS-CoV) was recorded, but no specific treatment has been investigated in randomized clinical trials. Results from in vitro and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> studies suggest that a combination of lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon-1b<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-1b<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) may be effective against MERS-CoV. The aim of this study is to investigate the efficacy of treatment with a combination of lopinavir/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">recombinant IFN-1b<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> provided with standard supportive care, compared to treatment with placebo provided with standard supportive care in patients with laboratory-confirmed MERS requiring hospital admission.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11080742\"><h2> Inhibitory Effects of Antiviral Drug Candidates on Canine Parvovirus in F81 cells</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Zhou, Hongzhuan; Su, Xia; Lin, Lulu; Zhang, Jin; Qi, Qi; Guo, Fangfang; Xu, Fuzhou; Yang, Bing</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Canine <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">parvovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>) is a common etiological agent of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acute enteritis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, which occurs globally in domestic and wild <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">carnivores<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Despite the widespread use of inactivated or live attenuated vaccines, the emergence of antigenic variants and the influence of maternal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> have raised some concerns regarding the efficacy of commercial vaccines. While no specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> exists, the only treatment option for the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is supportive therapy based on symptoms. Thus, there is an urgent medical need to develop <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapeutic options to reduce the burden of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-related disease. In this study, a <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cytopathic effect<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (CPE)-based high-throughput screening assay was used to screen <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> from a Food and Drug Administration (FDA)-approved drug library. After two rounds of screening, seven out of 1430 screened drugs were found to have &gt;50% CPE <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Three drugs-Nitazoxanide, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Closantel Sodium<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Closantel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-with higher anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> effects were further evaluated in F81 <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> by absolute PCR quantification and indirect immunofluorescence assay (IFA). The inhibitory effects of all three drugs were dose-dependent. Time of addition assay indicated that the drugs inhibited the early processes of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> replication cycle, and the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> effects were relatively high within 2 h postinfection. Western blot assay also showed that the three drugs had broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against different subspecies of three <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> variants. In addition, antiapoptotic effects were observed within 12 h in Nitazoxanide-treated F81 <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> regardless of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, while <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Closantel Sodium<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Closantel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-treated <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> had no proor antiapoptotic effects. In conclusion, Nitazoxanide, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Closantel Sodium<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Closantel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can effectively inhibit different subspecies of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Since the safety profiles of FDA-approved drugs have already been extensively studied, these three drugs can potentially become specific and effective anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> drugs.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11010049\"><h2> Natural Products Isolated from Oriental Medicinal Herbs Inactivate Zika Virus</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Batista, Mariana N.; Braga, Ana Cludia S.; Campos, Guilherme Rodrigues Fernandes; Souza, Marcos Michel; de Matos, Renata Prandini Adum; Lopes, Tairine Zara; Candido, Natalia Maria; Lima, Maria Leticia Duarte; Machado, Francielly Cristina; de Andrade, Stephane Tereza Queiroz; Bittar, Cntia; Nogueira, Maurcio L.; Carneiro, Bruno M.; Mariutti, Ricardo B.; Arni, Raghuvir Krishnaswamy; Calmon, Marilia Freitas; Rahal, Paula</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zika virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> has drawn much attention within the scientific community since 2015 as a result of the outbreak in Brazil. Efforts have been made to identify effective drugs to treat this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and to elucidate its fundamental characteristics. In this study, we showed that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">berberine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emodin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, two <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, have strong virucidal effect in vitro, directly impairing the ZIKV particles. After additional studies, given the high <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cellular<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> viability in the active concentrations both compounds are good candidates for treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zika virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-infected patients and possibly for preventive treatment in low doses in endemic areas.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10120678\"><h2> Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Cui, Qinghua; Cheng, Han; Xiong, Rui; Zhang, Gang; Du, Ruikun; Anantpadma, Manu; Davey, Robert A.; Rong, Lijun</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Although there is still no FDA approved therapy for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> use, several anti-EBOV drugs are being developed [11, 29, 30] . Research shows that a few <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-microbial agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, including anti-malarial, were also reported with reasonable <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities [31] . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Bedaquiline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is a FDA approved second line anti-<mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tuberculosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> drug, which is specifically used to treat multi-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">drug-resistant tuberculosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MDR<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>-TB). In this study, we screened a small library of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bedaquiline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> derivatives for potential novel <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> entry <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> using a pseudotyped (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>/EBOV) entry assay [32] . Three types of pseudoviruses (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>/EBOV, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>/<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">H5N1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>/LASV) were simultaneously used in the initial screen to reduce false positives and to identify Ebola-specific entry <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Many <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">quinoline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> compounds showed strong <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> against EBOV entry (Supplemental Table S1 ) at 10 M. Then, compounds with anti-EBOV activity (specific <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> &gt;80%, <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> viability &gt;70%) were selected for further evaluation and the results are listed in Table 1 . These compounds did not inhibit the entry of either <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>/<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">H5N1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>/LASV, whereas they displayed <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of Ebola GP-mediated entry (more than 80% at a final concentration of 10 M), and were non-toxic to the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> (<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell viability<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> &gt;90%, at the same concentration).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1155/2019/5797512\"><h2> Cicadidae Periostracum, the Cast-Off Skin of Cicada, Protects Dopaminergic Neurons in a Model of Parkinson's Disease</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Lim, Hye-Sun; Kim, Joong-Sun; Moon, Byeong Cheol; Choi, Goya; Ryu, Seung Mok; Lee, Jun; Ang, Mary Jasmin; Jeon, Mijin; Moon, Changjong; Park, Gunhyuk</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Cicadidae Periostracum<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (CP), the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cast<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>-off <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">skin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Cryptotympana pustulata Fabricius<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (also known as <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cicada<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> or Sun-Tae), was originally described in the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chung<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-bu category of Dongui Bogam, an ancient Korean medical book [15, 16] . In Korean traditional <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, CP has been used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">epilepsy<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, shock, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">smallpox<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sedation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">edema<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and night terror symptoms. In traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, CP is known as chantui and has long been used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">soreness<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">throat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hoarseness<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">itching<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">spasms<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and other symptoms [17] . Since then, it has been used in traditional <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for its many pharmacological effects. In 2003, a World Health Organization (WHO) international expert meeting to review and analyze the clinical reports on <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) treatment noted that the Chinese were using a combination of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cicada<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">silkworm droppings<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-associated fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [18, 19] . Recently, several studies have confirmed the pharmacological effects of CP, including its anti-<mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">skin aging<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, anti-<mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">kidney<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> injury, anticonvulsive, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sedative<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiallergy<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antianaphylactic shock<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> actions [20] [21] [22] [23] . However, scientific evidence for the use of CP in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neurodegenerative diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, including PD, is lacking. Therefore, in this study, we investigated the protective effects of CP on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-(MPTP-) induced neurotoxicity in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mice<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and explored the underlying mechanisms of action, focusing on <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nurr1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41368-020-0075-9\"><h2> Transmission routes of 2019-nCoV and controls in dental practice</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Peng, Xian; Xu, Xin; Li, Yuqing; Cheng, Lei; Zhou, Xuedong; Ren, Biao</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Mouthrinse before dental procedures A preoperational <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobial mouthrinse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is generally believed to reduce the number of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> microbes. However, as instructed by the Guideline for the Diagnosis and Treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Novel Coronavirus Pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (the 5th edition) released by the National Health Commission of the People's Republic of China, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chlorhexidine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which is commonly used as <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mouthrinse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> in dental practice, may not be effective to kill 2019-nCoV. Since 2019-nCoV is vulnerable to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oxidation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, preprocedural <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mouthrinse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> containing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oxidative agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> such as 1% <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hydrogen peroxide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or 0.2% <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">povidone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is recommended, for the purpose of reducing the salivary load of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> microbes, including potential 2019-nCoV carriage. A preprocedural <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mouthrinse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> would be most useful in cases when <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rubber<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> dam cannot be used.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2019.01462\"><h2> Application of Aptamers in Virus Detection and Antiviral Therapy</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Zou, Xinran; Wu, Jing; Gu, Jiaqi; Shen, Li; Mao, Lingxiang</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is a serious threat for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> beings. Although <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-based detection methods and drugs are widely used in clinics, their popularity is hindered by high cost, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody instability<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and the limitation of target types (Resch, 2017; Seo and Gu, 2017) . A comparison between aptamers and <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> is shown in Table 1 . Aptamers have great potential as a feasible tool in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> detection and therapeutics.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/molecules23061305\"><h2> Separation and Quantification of Four Main Chiral Glucosinolates in Radix Isatidis and Its Granules Using High-Performance Liquid Chromatography/Diode Array Detector Coupled with Circular Dichroism Detection</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Shi, Yanhong; Zheng, Cheng; Li, Jinhang; Yang, Li; Wang, Zhengtao; Wang, Rui</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Molecules 2018, 23, 1305 2 of 9 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of TCMs are chiral. Here, one isomer <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">possesses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> a desired therapeutic effect, whereas its paired enantiomer could be inactive or even have undesirable effects [2] . For example, S-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ibuprofen<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, the first chiral drugs of the non-steroidal <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-inflammatory drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> approved in 1994, was over a 100-fold more potent as an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cyclooxygenase 1 enzyme<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> than R-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ibuprofen<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [3] . Notably, 45 new drugs approved by the US food and Drug Administration in 2015 were single <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">enantiomers<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, except for lesinurad [4] . For this reason, investigating the biological activities of specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">enantiomers<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of chiral compounds in TCMs is becoming more important. Chiral analysis of the chemical constituents in TCMs is therefore urgent and desired.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/ijms19040965\"><h2> Oxymatrine Inhibits Influenza A Virus Replication and Inflammation via TLR4, p38 MAPK and NF-B Pathways</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Dai, Jian-Ping; Wang, Qian-Wen; Su, Yun; Gu, Li-Ming; Deng, Hui-Xiong; Chen, Xiao-Xuan; Li, Wei-Zhong; Li, Kang-Sheng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In fighting IAV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (TCM) has played an important role. In 2009 H1N1 '<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">swine flu<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>' outbreak, Chinese government had released a document entitled &quot;Recommended Schemes for Pandemic <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Influenza A<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> Diagnoses and Treatments&quot;, which recommended four anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">flu<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> TCM prescriptions [31] . In 2011 and 2018, Chinese National Health and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Family<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Planning Commission had also released a related document for the diagnoses and treatments of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">'flu<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>', respectively; both of which separately recommended five TCM prescriptions [32, 33] . In the past decade, we have always been devoted to the research of anti-IAV drug screening from TCMs. Recently, we have constructed a series of <mark class=\"entity\" style=\"background: #E6E6FA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">luciferase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ENZY</span></mark> reporter plasmids based on the gene promoters of the TLRs-<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MyD88<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>/<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">TRIF<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>-<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">TRAF6<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> signal <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathway<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, and have screened out several TCMs with excellent anti-IAV activity, and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sophora root<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is one of them. After investigating some previous researches and related literature, we find that <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sophora root<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and its major active compound OMT have been used for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic viral hepatitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in the clinic for many years [34] . Moreover, during the pandemic of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) in 2001, Chinese bureau of science and technology has announced that the composite <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sophora japonica<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> injection (mainly containing OMT) has distinct effects in the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, which has displayed the magical power of OMT to treat systemic <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inflammatory responses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [23] . So we speculate that if OMT can inhibit IAV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, it may be directly utilized to fight IAV in the clinic. As we initially expect, OMT really can inhibit the replications of IAV, including ST169 (H1N1), PR8 (H1N1), ST1233 (H1N1), HKG1 (H9N2), <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">GDA1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> </div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.986836\"><h2> A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Yiyue Ge; Tingzhong Tian; Suling Huang; Fangping Wan; Jingxin Li; Shuya Li; Hui Yang; Lixiang Hong; Nian Wu; Enming Yuan; Lili Cheng; Yipin Lei; Hantao Shu; Xiaolong Feng; Ziyuan Jiang; Ying Chi; Xiling Guo; Lunbiao Cui; Liang Xiao; Zeng Li; Chunhao Yang; Zehong Miao; Haidong Tang; Ligong Chen; Hainian Zeng; Dan Zhao; Fengcai Zhu; Xiaokun Shen; Jianyang Zeng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, including <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, remdesivir, baricitinib, olaparib and arbidol, were all provided by MCE (Medchem Express, China). The <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PARP1 inhibitor mefuparib hydrochloride<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (CVL218) with a purity of more than 99.0% was provided by Convalife, Shanghai, China.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Individual patients with life-threatening or severely debilitating diseases can petition the U.S. Food and Drug Administration (FDA) through their physicians to have expanded access (EA) to drugs that are in clinical trials but have not reached full FDA approval (the &quot;single-patient&quot; investigational new drug [IND] application). Additionally, recent state and federal laws-so-called &quot;right to try legislation&quot;-allow patients to approach drug companies directly for access prior to FDA approval. While these <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> provide potential access for individual patients to investigational drugs, different EA <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathways permit<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> entire groups of certain patients to access investigational drugs prior to FDA approval. This review focuses on special categories of EA INDs intended for multiple patients-the intermediate-group IND and the widespreadtreatment IND-as well as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> authorization for use of investigational drugs and biological products (e.g.,</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Individual patients with life-threatening or severely debilitating diseases can petition the U.S. Food and Drug Administration (FDA) through their physicians to have expanded access (EA) to drugs that are in clinical trials but have not reached full FDA approval (the &quot;single-patient&quot; investigational new drug [IND] application). Additionally, recent state and federal laws-so-called &quot;right to try legislation&quot;-allow patients to approach drug companies directly for access prior to FDA approval. While these <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> provide potential access for individual patients to investigational drugs, different EA <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathways permit<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> entire groups of certain patients to access investigational drugs prior to FDA approval. This review focuses on special categories of EA INDs intended for multiple patients-the intermediate-group IND and the widespreadtreatment IND-as well as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> authorization for use of investigational drugs and biological products (e.g.,</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11080742\"><h2> Inhibitory Effects of Antiviral Drug Candidates on Canine Parvovirus in F81 cells</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Zhou, Hongzhuan; Su, Xia; Lin, Lulu; Zhang, Jin; Qi, Qi; Guo, Fangfang; Xu, Fuzhou; Yang, Bing</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The following are available online at http://www.mdpi.com/1999-4915/11/8/742/s1, Table S1 : Percentage <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (%) of 21 drugs and 2 other tested drugs, Figure S1 : Evaluation of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cytotoxicity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CPV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> efficacy of other four drugs, Figure S2 </div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The ongoing <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 epidemic makes us painfully realize that our current For those targets which are difficult to find direct <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, or non-druggable targets, just like <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, Nsp3b, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp3c<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and E-channel, etc., currently popular PROTAC technology may be a good strategy to degrade these <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and then inhibit the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The potential <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> compounds found in this study for these targets might be a good start point.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The ongoing <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 epidemic makes us painfully realize that our current For those targets which are difficult to find direct <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, or non-druggable targets, just like <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, Nsp3b, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp3c<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and E-channel, etc., currently popular PROTAC technology may be a good strategy to degrade these <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and then inhibit the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The potential <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> compounds found in this study for these targets might be a good start point.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10120669\"><h2> Methanolic Extract of Rhizoma Coptidis Inhibits the Early Viral Entry Steps of Hepatitis C Virus Infection</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Hung, Ting-Chun; Jassey, Alagie; Lin, Chien-Ju; Liu, Ching-Hsuan; Lin, Chun-Ching; Yen, Ming-Hong; Lin, Liang-Tzung</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently no approved therapeutic treatment exists for <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> entry, and patients with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic hepatitis C<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are at risk for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">end-stage liver diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> such as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cirrhosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, which necessitate <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> transplantation. Importantly, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">donor livers<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> inadvertently become re-infected almost immediately after transplantation in <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatitis C<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> patients [29] . Given that the DAAs in current use cannot prevent <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver graft<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> re-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and have the propensity to select for drug-resistant mutants, combining entry <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with the DAAs would be expected to broaden the treatment strategies against <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatitis C<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> especially in the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver transplant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> setting. Interestingly, previous studies have demonstrated that combining DAAs and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> entry <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can produce a synergistic effect to improve drug efficacy [30] . Our discovery that RC can antagonize <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> entry makes it an ideal candidate for use in <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver transplant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> scenarios and to test in combination with the DAAs for better therapeutic efficacy.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10120669\"><h2> Methanolic Extract of Rhizoma Coptidis Inhibits the Early Viral Entry Steps of Hepatitis C Virus Infection</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Hung, Ting-Chun; Jassey, Alagie; Lin, Chien-Ju; Liu, Ching-Hsuan; Lin, Chun-Ching; Yen, Ming-Hong; Lin, Liang-Tzung</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently no approved therapeutic treatment exists for <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> entry, and patients with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic hepatitis C<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are at risk for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">end-stage liver diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> such as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cirrhosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, which necessitate <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> transplantation. Importantly, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">donor livers<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> inadvertently become re-infected almost immediately after transplantation in <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatitis C<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> patients [29] . Given that the DAAs in current use cannot prevent <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver graft<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> re-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and have the propensity to select for drug-resistant mutants, combining entry <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with the DAAs would be expected to broaden the treatment strategies against <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatitis C<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> especially in the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver transplant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> setting. Interestingly, previous studies have demonstrated that combining DAAs and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> entry <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can produce a synergistic effect to improve drug efficacy [30] . Our discovery that RC can antagonize <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> entry makes it an ideal candidate for use in <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver transplant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> scenarios and to test in combination with the DAAs for better therapeutic efficacy.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Theoretically, the drugs found through these therapies would exhibit better anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> effects, but the research procedure of new drug might cost several years, or even more than 10 years 11 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Theoretically, the drugs found through these therapies would exhibit better anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> effects, but the research procedure of new drug might cost several years, or even more than 10 years 11 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.12688/f1000research.16189.1\"><h2> Recent advances in understanding CrimeanCongo hemorrhagic fever virus</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Hawman, David W.; Feldmann, Heinz</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Favipiravir is approved in Japan for the treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> 83 inhibit <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CCHFV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in vitro, allowing lower doses of both drugs to be used in vivo with clinical efficacy, suggesting that combination therapies in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> may be effective in treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CCHF<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> while reducing unwanted side effects 53 . A similar approach has been used in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Lassa fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> cases 87 . In addition, a highthroughput screen using recombinant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CCHFV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> identified a compound, 2-deoxy-2-fluorocytidine, with inhibitory activity superior to that of favipiravir or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in vitro 88 . In vivo <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> studies will be needed to evaluate how this compound performs in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CCHF<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Lastly, monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> have shown efficacy against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CCHFV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in vivo 43 , and several clones were shown to neutralize divergent <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CCHFV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> strains 89 , suggesting that they may have promise for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CCHF<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41467-018-02828-6\"><h2> Bismuth antimicrobial drugs serve as broad-spectrum metallo--lactamase inhibitors</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Wang, Runming; Lai, Tsz-Pui; Gao, Peng; Zhang, Hongmin; Ho, Pak-Leung; Woo, Patrick Chiu-Yat; Ma, Guixing; Kao, Richard Yi-Tsun; Li, Hongyan; Sun, Hongzhe</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Drug-resistant superbugs pose a huge threat to <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> health. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> by <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Enterobacteriaceae<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> producing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metallo<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>--lactamases (MBLs), e.g., New Delhi <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metallo--lactamase 1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NDM-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) are very difficult to treat. <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of effective MBL <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to revive the efficacy of existing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is highly desirable. However, such <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are not clinically available till now. Here we show that an anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Helicobacter pylori<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> drug, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">colloidal bismuth subcitrate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (CBS), and related Bi(III) compounds irreversibly inhibit different types of MBLs via the mechanism, with one Bi(III) displacing two Zn(II) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ions<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> as revealed by X-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ray<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> crystallography, leading to the <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">release<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> of Zn(II) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cofactors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. CBS restores <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">meropenem<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (MER) efficacy against MBL-positive <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in vitro, and in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mice infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> model, importantly, also slows down the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of higher-level <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> in NDM-1-positive <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. This study demonstrates a high potential of Bi(III) compounds as the first broad-spectrum B1 MBL <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to treat <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MBL<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>-positive <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacterial infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in conjunction with existing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">carbapenems<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">[ Detailed information on <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">drug use<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> will be registered in the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CRF<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. All of the rescue <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> will provided by <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-long-yun-hai <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> Company and the doctor issues the drug according to the patient's needs. In the event of symptoms that the patients cannot tolerate, such as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe headache<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">myalgia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, the attending doctor will treat the patient according to the actual situation and decide whether to terminate the experiment. The cost will be provided by the research team.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">After randomisation, the study drug was used at least once and after intervention the effective outcome was recorded at least once. Use of the experimental drug has a reasonable relationship with time. Similar pharmacological effects of the drug or experimental drug are well known. It is difficult to identify a cause owing to disease or other explanations.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/healthcare8010051\"><h2> Outbreak of Novel Coronavirus (SARS-Cov-2): First Evidences From International Scientific Literature and Pending Questions</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Amodio, Emanuele; Vitale, Francesco; Cimino, Livia; Casuccio, Alessandra; Tramuto, Fabio</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Infusions of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blood plasma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> from people who have recovered from the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> could represent a valid approach to treat those still battling the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/333021\"><h2> Rapid Therapeutic Recommendations in the Context of a Global Public Health Crisis using Translational Bioinformatics Approaches: A proof-of-concept study using Nipah Virus Infection</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Shameer, K.; Johnson, K. W.; Readhead, B.; Glicksberg, B.; McCallum, C.; R, A.; Hirsch, J.; Bock, K.; Chelico, J.; Hajizadeh, N.; Oppenheim, M.; Dudley, J.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the absence of an effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agent<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or prophylactic vaccine for NiV in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, it is imperative to develop better therapeutic agents to address such <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> threats.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.04.20031237\"><h2> Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of 2019-nCov: A Mendelian Randomization analysis</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Shitao Rao; Alexandria Lau; Hon-Cheong So</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The drugs we highlighted in this study may help researchers to prioritize repositioning candidates for further studies, given the huge cost in developing a brand-new drug and that detailed investigations on every existing mediation will be impractical. We briefly discuss a few drugs highlighted by our analysis. Fostamatinib targets the largest number (seven) of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> potentially linked to <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2 expression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. According to DrugBank, it serves as an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for all these <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and all were linked to elevated <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2 expression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> in the present MR analysis except one. This drug has been approved for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Immune Thrombocytopenic Purpura<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ITP<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), and is a <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">spleen tyrosine kinase inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> 42 . There has been trials on <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rheumatoid arthritis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> (RA) 43 and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IgA nephropathy<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> as well 42 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.00372\"><h2> Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Brisse, Morgan E.; Ly, Hinh</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In addition to vaccine <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> as a preventative measure, the discovery of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is a burgeoning area of arenaviral research. Currently, the only anti-viral treatment clinically in use that is specific to mammarenaviruses is convalescent <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plasma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> therapy against JUNV (175) . Standard anti-viral <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogs, such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and Favipiravir (69, (371) (372) (373) (374) have seen moderate clinical success, but are only effective when given in the earliest stages of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> when symptoms are primarily non-specific (173) . Peptideconjugated morpholino oligomers have also been tested as alternative <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, reducing the titers of several <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">arenaviruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> culture and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">LCMV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-infected <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mice<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (375) . Nevertheless, recovery has been documented with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">symptom<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> management in place of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogs due to a delay in diagnosis being reached after the resolution of symptoms (376) , limiting the desire for using <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogs as anti-viral compounds.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1089/vbz.2017.2191\"><h2> What Have We Learned About Middle East Respiratory Syndrome Coronavirus Emergence in Humans? A Systematic Literature Review</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Dawson, Patrick; Malik, Mamunur Rahman; Parvez, Faruque; Morse, Stephen S.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Published data on applied therapeutic regimens for MERS-CoV patients are scarce, but there have been efforts to develop interventions.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Also, we <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dock<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> existing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with our targets, analyze the possible targets of each <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> horizontally, and analyze the drugs that may interact with 21 targets vertically. We analyzed 21 targets based on the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results and found that Nsp3b, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp3c<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, Nsp7_Nsp8 complex, Nsp14, Nsp15, PLpro, 3CLpro, <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">helicase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, E-channel, Spike and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> are more likely to be therapeutic targets of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The three targets Nsp3b, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp3c<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and E-channel are screened more <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. This may be due to the model problem because of flexible small protein (Nsp3b and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp3c<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) or partial model (E-channel).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Also, we <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dock<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> existing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with our targets, analyze the possible targets of each <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> horizontally, and analyze the drugs that may interact with 21 targets vertically. We analyzed 21 targets based on the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results and found that Nsp3b, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp3c<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, Nsp7_Nsp8 complex, Nsp14, Nsp15, PLpro, 3CLpro, <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">helicase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, E-channel, Spike and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACE2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> are more likely to be therapeutic targets of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The three targets Nsp3b, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp3c<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and E-channel are screened more <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. This may be due to the model problem because of flexible small protein (Nsp3b and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nsp3c<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) or partial model (E-channel).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, there are a variety of commercially available <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> preparations, and a Chinese patent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> containing <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> as the main ingredient, in China. A observational clinical study, conducted by the Second Affiliated Hospital of Kunming Medical University during the outbreak of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">H1N1 influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> virus in 2009, found that comparing with the clinical curative effect of Yinqiao Jiedu tablets, a Chinese patent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> containing <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> had a better <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> effect, effectively reduced the number of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in respiratory <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">secretions<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and accelerated the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> clearance. Additionally, good efficacy and safety and the quick relief of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sore throat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and other symptoms, without adverse reactions, has been shown in the treatment of children with <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> (H1N1). 22 However, it is lacking the evidence-based <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">EBM<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) clinical study to evaluate the efficacy and safety of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> granules in the treatment of seasonal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. In additional, previous clinical studies have focused on Western medical methods to evaluate the efficacy of Chinese herbal medicines, which is not suit, because of a lack of a mature TCM evaluation system. To develop <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> into a <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> drug with less side effects that can be widely used in the prevention and treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, an in-depth study needs to be conducted.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.26.20026971\"><h2> Clinical Features of COVID-19 Related Liver Damage</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Zhenyu Fan; Liping Chen; Jun Li; Cheng Tian; Yajun Zhang; Shaoping Huang; Zhanju Liu; Jilin Cheng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Because of no effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> available, symptomatic and supportive treatments are rather crucial. Many patients were applied with other <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antipyretic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drugs. However, both <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acetaminophen<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have adverse reactions, such as <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver function<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> injury. [24] [25] [26] Previous studies have not further analyzed whether these patients with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">abnormal liver function<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are caused by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or by the drugs used. In this study, the drugs used by patients before admission are mainly <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibacterial drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (including <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">moxifloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cephalosporins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (abidol, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acyclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antipyretic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drugs with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acetaminophen<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. We analyzed the prehospital medications of the two groups and found that there is no statistical difference between the two groups. Therefore, we speculated that the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver function<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> damage of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients is closely related to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. In addition, the proportion of male patients with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver damage<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> was large, and the specific mechanism was unclear. The <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">body<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> temperature of patients with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">liver damage<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> was significantly higher than that of the control group, which may be related to the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immune response<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> after <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1097/CM9.0000000000000787\"><h2> Voice from China: nomenclature of the novel coronavirus and related diseases</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> NaN</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Traditionally, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in the same <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">family<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> or <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">genus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are typed based on serological tests, as the results help with the diagnosis of the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, guide medications used for treatment, and assist in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of a vaccine. In more recent times, genetic sequence-based tests have advanced, and such genotyping tests have been able to provide a more rapid and precise typing approach than serological tests. Genotyping provides a new clinical diagnostic tool for directing the use of drugs and the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of vaccines. Based on genotyping, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 is unlikely to be significantly linked to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV. Rather, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 may lead to the misunderstanding of the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathogenesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of the new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, which is less pathogenic compared with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.06.20032342\"><h2> Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Yin Wang; Weiwei Jiang; Qi He; Cheng Wang; Baoju Wang; Pan Zhou; Nianguo Dong; Qiaoxia Tong</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Corticosteroid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are widely used as therapy for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ARDS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and have been used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with proof of efficacy, which could significantly decrease the mortality of severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients [7, 8] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1111/jcmm.13467\"><h2> Identification of a novel compound targeting the nuclear export of influenza A virus nucleoprotein</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Huang, Feng; Chen, Jingliang; Zhang, Junsong; Tan, Likai; Lu, Gui; Luo, Yongjie; Pan, Ting; Liang, Juanran; Li, Qianwen; Luo, Baohong; Zhang, Hui; Lu, Gen</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Influenza A virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (IAV) is an important <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> viral pathogen that is responsible for periodic <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> pandemics as well as seasonal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, resulting in substantial <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> morbidity and mortality and a worldwide financial burden annually [1] [2] [3] . Vaccines are currently available to control <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. However, mutations in the haemagglutinin (HA) and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neuraminidase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (NA) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of circulating <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> easily escape the surveillance by the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host immune system<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> [4] . Specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are available for prophylaxis and therapeutic treatment for individuals infected with IAV. Two classes of Food and Drug Administration (FDA)-approved anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs are currently used in the treatment of IAV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> including NA <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [5] , and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">matrix protein 2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (M2) <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ion channel inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and rimantadine [6, 7] . However, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> is a serious problem for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, particularly when the target viral <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> continuously undergo a high frequency of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antigenic drift<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> [8] [9] [10] . Most <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human influenza viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, including pandemic 2009 H1N1 and H7N9, are currently resistant to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/rimantadine or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [11] [12] [13] [14] . Therefore, identification of novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> targets and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for the treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> are imperative.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2020.00150\"><h2> Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Takayama-Ito, Mutsuyo; Saijo, Masayuki</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The anti-SFTSV efficacy of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> both in vitro and in vivo (Ning et al., 2019) was reported. Because <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFN-<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> is an FDAapproved drug, it has been suggested as a candidate <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for SFTSV alone or in combination with other drugs (Shimojima et al., 2015) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.00531\"><h2> Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Pizzorno, Andrs; Padey, Blandine; Terrier, Olivier; Rosa-Calatrava, Manuel</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Some of the best-known success stories of drug repurposing have their starting point on serendipitous observations recorded in the context of either preclinical models of disease or pre-/post-approval clinical trials, leading to a subsequent rationalized evaluation and validation of the new treatment potential (41) . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Thalidomide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sildenafil<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are two examples of such key observations. The first one was initially introduced as an antinausea for pregnant women but had to be rapidly removed from the market due to its teratogenicity. Further research enabled this molecule as well as some derivatives to be repurposed for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">leprosy<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">multiple myeloma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (45) . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Sildenafil<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, on the other hand, never reached the market for its originally intended use in the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hypertension<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> but the observed side-effects on <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">erectile<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> dysfunction ended in its approval in under the commercial <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">name<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of Viagra R . More recently, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sildenafil<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> found a third life under the commercial brand of Revatio R for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pulmonary hypertension<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (46) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fphar.2018.01448\"><h2> Systems Pharmacology Dissection of Multi-Scale Mechanisms of Action of Huo-Xiang-Zheng-Qi Formula for the Treatment of Gastrointestinal Diseases</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Zhao, Miaoqing; Chen, Yangyang; Wang, Chao; Xiao, Wei; Chen, Shusheng; Zhang, Shuwei; Yang, Ling; Li, Yan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A Network Pharmacology Study of Huo-Xiang-Zheng-Qi <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Formula<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> efficacy of the <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rest<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> 7 herbs (as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zuo<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>). This work not only provides an insight of the therapeutic mechanism of TCMs on treating GI diseases from a multi-scale perspective, but also may offer an efficient way for drug discovery and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> from herbal <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> as complementary drugs.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/ijms20051101\"><h2> Advances in Zika VirusHost Cell Interaction: Current Knowledge and Future Perspectives</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Lee, Jae Kyung; Shin, Ok Sarah</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In addition to the lack of preventable methods against ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, the increased pathogenicity of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> has triggered an extensive investigation of candidates for anti-ZIKV drugs and therapies. Currently, design and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of drugs <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> either the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> or factors of the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host immune response<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> are in progress, and these <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> range in target from <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral capsid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, nonstructural <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, including <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NS5<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, specifically <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RdRp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> and methyltransferase domain <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NS3 helicase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NS2B-NS3 protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analog <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside biosynthesis inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, in addition to the previously mentioned IFITMs [108] . Viral entry and replication have shown to be inhibited by the following drugs and drug-like molecules: Obatoclax, squalamine, cavinafungin, nanchangmycin, dyramycin-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">biotin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, ZINC33686641, and ZINC49605556 [108] . Sofosbuvir (Sovaldi), which terminates <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">synthesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of viral RNA prematurely, is one example of a drug that has been undergone clinical phase I and phase II trials, during which it has proven its safety and efficacy [108, 109] . Drug repurposing, a process during which a library of drugs that have already been FDA-approved is screened for potential ZIKV <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, has also risen as a viable alternative that saves time that would have been spent in design, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, and clinical testing of novel drugs. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">quinacrine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mefloquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and GSK369796 are some of the drugs that have shown promising potential through various screening methods [110] [111] [112] . Furthermore, the ability of ZIKV to cross barriers into sites previously considered as immune privileged is another concern that addresses the urgency for pregnancy-safe drugs to become available.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11060510\"><h2> Biological Function and Application of Picornaviral 2B Protein: A New Target for Antiviral Drug Development</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Li, Zengbin; Zou, Zixiao; Jiang, Zeju; Huang, Xiaotian; Liu, Qiong</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">There are also other drugs that act as viroporin <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, including 1,3-dibenzyl-5(2H-1,2,3,4tetraazol-5-yl) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hexahydropyrimidine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (CD), N-(1-phenylethyl)-2-[4-(phenylsulfonyl)-1-piperazinyl]-4quinazolinamine (LDS25), and 6-methyl-1,3,8-trihydroxyanth-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">raquinone<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Emodin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), among others [88, 96, 97] . The <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mechanism of action<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of these viroporin <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is based on the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of the <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viroporin channel activity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>. Therefore, these drugs may have the potential to be applied for the treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">picornavirus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> by <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2B gene<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. However, this application will require further detailed investigations and drug screening. Nevertheless, the 2B <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has the potential to widen the range of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment strategies.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2019.01327\"><h2> Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Behzadi, Mohammad Amin; Leyva-Grado, Victor H.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The initial approach has been to follow examples of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapies used during the recent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> outbreak; however, as described in this review, the approach using broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has not been very successful. Great advances have been made in the last few years and several <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are currently under <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and many have reached early stages in clinical trials. This is a very exciting and evolving field that will continue producing more effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that are highly needed for the treatment of respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of global public health concern.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/ijms19103266\"><h2> Traditional Chinese Medicine as a Potential Source for HSV-1 Therapy by Acting on Virus or the Susceptibility of Host</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Li, Wen; Wang, Xiao-Hua; Luo, Zhuo; Liu, Li-Fang; Yan, Chang; Yan, Chang-Yu; Chen, Guo-Dong; Gao, Hao; Duan, Wen-Jun; Kurihara, Hiroshi; Li, Yi-Fang; He, Rong-Rong</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">To date, drugs used in the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are mainly <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> at <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral DNA polymerase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and synthetic <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleotides<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. These current drugs cannot overcome the issues of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">drug resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and re-activation from latency of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. &quot;Preventing illness before it begins&quot; is the classical view of TCM. This scientific thought of &quot;prevention before illness, prevention of disease and change&quot; has been summed up by ancient physicians in the course of preventing and treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plague<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> for thousands of years, and is the model of health <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> dedicated to mankind by TCM. TCM has been widely used in the treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. As one of the main sources of natural active products, in recent years, extracts or compounds with anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> activity have been gradually excavated from TCM. The premise of &quot;preventing a disease before it becomes an illness&quot; applies to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-HSV-1 drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> as they can effectively improve <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immunity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, making <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> insensitive or latent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> difficult to be reactivated. This concept has been well documented in the existing anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> TCM that influence the innate immune <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathway<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10090448\"><h2> A Human DPP4-Knockin Mouses Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Fan, Changfa; Wu, Xi; Liu, Qiang; Li, Qianqian; Liu, Susu; Lu, Jianjun; Yang, Yanwei; Cao, Yuan; Huang, Weijin; Liang, Chunnan; Ying, Tianlei; Jiang, Shibo; Wang, Youchun</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Neutralizing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> mAbs are promising candidates for treatment and prevention of MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [15] . Several highly potent <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mouse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and humanized neutralizing mAbs <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> the receptor-<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> domain (RBD) of the spike (S) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have been reported [16] [17] [18] [19] [20] , and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> compounds and prophylactic vaccines are also under <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. These vaccines and therapeutic agents have typically been evaluated in in vitro systems using MERS-CoV pseudoviruses; however, their efficacy must eventually be confirmed in vivo using a suitable <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> model. Several Tg or KI <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mice<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> susceptible to MERS-CoV are available [9, 11, 12, 21] , and challenge experiments under BSL-3 conditions have been done for the evaluation of potential therapeutics and vaccines.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.983056\"><h2> Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Rui Xiong; Leike Zhang; Shiliang Li; Yuan Sun; Minyi Ding; Yong Wang; Yongliang Zhao; Yan Wu; Weijuan Shang; Xiaming Jiang; Jiwei Shan; Zihao Shen; Yi Tong; Liuxin Xu; Chen Yu; Yingle Liu; Gang Zou; Dimitri Lavillete; Zhenjiang Zhao; Rui Wang; Lili Zhu; Gengfu Xiao; Ke Lan; Honglin Li; Ke Xu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Emerging and re-emerging RNA <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> occasionally cause epidemics and pandemics worldwide, such as the on-going outbreak of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-CoV-2. Existing direct-acting <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">DAA<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) drugs cannot be applied immediately to new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> because of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-specificity, and the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">DAA drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> from the beginning is not timely for outbreaks. Thus, <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (HTA) drugs have many advantages to fight against a broad spectrum of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blocking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and overcoming the potential viral <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mutagenesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> simultaneously. Herein, we identified two potent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of DHODH, S312 and S416, with favorable drug-like and pharmacokinetic profiles, which all showed broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> effects against various RNA <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, including <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (H1N1, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">H3N2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, H9N2), <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zika virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and particularly against the recent <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-CoV-2.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The Chou-ling-dan granules have been approved as OTC drugs for many years and the drug 585 meet the Chinese Pharmacopoeia (2015) 37 . So the dosage determination in this study is according to 586 the instruction manual. However, in this clinical trial, we will not only evaluate the efficacy and 587 safety, but also the dosage of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 groups. However, after considering the limitations, we narrowed down the age range to 14-65.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.5195/jmla.2018.561\"><h2> Report from the Medical Library Associations InSight Initiative Summit 1: Engaging Users in a Disruptive Era</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Akers, Katherine G.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Pickering also demonstrated Yewno Life Sciences, a separate tool for expert users that additionally contains clinical trial and genetic information. She first searched for &quot;Middle East respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>,&quot; for which there is no approved drug. When she entered the keyword &quot;dipeptidyl peptidase 4,&quot; the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diabetes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drug <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sitagliptin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that targets the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dipeptidyl peptidase 4 protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> appeared in the graph as a connected concept, with accompanying information on relevant drug trials, targets, and interactions. Thus, Yewno Life Sciences can help researchers make connections between diseases and drug targets in biological systems.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.29.971101\"><h2> Mutations, Recombination and Insertion in the Evolution of 2019-nCoV</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Wu, A.; Niu, P.; Wang, L.; Zhou, H.; Zhao, X.; Wang, W.; Wang, J.; Ji, C.; Ding, X.; Wang, X.; Lu, R.; Gold, S.; Aliyari, S.; Zhang, S.; Vikram, E.; Zou, A.; Lenh, E.; Chen, J.; Ye, F.; Han, N.; Peng, Y.; Guo, H.; Wu, G.; Jiang, T.; Tan, W.; Cheng, G.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2) has spread more rapidly than any other <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">betacoronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> including <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV and MERS-CoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1128/mBio.00221-18\"><h2> Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Agostini, Maria L.; Andres, Erica L.; Sims, Amy C.; Graham, Rachel L.; Sheahan, Timothy P.; Lu, Xiaotao; Smith, Everett Clinton; Case, James Brett; Feng, Joy Y.; Jordan, Robert; Ray, Adrian S.; Cihlar, Tomas; Siegel, Dustin; Mackman, Richard L.; Clarke, Michael O.; Baric, Ralph S.; Denison, Mark R.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">KEYWORDS RNA polymerases, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> analogs, pandemic C oronaviruses (CoVs) are positive-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sense<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, single-stranded RNA <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that infect a wide range of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal hosts<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. In <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, CoVs were recognized as typically causing <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">colds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> until the emergence of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV) in 2002 and Middle East respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (MERS-CoV) in 2012 from zoonotic sources (1, 2) . Although the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> epidemic was controlled by public health measures within a year of its emergence, the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> spread to over 30 countries and was associated with a 10% mortality rate (3) . Efforts to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients with existing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> did not conclusively provide a clinical benefit and may have even worsened disease (4) (5) (6) (7) . MERS-CoV continues to circulate in the Middle East, with a case fatality rate approaching 40% (http://www.who.int/emergencies/mers -cov/en/). Currently, there are no FDA-approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or vaccines for the treatment and prevention of MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Supportive care and prevention of complications constitute the current standard of treatment for patients, emphasizing the need for direct-acting <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (8, 9) . Furthermore, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-and MERS-like <mark class=\"entity\" style=\"background: #E6E6FA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ENZY</span></mark> CoVs circulate in nature, can replicate efficiently in primary <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human airway cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and use the same <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cellular<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> receptors for entry as <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> CoVs (10) (11) (12) (13) . The imminent threat of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> emergence underscores the need for broadly active <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> any CoV that may emerge.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ijid.2020.02.018\"><h2> Discovery and development of safe-in-man broad-spectrum antiviral agents</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjrs, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">: <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Viral diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are one of the leading causes of morbidity and mortality in the world. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-specific vaccines and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are the most powerful tools to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat viral diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. However, broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (BSAAs, i.e. compounds <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> belonging to two or more viral families) could provide additional protection of general population from emerging and reemerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> reinforcing the arsenal of available <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> options. Here, we reviewed discovery and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of BSAAs and summarized the information on 119 safe-in-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">man<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> agents in freely accessible database (https://drugvirus.info/). Future and ongoing pre-clinical and clinical studies will increase the number of BSAAs, expand spectrum of their indications, and identify drug combinations for treatment of emerging and re-emerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> as well as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">co-infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. J o u r n a l P r e -p r o o f 2015). <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and vaccines are used to fight <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (De Clercq and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Li<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, 2016; Marston et al., 2014). Previously, there has been a focus on &quot;one drug, one <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>&quot; dogma, which relied on <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>-specific factors. A counterpoint to this is &quot;one drug, multiple <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>&quot; paradigm, which came with the discovery of broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (BSAAs), small-molecules that inhibit a wide range of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (Bekerman and Einav, 2015; de Clercq and Montgomery, 1983; Debing et al., 2015; Ianevski et al., 2019; Rada and Dragun, 1977; Sidwell et al., 1972). This paradigm was based on the observation that different <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> utilize similar <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> factors to replicate inside a <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> (Bosl et al., 2019). Although the concept of BSAAs has been around for almost 50 years, the field received a new impetus with recent outbreaks of Ebola, Zika, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Dengue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and other <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, the discovery of novel <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-directed agents as well as <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of drug repositioning methodology. Drug repurposing, also called repositioning, redirecting, reprofiling, is a strategy for generating additional value from an existing drug by <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> disease other than that for which it was originally intended (Nishimura and Hara, 2018; Pushpakom et al., 2019). This has significant advantages over new drug discovery since chemical <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">synthesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> steps, manufacturing processes, reliable safety, and pharmacokinetic properties in pre-clinical (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> model) and early clinical developmental phases (phase 0, I and IIa) are already available (Figure 1). Therefore, repositioning of launched or even failed drugs to <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> provides unique <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">translational<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> opportunities, including a substantially higher probability of success J o u r n a l P r e -p r o o f De Clercq, E., <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Li<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, G., 2016. Approved <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Antiviral Drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> over the Past 50 Years. Clin Microbiol Rev 29, 695-747. de Clercq, E., Montgomery, J.A., 1983. Broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity of the carbocyclic analog of 3-deazaadenosine. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Antiviral Res<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 3, 17-24. de Graaf, M., Herfst, S., Schrauwen, E.J., van <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">den<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> Hoogen, B.G., Osterhaus, A.D., Fouchier, R.A., 2007. An improved <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plaque<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> reduction <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus neutralization<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> assay for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human metapneumovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2018.01547\"><h2> Advancements in Host-Based Interventions for Influenza Treatment</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Yip, Tsz-Fung; Selim, Aisha Sami Mohammed; Lian, Ida; Lee, Suki Man-Yan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Aprotinin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, purified from <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bovine lung<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (32) , is a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with a long history of clinical use as an antifibrinolytic agent in <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cardiac<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> surgery (33) . Its potential as an anti-IAV drug has been recognized for over a decade (34) and has been shown to reduce the infectivity of a broad spectrum of IAV strains (34, 35) both in vitro (26) and in vivo (36) . Once <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">withdrawn<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> from the Western drug market due to its association with mortality (33), <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aprotinin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has been approved as a locally administered, small-particle aerosol drug for the treatment of IAV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in Russia (36) . However, side-effects associated with the systemic administration of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aprotinin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> raises the need for an alternative <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for use in treatment of IAV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s12929-019-0592-z\"><h2> Development of therapeutic antibodies for the treatment of diseases</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Lu, Ruei-Min; Hwang, Yu-Chyi; Liu, I-Ju; Lee, Chi-Chiu; Tsai, Han-Zen; Li, Hsin-Jung; Wu, Han-Chung</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The increasing importance of therapeutic mAbs is apparent ( <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Fig. 1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) , as mAbs have become the predominant treatment modality for various diseases over the past 25 years. During this time, major technological advances have made the discovery and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of mAb therapies quicker and more efficient. Since 2008, 48 new mAbs have been approved, contributing to a total global market of 61 mAbs in clinical use at the end of 2017, according to the US FDA. Strikingly, a total of 18 new <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> were granted approval by the US FDA from 2018 to 2019this number was tallied from information contained on various websites, including the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> society [3] , the database of therapeutic <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> [4] , and company pipelines and press releases. A list of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-based drugs approved by the US FDA is shown in Table 1 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fbioe.2018.00102\"><h2> Technoeconomic Modeling of Plant-Based Griffithsin Manufacturing</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Alam, Aatif; Jiang, Linda; Kittleson, Gregory A.; Steadman, Kenneth D.; Nandi, Somen; Fuqua, Joshua L.; Palmer, Kenneth E.; Tus, Daniel; McDonald, Karen A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The potential indications for Griffithsin as a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> prophylactic or therapeutic include its use as an active <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> ingredient (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">API<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>) in <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">vaginal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and rectal <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">microbicides<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. In spite of the value shown by pre-exposure prophylaxis (PrEP) drugs to prevent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> transmission, issues of cost, side effects, the potential for <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> through chronic use of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiretrovirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (ARV) as prevention modalities, and access to PrEP drugs by underresourced populations remain. These unmet needs could be <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">met<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> by the availability of affordable, safe and effective &quot;on demand&quot; <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, especially with Griffithsin as the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">API<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and its potential to control co-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">transmitted viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> such as <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, HSV-2 and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HCV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> during <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">intercourse<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Adoption of Griffithsin as a new biologic drug, especially in cost-constrained products such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">microbicides<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, is predicated on the feasibility of a scalable manufacturing process that can supply market-relevant volumes of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">API<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> at an acceptable cost of goods sold (COGS).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.05.935072\"><h2> The Essential Facts of Wuhan Novel Coronavirus Outbreak in China and Epitope-based Vaccine Designing against COVID-19</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Sarkar, B.; Ullah, M. A.; Johora, F. T.; Taniya, M. A.; Araf, Y.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 has caused one of the deadliest outbreaks in the recent times. Prevention of the newly emerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is very challenging as well as mandatory. The potentiality of in silico methods can be exploited to find desired solutions with fewer trials and errors and thus saving both time and costs of the scientists. In this study, potential subunit vaccines were designed against the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 using various methods of reverse vaccinology and immunoinformatics. To design the vaccines, the highly antigenic viral <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> as well as epitopes were used. Various computational studies of the suggested vaccine constructs revealed that these vaccines might confer good immunogenic response. For this reason, if satisfactory results are achieved in various in vivo and in vitro tests and trials, these suggested vaccine constructs might be used effectively for vaccination to prevent the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and spreading. Therefore, our present study should help the scientists to develop potential vaccines and therapeutics against the Wuhan <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Novel Coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> 2019. Authors declare no conflict of interest regarding the publication of the manuscript.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">An intermediate-size treatment IND is intended to provide EA to more than 1 patient at time, but generally to a smaller patient group than might, for example, be recruited for a clinical trial under an existing IND (15). A primary feature distinguishing an intermediate EA protocol from a clinical study under an existing IND is that an intermediate EA protocol is not primarily intended to obtain data or other information about a drug's safety or efficacy. Under an existing IND or protocol, EA can only be provided if the drug's sponsor is already actively pursuing marketing approval of the drug for the same use for which EA is being requested. However, other circumstances do allow EA if an existing treatment IND is not in place. EA can also occur: 1) when a drug has been <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">withdrawn<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> due to safety concerns, but there exists a patient group in which the benefits of the drug outweigh the risks; 2) use of a similar, unapproved drug (e.g., foreign-approved drug) is sought due to a shortage of the approved drug; 3) use of an approved drug where availability is limited due to a risk evaluation and mitigation strategy (REMS) for diagnostic monitoring, or treatment purposes, but the use is sought by patients who cannot obtain the drug under such REMS (see the following section); or 4) &quot;other reasons&quot; approved by the FDA. Both intermediate-and widespread-treatment INDs can each be obtained through 2 types of regulatory submissions to the FDA: 1) as an EA protocol submitted as an amendment to a protocol in an existing IND; or 2) as a new IND submission that is separate and distinct from any existing IND, and is intended only for the purpose of making a drug available for treatment use (15). When there is an existing IND, the FDA usually encourages submission of an EA protocol under the existing IND to keep all EA use and clinical trials consolidated. This may simplify identification of safety issues, decrease the administrative burden to investigators and the FDA, and eventually help the review of the drug for approval. When there is no existing IND on a drug, or if the sponsor under an existing IND declines to sponsor the proposed EA, then a new treatment IND must be filed.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">An intermediate-size treatment IND is intended to provide EA to more than 1 patient at time, but generally to a smaller patient group than might, for example, be recruited for a clinical trial under an existing IND (15). A primary feature distinguishing an intermediate EA protocol from a clinical study under an existing IND is that an intermediate EA protocol is not primarily intended to obtain data or other information about a drug's safety or efficacy. Under an existing IND or protocol, EA can only be provided if the drug's sponsor is already actively pursuing marketing approval of the drug for the same use for which EA is being requested. However, other circumstances do allow EA if an existing treatment IND is not in place. EA can also occur: 1) when a drug has been <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">withdrawn<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> due to safety concerns, but there exists a patient group in which the benefits of the drug outweigh the risks; 2) use of a similar, unapproved drug (e.g., foreign-approved drug) is sought due to a shortage of the approved drug; 3) use of an approved drug where availability is limited due to a risk evaluation and mitigation strategy (REMS) for diagnostic monitoring, or treatment purposes, but the use is sought by patients who cannot obtain the drug under such REMS (see the following section); or 4) &quot;other reasons&quot; approved by the FDA. Both intermediate-and widespread-treatment INDs can each be obtained through 2 types of regulatory submissions to the FDA: 1) as an EA protocol submitted as an amendment to a protocol in an existing IND; or 2) as a new IND submission that is separate and distinct from any existing IND, and is intended only for the purpose of making a drug available for treatment use (15). When there is an existing IND, the FDA usually encourages submission of an EA protocol under the existing IND to keep all EA use and clinical trials consolidated. This may simplify identification of safety issues, decrease the administrative burden to investigators and the FDA, and eventually help the review of the drug for approval. When there is no existing IND on a drug, or if the sponsor under an existing IND declines to sponsor the proposed EA, then a new treatment IND must be filed.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3347/kjp.2018.56.4.371\"><h2> Identification of Cystoisospora ohioensis in a Diarrheal Dog in Korea</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Lee, Sangmin; Kim, Junki; Cheon, Doo-Sung; Moon, Eun-A; Seo, Dong Joo; Jung, Soontag; Shin, Hansaem; Choi, Changsun</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Based on multiplex real-time PCR and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fecal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> smear analyses, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">trimethoprim-sulfamethoxazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metronidazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were initially administered to the puppy for treatment of the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">condition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> tentatively diagnosed as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">canine cyclosporiasis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. In general, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">trimethoprim-sulfamethoxazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is recommended for the treatment of cyclosporiasis and cystoisosporiasis [1] . However, an initial prescription of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">trimethoprim-sulfamethoxazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> did not improve the clinical signs of this case. A combination of clavamox (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amoxicillin trihydrate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>/<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">clavulanate potassium<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metronidazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was effective in the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diarrhea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in this case. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ciprofloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is an alternative drug for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diarrhea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-infected patients or patients allergic to sulfa drugs [1] . Recently, nitazoxanide was used in the treatment of a C. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cayetanensis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-infected patient who was not responsive to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">trimethoprim-sulfamethoxazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [10] . Although <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ciprofloxacin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> or nitazoxanide was not prescribed in this case, notably, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">trimethoprim-sulfamethoxazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was not effective. Thus, a combination of clavamox and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metronidazole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can be considered as an alternative treatment for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">canine cyclosporiasis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.00531\"><h2> Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Pizzorno, Andrs; Padey, Blandine; Terrier, Olivier; Rosa-Calatrava, Manuel</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Overall, Table 1 summarizes the main characteristics of the abovementioned currently available <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> options for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Such limited therapeutic arsenal coupled with the recurrent risk of emerging drug-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> highlights the obvious unmet need of novel approaches to complement existing therapies with new anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11111064\"><h2> Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Wang, Xiaohuan; Xia, Shuai; Zou, Peng; Lu, Lu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">ZIKV was found to be associated with Guillain-Barr <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in the epidemics of French Polynesia, and further damage caused by ZIKV, including severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">congenital malformation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">optic nerve<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> abnormality, and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reproductive<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> system injury, have been discovered in recent ZIKV outbreaks [7] [8] [9] [10] . <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Microcephaly<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, the most worrying abnormality caused by ZIKV, is a <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fetal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> neurodevelopmental defect with resulting physical and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">learning<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> disabilities, greatly impacting the quality of life of affected children [11] . As the increasing cases of ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sexual transmission<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and multiple harmful outcomes to <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fetuses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> have been reported, women who are pregnant or trying to conceive are now regarded as at especially high risk for ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and thus the need for effective treatments has become ever more pressing [12] . With the increasing recognition of the epidemiology and pathogenicity of ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, it is urgent to develop potent therapies. Currently, there are no vaccines or therapeutic drugs approved to treat ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, although great progress has been achieved. Many potent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which play roles in suppressing the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus-host interaction<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">membrane fusion<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, restraining <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">translation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, or disturbing <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">autophagy<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, have been explored and identified in vitro and in vivo [13] [14] [15] . However, the de novo <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of a novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> requires drug design and validation, which takes an extended amount of time. Therefore, repurposing FDA-approved medical and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> products may become an alternative choice to provide immediately available drugs for patients. Many already-approved drugs have been discovered to significantly inhibit ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, but few can be safely used by pregnant women because most are highly toxic [16] . Thus, the safety profile for pregnant women in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of ZIKV <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> must be considered a priority.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2019.01327\"><h2> Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Behzadi, Mohammad Amin; Leyva-Grado, Victor H.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">There are only two <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> approved by the FDA for the treatment or prevention of serious <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory tract infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>: aerosolized <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for treatment and palivizumab (Synagis  ) for prophylaxis.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3324/haematol.2018.215152\"><h2> Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Khawaja, Fareed; Chemaly, Roy F.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The current treatments for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in immunocompromised adult patients are <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, in different formulations [although it has not been approved by the Food and Drug Administration (FDA) for this purpose], and immuno-modulators, such as conventional IVIG or <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> (palivizumab).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41467-019-13940-6\"><h2> Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Sheahan, Timothy P.; Sims, Amy C.; Leist, Sarah R.; Schfer, Alexandra; Won, John; Brown, Ariane J.; Montgomery, Stephanie A.; Hogg, Alison; Babusis, Darius; Clarke, Michael O.; Spahn, Jamie E.; Bauer, Laura; Sellers, Scott; Porter, Danielle; Feng, Joy Y.; Cihlar, Tomas; Jordan, Robert; Denison, Mark R.; Baric, Ralph S.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Emerging <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> typically have very few if any effective treatment options. As such, treatments designed and approved for other diseases are administered to patients with emerging viral <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndromes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> empirically based on limited clinical or laboratory data. Multiple U.S. Food and Drug Administration (FDA) approved therapies have been evaluated for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against MERS-CoV in vitro including lopinavir (LPV), <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (RTV), and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon beta<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFNb<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>). LPV is a <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human immunodeficiency virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 1 (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>) <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that is usually combined with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RTV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> to increase LPV half-life through the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cytochrome P450 7<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> . Although the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity of LPV against MERS-CoV has been reported in <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Vero cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> (concentration causing a 50% reduction in replication (EC 50 ) = 8 M), other studies report complete inactivity similar to that of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RTV 8,9<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> . In contrast, studies evaluating the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity of type I and type II interferons have reported <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFNb<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> as the most potent <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (EC 50 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">1.37<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-17 IU/mL) in reducing MERS-CoV replication in vitro 8, 10 . The only in vivo study assessing the therapeutic efficacy of LPV/<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RTV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> or <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFNb<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> against MERS-CoV published thus far was performed in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">common marmosets<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> where modest improvements in clinical outcomes were noted 11 . In <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> MERS-CoV patients, two published case reports describe conflicting results on the use of a combination of LPV/<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RTV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, pegylated <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with one of two patients surviving 12, 13 . To this end, a randomized control trial (MIRACLE Trial) aimed at conclusively determining if LPV/<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RTV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>-<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFNb<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> improves clinical outcomes in MERS-CoV patients was initiated in 2016 and has thus far enrolled 76 patients in KSA 14, 15 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">EA rules allow patient access to drugs that have had at least some in-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> exposure. The <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ganciclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> saga, ZMapp, and other experiences raise the question of what to do when a potentially beneficial drug is needed that has not undergone any in-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> testing, and furthermore cannot undergo such <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> studies due to ethical concerns. In 2015, the FDA released a guidance for industry to address &quot;drugs developed to ameliorate or prevent serious or lifethreatening conditions caused by exposure to lethal or permanently disabling toxic substances, when <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> efficacy studies are not ethical and field trials are not feasible&quot; (38). Under certain conditions, the FDA may accept <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> studies in lieu of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> clinical trials, provided that there is reasonable expectation that the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> studies are predictive of</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">EA rules allow patient access to drugs that have had at least some in-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> exposure. The <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ganciclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> saga, ZMapp, and other experiences raise the question of what to do when a potentially beneficial drug is needed that has not undergone any in-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> testing, and furthermore cannot undergo such <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> studies due to ethical concerns. In 2015, the FDA released a guidance for industry to address &quot;drugs developed to ameliorate or prevent serious or lifethreatening conditions caused by exposure to lethal or permanently disabling toxic substances, when <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> efficacy studies are not ethical and field trials are not feasible&quot; (38). Under certain conditions, the FDA may accept <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> studies in lieu of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> clinical trials, provided that there is reasonable expectation that the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> studies are predictive of</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41598-018-19456-1\"><h2> Novel Immunoinformatics Approaches to Design Multi-epitope Subunit Vaccine for Malaria by Investigating Anopheles Salivary Protein</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Pandey, Rajan Kumar; Bhatt, Tarun Kumar; Prajapati, Vijay Kumar</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">increase the drug efficacy and kills the remaining parasites. The most widely used combination therapies are Artemether-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lumefantrine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (commercial <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">name<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>: Coartem) and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amodiaquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">artesunate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (commercial <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">name<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>: <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Coarsucam<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) 10 . While the recently approved combination therapies are <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">artesunate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pyronaridine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (commercial <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">name<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>: Pyramax) and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dihydroartemisinin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-piperaquine (Euartesim) 10 . The recent emerging <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> against <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">artemisinin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> urges to develop some new strategy to prevent the <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">malaria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> diseases <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">condition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 11 . Therefore, in this study, we applied a novel immunoinformatics approach to design multi-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">epitope<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> based subunit vaccine that may prevent the disease by maintaining the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host hemostasis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> by the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anticoagulant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and anti-inflammatory <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> present in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mosquito saliva<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. It will also inhibit the entry of parasite within the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host body<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> by a similar mechanism. Apart from this, if any way parasite enters into the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host body<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, vaccine candidate will stop the salivary <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-mediated induction of parasitic <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s12879-019-4530-1\"><h2> Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series</h2></a> (<i>relevance: 0.52</i>)\n",
       "<h6> Torti, Carlo; Mazzitelli, Maria; Longhini, Federico; Garofalo, Eugenio; Bruni, Andrea; Giancotti, Aida; Barreca, Giorgio Settimo; Quirino, Angela; Liberto, Maria Carla; Serapide, Francesca; Matera, Giovanni; Trecarichi, Enrico Maria; Navalesi, Paolo</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">On 28 February 2019, the Committee for Medicinal Products for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Use (CHMP) adopted a positive opinion, authorizing the marketing of IV <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> under exceptional circumstances [10, 11] . It is indicated for the treatment of complicated and potentially life-threatening <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">B virus infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in adult and paediatric patients (aged 6 months) when: (i) the patient's <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is known or suspected to be resistant to anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> medicinal products other than <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and/or (ii) other anti-viral medicinal products for treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, including <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhaled zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, are not suitable for the individual patient.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11010059\"><h2> From SARS to MERS, Thrusting Coronaviruses into the Spotlight</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Song, Zhiqi; Xu, Yanfeng; Bao, Linlin; Zhang, Ling; Yu, Pin; Qu, Yajin; Zhu, Hua; Zhao, Wenjie; Han, Yunlin; Qin, Chuan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Potential treatments must undergo in vitro and in vivo studies to select the most promising options. The <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of stable and reproducible <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models of MERS, especially in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NHPs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, is therefore a decisive step forward. The next step in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of standardized and controllable therapies against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and MERS will be clinical trials in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, validating a standard protocol for dosage and timing, and accruing data in real time during future outbreaks to monitor specific <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adverse effects<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and help inform treatment.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.12.977918\"><h2> A Combined Evidence Approach to Prioritize Nipah Virus Inhibitors</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Nishi Kumari; Ayush Upadhyay; Kishan Kalia; Rakesh Kumar; Kanika Tuteja; Priyanka Rani Paul; Eugenia Covernton; Tina Sharma; Vinod Scaria; Anshu Bhardwaj</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Comparison of NVIs is done with FDA approved compounds (2346) and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> obtained from Enamine library (4644). <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Enamine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is a library of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> like compounds (https://enamine.net/hitfinding/focused-libraries/view-all/antiviral-library). On the basis of physicochemical properties as suggested by Lipinski and Veber [33] it is observed that for the majority of NVIs, the distribution of all the six properties is similar to FDA approved drugs and also in some cases with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Enamine compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (Figure 3 ). Drugs with good <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> availability, demonstrate TopoPSA  140 2 and number of rotatable bonds  10. </div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.03.972133\"><h2> AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Tang, B.; He, F.; Liu, D.; Fang, M.; Wu, Z.; Xu, D.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Meanwhile, 46-14-1, 46-14-2 and 46-14-3 are chosen as our candidates for chemical <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">synthesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-SARS-CoV-2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> activity testing, which is ongoing. The copyright holder for this preprint (which was not peer-reviewed) is the . efficient and effective as ADQN-FBBD is molecular fragment-based growing with the knowledge of chemical reactions, while other models are all <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">atom<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-based with no rules of chemical reactions at all 34, 38, 39 . 4) ADQN-FBDD is highly flexible and user-friendly for the medicinal chemists, who can easily inject their drug discovery experience into the reward function to guide the novel molecule generation. Our ADQN-FBDD and related pipeline can be used not only for designing anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs but also other structure-based drug discoveries, especially for emerging infetious diseases that require treatments timely.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.05.20031476\"><h2> Appealing for Efficient, Well Organized Clinical Trials on COVID-19</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Yang Zhao; Yongyue Wei; Sipeng Shen; Mingzhi Zhang; Feng Chen</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A total of 171 COVID-19-related interventional trials were identified (138 from ChiCTR and 33 from ClinicalTrials.gov). The registration date distribution of these trials was shown in Figure 1 . Of the trials registered at ChiCTR, 120 were approved by the institutional review boards. The 171 trials are classified into 4 categories based on treatment modalities, including chemical drugs (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CDs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), biological therapies (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">BTs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (TCM) treatments and other therapies. The characteristics of these trials were summarized in Table 1 More trials on TCM treatment use 2 or more primary endpoints (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PEs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) than those on <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CDs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">BTs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (57.6%, 39.4% and 40.5%, respectively). Some trials even have 6 or more <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PEs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The most 3 common used <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PEs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are associated with clinical symptoms(73.1%), pathogen(29.2%) and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lung<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> function(27.5%). Trials on <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CDs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> have greater proportions of pathogen (41.0%) or fatality (18.0%) related <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PEs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> than the others. It is worth noting that these trials have registered over 300 distinct <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">PEs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> totally.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10020093\"><h2> MERS-CoV: Understanding the Latest Human Coronavirus Threat</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Chafekar, Aasiyah; Fielding, Burtram C.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">When no vaccines or specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are available during an outbreak, nonspecific therapeutic interventions are often introduced to prevent severe morbidity and mortality. However, for this to be done effectively, a basic understanding of the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathogenesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of the disease is required and interventions are implemented based on observations of the clinical course of disease and complications. Due to the nature of many diseases, however, it is often not possible to assess, or systematically compare, different therapeutic approaches during an outbreak [118] . Similarly, in the case of MERS-CoV, it is necessary to monitor epidemic patterns and investigate the spread of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> to efficiently identify, control and prevent possible epidemics. For MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, supportive care, which includes <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rest<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark>, <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fluids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and analgesics are used, and mainly depends on the provision of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">organ<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> support and management of complications [49, 119, 120] . Broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobials<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [121, 122] , <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon-2b<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (96) and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antifungals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can be used to minimize the risk of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">co-infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with opportunistic pathogens [49, 119] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/pathogens8010017\"><h2> VirusHost Interactions Involved in Lassa Virus Entry and Genome Replication</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Loureiro, Mara Eugenia; DAntuono, Alejandra; Lpez, Nora</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">LASV is currently considered a top priority emerging pathogen causing severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hemorrhagic fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> outbreaks [140] . At this moment, treatment is limited to the nonspecific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, shown to be partially effective in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">LASV infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [141] , and the use of favipiravir is still under investigation [142, 143] . Moreover, there is no FDA-approved vaccine against LASV or any other <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">arenavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to date. Therefore, there is an urgent need to develop novel approaches to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and prevent the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with these <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10120721\"><h2> Development of Small-Molecule MERS-CoV Inhibitors</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Liang, Ruiying; Wang, Lili; Zhang, Naru; Deng, Xiaoqian; Su, Meng; Su, Yudan; Hu, Lanfang; He, Chen; Ying, Tianlei; Jiang, Shibo; Yu, Fei</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Any compounds that interfere with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> may be harmful to <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>. Therefore, the establishment of a safety profile is essential. Furthermore, an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> should effectively inhibit the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> because a small amount of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virion replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> can lead to resistant mutations. The advantages of small-molecule <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> include low price, stability, and the convenience of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> administration. Three main approaches are currently used to develop <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MERS-CoV small-molecule inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. The first is the de novo <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">synthesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> the unique structure in the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of MERS-CoV appearing in its <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> process. The second approach involves screening <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> from an existing drug database by various chemical <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">synthesis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> strategies. The third approach involves changing the chemical group of a fully developed drug to enhance its pharmacological activity against MERS-CoV. More novel strategies in improving the efficacy of screening small-molecule <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are anticipated to reduce the threat of future MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. </div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s12906-019-2586-5\"><h2> Virucidal activity of Garcinia parvifolia leaf extracts in animal cell culture</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Adnan, Aziera; Allaudin, Zeenathul Nazariah; Hani, Homayoun; Loh, Hwei-San; Khoo, Teng-Jin; Ting, Kang Nee; Abdullah, Rasedee</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">There are several ways by which therapeutic compounds interfere with <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. The <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> effects can either be through prevention of viral attachment to <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> to enzymes responsible for <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">transcription<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, and prevention of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cleavage<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral particles<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> [1] . <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Viruses mutate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> over time and develop <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and therapeutic compounds [2] . Thus, there is a need to discover and develop <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral agents<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that do not become ineffective over time owing to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> by the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. But the pipeline of new drugs is drying up. There would be a tremendous benefit by integrating combinations of modern drugs with traditional medicinal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> extracts that have been used as folk <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to broaden the curing spectrum via generating synergistic effects.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.09.983247\"><h2> Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Shuai Xia; Meiqin Liu; Chao Wang; Wei Xu; Qiaoshuai Lan; Siliang Feng; Feifei Qi; Linlin Bao; Lanying Du; Shuwen Liu; Chuan Qin; Fei Sun; Zhengli Shi; Yun Zhu; Shibo Jiang; Lu Lu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the past 20 years, highly <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> pathogens have been emerging 349 increasingly, such as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV in 2003 and MERS-CoV in 2012 20-22 . In 2018, 350 WHO proposed &quot;Disease X&quot; in the blueprint priority diseases for any new unknown 351 pathogen that may cause an epidemic or pandemic in the future, calling for the 352 <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of effective and safe vaccines and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to prevent and treat such 353 Disease X. Indeed, at the end of 2019, the outbreak of Wuhan <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with an 354 unknown etiological agent, the first Disease X following WHO's announcement was 355 reported to WHO. Shortly thereafter, a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 (also known 356 as 2019-nCoV or HCoV-19), was identified to be the etiology of the Wuhan 357 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, i.e., <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> as designated by WHO.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/jcm8010006\"><h2> Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Asha, Kumari; Kumar, Prashant; Sanicas, Melvin; Meseko, Clement A.; Khanna, Madhu; Kumar, Binod</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Aptamers have been developed against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> for therapeutics purposes. Many of these aptamers developed against HA could prevent the entry of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blocking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> </div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11030274\"><h2> Ebola Virus Entry: From Molecular Characterization to Drug Discovery</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Salata, Cristiano; Calistri, Arianna; Alvisi, Gualtiero; Celestino, Michele; Parolin, Cristina; Pal, Giorgio</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Among drugs correlated with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amodiaquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, hydroxychloroquine, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">aminoquinoline<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have been shown to inhibit <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">filovirus infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in vitro using a pseudotyped <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> assay and the authentic EBOV [75] . Although no in vivo experiments have been undertaken yet, a promising result was obtained by a retrospective analysis performed on patients treated in Liberia with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">artesunate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amodiaquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> during the Western Africa outbreak of EVD. In fact, these patients showed a lower risk of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">death<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> from EVD than patients treated with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">artemether<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lumefantrine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Although this observation lacks of several controls, the clinical effect of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">artesunate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amodiaquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment should be better investigated as a possible therapeutic option for patients with EVD [78] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/ijms20112754\"><h2> HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Boni, Carolina; Barili, Valeria; Acerbi, Greta; Rossi, Marzia; Vecchi, Andrea; Laccabue, Diletta; Penna, Amalia; Missale, Gabriele; Ferrari, Carlo; Fisicaro, Paola</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Therefore, there is a clinical need for safe, novel treatments to shorten the duration of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NUC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> therapy by accelerating <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> control, and to enhance the effect of current anti-viral therapies.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11030274\"><h2> Ebola Virus Entry: From Molecular Characterization to Drug Discovery</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Salata, Cristiano; Calistri, Arianna; Alvisi, Gualtiero; Celestino, Michele; Parolin, Cristina; Pal, Giorgio</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is a drug widely used in the past in the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimalarial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy and prophylaxis before the emergence of resistant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Plasmodium spp<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> strains. This drug, readily available and well tolerated, is also endowed with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> properties, acting at two levels: the entry step and the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inflammation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> process.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.ebiom.2019.06.036\"><h2> Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Tsoumpra, Maria K.; Fukumoto, Seiji; Matsumoto, Toshio; Takeda, Shin'ichi; Wood, Matthew J.A.; Aoki, Yoshitsugu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">It is evident that since PMO therapeutic based strategy is already successfully applicable to many <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neurodegenerative diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, the most potent PPMOs may hold tremendous therapeutic potential in this field as well as other <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ASO<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> chemistries.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11070604\"><h2> Anti-Respiratory Syncytial Virus Activity of Plantago asiatica and Clerodendrum trichotomum Extracts In Vitro and In Vivo</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Chathuranga, Kiramage; Kim, Myun Soo; Lee, Hyun-Cheol; Kim, Tae-Hwan; Kim, Jae-Hoon; Gayan Chathuranga, W. A.; Ekanayaka, Pathum; Wijerathne, H. M. S. M.; Cho, Won-Kyung; Kim, Hong Ik; Ma, Jin Yeul; Lee, Jong-Soo</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Fossil evidence has revealed that <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> use of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> as folk <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> dates <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">back<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> at least 60,000 years [6] . According to the World Health Organization (WHO), almost 65% of the world's population reports the use of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> as medicinal agents [7] . Modern analytical technologies applied towards the active compounds found in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> have allowed for greater insights into <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plant<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-derived <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> compounds [8] . <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Plantago asiatica<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is a perennial belonging to the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">family Plantaginaceae<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and is commonly used as a folk <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in Korea, China, and Japan [9] . <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Plantago asiatica<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> extract (PAE) has been used to treat a variety of health conditions, such as wounds, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cholesterolemia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diarrhea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bronchitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic constipation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [10] [11] [12] . Moreover, it has been shown to inhibit <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">leukemia growth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and to enhance <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell-mediated immunity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> [13] . <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Clerodendrum trichotomum<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is a deciduous shrub that belongs to the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">family Lamiaceae<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (formerly Verbenaceae) and is widely distributed in South Korea, China, Japan, and the Philippines. <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Clerodendrum trichotomum<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> extract (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CTE<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">possesses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> broad-spectrum anti-inflammatory [14, 15] , anti-hypertensive [16] , anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">asthmatic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [17] , anti-oxidative [18] and immunotoxin [19] properties. However, the effects of PAE and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CTE<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and their active components on <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> replication in vitro and in vivo have not been reported.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1371/journal.pntd.0006715\"><h2> The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Kao, Jo-Chi; HuangFu, Wei-Chun; Tsai, Tsung-Ting; Ho, Min-Ru; Jhan, Ming-Kai; Shen, Ting-Jing; Tseng, Po-Chun; Wang, Yung-Ting; Lin, Chiou-Feng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">PLOS Neglected <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Tropical Diseases |<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> https://doi.<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Dengue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dengue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> cause global health concerns annually. Without <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, supportive care is the only treatment option for patients with DENV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. A current vaccine has been approved for protection against DENV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>; however, the potential risks and challenges associated with the immunopathogenesis of DENV remain unresolved. For anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dengue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> therapy, the repurposing of drugs with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and anticancer properties is a possible pharmacological strategy. In this study, we evaluated the potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> effects of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiparasitic drug niclosamide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, considering its current pharmacological efficacy against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">arthropod<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-borne <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zika virus infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Using in vitro and in vivo models of DENV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, we demonstrated that one of the therapeutic effects of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">niclosamide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is to significantly target endosomal <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acidification<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Following safety screening, repurposing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">niclosamide<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment may facilitate the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dengue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drugs in the near future. Niclosamide diminishes DENV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> PLOS Neglected Tropical Diseases <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">|<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> https://doi.org/10.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.00531\"><h2> Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Pizzorno, Andrs; Padey, Blandine; Terrier, Olivier; Rosa-Calatrava, Manuel</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">As mentioned before, the intrinsic ever-evolving nature of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, high transmissibility, <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> promiscuity, suboptimal vaccine efficacy, limited <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> arsenal, and zoonotic, and pandemic potential are more than convincing factors to consider <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> as attractive targets for drug repurposing. Despite many interesting omics-based approaches (76) or high-throughput screening of specific drug libraries, such as <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">kinase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (77) , no anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> agent issued from drug repurposing has yet reached regulatory market approval. However, advances made during the last years forecast optimism. The following selected examples constitute a very good illustration of the diversity and capabilities of drug repurposing strategies for <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>. An exhaustive list of anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> candidates issued from drug repurposing approaches is presented in Table 2 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/antibiotics8040252\"><h2> Antimicrobial Stewardship Programs in Community Health Systems Perceived by Physicians and Pharmacists: A Qualitative Study with Gap Analysis</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Park, Sohyun; Kang, Ji Eun; Choi, Hee Jung; Kim, Chung-Jong; Chung, Eun Kyoung; Kim, Sun Ah; Rhie, Sandy Jeong</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">&quot;I see many more of my patients with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> were actually infected by pretty nasty resistant strains than patients in the other services... in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">order<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to treat them effectively. I have found myself using several <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobials<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> instead of narrowing them down.&quot; (non-IDphy7-2-44)</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.02.968388\"><h2> Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Kim, Y.; Jedrzejczak, R.; Maltseva, N. I.; Endres, M.; Godzik, A.; Michalska, K.; Joachimiak, A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Severe Acute Respiratory Syndrome Coronavirus 2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is rapidly spreading around the world. There is no existing vaccine or proven drug to prevent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and stop <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus proliferation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Although this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> is similar to <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-and MERS-CoVs the detailed information about <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> structures and functions is urgently needed to rapidly develop effective vaccines, <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. We applied high-throughput <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> production and structure determination pipeline at the Center for Structural Genomics of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Infectious Diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> to produce <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and structures. Here we report the high-resolution <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">crystal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> structure of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">endoribonuclease Nsp15<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>/NendoU from <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 -a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> causing current world-wide epidemics. We compare this structure with previously reported models of Nsp15 from <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and MERS coronaviruses.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2020.00298\"><h2> Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Du, Ning Wang; Jian, Shang; Shibo, Jiang; Lanying</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A number of subunit vaccines against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV and MERS-CoV have been developed, and these are described in detail in the next paragraphs. The targets used for the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV and MERS-CoV subunit vaccines are also be discussed.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/ph12020097\"><h2> Lipid Metabolism as a Source of Druggable Targets for Antiviral Discovery against Zika and Other Flaviviruses</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Martn-Acebes, Miguel A.; Jimnez de Oya, Nereida; Saiz, Juan-Carlos</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Another important point that has to be taken into consideration is that most of the drugs <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting lipid metabolism<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> here reviewed are effective against more than one <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">flavivirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, confirming their broad-spectrum potential. Because most <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">flaviviruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> constitute neglected <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> pathogens, which complicates the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> strategies, repositioning drugs that target <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lipid metabolism<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> candidates could lead to more affordable broad-spectrum compounds. Although the utilization of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, especially in pregnant women, raises multiple safety concerns, it should be noted that they could be useful for the treatment of other infected patients for the prevention of ZIKV-associated illnesses. Even more, effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatments lowering the viral load should be useful to prevent ZIKV transmission by diminishing the risk of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mosquito infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> during <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">blood<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>-feeding, and by reducing the viral burden in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">reproductive<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> system of infected patients that could therefore also block any <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sexual transmission<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. It is important to remark that the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> effect <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">exerted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> by some of the compounds <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting lipid metabolism<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> in the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> models used is not very strong (showing a reduction of only about 1 log of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> production), so we still have to be cautious about the relevance of these drugs for more advanced studies. Nevertheless, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lipid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> drugs could ideally be utilized, not only alone, but also in combinatorial therapies, together with other <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (i.e., DAAs), providing another weapon in the arsenal to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> the ZIKV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s13613-017-0350-x\"><h2> Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Alshahrani, Mohammed S.; Sindi, Anees; Alshamsi, Fayez; Al-Omari, Awad; El Tahan, Mohamed; Alahmadi, Bayan; Zein, Ahmed; Khatani, Naif; Al-Hameed, Fahad; Alamri, Sultan; Abdelzaher, Mohammed; Alghamdi, Amenah; Alfousan, Faisal; Tash, Adel; Tashkandi, Wail; Alraddadi, Rajaa; Lewis, Kim; Badawee, Mohammed; Arabi, Yaseen M.; Fan, Eddy; Alhazzani, Waleed</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In this study, we observed no significant differences in the use of adjunctive therapies except for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> use in the ECMO group. The benefit of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy in MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> remains unclear. Recent Korean guidelines published during the 2015 MERS-CoV outbreak in South Korea suggested the use of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy in patients with severe MERS-CoV [14] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.01.27.921627\"><h2> Nelfinavir was predicted to be a potential inhibitor of 2019 nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Xu, Z.; Peng, C.; Shi, Y.; Zhu, Z.; Mu, K.; Wang, X.; Zhu, W.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">2019-nCov has caused more than 80 <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">deaths<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> as of 27 January 2020 in China, and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> cases have been reported in more than 10 countries. However, there is no approved drug to treat the disease. <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCov M pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> is a potential drug target to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. We built homology models based on <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS M<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> structures, and docked 1903 small molecule drugs to the models. Based on the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> score and the 3D similarity of the <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> mode to the known M <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> ligands, 4 drugs were selected for <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> free energy calculations. Both MM/GBSA and SIE methods voted for nelfinavir, with the <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> free energy of -24.690.52 kcal/mol and -9.420.04 kcal/mol, respectively. Therefore, we suggested that nelfinavir might be a potential <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCov M pro<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11020092\"><h2> Human Polyclonal Antibodies Produced from Transchromosomal Bovine Provides Prophylactic and Therapeutic Protections Against Zika Virus Infection in STAT2 KO Syrian Hamsters</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Siddharthan, Venkatraman; Miao, Jinxin; Van Wettere, Arnaud J; Li, Rong; Wu, Hua; Sullivan, Eddie; Jiao, Jinan; Hooper, Jay W.; Safronetz, David; Morrey, John D.; Julander, Justin G.; Wang, Zhongde</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In summary, we first demonstrated ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and immunotherapy in a new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rodent animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> model, the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">STAT2 KO hamsters<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. According to the FDA <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> efficacy rule, the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of therapeutic interventions against serious conditions, such as those caused by ZIKV, should be demonstrated to be efficacious in more than one <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal species<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Second, we demonstrated that SAB-155 is highly effective, both prophylactically and therapeutically, in treating ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hamster<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> model. In contrast to other <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-derived monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, SAB-155 is fully-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (non-immunogenic to patients), polyclonal (recognizing multiple <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antigens<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> on a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to effectively reduce or eliminate <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral evasion<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> caused by <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral mutations<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>) and can be produced very quickly and in large quantities (up to 600 g fully <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human immunoglobulin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> can be produced per Tc bovineper month; our unpublished observations). These advantages over other <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapies could potentially make SAB-155, as well as the TcB platform, a powerful countermeasure in fighting ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. It is worth noting that <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">TcB<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> derived fully <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> polyclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> elicited against several other <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> or <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> have been shown to be effective to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by various <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> pathogens [5, 6, 11, [28] [29] [30] [31] . Some of these <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">TcB antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> have already been proven to be safe and efficacious in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> clinical trials [31, 32] . The <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-ZIKV TcB antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> reported in this study are yet to be tested in rigorous <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> clinical trials to be proven effective in treating ZIKV in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. </div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s12929-019-0540-y\"><h2> Recent advances on the role of host factors during non-poliovirus enteroviral infections</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Owino, Collins Oduor; Chu, Justin Jang Hann</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Much has not been achieved in the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against NPEV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The major challenge for <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has always been the mutations on the viral genomes. Several compounds have been tested for possible use as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">enteroviruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> as shown in Table 3 below but no much success has been achieved. Most of the drug screening have been done in vitro with little success in vivo and in clinical trials. Screening FDA approved drugs and repurposing of existing drugs based on known viral-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> interactions are some of the strategies that has been adopted by scientists to identify <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against NPEVs. For example, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Li<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and colleagues evaluated the effects of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ribavirin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> a known <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against other RNA <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> on EV-A71 for possible repurposing of the drug [179] . Their study showed decreased EV-A71 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> yield in vitro and reduced disease status, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">death<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adverse effects<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> associated with its <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in vivo; highlighting the possible role as an <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> compound against EV-A71 [179] . <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Plant metabolites<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> have also been <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> as possible <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> compounds against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">enteroviruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. For example, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Quercetin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>; a well distributed <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plant flavonoid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> has been shown recently to inhibit EV-A71 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> by inhibiting <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> attachment, adsorption and by <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting viral 3C protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> [180] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/medicina55090519\"><h2> Antiviral Activity of Exopolysaccharides Produced by Lactic Acid Bacteria of the Genera Pediococcus, Leuconostoc and Lactobacillus against Human Adenovirus Type 5</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Biliavska, Liubov; Pankivska, Yulia; Povnitsa, Olga; Zagorodnya, Svitlana</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Therefore, the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> that would be effective against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adenoviruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> without <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adverse effects<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, for a wide range of patients, including long-term users, is very urgent.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1186/s13071-019-3486-8\"><h2> Delivery of SA35 and SA40 peptides in mice enhances humoral and cellular immune responses and confers protection against Cryptosporidium parvum infection</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Tosini, Fabio; Ludovisi, Alessandra; Tonanzi, Daniele; Amati, Marco; Cherchi, Simona; Pozio, Edoardo; Gmez-Morales, Maria Angeles</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">At present, nitazoxanide is the only drug approved for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cryptosporidiosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> by the US Food and Drug Administration (US-FDA), but this drug cannot be used in children younger than one year and is ineffective in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immunodeficient<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients [12] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.00531\"><h2> Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Pizzorno, Andrs; Padey, Blandine; Terrier, Olivier; Rosa-Calatrava, Manuel</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Frontiers in Immunology <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">|<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> www.frontiersin.org site of NP structure, has identified naproxen, a known <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of inducible <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cyclooxygenase type 2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COX-2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) commonly used as non-steroidal <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-inflammatory drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. This identified molecule has shown <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> properties against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> in vitro and in vivo (94) . More recently, naproxen analogs with improved efficacy have been developed, showing high level of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of both NP-RNA and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NP-polymerase subunit PA<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> complexes, without parallel <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COX-2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (111, 112) . Interestingly, in contrast to other examples of drug repurposing strategies, the example of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">naproxen<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> remains <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and future works will determine if this drug will present the same Achille's <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">heel<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> than classic <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> regarding selection of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The last two examples of this chapter are <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">midodrine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diltiazem<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, that we identified as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in the context of an in-silico assisted strategy based on <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">transcriptional<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> profiling. An emerging approach in drug repurposing is based on signature matching, which consists of comparing a specific characteristic of a drug-its <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cellular<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> signature-to that of a disease (42) . This approach, mostly based on transcriptomic data, was successfully exploited to identify drug repurposing opportunities in a large range of therapeutics areas, and notably in the field of oncology and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rare diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (42) . Our group was the first to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">transpose<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> this approach to the field of viral <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, thanks to the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and democratization of DNA-microarray and more recently RNAseq techniques. In a proof-of-concept study using an in vitro model of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, we postulated that <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> global <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gene expression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> profiling can be considered as a &quot;fingerprint&quot; or signature of any specific <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell state<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, including during <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or drug treatment, and hypothesized that the screening of databases for compounds that counteract virogenomic signatures could enable rapid identification of effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (97) . Among the molecules identified in silico, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">midodrine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, an <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">adrenergic alpha receptor agonist<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> widely used to treat hypotension, demonstrated very interesting in vitro <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities (97) . These results prompted the Phase II clinical evaluation of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">midodrine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (NCT01546506) for the treatment of uncomplicated seasonal <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">flu<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in primary care centers.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.987016\"><h2> The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Shutoku Matsuyama; Miyuki Kawase; Naganori Nao; Kazuya Shirato; Makoto Ujike; Wataru Kamitani; Masayuki Shimojima; Shuetsu Fukushi</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">COVID-19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> outbreak began on December 2019 in Wuhan, China (1), and the causative <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2, has rapidly spread into 43 countries as of February 27, 2020. The number of infected patients exceeds 81,000, and the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">death<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> toll exceeds 2,700. Several drugs, including lopinavir, remdesivir, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, have been reported to be presumably effective in treating this disease (2, 3) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10040152\"><h2> Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Cui, Qinghua; Du, Ruikun; Anantpadma, Manu; Schafer, Adam; Hou, Lin; Tian, Jingzhen; Davey, Robert A.; Cheng, Han; Rong, Lijun</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The recent 2014-2016 West African <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> epidemic underscores the need for the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of novel anti-Ebola therapeutics, due to the high mortality rates of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and the lack of FDA-approved vaccine or therapy that is available for the prevention and treatment. Traditional Chinese medicines (TCMs) represent a huge reservoir of bioactive chemicals and many TCMs have been shown to have <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activities. 373 extracts from 128 TCMs were evaluated using a high throughput assay to screen for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> entry. Extract of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Rhodiola rosea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> displayed specific and potent <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> against <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> entry of both <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Marburg virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. In addition, twenty commercial compounds that were isolated from <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Rhodiola rosea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> were evaluated using the pseudotyped <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> entry assay, and it was found that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ellagic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gallic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which are two structurally related compounds, are the most effective ones. The activity of the extract and the two <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pure<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> compounds were validated using <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. The time-of-addition experiments suggest that, mechanistically, the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Rhodiola rosea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> extract and the effective compounds act at an early step in the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> cycle following initial <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> attachment, but prior to viral/<mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell membrane<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> fusion. Our findings provide evidence that <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Rhodiola rosea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> has potent anti-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">filovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> properties that may be developed as a novel anti-Ebola treatment.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.03.11.983056\"><h2> Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Rui Xiong; Leike Zhang; Shiliang Li; Yuan Sun; Minyi Ding; Yong Wang; Yongliang Zhao; Yan Wu; Weijuan Shang; Xiaming Jiang; Jiwei Shan; Zihao Shen; Yi Tong; Liuxin Xu; Chen Yu; Yingle Liu; Gang Zou; Dimitri Lavillete; Zhenjiang Zhao; Rui Wang; Lili Zhu; Gengfu Xiao; Ke Lan; Honglin Li; Ke Xu</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The data in all refresh DHODH as an attractive <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> target in treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with equivalent efficacy to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">DAA<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug, and is advantageous when facing DAA-drugresistant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have been marketed in China and are mainly used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in adults and children over 2 years of age. In vitro studies have shown that lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can inhibit the replication of MERS-CoV and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">exert<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> anti-viral effects. The drug is listed as a recommended drug in the Anti-viral Drugs section of the New <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Infected <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> Diagnosis and Treatment Program. The molecular <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results showed that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>'s possible target is Nsp3c or E-channel with the mfScores of -152.100 and -277.769, respectively. Lopinavir's possible target is Nsp3b, a broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, mainly for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">upper respiratory tract infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> and B <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, etc. In recent years, many studies have proven its effectiveness against both <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and MERS-CoV. Arbidol <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hydrochloride<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can block <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> by inhibiting the fusion of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lipid membrane<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> with the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>. Compared with the untreated control group, arbidol can effectively inhibit <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> up to 60 times at a concentration of 10-30 mol/L, and significantly inhibit the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>'s pathological effects on <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>. The <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results of arbidol with the possible drug targets of the new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> showed that it may interact with Nsp7_Nsp8 complex, Nsp14, Nsp15, E-channel, or Spike with the mfScores of -136.087, -118.253, -118.253, -117.879, and -145.125, respectively. Darunavir is an <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1 protease inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that selectively inhibits the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cleavage<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-encoded <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Gag<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>-<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> polyprotein in virally infected <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, thereby preventing the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">formation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of mature <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious virus particles<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. At a concentration of 300 mol/L, darunavir can significantly inhibit <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, and the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> efficiency is 280 times compared with the untreated group. Our <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results showed that the possible targets of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">darunavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are Nsp3c, PLpro, E-channel or Spike <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with the mfScores of -126.149, -110.759, -157.184, and -111.865, respectively. Favipiravir, a broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, is used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">flu<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The Shenzhen Health Commission has now initiated clinical studies on the use of favipiravir to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. While, the scores of favipiravir <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> with the targets in our virtual screening are relatively low. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chloroquine phosphate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has been used in the treatment of <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">malaria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> since the 1940s and later in <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rheumatoid arthritis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has been reported in some earlier studies to have direct anti-viral effects, such as inhibiting <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">flavivirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">retrovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (such as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), and many coronaviruses. Recent study showed that with EC 50 of 1.13 mol/L and SI greater than 88, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can effectively inhibit <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 in the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> level. Its efficiency in the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human body<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> has not yet been clinically proven. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chloroquine phosphate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was turned into <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">body<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> to play therapeutic effect. Our <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results showed that the possible target of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is Nsp3b or E-channel with the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> mfScores of -130.355 and -107.889, respectively.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have been marketed in China and are mainly used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in adults and children over 2 years of age. In vitro studies have shown that lopinavir and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can inhibit the replication of MERS-CoV and <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> to <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">exert<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> anti-viral effects. The drug is listed as a recommended drug in the Anti-viral Drugs section of the New <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Infected <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> Diagnosis and Treatment Program. The molecular <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results showed that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ritonavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>'s possible target is Nsp3c or E-channel with the mfScores of -152.100 and -277.769, respectively. Lopinavir's possible target is Nsp3b, a broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, mainly for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">upper respiratory tract infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> and B <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, etc. In recent years, many studies have proven its effectiveness against both <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and MERS-CoV. Arbidol <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hydrochloride<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can block <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> by inhibiting the fusion of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lipid membrane<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> with the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>. Compared with the untreated control group, arbidol can effectively inhibit <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> up to 60 times at a concentration of 10-30 mol/L, and significantly inhibit the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>'s pathological effects on <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>. The <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results of arbidol with the possible drug targets of the new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> showed that it may interact with Nsp7_Nsp8 complex, Nsp14, Nsp15, E-channel, or Spike with the mfScores of -136.087, -118.253, -118.253, -117.879, and -145.125, respectively. Darunavir is an <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV-1 protease inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that selectively inhibits the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cleavage<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-encoded <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Gag<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>-<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> polyprotein in virally infected <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, thereby preventing the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">formation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of mature <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious virus particles<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. At a concentration of 300 mol/L, darunavir can significantly inhibit <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, and the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> efficiency is 280 times compared with the untreated group. Our <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results showed that the possible targets of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">darunavir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are Nsp3c, PLpro, E-channel or Spike <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with the mfScores of -126.149, -110.759, -157.184, and -111.865, respectively. Favipiravir, a broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-viral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, is used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">flu<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The Shenzhen Health Commission has now initiated clinical studies on the use of favipiravir to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. While, the scores of favipiravir <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> with the targets in our virtual screening are relatively low. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chloroquine phosphate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has been used in the treatment of <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">malaria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> since the 1940s and later in <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rheumatoid arthritis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has been reported in some earlier studies to have direct anti-viral effects, such as inhibiting <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">flavivirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">retrovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (such as <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), and many coronaviruses. Recent study showed that with EC 50 of 1.13 mol/L and SI greater than 88, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> can effectively inhibit <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV-2 in the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> level. Its efficiency in the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human body<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV-2 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> has not yet been clinically proven. <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Chloroquine phosphate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> was turned into <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">body<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> to play therapeutic effect. Our <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> results showed that the possible target of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chloroquine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is Nsp3b or E-channel with the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">docking<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> mfScores of -130.355 and -107.889, respectively.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41467-018-02828-6\"><h2> Bismuth antimicrobial drugs serve as broad-spectrum metallo--lactamase inhibitors</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Wang, Runming; Lai, Tsz-Pui; Gao, Peng; Zhang, Hongmin; Ho, Pak-Leung; Woo, Patrick Chiu-Yat; Ma, Guixing; Kao, Richard Yi-Tsun; Li, Hongyan; Sun, Hongzhe</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In summary, we demonstrate that CBS and related <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bismuth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> compounds are a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of novel and potent <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NDM-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and other MBLs both in vitro and in vivo. Distinct from previously reported organic molecule-based <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, Bi(III) irreversibly inhibits MBLs via a unique <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> displacement mechanism, with the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cysteine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> residues at the active site being critical for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bismuth coordination<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. We thus anticipate that CBS or other <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bismuth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> compounds can be repositioned or developed as a new <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of broad-spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for B1 MBLs. Given that Bi(III) compounds are already clinically used drugs and their selective toxicity toward pathogens. Such broad-spectrum MBL <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> together with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> as co-therapy will undoubtedly open a new horizon for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by MBL-positive <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Indeed, combined use of such resistant breakers with existing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> represents a new and more economical therapy to effectively solve the problem of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 60 .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">drugs used in this clinical trial (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> granules and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) have been approved for</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3947/ic.2018.50.2.160\"><h2> Guideline for Antibiotic Use in Adults with Community-acquired Pneumonia</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Lee, Mi Suk; Oh, Jee Youn; Kang, Cheol-In; Kim, Eu Suk; Park, Sunghoon; Rhee, Chin Kook; Jung, Ji Ye; Jo, Kyung-Wook; Heo, Eun Young; Park, Dong-Ah; Suh, Gee Young; Kiem, Sungmin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">For adults who may have contracted community-acquired <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, are the tests used to identify causative helpful for selecting therapeutic <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>?</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Potential 3CLpro <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> from <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug database.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.apsb.2020.02.008\"><h2> Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Wu, Canrong; Liu, Yang; Yang, Yueying; Zhang, Peng; Zhong, Wu; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Li, Xingzhou; Zheng, Mengzhu; Chen, Lixia; Li, Hua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Potential 3CLpro <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> from <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZINC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> drug database.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.00531\"><h2> Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Pizzorno, Andrs; Padey, Blandine; Terrier, Olivier; Rosa-Calatrava, Manuel</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">As most alternative <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> strategies for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, including those related to drug repurposing and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> instead of viral determinants, an emerging trend consists to propose innovative therapies that combine classic <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> drugs, which starts to show promising results (87) . For example, Belardo et al. have demonstrated, in <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> culture-based assays using different <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">avian<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models, that the combination of NA <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and nitazoxanide presents synergistic anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> effects (117) . Convincing results were also obtained using a combination treatment including naproxen. In a clinical trial enrolling hospitalized patients infected by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A(H3N2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>), combination therapy with naproxen, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">clarithromycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> showed improved efficacy in terms of hospital stay duration and patient mortality, when compared to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment alone (118) . In the context of the evaluation of the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diltiazem<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in the reconstituted <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human airway epithelium<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> model MucilAir TM , our group demonstrated that the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diltiazem<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> combination treatment conferred a greater reduction of apical viral titers than that was measured with the same-dose monotherapy, with a marked delay of viral production (98) . An ongoing French multicenter randomized clinical trial is investigating the effect of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diltiazem<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> bitherapy compared with standard <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> monotherapy for the treatment of severe <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in intensive care units (FLUNEXT trial NCT03212716).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41467-018-02828-6\"><h2> Bismuth antimicrobial drugs serve as broad-spectrum metallo--lactamase inhibitors</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Wang, Runming; Lai, Tsz-Pui; Gao, Peng; Zhang, Hongmin; Ho, Pak-Leung; Woo, Patrick Chiu-Yat; Ma, Guixing; Kao, Richard Yi-Tsun; Li, Hongyan; Sun, Hongzhe</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Metal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> compounds have been used as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> agents for centuries 26 . Auranofin (a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gold<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> antirheumatic agent) <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">exerts<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> broadspectrum <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bactericidal activity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> via <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacterial thioredoxin reductase 27<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Silver nitrate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gallium nitrate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> enhance <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against (multidrug-) resistant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic adjuvants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 28, 29 . Bismuth (Bi(III)) compounds such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">colloidal bismuth subcitrate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (CBS, De-Nol  ) and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ranitidine bismuth citrate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RBC<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, Pylorid  ) are clinically used drugs in combination with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to treat <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Helicobacter pylori<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (H. pylori)-associated <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> even for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">clarithromycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-and metronidazoleresistant strains, and confer no <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> even after usage for a long period of time 30, 31 . Thus, reuse of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> compounds has been considered as a promising alternative to deal with current crisis on AMR 32 . Considering that MBLs are <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zinc<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (Zn(II))-containing enzymes, the use of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">metal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> compounds to inactivate their activity may represent a new approach for the discovery of MBL <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1038/s41467-018-02828-6\"><h2> Bismuth antimicrobial drugs serve as broad-spectrum metallo--lactamase inhibitors</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Wang, Runming; Lai, Tsz-Pui; Gao, Peng; Zhang, Hongmin; Ho, Pak-Leung; Woo, Patrick Chiu-Yat; Ma, Guixing; Kao, Richard Yi-Tsun; Li, Hongyan; Sun, Hongzhe</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Carbapenems are the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotic class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of choice for the treatment of serious <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> caused by <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Enterobacteriaceae<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> producing AmpC type enzymes or extended-spectrum -lactamases 46 . Their clinical utility is, however, greatly challenged by the emergence of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">carbapenemase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, i.e., SBLs and more difficult-to-treat MBLs, which have extremely broad substrate spectrum on almost all lactams (except for aztreonam 47 ), as well as being resistant to all commercially available <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of SBLs. In particular, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NDM-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is one of the most widespread and threatening MBLs that <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> and hydrolyzes almost all -<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">lactam antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with Zn(II) as a <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cofactor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Therefore, no effective therapy is available currently. Other classes of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibiotics<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">colistin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fosfomycin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> though exhibit <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antimicrobial<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MBL<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>-positive <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacteria<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, usually <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">suffer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> severe side effects or limitations in drug delivery 48 , which further restrains the medication therapy against MBL producers. Thus, an alternative strategy is needed to develop more effective MBL <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/333021\"><h2> Rapid Therapeutic Recommendations in the Context of a Global Public Health Crisis using Translational Bioinformatics Approaches: A proof-of-concept study using Nipah Virus Infection</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Shameer, K.; Johnson, K. W.; Readhead, B.; Glicksberg, B.; McCallum, C.; R, A.; Hirsch, J.; Bock, K.; Chelico, J.; Hajizadeh, N.; Oppenheim, M.; Dudley, J.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Detailed account of related methods to match gene signature to corresponding drugs are explained elsewhere [111, samples (2 NiV infected (isolate UMMC1, Genebank AY029767) HUVEC <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell lines<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> with multiplicity of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>; 2 <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell lines<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> infected with recombinant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> lacking the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">expression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">accessory NiV C protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> (NiVC) and 2 mock-infected HUVEC <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>. <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pathology<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> studies indicate that the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">endothelium<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">central nervous system<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> was susceptible to NiV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and may thus represent a representative model system to study NiV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> using molecular level data [119]. Downregulated genes: n=2869. Eight upregulated genes were shared across both signatures (<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFIT1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFI44L<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">OASL<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CXCL10<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFIT2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">OAS2<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">OAS1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IFI44<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>) and one gene was common across down regulated genes (TAF4B). Both gene lists were used independently to perform drug matching using CGEA approach using a library of drugs were annotated in conjunction with RepurposeDB. In the interpretation step, we primarily focus on the approved subset of compounds to extent the feasibility of launching immediate clinical trials. Briefly the gene set-drug matching data was compiled and annotated using data from the Connectivity Map, Anatomical Therapeutic Chemical (ATC) Classification System, PubChem, SIDER, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Offsides<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and Drug Bank. Results compiled from CGEA consist of compound information including chemoinformatics signatures, drug target information, indications, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mechanism of action<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and side effects. Computational Drug Repositioning using <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Gene Expression<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> Signature Identifies Potential, FDA approved Therapies for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Nipah Virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>: Following sections summarize a subset of compounds predicted using computational drug repositioning. These drugs are not ready for clinical use and need extensive testing and clinical trials before use at the point of care. Seven compounds have shown to optimally perturb the published gene signature (trihexyphenidyl, 5186223, convolamine, 5186324, tiletamine, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">S-propranolol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>). Two of these drugs are FDA approved for different indications, trihexyphenidyl (Score= -0.47, P= 0.0006; parkinsonian disorders, drug-induced extrapyramidal <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">movement<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> disorders and antispasmodic drugs. See: https, //www.drugbank.ca/drugs/DB00376); <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">S-propranolol<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (Score= -0.44, P= 0.002) indications in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acute myocardial infarction<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">arrhythmias<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">angina pectoris<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hypertension<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, hypertensive <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergencies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hyperthyroidism<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">migraine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, //www.drugbank.ca/drugs/DB00571).Table 1 lists drugs capable of perturbing published gene signature with FDR &lt;=0.10 (See: Supplementary Material for full list of compounds and annotations). Nine compounds have shown to optimally perturb Characteristic direction-based gene P= 0.001; See: https, //www.drugbank.ca/drugs/DB00394) is an approved,anti-inflammatory small molecule with indications for <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">asthma<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">allergic rhinitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (seasonal and perennial). It is currently an investigational compound for indications including <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Crohn's disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">graft-versus-host disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>.Table 2lists drugs capable of perturbing characteristic direction gene signature with FDR &lt;=0.10 (Also See Supplementary Material for full list of compounds and annotations).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.05.935387\"><h2> Teicoplanin potently blocks the cell entry of 2019-nCoV</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Zhang, J.; Ma, X.; Yu, F.; Liu, J.; Zou, F.; Pan, T.; Zhang, H.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The well-known examples, which have emerged as important <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> pathogens, include <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> CoV (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-CoV) in China in 2003 and middle east respiratory <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> CoV (MERS-CoV) in the Arabian Peninsula since 2012 3-9 . Recently a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> outbreaks in December 2019 as the pathogenic agent that causes series of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> cases in Wuhan of China has quickly raised intense attention not only in China but also internationally 10-14 . This <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, named as <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019 novel coronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (2019-nCoV), belongs to the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">betacoronavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> according to the sequence released 13,15 . Evolutionary analyses have shown that the 2019-nCoV shares 79% homology with <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and 50% with MERS-CoV 15-17 . Given the high <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> rate and the lack of effective treatment for 2019-nCoV, it is quite urgent to develop an efficient <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drug<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for 2019-nCoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.2217/fvl-2018-0016\"><h2> Antiviral therapeutic approaches for human rhinovirus infections</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Casanova, Victor; Sousa, Filipa H; Stevens, Craig; Barlow, Peter G</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The number of established chemotherapeutic options for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is still relatively low, and studies have been undertaken with a view to characterizing the anti-RV activity of drugs already licensed for use against other <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. There have been in excess of 90 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> used for the medical treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and these have been categorized into 13 functional groups (reviewed in [20] ). The <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment options include <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HIV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hepatitis B<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and C <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">herpesvirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human cytomegalovirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">varicella-zoster virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory syncytial virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>) and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human papillomavirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. While none of these drugs have been licensed for use in RV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, a number of existing therapeutics have been demonstrated to have <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against a number of RV serotypes and thus are exciting prospects for therapeutic use in this <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10120721\"><h2> Development of Small-Molecule MERS-CoV Inhibitors</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Liang, Ruiying; Wang, Lili; Zhang, Naru; Deng, Xiaoqian; Su, Meng; Su, Yudan; Hu, Lanfang; He, Chen; Ying, Tianlei; Jiang, Shibo; Yu, Fei</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Disulfiram<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, a drug used in alcohol aversion therapy, has been approved by the U.S. Food and Drug Administration (FDA) since 1951 ( Figure 5(10) ). It can inhibit the activity of some enzymes, such as urease [45] , methyltransferase [46] , and kinase [45] , all by reacting with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cysteine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> residues, suggesting broad-spectrum characteristics [47] . Notably, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">disulfiram<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> also acts as an allosteric <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MERS-CoV papain-like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> [47] . Multiple <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> assays also support a kinetic mechanism by which <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">disulfiram<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, together with 6TG (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">6-thioguanine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) and/or MPA (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mycophenolic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), can synergistically inhibit <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MERS-CoV papain-like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> [47] . Hence, the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">recombination<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of three clinically available drugs could feasibly be used to treat MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10120721\"><h2> Development of Small-Molecule MERS-CoV Inhibitors</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Liang, Ruiying; Wang, Lili; Zhang, Naru; Deng, Xiaoqian; Su, Meng; Su, Yudan; Hu, Lanfang; He, Chen; Ying, Tianlei; Jiang, Shibo; Yu, Fei</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Disulfiram<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, a drug used in alcohol aversion therapy, has been approved by the U.S. Food and Drug Administration (FDA) since 1951 ( Figure 5(10) ). It can inhibit the activity of some enzymes, such as urease [45] , methyltransferase [46] , and kinase [45] , all by reacting with <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cysteine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> residues, suggesting broad-spectrum characteristics [47] . Notably, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">disulfiram<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> also acts as an allosteric <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MERS-CoV papain-like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> [47] . Multiple <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> assays also support a kinetic mechanism by which <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">disulfiram<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, together with 6TG (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">6-thioguanine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>) and/or MPA (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mycophenolic acid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>), can synergistically inhibit <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MERS-CoV papain-like protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> [47] . Hence, the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">recombination<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of three clinically available drugs could feasibly be used to treat MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.2147/IDR.S224291\"><h2> Epidemiology, Outcome and Risk Factors Analysis of Viral Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral Drugs Do Not Prevent EpsteinBarr Virus Reactivation</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Czyzewski, Krzysztof; Dziedzic, Magdalena; Salamonowicz, Malgorzata; Fraczkiewicz, Jowita; Zajac-Spychala, Olga; Zaucha-Prazmo, Agnieszka; Gozdzik, Jolanta; Galazka, Przemyslaw; Bartoszewicz, Natalia; Demidowicz, Ewa; Styczynski, Jan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Standard uniform prophylaxis has been applied for all patients undergoing HCT. 8, 9, 11 Commonly accepted strategies were performed for prophylactic, empirical and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> therapy with various agents. 8, 9, 11, 12 In the case of significant <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CMV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-DNA-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and EBV-DNA -emia and/or <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CMV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-or EBV-disease, specific treatment was implemented.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.05.20020545\"><h2> ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Jun Wang; Shanmeizi Zhao; Ming Liu; Zhiyao Zhao; Yiping Xu; Ping Wang; Meng Lin; Yanhui Xu; Bing Huang; Xiaoyu Zuo; Zhanghua Chen; Fan Bai; Jun Cui; Andrew M Lew; Jincun Zhao; Yan Zhang; Haibin Luo; Yuxia Zhang</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">and the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">AT1R<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> blocker <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">valsartan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (DOI:10.1183/13993003.congress-2019.PA2469) are effective in relieving <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pulmonary<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> injury and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">embolism<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in experimental models and clinical trials, their efficacy in treating 2019-nCoV may worth consideration. Dipyridamole is another anti-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">coagulation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> drug. In a pilot trial, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dipyridamole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> administration promoted <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mucosal healing<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and improved clinical symptoms in patients with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">colitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> or <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">IBD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [13]. More importantly, published clinical studies [15-20], including those conducted in China (DOI: CNKI:SUN:XIYI.0.2010-12-026;[21]; CNKI:SUN:YXLT.0.2014-32-031), have demonstrated that <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dipyridamole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has broad spectrum <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity against <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. It may also be worth investigating the therapeutic effects of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dipyridamole<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> in patients infected by 2019-nCoV.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2019.02725\"><h2> Development of Small-Molecule Inhibitors Against Zika Virus Infection</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Wang, Lili; Liang, Ruiying; Gao, Yaning; Li, Yanbai; Deng, Xiaoqian; Xiang, Rong; Zhang, Yina; Ying, Tianlei; Jiang, Shibo; Yu, Fei</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of anti-ZIKV drugs requires effective strategies. For example, using existing drug libraries to screen drug molecules that inhibit new targets is an effective method to develop new drugs Kumar et al., 2018) . In <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">silicon<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-based drug modeling, it is another economical and useful strategy to identify candidate drugs in a short amount of time (<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Pal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> et al., 2017; Kumar et al., 2018) . In addition, virtual screening and electronic pharmacokinetic modeling also facilitate the discovery of effective drug molecules (Rohini et al., 2019) . First, the virtual screening method based on electronic pharmacodynamics was adopted to screen effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ZIKV NS2B-NS3 protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> from the ASINE database (including 467,802 molecules) (Rohini et al., 2019) . Then, the complexes of known <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NS2B-NS3 protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and its <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> were used to establish a five-featured pharmacophore hypothesis, ADDRR, which consists of one <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hydrogen<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> bond <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acceptor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (A), two <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hydrogen<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> bond donors (D), and two aromatic rings (R) (Rohini et al., 2019 ). The pharmacophore model was verified by enrichment analysis before the virtual screening process (Rohini et al., 2019) . Active <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of screening methods to assess the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity of compounds is a key step in the discovery of new drugs (Ekins et al., 2016) . <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Virus replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> relies on <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cellular<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> mechanisms, which means that in vitro experiments use <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> for culture and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. Since ZIKV can infect many different <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, multiple <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell lines<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> should be used to study ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. The screening of effective drugs using multiple <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cells<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> provides a good framework for drug discovery (Barr et al., 2016) . Other strategies include <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RNA interference<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, long non-coding RNAs, miRNAs, interfering <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">peptides<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and compounds <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">targeting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> viral RNA (Han and Mesplede, 2018) , underexplored building blocks, and elements introducing into medicinal chemistry (Nitsche et al., 2017) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/molecules24071279\"><h2> Anti-Herpetic, Anti-Dengue and Antineoplastic Activities of Simple and Heterocycle-Fused Derivatives of Terpenyl-1,4-Naphthoquinone and 1,4-Anthraquinone </h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Roa-Linares, Vicky C.; Miranda-Brand, Yaneth; Tangarife-Castao, Vernica; Ochoa, Rodrigo; Garca, Pablo A.; Castro, M ngeles; Betancur-Galvis, Liliana; San Feliciano, Arturo</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Currently, it is necessary to discover new and better <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with novel mechanisms of action for the treatment of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Human Herpesvirus type 1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and 2 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, mainly for the treatment of immunocompromised and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">transplanted<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> patients, considering the continuous emergence of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HHV acyclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-resistant strains. Moreover, to discover medicines for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Dengue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> disease is imperative, taking into account the impact of this disease on public health.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1371/journal.pone.0216700\"><h2> Three asymptomatic animal infection models of hemorrhagic fever with renal syndrome caused by hantaviruses</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Perley, Casey C.; Brocato, Rebecca L.; Kwilas, Steven A.; Daye, Sharon; Moreau, Alicia; Nichols, Donald K.; Wetzel, Kelly S.; Shamblin, Joshua; Hooper, Jay W.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Medical countermeasures are products including biologics (e.g., vaccines and <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>) and small molecule drugs that can be used to prevent or <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat infectious disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> outbreaks. This study presents three <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models of HTNV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, and two models of PUUV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> that can be used to evaluate the efficacy of medical countermeasure that are intended to prevent or mitigate <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (e.g., vaccines) by these <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> through induction of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">sterile immunity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v12020194\"><h2> Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Schwartz, David A.; Graham, Ashley L.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">While multiple agents have been used to treat MERS, none have been tested in large clinical studies. Available data are limited to the use of combination therapies of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">interferon<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and other agents in case reports and case series [63] . A prospective or randomized study may prove difficult given the sporadic nature of MERS-CoV outbreaks.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">) (40). Approval via the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Rule is usually subject to several conditions: 1) post-marketing &quot;field&quot; studies must verify and describe the product's clinical efficacy and safety when such studies are ethical and feasible; 2) restrictions may be imposed to ensure safe use only under the approved labelling (i.e., off-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">label<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> use may be forbidden); and 3) information must be provided to patients prior to administration regarding the conditions of approval and directions for use, contraindications, foreseeable risks, adverse reactions, and drug interactions. The FDA provides guidance on product <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> under the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Rule, including general expectations and qualified <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models under FDA Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research programs, as well as study design considerations (38). The guidance was not in place during the 2014 to 2015 West African <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> outbreak. At that time, vaccines and drugs that were considered for use had not yet undergone <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> trials, and the quantities of these agents were not sufficient at the start of the epidemic to support <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> use. Currently, studies are underway of Ebola survivors (41,42). FDA INTERMEDIATE OR WIDESPREAD TREATMENT IND FILINGS EA INDs in the United States usually involve individual patients, rather than groups. In contrast with individual patient IND applications, which numbered between 322 and 1,110 annually between 2010 and 2016, intermediate EA IND submissions ranged between 0 and 50 annually (total  171 over the entire period), and only 2 widespread treatment IND applications were filed during that same period. FDA refusals of EA INDs are uncommon, with a total of 10 intermediate IND refusals and zero widespread treatment IND refusals from 2010 through 2016 Supplemental Figure 1) (43). INTERMEDIATE VERSUS WIDESPREAD TREATMENT IND: WHICH IS THE APPROPRIATE PATHWAY? CONSOLIDATING MULTIPLE SINGLE-PATIENT EA INDs. When multiple individual patients are seeking EA to a particular drug and meet criteria for EA, the FDA encourages all individual applications to be consolidated under a single intermediate-sized IND or EA protocol, and that the commercial sponsor be the sponsor of the EA IND or EA protocol. This is to avoid having multiple single-patient INDs and multiple sponsors for a single investigational drug. That being said, regulations do not actually forbid authorizing more than 1 single-or intermediate-patient IND for the same drug. HOW MANY PATIENTS <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ARE APPROPRIATE<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> FOR AN INTERMEDIATE-SIZE EA INDs? The FDA generally considers the following factors when determining whether an intermediate-size EA IND or widespread treatment protocol is appropriate (Figure 3) (15).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">) (40). Approval via the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Rule is usually subject to several conditions: 1) post-marketing &quot;field&quot; studies must verify and describe the product's clinical efficacy and safety when such studies are ethical and feasible; 2) restrictions may be imposed to ensure safe use only under the approved labelling (i.e., off-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">label<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> use may be forbidden); and 3) information must be provided to patients prior to administration regarding the conditions of approval and directions for use, contraindications, foreseeable risks, adverse reactions, and drug interactions. The FDA provides guidance on product <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> under the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Rule, including general expectations and qualified <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> models under FDA Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research programs, as well as study design considerations (38). The guidance was not in place during the 2014 to 2015 West African <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> outbreak. At that time, vaccines and drugs that were considered for use had not yet undergone <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> trials, and the quantities of these agents were not sufficient at the start of the epidemic to support <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> use. Currently, studies are underway of Ebola survivors (41,42). FDA INTERMEDIATE OR WIDESPREAD TREATMENT IND FILINGS EA INDs in the United States usually involve individual patients, rather than groups. In contrast with individual patient IND applications, which numbered between 322 and 1,110 annually between 2010 and 2016, intermediate EA IND submissions ranged between 0 and 50 annually (total  171 over the entire period), and only 2 widespread treatment IND applications were filed during that same period. FDA refusals of EA INDs are uncommon, with a total of 10 intermediate IND refusals and zero widespread treatment IND refusals from 2010 through 2016 Supplemental Figure 1) (43). INTERMEDIATE VERSUS WIDESPREAD TREATMENT IND: WHICH IS THE APPROPRIATE PATHWAY? CONSOLIDATING MULTIPLE SINGLE-PATIENT EA INDs. When multiple individual patients are seeking EA to a particular drug and meet criteria for EA, the FDA encourages all individual applications to be consolidated under a single intermediate-sized IND or EA protocol, and that the commercial sponsor be the sponsor of the EA IND or EA protocol. This is to avoid having multiple single-patient INDs and multiple sponsors for a single investigational drug. That being said, regulations do not actually forbid authorizing more than 1 single-or intermediate-patient IND for the same drug. HOW MANY PATIENTS <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ARE APPROPRIATE<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> FOR AN INTERMEDIATE-SIZE EA INDs? The FDA generally considers the following factors when determining whether an intermediate-size EA IND or widespread treatment protocol is appropriate (Figure 3) (15).</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2019.00531\"><h2> Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Pizzorno, Andrs; Padey, Blandine; Terrier, Olivier; Rosa-Calatrava, Manuel</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Drug repurposing approaches for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza viral infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Before marketing, manufacture of the drug for clinical studies is nearly an &quot;all cost&quot; proposition for the commercial entity; the drug cannot be marketed to cover its costs. Thus, companies generally only manufacture sufficient quantities (plus a small <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">margin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>) to cover the requirements of clinical studies, rather than devote resources to manufacturing large quantities of a drug which has a &lt;10% chance of ever making it to market (1, 2) . The FDA approval process begins with the filing of an investigational new drug (IND). Making the drug available to groups or classes of patients who might then deplete the supply of drug for clinical studies could compromise the very research that would more completely disclose a drug's risks and benefits; thus, it could possibly impede full market approval that would make the drug more widely available.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.jacbts.2018.02.001\"><h2> Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Van Norman, Gail A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Before marketing, manufacture of the drug for clinical studies is nearly an &quot;all cost&quot; proposition for the commercial entity; the drug cannot be marketed to cover its costs. Thus, companies generally only manufacture sufficient quantities (plus a small <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">margin<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>) to cover the requirements of clinical studies, rather than devote resources to manufacturing large quantities of a drug which has a &lt;10% chance of ever making it to market (1, 2) . The FDA approval process begins with the filing of an investigational new drug (IND). Making the drug available to groups or classes of patients who might then deplete the supply of drug for clinical studies could compromise the very research that would more completely disclose a drug's risks and benefits; thus, it could possibly impede full market approval that would make the drug more widely available.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2018.03097\"><h2> Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Hijano, Diego R.; Maron, Gabriela; Hayden, Randall T.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pediatric cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> patients, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> treatment should be initiated as early as possible, even if patients have been symptomatic for over 48 h, since there may be benefits even with delayed therapy (AAP, 2018). While <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> B is inherently resistant to M2 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">amantadine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and rimantadine), <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> has become resistant overtime. Hence, their use is limited. <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Neuraminidase inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> (<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NAIs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>), such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and peramivir are now first line for prophylaxis and treatment of <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza A<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> and B (Casper et al., 2010; Fiore et al., 2011; Chemaly et al., 2014) . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is given by <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mouth<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, and its main side effects are <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nausea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">vomiting<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">diarrhea<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Inhaled zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> can cause <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bronchospasm<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, so it should be used cautiously in in patients with <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chronic lung disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Intravenous <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">zanamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is available for compassionate use only. Peramivir is the only NAI approved for IV use (Ison and Hayden, 2002; Louie et al., 2012a,b; Ison, 2014) . Studies comparing <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> to peramivir have shown similar outcomes. However, the efficacy and safety of peramivir in immunocompromised patients needs further assessment (de Jong et al., 2014) .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/ijms19103266\"><h2> Traditional Chinese Medicine as a Potential Source for HSV-1 Therapy by Acting on Virus or the Susceptibility of Host</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Li, Wen; Wang, Xiao-Hua; Luo, Zhuo; Liu, Li-Fang; Yan, Chang; Yan, Chang-Yu; Chen, Guo-Dong; Gao, Hao; Duan, Wen-Jun; Kurihara, Hiroshi; Li, Yi-Fang; He, Rong-Rong</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are also important resources for the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Active substances against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> extracted from <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, microorganisms, and <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">animals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> have attracted widespread interest in the past few decades [28] [29] [30] [31] . The scientific and theoretical values of TCM are increasingly recognized and accepted, since TCM is one of the main sources of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural products<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. Many valuable drugs have been developed with the aid of TCM and it proves that TCM plays a significant role in drug discovery and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>. The fractions/extracts and <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pure<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> compounds with promising anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV-1<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> activities isolated from TCM will be discussed in the following section.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fimmu.2018.01547\"><h2> Advancements in Host-Based Interventions for Influenza Treatment</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Yip, Tsz-Fung; Selim, Aisha Sami Mohammed; Lian, Ida; Lee, Suki Man-Yan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Another <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">MEK inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, CI-1040 (also known as PD184352) was shown to have high potency against IAV in vitro (106). CI-1040 has completed phase II clinical trials as an anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tumor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drug, with the application of CI-1040 as a potential anti-IAV drug candidate recently revisited. Unlike U0126, CI-1040 is <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">orally<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> bioavailable and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> administration of CI-1040 at 48 h post-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> protected 60% of the IAV-infected <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mice<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, while the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-treated group experienced a 100% <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">death<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> rate (109) . <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Oseltamivir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> is known to be effective only when administered in the early stages of IAV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. This suggests the potential use of CI-1040 as an agent used in IAV treatment due to its potentially longer therapeutic time window than mainstay <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/ijms19103266\"><h2> Traditional Chinese Medicine as a Potential Source for HSV-1 Therapy by Acting on Virus or the Susceptibility of Host</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Li, Wen; Wang, Xiao-Hua; Luo, Zhuo; Liu, Li-Fang; Yan, Chang; Yan, Chang-Yu; Chen, Guo-Dong; Gao, Hao; Duan, Wen-Jun; Kurihara, Hiroshi; Li, Yi-Fang; He, Rong-Rong</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The main therapeutic drugs frequently used in clinical practice are <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogues<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> represented by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, which affects the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> mainly by affecting the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">DNA replication<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> process. Although <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ACV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is very effective to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV-1 infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, it is likely for the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to develop into drug-resistant strains with long term use, due to mutations of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">DNA polymerase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> or mutational <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">thymidine nucleoside kinase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> [26] . The mutagenicity of some <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogues<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are high, such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ganciclovir<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and hence less safe to use. Moreover, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> vaccine research is mainly aimed at <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">genital herpes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Yet the vaccine is not effective against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">genital herpes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, let alone other <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">HSV infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Therefore, it is of great significance to develop new <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-HSV-1 drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with lower toxicity by acting via a different mechanism compared to the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nucleoside analogue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The issue of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">drug resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> should also be tackled; the drugs to be developed should not introduce a selective pressure that induces the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> to evolve into drug resistant strains.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1007/s00018-018-2935-4\"><h2> mRNA as novel technology for passive immunotherapy</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Schlake, Thomas; Thess, Andreas; Thran, Moritz; Jordan, Ingo</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Today, monoclonal <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> play an important role in the therapeutic armamentarium. Dozens of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> have been licensed to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rheumatoid arthritis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">multiple sclerosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">psoriasis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">allergy<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">systemic lupus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark>, and other diseases. In addition, mAbs have shown promise in protecting against various microorganisms, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fungal infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> as well as in treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">neurodegenerative diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [86] [87] [88] [89] . However, mAbs for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infectious disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> indications are still scarce among licensed products. Palivizumab for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory syncytial virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> prophylaxis in high-risk infants was the first <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> mAb approved by the FDA [90] . Since then, <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> against <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anthrax<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rabies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in India became available. In addition, bezlotoxumab <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> to <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Clostridium difficile<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> toxin is used to prevent recurrent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bacterial infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [91] . mAbs for treating <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cancer<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> are still the largest group of licensed products. Here, rituximab, directed against the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">transmembrane protein CD20<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> on the surface of <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">B lymphocytes<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark>, was the first mAb in clinical use [92] . However, as for many other mAbs in antitumor therapy, high doses are needed to obtain clinical efficacy [93] . A successful example for a bispecific <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibody<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> is the first-in-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> BiTE against <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CD19<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>/<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CD3<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, blinatumomab, which is approved for the treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acute lymphoblastic leukemia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [94] [95] [96] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/599043\"><h2> Prediction of antiviral drugs against African Swine Fever Viruses based on protein-protein interaction analysis</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> zhu, z.; Fan, Y.; Cai, Z.; Zhang, Z.; Lu, C.; Zhang, G.; Jiang, T.; Peng, Y.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Vaccine and <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> are believed to be the best tool for prevent <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and spread 5 . Unfortunately, all the attempts to develop effective vaccines against ASFVs had failed. Therefore, it is in great need to develop effective <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> against ASFVs. Several studies have identified multiple compounds which could inhibit <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ASFV infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> 4 . For example, a recent study by <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Hakobyan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> et al. found that the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rigid<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> amphipathic fusion <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> displayed a potent and dose-dependent inhibitory effect on <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ASFV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> 6 . Another recent study by Arabyan et al. showed that the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">genistein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> could hamper the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ASFV infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> by inhibiting the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ASFV type II topoisomerase 7<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> . However, all the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> mentioned above have not been taken forward for commercial production. More candidate drugs are needed for further <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v10090453\"><h2> Host-Directed Antivirals: A Realistic Alternative to Fight Zika Virus</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Saiz, Juan-Carlos; de Oya, Nereida Jimnez; Blzquez, Ana-Beln; Escribano-Romero, Estela; Martn-Acebes, Miguel A.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zika virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (ZIKV), a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">mosquito<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-borne <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">flavivirus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, was an almost neglected pathogen until its introduction in the Americas in 2015, where it has been responsible for a threat to global health, causing a great social and sanitary alarm due to its increased <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virulence<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, rapid spread, and an association with severe neurological and ophthalmological complications. Currently, no specific <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> therapy against ZIKV is available, and treatments are palliative and mainly directed toward the relief of symptoms, such as <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">rash<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, by administering antipyretics, anti-histamines, and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fluids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">dehydration<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Nevertheless, lately, search for <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has been a major aim in ZIKV investigations. To do so, screening of libraries from different sources, testing of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, and repurposing of drugs with known <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> activity have allowed the identification of several <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> candidates directed to both viral (structural <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and enzymes) and <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cellular<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> elements. Here, we present an updated review of current knowledge about anti-ZIKV strategies, focusing on <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">host<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>-directed <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antivirals<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> as a realistic alternative to <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">combat<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/v11010059\"><h2> From SARS to MERS, Thrusting Coronaviruses into the Spotlight</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Song, Zhiqi; Xu, Yanfeng; Bao, Linlin; Zhang, Ling; Yu, Pin; Qu, Yajin; Zhu, Hua; Zhao, Wenjie; Han, Yunlin; Qin, Chuan</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Similarly, the therapeutic agents that have been developed against MERS-CoV are based on the <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">S protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and basically restrain the <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> of receptors or the fusion of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">membrane proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark>, thereby leading to the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of MERS-CoV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. These methods mainly involve peptidic fusion <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> [56, 63, 116, 130] , anti-MERS-CoV neutralizing mAbs [86, 131] , <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-DPP4 mAbs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> [86, 132, 133] , <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">DPP4 antagonists<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> [134] , and <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> [135] [136] [137] . However, none of these anti-MERS-CoV curative agents are approved for commercial use in <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">humans<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>. Table 4 . Potential therapeutics for <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>) and MERS.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3389/fmicb.2019.03079\"><h2> Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Chen, Yongkang; Li, Yuan; Wang, Xiaohuan; Zou, Peng</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The association of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Zika virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> (ZIKV) <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and severe complications including neurological sequelae especially <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fetal microcephaly<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> has aroused global attentions since its outbreak in 2015. Currently, there are no vaccines or therapeutic drugs clinically approved for treatments of ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, however. And the drugs used for treating ZIKV in pregnant women require a higher safety profile. Here, we identified an anti-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">asthmatic<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> drug, montelukast, which is of safety profile for pregnant women and exhibited <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antiviral<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> efficacy against ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> in vitro and in vivo. And we showed that montelukast could disrupt the integrity of the <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virions<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> to <mark class=\"entity\" style=\"background: #FFFF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">release<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PATH</span></mark> the viral genomic RNA, hence irreversibly inhibiting viral infectivity. In consideration of the neuro-protective activity that montelukast <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">possessed<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, which was previously reported, it is promising that montelukast could be used for patients with ZIKV <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, particularly for pregnant women.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/medethics-2016-103474\"><h2> The Ebola clinical trials: a precedent for research ethics in disasters</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Calain, Philippe</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The deliberations of the WHO panel initially focused on 'unregistered interventions' then moved to encompass a broader set of categories. For therapeutic agents, the lexicon of possibilities includes more or less distinct situations that require further specifications, for example experimental, unproven, untested, unregistered, off trial, repurposed or investigational drugs. Leaving vocabulary conventions apart, the fact is that candidate interventions to treat or prevent EVD occupy variable positions along the spectrum of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. 16 More specifically, they differ in the extent of available knowledge about their possible efficacy and toxicity. Experts have thus been bound to making subjective evaluations when weighing risk/ benefit ratios, scientific evidence or mere plausibility. One could argue that this situation is not fundamentally different from the routine appraisal of novel therapeutic agents. For example, the US Food and Drug Administration approval process for novel therapeutic agents appears more flexible than expected, relying on evidences of variable quality. 17 Furthermore, US federal regulations include provisions to accommodate <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">emergency<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> situations, such as requests for compassionate use. 18 19 Even where national regulations do not provide such guidance, the catastrophic situation created by the Ebola epidemic could justify efficacy trials with candidate drugs, irrespective of their stage of Figure 1 Eligibility of investigational interventions for clinical trials in <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ebola virus disease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (EVD) patients: an example of a risk-benefit matrix. A possible mapping scheme of risks/benefits is shown. Acceptable combinations were considered for two situations: (i) treatment of confirmed cases or post-exposure after high risk events (shaded area) and (ii) post-exposure after low risk events (bordered area). The vertical <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">axis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> shows if evidence of efficacy (E) exists from: E1, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> compassionate use (considering the number treated and expert judgement on plausibility of efficacy); E2, in vivo, non-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human primate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>; E3, in vivo, non-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">primate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>; E4, <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cell<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> culture: <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> neutralisation or <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of replication; and E5, other in vitro assays (eg, pseudo typed <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>, molecular assays). The horizontal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">axis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> shows if evidence of safety (S) exists from: S1, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> use: repurposed drug marketed for another indication; S2, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> trial with healthy volunteers: phase 1; S3, <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> compassionate use (considering number treated and expert judgement on evidence of safety); S4, in vivo, non-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human primate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>; S5, in vivo, non-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">primate<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>; and S6, in vitro demonstration that predictable toxicity is unlikely to occur (eg, <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cross reactivity<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of <mark class=\"entity\" style=\"background: #ADFF2F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">antibodies<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">COMP</span></mark> with <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human cell lines<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>). <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pharmaceutical development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. This is what the WHO panel concluded in <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">essence<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, setting an important precedent for research ethics in general.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Our second principle for screening should also be emphasized and elaborated upon. It states that the selected herbal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> must conform to traditional usages. There are many kinds of Chinese herbs that have been used for thousands of years. Based on this rich history and experience, Chinese herbal medicines are divided into different types, each type dedicated to certain kinds of diseases. Ignoring these grouping guidelines can lead to serious side effects. Therefore, as a further <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">condition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> for the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> screened here, we verified that they have been routinely used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. To meet this principle, we conducted another threestep screening process for the herbal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1016/j.joim.2020.02.005\"><h2> In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Zhang, Deng-hai; Wu, Kun-lun; Zhang, Xue; Deng, Sheng-qiong; Peng, Bin</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Our second principle for screening should also be emphasized and elaborated upon. It states that the selected herbal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> must conform to traditional usages. There are many kinds of Chinese herbs that have been used for thousands of years. Based on this rich history and experience, Chinese herbal medicines are divided into different types, each type dedicated to certain kinds of diseases. Ignoring these grouping guidelines can lead to serious side effects. Therefore, as a further <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">condition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> for the <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> screened here, we verified that they have been routinely used to treat <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viral pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. To meet this principle, we conducted another threestep screening process for the herbal <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">plants<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1155/2019/6150357\"><h2> The Screening Research of NF-B Inhibitors from Moutan Cortex Based on Bioactivity-Integrated UPLC-Q/TOF-MS</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Lu, Yujie; Liu, Wenjuan; Zhang, Man; Deng, Yanfang; Jiang, Min; Bai, Gang</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Inflammation<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is a multicomponent response to injury, <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tissue<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> stress, and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infection<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, associated with most diseases, and it can occur in various <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">tissues<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">organs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> of the organism [1] . Clinically, there are two main categories of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-inflammatory drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>: steroidal drugs and non-steroidal <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-inflammatory drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">NSAIDs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>). Steroidal drugs generally refer to adrenocortical <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">hormones<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, which have strong anti-inflammatory effect, but have obvious side effects such as <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">water<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-sodium <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">retention<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, puffiness, and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">osteoporosis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> [2] . And NSAID is one of the most widely used drugs in the world and are mainly classified into salicylates, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">propionic acids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">indoles<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fenamic acids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">acetic acids<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> and pyrazolones [3] . However, it has potential <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">cardiovascular<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">gastrointestinal bleeding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> risks [4] . Due to the strong toxic and side effects of many synthetic drugs, and because traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (TCM) has the advantages of abundant resources, definite therapeutic effectiveness, and fewer side effects, the discovery of novel <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">anti-inflammatory drugs<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> from <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">natural compounds<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> has gradually become a research hotspot [5] .</div><p><hr>\n",
       "<a href = \"https://doi.org/10.3390/genes10060457\"><h2> Special Issue: MicroRNA Regulation in Health and Disease</h2></a> (<i>relevance: 0.51</i>)\n",
       "<h6> Subramanian, Subbaya; Steer, Clifford J.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">As FDA-approved small RNA drugs begin to enter the arena of clinical <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, it is critical to expand both preclinical and clinical research studies for miRNAs. A growing number of reports suggest a significant utility of miRNAs as biomarkers for pathogenic conditions, modulators of <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">drug resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, and/or as drugs for medical intervention in almost all <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> health conditions. The pleiotropic nature of this <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nonprotein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-coding RNAs makes them particularly attractive drug targets for diseases with a multifactorial origin and few, if any, available treatments. The landscape of both diagnostic and interventional <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> will arguably continue to evolve as candidate miRNAs pass successfully through phase 2 and 3 clinical trials. In this special issue of Genes, we provide a series of articles that highlight microRNAs as diagnostic, predictive and therapeutic agents for <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> disease. The <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> of bioinformatics programs to identify miRNA-<mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> sites in target genes and their corresponding biological <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pathways<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, along with an expanding platform of in vitro and in vivo preclinical research models, has propelled miRNAs into clinical <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>. The first siRNA <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> trial was conducted in 2004 and, in 2018, the first siRNA drug was approved, paving the way for a <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">class<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> of miRNA transcripts whose active investigation began only a little more than 15 years ago. The future of <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> miRNA clinical trials is absolutely guaranteed and that time has arrived.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1101/2020.02.05.936013\"><h2> Potentially highly potent drugs for 2019-nCoV</h2></a> (<i>relevance: 0.5</i>)\n",
       "<h6> Nguyen, D.; Gao, K.; Chen, J.; Wang, R.; Wei, G.</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In SBDR, one needs to select one or a few effective targets. Study shows that 2019-nCoV genome is very close to that of the <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">severe acute respiratory syndrome<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> (SARS)-CoV [11] . The sequence identities of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCoV 3CL protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">RNA polymerase<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>, and the spike <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> with corresponding <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS-CoV proteins<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> are 96.08%, 96%, and 76%, respectively [12] . We, therefore, hypothesize that a potent <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS 3CL protease inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> is also a potent <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCoV 3CL protease inhibitor<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>. Unfortunately, there is no effective <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> therapy at present. Nevertheless, the X-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ray crystal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> structure of <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS 3CL protease<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> has been reported [13] and the <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> affinities of 115 potential <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">SARS 3CL protease inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> are available in ChEMBL database [14] . Additionally, there are 15,843 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">protein<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>-<mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ligand<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> complexes in PDBbind 2018 general set with <mark class=\"entity\" style=\"background: #FFC0CB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">binding<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">FUNC</span></mark> affinities and X-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">ray crystal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> structures [15] . Moreover, the DrugBank contains about 1600 drugs approved by the U.S. Food and Drug Administration (FDA) [16] . The aforementioned information provides a sound foundation to develop an SBDR machine <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">learning<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> model for <mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">2019-nCoV 3CL protease inhibition<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark>.</div><p><hr>\n",
       "<a href = \"https://doi.org/10.1136/bmjopen-2018-024800\"><h2> Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</h2></a> (<i>relevance: 0.5</i>)\n",
       "<h6> He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua</h6>\n",
       "<p><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"><mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">infections<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, can specifically suppress both <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> A and B, but because of 83 intensive use, viral strains resistant towards NA <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> have also been found (including the 84 pandemic H1N1 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>). NA <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">inhibitors<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> also have potential side effects on the <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nervous system<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> 9 .85Compared with Western <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, Chinese herbal medicines, widely used in Chinese clinics, can 86 regulate multiple targets for treatment and can improve the <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">immune function<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, which is an advantage 87 in relieving <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">upper respiratory tract<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> symptoms10 . Considering the pandemic H1N1 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">virus<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> and other 88 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">viruses<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> that may occur in the future, investigating the potential use of Chinese herbal medicines for 89 the prevention and treatment of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is of great research value.90In traditional Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (TCM), <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> is said to resemble &quot;Feng Wen&quot; <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Wind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-heat), a type of &quot;Wen-bing&quot; meaning <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">feverish<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> diseases. Practitioners of Chinese <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 92 believed that the occurrence of &quot;Feng Wen&quot; (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Wind<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-heat) was associated with a seasonal climate, 93 which closely resembles <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 11 . Respiratory ailments and diseases were so prevalent in ancient94China that Wen Bing developed into a highly specialised <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">branch<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> of TCM, which can be traced back95 500 years. Abnormal climate change facilitates epidemics of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">respiratory diseases<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>. Meanwhile, the 96 <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">human body<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> has failed to adapt, leading to <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">brain<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> centre adjust disorder and decreased disease 97 <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">resistance<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>, and thus increased susceptibility to viral <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">invasion<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>, causing the prevalence of respiratory 98 diseases. According to the traditional Wen Bing precepts, the progression of <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">influenza<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-like diseases 99 can be divided into four stages: (1) <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever development<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark>; (2) <mark class=\"entity\" style=\"background: #00FFFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">nasal<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ANAT</span></mark> symptoms; (3) <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> and <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">chills<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>; and 100 (4) <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">haemoptysis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> 12 . In modern <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark>, the first two of these stages may be viewed as symptoms 101 that usually subside without treatment. The later stages represent unusual conditions, when 102 <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">bronchitis<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> and late-onset <mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">pneumonia<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> occur 13 . 103 Excessive <mark class=\"entity\" style=\"background: #7FFFD4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">fever<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PROC</span></mark> is regarded as a kind of toxin, and TCM and China herbal medicines for 104 clearing away heat and toxic materials are recommended to be used, such as Ban-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Lan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>-Gen, 105 Jin-Yin-<mark class=\"entity\" style=\"background: #BC8F8F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Hua<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PRGE</span></mark> and Yu-Xing-Cao 14 . One herbal <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> for clearing away heat and toxic materials, 106 Chou-<mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Ling<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark>-<mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Dan<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> (<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">CLD<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark>; Laggera pterodonta) of the <mark class=\"entity\" style=\"background: #D8BFD8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">family<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SPEC</span></mark> Laggera Sch-<mark class=\"entity\" style=\"background: #FFA07A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">Bip<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISO</span></mark> ex Hochst, widely 107 cultivated in Yunnan province in China, has been approved and listed in &quot;Yunnan Chinese herbal 108 <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 15 &quot;, &quot;Kunming common folk herbal <mark class=\"entity\" style=\"background: #B0C4DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">medicine<span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHED</span></mark> 16 &quot; and &quot;Yunnan Material Medical 17 &quot; for</div><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# generate solr query and get scores\n",
    "solr_query_url, index_score = generate_solr_query(query_result)\n",
    "top_results_ = extract_results_from_solr(solr_query_url)\n",
    "\n",
    "if top_results_:\n",
    "    display(HTML('<hr>\\n'.join(convert_html(top_results_, index_score))))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python [conda env:scispacy]",
   "language": "python",
   "name": "conda-env-scispacy-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
